

39

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 April 2002 (25.04.2002)

PCT

(10) International Publication Number
WO 02/33099 A2

(51) International Patent Classification⁷: C12N 15/54,
9/12, A01K 67/027, C07K 16/40, C12Q 1/68, 1/48, G01N
33/50, A61K 38/45

(21) International Application Number: PCT/US01/47728

(22) International Filing Date: 20 October 2001 (20.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/242,410	20 October 2000 (20.10.2000)	US
60/244,068	27 October 2000 (27.10.2000)	US
60/245,708	3 November 2000 (03.11.2000)	US
60/247,672	9 November 2000 (09.11.2000)	US
60/249,565	16 November 2000 (16.11.2000)	US
60/252,730	22 November 2000 (22.11.2000)	US
60/250,807	1 December 2000 (01.12.2000)	US

(71) Applicant (for all designated States except US): INCYTE
GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo
Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GURURAJAN,
Rajagopal [US/US]; 5591 Dent Avenue, San Jose, CA
95118 (US). BAUGHN, Mariah, R. [US/US]; 14244
Santiago Road, San Leandro, CA 94577 (US). WALIA,
Narinder, K. [US/US]; 890 David Street, #205, San Lean-
dro, CA 94577 (US). ELLIOTT, Vicki, S. [US/US]; 3770
Polton Place Way, San Jose, CA 95121 (US). XU, Yuming
[US/US]; 1739 Walnut Drive, Mountain View, CA 94040
(US). ARVIZU, Chandra [US/US]; 490 Sherwood Way
#1, Menlo Park, CA 94025 (US). YAO, Monique, G.
[US/US]; 1189 Woodgate Drive, Carmel, IN 46033 (US).
RAMKUMAR, Jaya [IN/US]; 34359 Maybird Circle,
Fremont, CA 94555 (US). DING, Li [CN/US]; 3353 Alma
Street #146, Palo Alto, CA 94306 (US). TANG, Y., Tom
[US/US]; 4230 Ranwick Court, San Jose, CA 95118 (US).
HAFALIA, April, J., A. [US/US]; 2227 Calle de Primavera,
Santa Clara, CA 95054 (US). NGUYEN, Dannel,
B. [US/US]; 1403 Ridgewood Drive, San Jose, CA 95118
(US). GANDHI, Ameena, R. [US/US]; 705 5th Avenue,
San Francisco, CA 94118 (US). LU, Yan [CN/US];
3885 Cornia Way, Palo Alto, CA 94303 (US). YUE,

Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087
(US). BURFORD, Neil [GB/US]; 105 Wildwood Circle,
Durham, CT 06422 (US). BANDMAN, Olga [US/US];
366 Anna Avenue, Mountain View, CA 94043 (US). TRI-
BOULEY, Catherine, M. [FR/US]; 1121 Tennessee, #5,
San Francisco, CA 94107 (US). LAL, Preeti, G. [IN/US];
P.O. Box 5142, Santa Clara, CA 95056 (US). RECIPON,
Shirley, A. [US/US]; 85 Fortuna Avenue, San Francisco,
CA 94115 (US). LU, Dyung, Aina, M. [US/US]; 233 Coy
Drive, San Jose, CA 95123 (US). BOROWSKY, Mark,
L. [US/US]; 122 Orchard Avenue, Redwood City, CA
94061 (US). THORNTON, Michael [US/US]; 9 Medway
Road, Woodside, CA 94062 (US). SWARNAKER, Anita
[CA/US]; 8 Locksley Avenue, #5D, San Francisco, CA
94122 (US). THANGAVELU, Kavitha [IN/US]; 1950
Montecito Avenue #23, Mountain View, CA 94304 (US).
KHAN, Farrah, A. [IN/US]; 3617 Central Road, #102,
Glenview, IL 60025 (US). ISON, Craig, H. [US/US];
1242 Weathersfield Way, San Jose, CA 95118 (US).

(74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics,
Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 02/33099 A2

(54) Title: HUMAN KINASES

(57) Abstract: The invention provides human human kinases (PKIN) and polynucleotides which identify and encode PKIN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PKIN.

HUMAN KINASES

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of human kinases and to the use of these sequences in the diagnosis, treatment, and prevention of cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of human kinases.

BACKGROUND OF THE INVENTION

Kinases comprise the largest known enzyme superfamily and vary widely in their target molecules. Kinases catalyze the transfer of high energy phosphate groups from a phosphate donor to a phosphate acceptor. Nucleotides usually serve as the phosphate donor in these reactions, with most kinases utilizing adenosine triphosphate (ATP). The phosphate acceptor can be any of a variety of molecules, including nucleosides, nucleotides, lipids, carbohydrates, and proteins. Proteins are phosphorylated on hydroxyamino acids. Addition of a phosphate group alters the local charge on the acceptor molecule, causing internal conformational changes and potentially influencing intermolecular contacts. Reversible protein phosphorylation is the primary method for regulating protein activity in eukaryotic cells. In general, proteins are activated by phosphorylation in response to extracellular signals such as hormones, neurotransmitters, and growth and differentiation factors. The activated proteins initiate the cell's intracellular response by way of intracellular signaling pathways and second messenger molecules such as cyclic nucleotides, calcium-calmodulin, inositol, and various mitogens, that regulate protein phosphorylation.

Kinases are involved in all aspects of a cell's function, from basic metabolic processes, such as glycolysis, to cell-cycle regulation, differentiation, and communication with the extracellular environment through signal transduction cascades. Inappropriate phosphorylation of proteins in cells has been linked to changes in cell cycle progression and cell differentiation. Changes in the cell cycle have been linked to induction of apoptosis or cancer. Changes in cell differentiation have been linked to diseases and disorders of the reproductive system, immune system, and skeletal muscle.

There are two classes of protein kinases. One class, protein tyrosine kinases (PTKs), phosphorylates tyrosine residues, and the other class, protein serine/threonine kinases (STKs), phosphorylates serine and threonine residues. Some PTKs and STKs possess structural characteristics of both families and have dual specificity for both tyrosine and serine/threonine

residues. Almost all kinases contain a conserved 250-300 amino acid catalytic domain containing specific residues and sequence motifs characteristic of the kinase family. The protein kinase catalytic domain can be further divided into 11 subdomains. N-terminal subdomains I-IV fold into a two-lobed structure which binds and orients the ATP donor molecule, and subdomain V spans the two lobes. C-terminal subdomains VI-XI bind the protein substrate and transfer the gamma phosphate from ATP to the hydroxyl group of a tyrosine, serine, or threonine residue. Each of the 11 subdomains contains specific catalytic residues or amino acid motifs characteristic of that subdomain. For example, subdomain I contains an 8-amino acid glycine-rich ATP binding consensus motif, subdomain II contains a critical lysine residue required for maximal catalytic activity, and subdomains VI through IX comprise the highly conserved catalytic core. PTKs and STKs also contain distinct sequence motifs in subdomains VI and VIII which may confer hydroxyamino acid specificity.

In addition, kinases may also be classified by additional amino acid sequences, generally between 5 and 100 residues, which either flank or occur within the kinase domain. These additional amino acid sequences regulate kinase activity and determine substrate specificity. (Reviewed in Hardie, G. and Hanks, S. (1995) The Protein Kinase Facts Book, Vol I p.p. 17-20 Academic Press, San Diego, CA.). In particular, two protein kinase signature sequences have been identified in the kinase domain, the first containing an active site lysine residue involved in ATP binding, and the second containing an aspartate residue important for catalytic activity. If a protein analyzed includes the two protein kinase signatures, the probability of that protein being a protein kinase is close to 100% (PROSITE: PDOC00100, November 1995).

Protein Tyrosine Kinases

Protein tyrosine kinases (PTKs) may be classified as either transmembrane, receptor PTKs or nontransmembrane, nonreceptor PTK proteins. Transmembrane tyrosine kinases function as receptors for most growth factors. Growth factors bind to the receptor tyrosine kinase (RTK), which causes the receptor to phosphorylate itself (autophosphorylation) and specific intracellular second messenger proteins. Growth factors (GF) that associate with receptor PTKs include epidermal GF, platelet-derived GF, fibroblast GF, hepatocyte GF, insulin and insulin-like GFs, nerve GF, vascular endothelial GF, and macrophage colony stimulating factor.

Nontransmembrane, nonreceptor PTKs lack transmembrane regions and, instead, form signaling complexes with the cytosolic domains of plasma membrane receptors. Receptors that function through non-receptor PTKs include those for cytokines and hormones (growth hormone and prolactin), and antigen-specific receptors on T and B lymphocytes.

Many PTKs were first identified as oncogene products in cancer cells in which PTK

activation was no longer subject to normal cellular controls. In fact, about one third of the known oncogenes encode PTKs. Furthermore, cellular transformation (oncogenesis) is often accompanied by increased tyrosine phosphorylation activity (Charbonneau, H. and Tonks, N. K. (1992) *Annu. Rev. Cell Biol.* 8:463-93). Regulation of PTK activity may therefore be an important strategy in controlling some types of cancer.

Protein Serine/Threonine Kinases

Protein serine/threonine kinases (STKs) are nontransmembrane proteins. A subclass of STKs are known as ERKs (extracellular signal regulated kinases) or MAPs (mitogen-activated protein kinases) and are activated after cell stimulation by a variety of hormones and growth factors. Cell stimulation induces a signaling cascade leading to phosphorylation of MEK (MAP/ERK kinase) which, in turn, activates ERK via serine and threonine phosphorylation. A varied number of proteins represent the downstream effectors for the active ERK and implicate it in the control of cell proliferation and differentiation, as well as regulation of the cytoskeleton. Activation of ERK is normally transient, and cells possess dual specificity phosphatases that are responsible for its down-regulation. Also, numerous studies have shown that elevated ERK activity is associated with some cancers. Other STKs include the second messenger dependent protein kinases such as the cyclic-AMP dependent protein kinases (PKA), calcium-calmodulin (CaM) dependent protein kinases, and the mitogen-activated protein kinases (MAP); the cyclin-dependent protein kinases; checkpoint and cell cycle kinases; proliferation-related kinases; 5'-AMP-activated protein kinases; and kinases involved in apoptosis.

The second messenger dependent protein kinases primarily mediate the effects of second messengers such as cyclic AMP (cAMP), cyclic GMP, inositol triphosphate, phosphatidylinositol, 3,4,5-triphosphate; cyclic ADPribose, arachidonic acid, diacylglycerol and calcium-calmodulin. The PKAs are involved in mediating hormone-induced cellular responses and are activated by cAMP produced within the cell in response to hormone stimulation. cAMP is an intracellular mediator of hormone action in all animal cells that have been studied. Hormone-induced cellular responses include thyroid hormone secretion, cortisol secretion, progesterone secretion, glycogen breakdown, bone resorption, and regulation of heart rate and force of heart muscle contraction. PKA is found in all animal cells and is thought to account for the effects of cAMP in most of these cells. Altered PKA expression is implicated in a variety of disorders and diseases including cancer, thyroid disorders, diabetes, atherosclerosis, and cardiovascular disease (Isselbacher, K.J. et al. (1994) Harrison's Principles of Internal Medicine, McGraw-Hill, New York, NY, pp. 416-431, 1887).

The casein kinase I (CKI) gene family is another subfamily of serine/threonine protein

kinases. This continuously expanding group of kinases have been implicated in the regulation of numerous cytoplasmic and nuclear processes, including cell metabolism, and DNA replication and repair. CKI enzymes are present in the membranes, nucleus, cytoplasm and cytoskeleton of eukaryotic cells, and on the mitotic spindles of mammalian cells (Fish, K.J. et al., (1995) J. Biol. Chem. 270:14875-14883.

The CKI family members all have a short amino-terminal domain of 9-76 amino acids, a highly conserved kinase domain of 284 amino acids, and a variable carboxyl-terminal domain that ranges from 24 to over 200 amino acids in length (Cegielska, A. et al., (1998) J. Biol. Chem. 273:1357-1364.) The CKI family is comprised of highly related proteins, as seen by the identification of isoforms of casein kinase I from a variety of sources. There are at least five mammalian isoforms, α , β , γ , δ , and ϵ . Fish et al., identified CKI-epsilon from a human placenta cDNA library. It is a basic protein of 416 amino acids and is closest to CKI-delta. Through recombinant expression, it was determined to phosphorylate known CKI substrates and was inhibited by the CKI-specific inhibitor CKI-7. The human gene for CKI-epsilon was able to rescue yeast with a slow-growth phenotype caused by deletion of the yeast CKI locus, HRR250 (Fish et al, *supra*.)

The mammalian circadian mutation tau was found to be a semidominant autosomal allele of CKI-epsilon that markedly shortens period length of circadian rhythms in Syrian hamsters. The tau locus is encoded by casein kinase I-epsilon, which is also a homolog of the Drosophila circadian gene double-time. Studies of both the wildtype and tau mutant CKI-epsilon enzyme indicated that the mutant enzyme has a noticeable reduction in the maximum velocity and autophosphorylation state. Further, *in vitro*, CKI-epsilon is able to interact with mammalian PERIOD proteins, while the mutant enzyme is deficient in its ability to phosphorylate PERIOD. Lowrey et al., have proposed that CKI-epsilon plays a major role in delaying the negative feedback signal within the transcription-translation-based autoregulatory loop that composes the core of the circadian mechanism. Therefore the CKI-epsilon enzyme is an ideal target for pharmaceutical compounds influencing circadian rhythms, jet-lag and sleep, in addition to other physiologic and metabolic processes under circadian regulation (Lowrey, P.L. et al., (2000) Science 288:483-491.)

Calcium-Calmodulin Dependent Protein Kinases

Calcium-calmodulin dependent (CaM) kinases are involved in regulation of smooth muscle contraction, glycogen breakdown (phosphorylase kinase), and neurotransmission (CaM kinase I and CaM kinase II). CaM dependent protein kinases are activated by calmodulin, an intracellular calcium receptor, in response to the concentration of free calcium in the cell. Many CaM kinases are also activated by phosphorylation. Some CaM kinases are also activated by autophosphorylation or by

other regulatory kinases. CaM kinase I phosphorylates a variety of substrates including the neurotransmitter-related proteins synapsin I and II, the gene transcription regulator, CREB, and the cystic fibrosis conductance regulator protein, CFTR (Haribabu, B. et al. (1995) EMBO Journal 14:3679-3686). CaM kinase II also phosphorylates synapsin at different sites and controls the synthesis of catecholamines in the brain through phosphorylation and activation of tyrosine hydroxylase. CaM kinase II controls the synthesis of catecholamines and serotonin, through phosphorylation/activation of tyrosine hydroxylase and tryptophan hydroxylase, respectively (Fujisawa, H. (1990) BioEssays 12:27-29). The mRNA encoding a calmodulin-binding protein kinase-like protein was found to be enriched in mammalian forebrain. This protein is associated with vesicles in both axons and dendrites and accumulates largely postnatally. The amino acid sequence of this protein is similar to CaM-dependent STKs, and the protein binds calmodulin in the presence of calcium (Godbout, M. et al. (1994) J. Neurosci. 14:1-13).

Mitogen-Activated Protein Kinases

The mitogen-activated protein kinases (MAP) which mediate signal transduction from the cell surface to the nucleus via phosphorylation cascades are another STK family that regulates intracellular signaling pathways. Several subgroups have been identified, and each manifests different substrate specificities and responds to distinct extracellular stimuli (Egan, S.E. and Weinberg, R.A. (1993) Nature 365:781-783). MAP kinase signaling pathways are present in mammalian cells as well as in yeast. The extracellular stimuli which activate MAP kinase pathways include epidermal growth factor (EGF), ultraviolet light, hyperosmolar medium, heat shock, endotoxic lipopolysaccharide (LPS), and pro-inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1). Altered MAP kinase expression is implicated in a variety of disease conditions including cancer, inflammation, immune disorders, and disorders affecting growth and development.

Cyclin-Dependent Protein Kinases

The cyclin-dependent protein kinases (CDKs) are STKs that control the progression of cells through the cell cycle. The entry and exit of a cell from mitosis are regulated by the synthesis and destruction of a family of activating proteins called cyclins. Cyclins are small regulatory proteins that bind to and activate CDKs, which then phosphorylate and activate selected proteins involved in the mitotic process. CDKs are unique in that they require multiple inputs to become activated. In addition to cyclin binding, CDK activation requires the phosphorylation of a specific threonine residue and the dephosphorylation of a specific tyrosine residue on the CDK.

Another family of STKs associated with the cell cycle are the NIMA (never in mitosis)-related kinases (Neks). Both CDKs and Neks are involved in duplication, maturation, and separation

of the microtubule organizing center, the centrosome, in animal cells (Fry, A.M., et al. (1998) EMBO J. 17:470-481). The NIM-related kinases also include NIK1 histidine kinases, which function in signal transmission (Yamada-Okabe, T. et al. (1999) J. Bacteriol. 181:7243-7247).

Checkpoint and Cell Cycle Kinases

5 In the process of cell division, the order and timing of cell cycle transitions are under control of cell cycle checkpoints, which ensure that critical events such as DNA replication and chromosome segregation are carried out with precision. If DNA is damaged, e.g. by radiation, a checkpoint pathway is activated that arrests the cell cycle to provide time for repair. If the damage is extensive, apoptosis is induced. In the absence of such checkpoints, the damaged DNA is inherited by aberrant
10 cells which may cause proliferative disorders such as cancer. Protein kinases play an important role in this process. For example, a specific kinase, checkpoint kinase 1 (Chk1), has been identified in yeast and mammals, and is activated by DNA damage in yeast. Activation of Chk1 leads to the arrest of the cell at the G2/M transition. (Sanchez, Y. et al. (1997) Science 277:1497-1501.) Specifically, Chk1 phosphorylates the cell division cycle phosphatase CDC25, inhibiting its normal function which is
15 to dephosphorylate and activate the cyclin-dependent kinase Cdc2. Cdc2 activation controls the entry of cells into mitosis. (Peng, C-Y et al. (1997) Science 277:1501- 1505.) Thus, activation of Chk1 prevents the damaged cell from entering mitosis. A similar deficiency in a checkpoint kinase, such as Chk1, may also contribute to cancer by failure to arrest cells with damaged DNA at other checkpoints such as G2/M.

20 Proliferation-Related Kinases

Proliferation-related kinase is a serum/cytokine inducible STK that is involved in regulation of the cell cycle and cell proliferation in human megakaryocytic cells (Li, B. et al. (1996) J. Biol. Chem. 271:19402-8). Proliferation-related kinase is related to the polo (derived from Drosophila polo gene) family of STKs implicated in cell division. Proliferation-related kinase is downregulated in lung tumor
25 tissue and may be a proto-oncogene whose deregulated expression in normal tissue leads to oncogenic transformation.

The RET (rearranged during transfection) proto-oncogene encodes a tyrosine kinase receptor involved in both multiple endocrine neoplasia type 2, an inherited cancer syndrome, and Hirschsprung disease, a developmental defect of enteric neurons. RET and its functional ligand, glial cell line-
30 derived neurotrophic factor, play key roles in the development of the human enteric nervous system (Pachnis, V. et al. (1998) Am. J. Physiol. 275:G183-G186).

5'-AMP-activated protein kinase

A ligand-activated STK protein kinase is 5'-AMP-activated protein kinase (AMPK) (Gao, G.

et al. (1996) J. Biol Chem. 271:8675-8681). Mammalian AMPK is a regulator of fatty acid and sterol synthesis through phosphorylation of the enzymes acetyl-CoA carboxylase and hydroxymethylglutaryl-CoA reductase and mediates responses of these pathways to cellular stresses such as heat shock and depletion of glucose and ATP. AMPK is a heterotrimeric complex comprised of a catalytic alpha subunit and two non-catalytic beta and gamma subunits that are believed to regulate the activity of the alpha subunit. Subunits of AMPK have a much wider distribution in non-lipogenic tissues such as brain, heart, spleen, and lung than expected. This distribution suggests that its role may extend beyond regulation of lipid metabolism alone.

Kinases in Apoptosis

Apoptosis is a highly regulated signaling pathway leading to cell death that plays a crucial role in tissue development and homeostasis. Deregulation of this process is associated with the pathogenesis of a number of diseases including autoimmune disease, neurodegenerative disorders, and cancer. Various STKs play key roles in this process. ZIP kinase is an STK containing a C-terminal leucine zipper domain in addition to its N-terminal protein kinase domain. This C-terminal domain appears to mediate homodimerization and activation of the kinase as well as interactions with transcription factors such as activating transcription factor, ATF4, a member of the cyclic-AMP responsive element binding protein (ATF/CREB) family of transcriptional factors (Sanjo, H. et al. (1998) J. Biol. Chem, 273:29066-29071). DRAK1 and DRAK2 are STKs that share homology with the death-associated protein kinases (DAP kinases), known to function in interferon- γ induced apoptosis (Sanjo et al. supra). Like ZIP kinase, DAP kinases contain a C-terminal protein-protein interaction domain, in the form of ankyrin repeats, in addition to the N-terminal kinase domain. ZIP, DAP, and DRAK kinases induce morphological changes associated with apoptosis when transfected into NIH3T3 cells (Sanjo et al. supra). However, deletion of either the N-terminal kinase catalytic domain or the C-terminal domain of these proteins abolishes apoptosis activity, indicating that in addition to the kinase activity, activity in the C-terminal domain is also necessary for apoptosis, possibly as an interacting domain with a regulator or a specific substrate.

RICK is another STK recently identified as mediating a specific apoptotic pathway involving the death receptor, CD95 (Inohara, N. et al. (1998) J. Biol. Chem. 273:12296-12300). CD95 is a member of the tumor necrosis factor receptor superfamily and plays a critical role in the regulation and homeostasis of the immune system (Nagata, S. (1997) Cell 88:355-365). The CD95 receptor signaling pathway involves recruitment of various intracellular molecules to a receptor complex following ligand binding. This process includes recruitment of the cysteine protease caspase-8 which, in turn, activates a caspase cascade leading to cell death. RICK is composed of an N-terminal kinase

catalytic domain and a C-terminal "caspase-recruitment" domain that interacts with caspase-like domains, indicating that RICK plays a role in the recruitment of caspase-8. This interpretation is supported by the fact that the expression of RICK in human 293T cells promotes activation of caspase-8 and potentiates the induction of apoptosis by various proteins involved in the CD95 apoptosis pathway (Inohara et al. supra).

Mitochondrial Protein Kinases

A novel class of eukaryotic kinases, related by sequence to prokaryotic histidine protein kinases, are the mitochondrial protein kinases (MPKs) which seem to have no sequence similarity with other eukaryotic protein kinases. These protein kinases are located exclusively in the mitochondrial matrix space and may have evolved from genes originally present in respiration-dependent bacteria which were endocytosed by primitive eukaryotic cells. MPKs are responsible for phosphorylation and inactivation of the branched-chain alpha-ketoacid dehydrogenase and pyruvate dehydrogenase complexes (Harris, R.A. et al. (1995) Adv. Enzyme Regul. 34:147-162). Five MPKs have been identified. Four members correspond to pyruvate dehydrogenase kinase isozymes, regulating the activity of the pyruvate dehydrogenase complex, which is an important regulatory enzyme at the interface between glycolysis and the citric acid cycle. The fifth member corresponds to a branched-chain alpha-ketoacid dehydrogenase kinase, important in the regulation of the pathway for the disposal of branched-chain amino acids. (Harris, R.A. et al. (1997) Adv. Enzyme Regul. 37:271-293). Both starvation and the diabetic state are known to result in a great increase in the activity of the pyruvate dehydrogenase kinase in the liver, heart and muscle of the rat. This increase contributes in both disease states to the phosphorylation and inactivation of the pyruvate dehydrogenase complex and conservation of pyruvate and lactate for gluconeogenesis (Harris (1995) supra).

KINASES WITH NON-PROTEIN SUBSTRATES

Lipid and Inositol kinases

Lipid kinases phosphorylate hydroxyl residues on lipid head groups. A family of kinases involved in phosphorylation of phosphatidylinositol (PI) has been described, each member phosphorylating a specific carbon on the inositol ring (Leevers, S.J. et al. (1999) Curr. Opin. Cell. Biol. 11:219-225). The phosphorylation of phosphatidylinositol is involved in activation of the protein kinase C signaling pathway. The inositol phospholipids (phosphoinositides) intracellular signaling pathway begins with binding of a signaling molecule to a G-protein linked receptor in the plasma membrane. This leads to the phosphorylation of phosphatidylinositol (PI) residues on the inner side of the plasma

membrane by inositol kinases, thus converting PI residues to the biphosphate state (PIP₂). PIP₂ is then cleaved into inositol triphosphate (IP₃) and diacylglycerol. These two products act as mediators for separate signaling pathways. Cellular responses that are mediated by these pathways are glycogen breakdown in the liver in response to vasopressin, smooth muscle contraction in response to acetylcholine, and thrombin-induced platelet aggregation.

PI 3-kinase (PI3K), which phosphorylates the D3 position of PI and its derivatives, has a central role in growth factor signal cascades involved in cell growth, differentiation, and metabolism. PI3K is a heterodimer consisting of an adapter subunit and a catalytic subunit. The adapter subunit acts as a scaffolding protein, interacting with specific tyrosine-phosphorylated proteins, lipid moieties, and other cytosolic factors. When the adapter subunit binds tyrosine phosphorylated targets, such as the insulin responsive substrate (IRS)-1, the catalytic subunit is activated and converts PI (4,5) biphosphate (PIP₂) to PI (3,4,5) P₃ (PIP₃). PIP₃ then activates a number of other proteins, including PKA, protein kinase B (PKB), protein kinase C (PKC), glycogen synthase kinase (GSK)-3, and p70 ribosomal s6 kinase. PI3K also interacts directly with the cytoskeletal organizing proteins, Rac, rho, and cdc42 (Shepherd, P.R., et al. (1998) Biochem. J. 333:471-490). Animal models for diabetes, such as *obese* and *fat* mice, have altered PI3K adapter subunit levels. Specific mutations in the adapter subunit have also been found in an insulin-resistant Danish population, suggesting a role for PI3K in type-2 diabetes (Shepard, *supra*).

PKC is also activated by diacylglycerol (DAG). Phorbol esters (PE) are analogs of DAG and tumor promoters that cause a variety of physiological changes when administered to cells and tissues. PE and DAG bind to the N-terminal region of PKC. This region contains one or more copies of a cysteine-rich domain about 50 amino-acid residues long and essential for DAG/PE-binding. Diacylglycerol kinase (DGK), the enzyme that converts DAG into phosphatidate, contains two copies of the DAG/PE-binding domain in its N-terminal section (Azzi, A. et al. (1992) Eur. J. Biochem. 208:547-557).

An example of lipid kinase phosphorylation activity is the phosphorylation of D-erythro-sphingosine to the sphingolipid metabolite, sphingosine-1-phosphate (SPP). SPP has emerged as a novel lipid second-messenger with both extracellular and intracellular actions (Kohama, T. et al. (1998) J. Biol. Chem. 273:23722-23728). Extracellularly, SPP is a ligand for the G-protein coupled receptor EDG-1 (endothelial-derived, G-protein coupled receptor). Intracellularly, SPP regulates cell growth, survival, motility, and cytoskeletal changes. SPP levels are regulated by sphingosine kinases that specifically phosphorylate D-erythro-sphingosine to SPP. The importance of sphingosine kinase in cell signaling is indicated by the fact that various stimuli, including

platelet-derived growth factor (PDGF), nerve growth factor, and activation of protein kinase C, increase cellular levels of SPP by activation of sphingosine kinase, and the fact that competitive inhibitors of the enzyme selectively inhibit cell proliferation induced by PDGF (Kohama et al. supra).

Purine Nucleotide Kinases

5 The purine nucleotide kinases, adenylate kinase (ATP:AMP phosphotransferase, or AdK) and guanylate kinase (ATP:GMP phosphotransferase, or GuK) play a key role in nucleotide metabolism and are crucial to the synthesis and regulation of cellular levels of ATP and GTP, respectively. These two molecules are precursors in DNA and RNA synthesis in growing cells and provide the primary source of biochemical energy in cells (ATP), and signal transduction pathways (GTP). Inhibition of
10 various steps in the synthesis of these two molecules has been the basis of many antiproliferative drugs for cancer and antiviral therapy (Pillwein, K. et al. (1990) Cancer Res. 50:1576-1579).

AdK is found in almost all cell types and is especially abundant in cells having high rates of ATP synthesis and utilization such as skeletal muscle. In these cells AdK is physically associated with mitochondria and myofibrils, the subcellular structures that are involved in energy production and
15 utilization, respectively. Recent studies have demonstrated a major function for AdK in transferring high energy phosphoryls from metabolic processes generating ATP to cellular components consuming ATP (Zelevnikar, R.J. et al. (1995) J. Biol. Chem. 270:7311-7319). Thus AdK may have a pivotal role in maintaining energy production in cells, particularly those having a high rate of growth or metabolism such as cancer cells, and may provide a target for suppression of its activity to treat
20 certain cancers. Alternatively, reduced AdK activity may be a source of various metabolic, muscle-energy disorders that can result in cardiac or respiratory failure and may be treatable by increasing AdK activity.

GuK, in addition to providing a key step in the synthesis of GTP for RNA and DNA synthesis, also fulfills an essential function in signal transduction pathways of cells through the regulation of GDP
25 and GTP. Specifically, GTP binding to membrane associated G proteins mediates the activation of cell receptors, subsequent intracellular activation of adenylyl cyclase, and production of the second messenger, cyclic AMP. GDP binding to G proteins inhibits these processes. GDP and GTP levels also control the activity of certain oncogenic proteins such as p21^{ras} known to be involved in control of cell proliferation and oncogenesis (Bos, J.L. (1989) Cancer Res. 49:4682-4689). High ratios of
30 GTP:GDP caused by suppression of GuK cause activation of p21^{ras} and promote oncogenesis. Increasing GuK activity to increase levels of GDP and reduce the GTP:GDP ratio may provide a therapeutic strategy to reverse oncogenesis.

GuK is an important enzyme in the phosphorylation and activation of certain antiviral drugs

useful in the treatment of herpes virus infections. These drugs include the guanine homologs acyclovir and bucidovir (Miller, W.H. and Miller R.L. (1980) J. Biol. Chem. 255:7204-7207; Stenberg, K. et al. (1986) J. Biol. Chem. 261:2134-2139). Increasing GuK activity in infected cells may provide a therapeutic strategy for augmenting the effectiveness of these drugs and possibly for reducing the necessary dosages of the drugs.

Pyrimidine Kinases

The pyrimidine kinases are deoxycytidine kinase and thymidine kinase 1 and 2. Deoxycytidine kinase is located in the nucleus, and thymidine kinase 1 and 2 are found in the cytosol (Johansson, M. et al. (1997) Proc. Natl. Acad. Sci. U.S.A. 94:11941-11945). Phosphorylation of deoxyribonucleosides by pyrimidine kinases provides an alternative pathway for *de novo* synthesis of DNA precursors. The role of pyrimidine kinases, like purine kinases, in phosphorylation is critical to the activation of several chemotherapeutically important nucleoside analogues (Arner E.S. and Eriksson, S. (1995) Pharmacol. Ther. 67:155-186).

The discovery of new human kinases, and the polynucleotides encoding them, satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of human kinases.

SUMMARY OF THE INVENTION

The invention features purified polypeptides, human kinases, referred to collectively as "PKIN" and individually as "PKIN-1," "PKIN-2," "PKIN-3," "PKIN-4," "PKIN-5," "PKIN-6," "PKIN-7," "PKIN-8," "PKIN-9," "PKIN-10," "PKIN-11," "PKIN-12," "PKIN-13," "PKIN-14," "PKIN-15," "PKIN-16," "PKIN-17," "PKIN-18," "PKIN-19," "PKIN-20," "PKIN-21," and "PKIN-22." In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-22.

The invention further provides an isolated polynucleotide encoding a polypeptide selected from

the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-22. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:23-44.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, c) a biologically active fragment of a polypeptide having an

amino acid sequence selected from the group consisting of SEQ ID NO:1-22, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22.

The invention further provides an isolated polynucleotide selected from the group consisting of

5 a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide

10 comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of

a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least

15 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to

20 said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said

25 target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said

30 target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group
5 consisting of SEQ ID NO:1-22, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-22. The invention additionally
10 provides a method of treating a disease or condition associated with decreased expression of functional PKIN, comprising administering to a patient in need of such treatment the composition.

The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a polypeptide comprising a
15 naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22. The method comprises a) exposing a sample comprising the
20 polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional PKIN, comprising administering to a patient in need of such treatment the composition.

25 Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, c) a biologically active fragment of
30 a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the

invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional PKIN, comprising administering to a patient in need of such treatment the composition.

5 The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, c) a biologically active fragment of a polypeptide
10 having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

15 The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, c) a biologically active fragment of a polypeptide
20 having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the
25 polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

 The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a
30 polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

 The invention further provides a method for assessing toxicity of a test compound, said

method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44, ii) a
5 polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological
10 sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of
15 ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of
20 toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

25 Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability score for the match between each polypeptide and its GenBank homolog is also shown.

Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for
30 analysis of the polypeptides.

Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.

Table 5 shows the representative cDNA library for polynucleotides of the invention.

Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"PKIN" refers to the amino acid sequences of substantially purified PKIN obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of PKIN. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of PKIN either by directly interacting with PKIN or by acting on components of the biological pathway in which PKIN participates.

An "allelic variant" is an alternative form of the gene encoding PKIN. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding PKIN include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as PKIN or a polypeptide with at least one functional characteristic of PKIN. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding PKIN, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding PKIN. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent PKIN. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of PKIN is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence.

Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of PKIN. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small

molecules, or any other compound or composition which modulates the activity of PKIN either by directly interacting with PKIN or by acting on components of the biological pathway in which PKIN participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind PKIN polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "aptamer" refers to a nucleic acid or oligonucleotide molecule that binds to a specific molecular target. Aptamers are derived from an in vitro evolutionary process (e.g., SELEX (Systematic Evolution of Ligands by EXponential Enrichment), described in U.S. Patent No. 5,270,163), which selects for target-specific aptamer sequences from large combinatorial libraries. Aptamer compositions may be double-stranded or single-stranded, and may include deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules. The nucleotide components of an aptamer may have modified sugar groups (e.g., the 2'-OH group of a ribonucleotide may be replaced by 2'-F or 2'-NH₂), which may improve a desired property, e.g., resistance to nucleases or longer lifetime in blood. Aptamers may be conjugated to other molecules, e.g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system. Aptamers may be specifically cross-linked to their cognate ligands, e.g., by photo-activation of a cross-linker. (See, e.g., Brody, E.N. and L. Gold (2000) J. Biotechnol. 74:5-13.)

The term "intramer" refers to an aptamer which is expressed in vivo. For example, a vaccinia virus-based RNA expression system has been used to express specific RNA aptamers at high levels in the cytoplasm of leukocytes (Blind, M. et al. (1999) Proc. Natl Acad. Sci. USA 96:3606-3610).

The term "spiegelmer" refers to an aptamer which includes L-DNA, L-RNA, or other left-

handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on substrates containing right-handed nucleotides.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic PKIN, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding PKIN or fragments of PKIN may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been

assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

5 “Conservative amino acid substitutions” are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

10	Original Residue	Conservative Substitution
	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
	Asp	Asn, Glu
15	Cys	Ala, Ser
	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
	Gly	Ala
	His	Asn, Arg, Gln, Glu
20	Ile	Leu, Val
	Leu	Ile, Val
	Lys	Arg, Gln, Glu
	Met	Leu, Ile
	Phe	His, Met, Leu, Trp, Tyr
25	Ser	Cys, Thr
	Thr	Ser, Val
	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
30	Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

35 A “deletion” refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term “derivative” refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains
40 at least one biological or immunological function of the natural molecule. A derivative polypeptide is

one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

5 "Differential expression" refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.

"Exon shuffling" refers to the recombination of different coding regions (exons). Since an
10 exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.

A "fragment" is a unique portion of PKIN or the polynucleotide encoding PKIN which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up
15 to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For
20 example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

25 A fragment of SEQ ID NO:23-44 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:23-44, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:23-44 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:23-44 from related polynucleotide sequences. The precise length of a fragment of SEQ ID
30 NO:23-44 and the region of SEQ ID NO:23-44 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-22 is encoded by a fragment of SEQ ID NO:23-44. A fragment of SEQ ID NO:1-22 comprises a region of unique amino acid sequence that specifically

identifies SEQ ID NO:1-22. For example, a fragment of SEQ ID NO:1-22 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-22. The precise length of a fragment of SEQ ID NO:1-22 and the region of SEQ ID NO:1-22 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A "full length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A "full length" polynucleotide sequence encodes a "full length" polypeptide sequence.

"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The

"BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

5 *Matrix: BLOSUM62*
 Reward for match: 1
 Penalty for mismatch: -2
 Open Gap: 5 and Extension Gap: 2 penalties
 Gap x drop-off: 50
 10 *Expect: 10*
 Word Size: 11
 Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example,
 15 over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

20 Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to
 25 the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

30 Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap

penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise
5 comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalties

10 *Gap x drop-off: 50*

Expect: 10

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence,
15 for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be
20 used to describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

The term "humanized antibody" refers to an antibody molecule in which the amino acid
25 sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity.
30 Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive

conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 5 1% (w/v) SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of 10 the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention 15 include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as 20 formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

25 The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate 30 to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune

disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of PKIN which is
5 capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of PKIN which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

10 The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of PKIN. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of PKIN.

15 The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a
20 functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which
25 comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an PKIN may involve lipidation, glycosylation,
30 phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of PKIN.

"Probe" refers to nucleic acid sequences encoding PKIN, their complements, or fragments

thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target

- 5 polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also
10 be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for
15 example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that
20 purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000
25 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer
30 selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may

also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned
5 nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are
10 not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques
15 such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a
20 vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription,
25 translation, or RNA stability.

"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

30 An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The term "sample" is used in its broadest sense. A sample suspected of containing PKIN, nucleic acids encoding PKIN, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

5 The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the
10 epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

 The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with
15 which they are naturally associated.

 A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

 "Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers,
20 microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

 A "transcript image" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

 "Transformation" describes a process by which exogenous DNA is introduced into a recipient
25 cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed
30 cells" includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

 A "transgenic organism," as used herein, is any organism, including but not limited to animals

and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or *in vitro* fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), *supra*.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at

least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.

5 THE INVENTION

The invention is based on the discovery of new human human kinases (PKIN), the polynucleotides encoding PKIN, and the use of these compositions for the diagnosis, treatment, or prevention of cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders.

10 Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is
15 denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte
20 polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (Genbank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 5 shows the annotation of the GenBank homolog along with relevant citations where applicable, all of which are expressly incorporated by reference herein.

25 Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS
30 program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are human kinases.

For example, SEQ ID NO:1 is 91% identical to human casein kinase I-alpha (GenBank ID g852055) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The
5 BLAST probability score is $2.9e-167$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:1 also contains a eukaryotic protein kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from
10 BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:1 is a protein kinase.

For example, SEQ ID NO:10 is 91% identical to Mus musculus FYVE finger-containing phosphoinositide kinase (GenBank ID g4200446) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of
15 obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:10 also contains a phosphatidyl inositol 4-phosphate 5-kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from PRODOM analysis provides further corroborative evidence that SEQ ID NO:10 is a phosphoinositide kinase.

For example, SEQ ID NO:12 is 71% identical to human serine/threonine protein kinase
20 (GenBank ID g7160989) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $1.7e-148$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:12 also contains a eukaryotic protein kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.)
25 Data from BLIMPS and MOTIFS analyses provide further corroborative evidence that SEQ ID NO:12 is protein kinase.

For example, SEQ ID NO:13 is 86% identical to murine pantothenate kinase 1 beta (GenBank ID g6690020) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.)
30 The BLAST probability score is $1.6e-129$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. Pantothenate kinase (PanK) is proposed to be the master regulator of CoA biosynthesis in mammalian cells, by controlling flux through the CoA biosynthetic pathway. Changes in the level of tissue PanK activity is reflected by the concurrent changes in the levels of CoA as seen in various metabolic states. Alterations in CoA levels and PanK activity are

seen during starvation/feeding, pathological states such as diabetes and by treatment with hypolipidemic drugs (Rock, C.O. et al., (2000) J. Biol. Chem. 275:1377-1383.)

For example, SEQ ID NO:16 is 68% identical to Mus musculus Nck-interacting kinase-like embryo specific kinase (GenBank ID g6472874) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:16 also contains a eukaryotic protein kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:16 is a protein kinase.

For example, SEQ ID NO:19 is 99% identical to human RET tyrosine kinase receptor (GenBank ID g5419753) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:19 also contains a eukaryotic protein kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:19 is a tyrosine kinase.

For example, SEQ ID NO:22 is 33% identical to *Gallus gallus* smooth muscle myosin light chain kinase precursor (GenBank ID g212661) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 1.2 e-60, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:22 also contains two eukaryotic protein kinase domains as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:22 is a protein kinase.

SEQ ID NO:2-9, SEQ ID NO:11, SEQ ID NO:14-15, SEQ ID NO:17-18, and SEQ ID NO:20-21 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ ID NO:1-22 are described in Table 7.

As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Columns 1 and 2 list the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte polynucleotide

consensus sequence number (Incyte Polynucleotide ID) for each polynucleotide of the invention. Column 3 shows the length of each polynucleotide sequence in basepairs. Column 4 lists fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:23-44 or that distinguish between SEQ ID NO:23-44 and
 5 related polynucleotide sequences. Column 5 shows identification numbers corresponding to cDNA sequences, coding sequences (exons) predicted from genomic DNA, and/or sequence assemblages comprised of both cDNA and genomic DNA. These sequences were used to assemble the full length polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the nucleotide start (5') and stop (3') positions of the cDNA and/or genomic sequences in column 5 relative to their respective
 10 full length sequences.

The identification numbers in Column 5 of Table 4 may refer specifically, for example, to Incyte cDNAs along with their corresponding cDNA libraries. For example, 183812R7 is the identification number of an Incyte cDNA sequence, and CARDNOT01 is the cDNA library from which it is derived. Incyte cDNAs for which cDNA libraries are not indicated were derived from
 15 pooled cDNA libraries (e.g., 71583296V1). Alternatively, the identification numbers in column 5 may refer to GenBank cDNAs or ESTs which contributed to the assembly of the full length polynucleotide sequences. In addition, the identification numbers in column 5 may identify sequences derived from the ENSEMBL (The Sanger Centre, Cambridge, UK) database (*i.e.*, those sequences including the designation "ENST"). Alternatively, the identification numbers in column 5 may be derived from the
 20 NCBI RefSeq Nucleotide Sequence Records Database (*i.e.*, those sequences including the designation "NM" or "NT") or the NCBI RefSeq Protein Sequence Records (*i.e.*, those sequences including the designation "NP"). Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. For example, FL_XXXXXX_N₁N₂YYYY_N₃N₄ represents a "stitched" sequence in
 25 which XXXXXX is the identification number of the cluster of sequences to which the algorithm was applied, and YYYY is the number of the prediction generated by the algorithm, and N_{1,2,3,...}, if present, represent specific exons that may have been manually edited during analysis (See Example V). Alternatively, the identification numbers in column 5 may refer to assemblages of exons brought together by an "exon-stretching" algorithm. For example, FLXXXXXX_gAAAAA_gBBBBB_1_N is the
 30 identification number of a "stretched" sequence, with XXXXXX being the Incyte project identification number, gAAAAA being the GenBank identification number of the human genomic sequence to which the "exon-stretching" algorithm was applied, gBBBBB being the GenBank identification number or NCBI RefSeq identification number of the nearest GenBank protein homolog, and N referring to

specific exons (See Example V). In instances where a RefSeq sequence was used as a protein homolog for the "exon-stretching" algorithm, a RefSeq identifier (denoted by "NM," "NP," or "NT") may be used in place of the GenBank identifier (*i.e.*, gBBBBB).

Alternatively, a prefix identifies component sequences that were hand-edited, predicted from genomic DNA sequences, or derived from a combination of sequence analysis methods. The following Table lists examples of component sequence prefixes and corresponding sequence analysis methods associated with the prefixes (see Example IV and Example V).

Prefix	Type of analysis and/or examples of programs
GNN, GFG, ENST	Exon prediction from genomic sequences using, for example, GENSCAN (Stanford University, CA, USA) or FGENES (Computer Genomics Group, The Sanger Centre, Cambridge, UK).
GBI	Hand-edited analysis of genomic sequences.
FL	Stitched or stretched genomic sequences (see Example V).
INCY	Full length transcript and exon prediction from mapping of EST sequences to the genome. Genomic location and EST composition data are combined to predict the exons and resulting transcript.

In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in column 5 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

The invention also encompasses PKIN variants. A preferred PKIN variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the PKIN amino acid sequence, and which contains at least one functional or structural characteristic of PKIN.

The invention also encompasses polynucleotides which encode PKIN. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:23-44, which encodes PKIN. The polynucleotide sequences of SEQ ID NO:23-44, as presented in the Sequence Listing, embrace the equivalent RNA sequences,

wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses a variant of a polynucleotide sequence encoding PKIN. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least
5 about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding PKIN. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:23-44 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ
10 ID NO:23-44. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of PKIN.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding PKIN, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus,
15 the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring PKIN, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode PKIN and its variants are generally capable of
20 hybridizing to the nucleotide sequence of the naturally occurring PKIN under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding PKIN or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which
25 particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding PKIN and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode PKIN and
30 PKIN derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding PKIN or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:23-44 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding PKIN may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) *PCR Methods Applic.* 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) *Nucleic Acids Res.* 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) *PCR Methods Applic.* 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) *Nucleic Acids Res.* 19:3055-3060).

Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode PKIN may be cloned in recombinant DNA molecules that direct expression of PKIN, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express PKIN.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter PKIN-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent No. 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve
5 the biological properties of PKIN, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and
10 selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple
15 naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding PKIN may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, PKIN itself or a fragment thereof may be synthesized using chemical methods. For example, peptide
20 synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of PKIN, or any part thereof, may be altered during direct synthesis and/or combined with sequences
25 from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing.
30 (See, e.g., Creighton, supra, pp. 28-53.)

In order to express a biologically active PKIN, the nucleotide sequences encoding PKIN or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in

a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding PKIN. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding PKIN. Such signals
5 include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding PKIN and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided
10 by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression
15 vectors containing sequences encoding PKIN and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

20 A variety of expression vector/host systems may be utilized to contain and express sequences encoding PKIN. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or
25 tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Hecke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509; Engelhard, E.K. et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:3224-3227; Sandig, V. et al. (1996) *Hum. Gene Ther.* 7:1937-1945; Takamatsu, N. (1987) *EMBO J.* 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New
30 York NY, pp. 191-196; Logan, J. and T. Shenk (1984) *Proc. Natl. Acad. Sci. USA* 81:3655-3659; and Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola,

M. et al. (1998) *Cancer Gen. Ther.* 5(6):350-356; Yu, M. et al. (1993) *Proc. Natl. Acad. Sci. USA* 90(13):6340-6344; Buller, R.M. et al. (1985) *Nature* 317(6040):813-815; McGregor, D.P. et al. (1994) *Mol. Immunol.* 31(3):219-226; and Verma, I.M. and N. Somia (1997) *Nature* 389:239-242.) The invention is not limited by the host cell employed.

5 In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding PKIN. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding PKIN can be achieved using a multifunctional *E. coli* vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1
10 plasmid (Life Technologies). Ligation of sequences encoding PKIN into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for *in vitro* transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509.) When large quantities of PKIN are needed, e.g. for the production of
15 antibodies, vectors which direct high level expression of PKIN may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of PKIN. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast *Saccharomyces cerevisiae* or *Pichia pastoris*. In addition, such
20 vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, *supra*; Bitter, G.A. et al. (1987) *Methods Enzymol.* 153:516-544; and Scorer, C.A. et al. (1994) *Bio/Technology* 12:181-184.)

Plant systems may also be used for expression of PKIN. Transcription of sequences
25 encoding PKIN may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105.) These
30 constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., *The McGraw Hill Yearbook of Science and Technology* (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases

where an adenovirus is used as an expression vector, sequences encoding PKIN may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses PKIN in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of PKIN in cell lines is preferred. For example, sequences encoding PKIN can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* and *apr* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate

luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) *Methods Mol. Biol.* 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding PKIN is inserted within a marker gene sequence, transformed cells containing sequences encoding PKIN can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding PKIN under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding PKIN and that express PKIN may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of PKIN using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on PKIN is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding PKIN include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding PKIN, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety

of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

5 Host cells transformed with nucleotide sequences encoding PKIN may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode PKIN may be designed to contain signal sequences which direct
10 secretion of PKIN through a prokaryotic or eukaryotic cell membrane.

 In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the
15 protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

20 In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding PKIN may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric PKIN protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of PKIN activity. Heterologous protein and
25 peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins,
30 respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the PKIN encoding sequence and the heterologous protein sequence, so that PKIN

may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled PKIN may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ³⁵S-methionine.

PKIN of the present invention or fragments thereof may be used to screen for compounds that specifically bind to PKIN. At least one and up to a plurality of test compounds may be screened for specific binding to PKIN. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of PKIN, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which PKIN binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express PKIN, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing PKIN or cell membrane fractions which contain PKIN are then contacted with a test compound and binding, stimulation, or inhibition of activity of either PKIN or the compound is analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with PKIN, either in solution or affixed to a solid support, and detecting the binding of PKIN to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

PKIN of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of PKIN. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for PKIN

activity, wherein PKIN is combined with at least one test compound, and the activity of PKIN in the presence of a test compound is compared with the activity of PKIN in the absence of the test compound. A change in the activity of PKIN in the presence of the test compound is indicative of a compound that modulates the activity of PKIN. Alternatively, a test compound is combined with an in vitro or cell-free system comprising PKIN under conditions suitable for PKIN activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of PKIN may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

In another embodiment, polynucleotides encoding PKIN or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent No. 5,175,383 and U.S. Patent No. 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

Polynucleotides encoding PKIN may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

Polynucleotides encoding PKIN can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding PKIN is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with

potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress PKIN, e.g., by secreting PKIN in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) *Biotechnol. Annu. Rev.* 4:55-74).

THERAPEUTICS

- 5 Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of PKIN and human kinases. In addition, the expression of PKIN is closely associated with brain, breast tumor, cardiovascular, digestive, fallopian tube tumor, fetal stomach, nervous, ovarian tumor, pancreatic tumor, peritoneal tumor, pituitary gland, placental, prostate tumor, neural, spinal cord, and testicular tissues, and with umbilical cord blood dendritic cells. Therefore, PKIN appears to play a
- 10 role in cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders. In the treatment of disorders associated with increased PKIN expression or activity, it is desirable to decrease the expression or activity of PKIN. In the treatment of disorders associated with decreased PKIN expression or activity, it is desirable to increase the expression or activity of PKIN.
- 15 Therefore, in one embodiment, PKIN or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PKIN. Examples of such disorders include, but are not limited to, a cancer, such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia,
- 20 gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus, leukemias such as multiple myeloma, and lymphomas such as Hodgkin's disease; an immune disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune
- 25 thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis,
- 30 myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral,

- bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a growth and developmental disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including
- 5 adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus, renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy,
- 10 gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and
- 15 sensorineural hearing loss; a cardiovascular disease, such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, and complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease,
- 20 degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation, congenital lung
- 25 anomalies, atelectasis, pulmonary congestion and edema, pulmonary embolism, pulmonary hemorrhage, pulmonary infarction, pulmonary hypertension, vascular sclerosis, obstructive pulmonary disease, restrictive pulmonary disease, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, bronchial asthma, bronchiectasis, bacterial pneumonia, viral and mycoplasmal pneumonia, lung abscess, pulmonary tuberculosis, diffuse interstitial diseases, pneumoconioses, sarcoidosis, idiopathic
- 30 pulmonary fibrosis, desquamative interstitial pneumonitis, hypersensitivity pneumonitis, pulmonary eosinophilia bronchiolitis obliterans-organizing pneumonia, diffuse pulmonary hemorrhage syndromes, Goodpasture's syndromes, idiopathic pulmonary hemosiderosis, pulmonary involvement in collagen-vascular disorders, pulmonary alveolar proteinosis, lung tumors, inflammatory and

noninflammatory pleural effusions, pneumothorax, pleural tumors, drug-induced lung disease, radiation-induced lung disease, and complications of lung transplantation; and a lipid disorder such as fatty liver, cholestasis, primary biliary cirrhosis, carnitine deficiency, carnitine palmitoyltransferase deficiency, myoadenylate deaminase deficiency, hypertriglyceridemia, lipid storage disorders such Fabry's
5 disease, Gaucher's disease, Niemann-Pick's disease, metachromatic leukodystrophy, adrenoleukodystrophy, GM₂ gangliosidosis, and ceroid lipofuscinosis, abetalipoproteinemia, Tangier disease, hyperlipoproteinemia, diabetes mellitus, lipodystrophy, lipomatosis, acute panniculitis, disseminated fat necrosis, adiposis dolorosa, lipoid adrenal hyperplasia, minimal change disease, lipomas, atherosclerosis, hypercholesterolemia, hypercholesterolemia with hypertriglyceridemia,
10 primary hypoalphalipoproteinemia, hypothyroidism, renal disease, liver disease, lecithin:cholesterol acyltransferase deficiency, cerebrotendinous xanthomatosis, sitosterolemia, hypocholesterolemia, Tay-Sachs disease, Sandhoff's disease, hyperlipidemia, hyperlipemia, lipid myopathies, and obesity.

In another embodiment, a vector capable of expressing PKIN or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased
15 expression or activity of PKIN including, but not limited to, those described above.

In a further embodiment, a composition comprising a substantially purified PKIN in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PKIN including, but not limited to, those provided above.

20 In still another embodiment, an agonist which modulates the activity of PKIN may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PKIN including, but not limited to, those listed above.

In a further embodiment, an antagonist of PKIN may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of PKIN. Examples of such
25 disorders include, but are not limited to, those cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders described above. In one aspect, an antibody which specifically binds PKIN may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express PKIN.

30 In an additional embodiment, a vector expressing the complement of the polynucleotide encoding PKIN may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of PKIN including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary

sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of PKIN may be produced using methods which are generally known in the art. In particular, purified PKIN may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind PKIN. Antibodies to PKIN may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with PKIN or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to PKIN have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of PKIN amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to PKIN may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the

splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce PKIN-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for PKIN may also be generated. For example, such fragments include, but are not limited to, $F(ab)_2$ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the $F(ab)_2$ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between PKIN and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering PKIN epitopes is generally used, but a competitive binding assay may also be employed (Pound, *supra*).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for PKIN. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of PKIN-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple PKIN epitopes, represents the average affinity, or avidity, of the antibodies for PKIN. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular PKIN epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a

ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the PKIN-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_d ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of PKIN, preferably in active form, from the antibody

5 (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a

10 polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of PKIN-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

15 In another embodiment of the invention, the polynucleotides encoding PKIN, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding PKIN. Such technology is well known in the art, and antisense oligonucleotides or larger fragments

20 can be designed from various locations along the coding or control regions of sequences encoding PKIN. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence

25 complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) *J. Allergy Clin. Immunol.* 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) *Blood* 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) *Pharmacol. Ther.* 63(3):323-347.) Other

30 gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R.J. et al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M.C. et al. (1997) *Nucleic Acids Res.* 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding PKIN may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) *Science* 288:669-672), severe combined

5 immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) *Science* 270:475-480; Bordignon, C. et al. (1995) *Science* 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) *Cell* 75:207-216; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:643-666; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:667-703), thalassemias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal,

10 R.G. (1995) *Science* 270:404-410; Verma, I.M. and N. Somia (1997) *Nature* 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) *Nature* 335:395-396; Poeschla, E. et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:11395-11399),

15 hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in PKIN expression or regulation causes disease, the expression of PKIN from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

20 In a further embodiment of the invention, diseases or disorders caused by deficiencies in PKIN are treated by constructing mammalian expression vectors encoding PKIN and introducing these vectors by mechanical means into PKIN-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and

25 (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) *Annu. Rev. Biochem.* 62:191-217; Ivics, Z. (1997) *Cell* 91:501-510; Boulay, J-L. and H. Récipon (1998) *Curr. Opin. Biotechnol.* 9:445-450).

Expression vectors that may be effective for the expression of PKIN include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX, PCR2-TOPOTA vectors

30 (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). PKIN may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β -actin genes), (ii) an inducible promoter

(e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) *Proc. Natl. Acad. Sci. USA* 89:5547-5551; Gossen, M. et al. (1995) *Science* 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) *Curr. Opin. Biotechnol.* 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the
5 FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding PKIN from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver
10 polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) *Virology* 52:456-467), or by electroporation (Neumann, E. et al. (1982) *EMBO J.* 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

15 In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to PKIN expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding PKIN under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences
20 required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) *Proc. Natl. Acad. Sci. USA* 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al.
25 (1987) *J. Virol.* 61:1647-1650; Bender, M.A. et al. (1987) *J. Virol.* 61:1639-1646; Adam, M.A. and A.D. Miller (1988) *J. Virol.* 62:3802-3806; Dull, T. et al. (1998) *J. Virol.* 72:8463-8471; Zufferey, R. et al. (1998) *J. Virol.* 72:9873-9880). U.S. Patent No. 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference.
30 Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) *J. Virol.* 71:7020-7029; Bauer, G. et al. (1997) *Blood* 89:2259-2267; Bonyhadi, M.L. (1997) *J. Virol.* 71:4707-4716; Ranga, U. et al. (1998)

Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding PKIN to cells which have one or more genetic abnormalities with respect to the expression of PKIN. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent No. 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I.M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding PKIN to target cells which have one or more genetic abnormalities with respect to the expression of PKIN. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing PKIN to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res. 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent No. 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent No. 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) J. Virol. 73:519-532 and Xu, H. et al. (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding PKIN to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based

on the SFV genome (Garoff, H. and K.-J. Li (1998) *Curr. Opin. Biotechnol.* 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for PKIN into the alphavirus genome in place of the capsid-coding region results in the production of a large number of PKIN-coding RNAs and the synthesis of high levels of PKIN in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) *Virology* 228:74-83). The wide host range of alphaviruses will allow the introduction of PKIN into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding PKIN.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for

secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared
5 by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding PKIN. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs
10 that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages
15 within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

An additional embodiment of the invention encompasses a method for screening for a
20 compound which is effective in altering expression of a polynucleotide encoding PKIN. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective
25 compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased PKIN expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding PKIN may be therapeutically useful, and in the treatment of disorders associated with decreased PKIN expression or activity, a compound which specifically promotes expression of the
30 polynucleotide encoding PKIN may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in

altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a

5 polynucleotide encoding PKIN is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding PKIN are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the

10 polynucleotide encoding PKIN. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide

15 can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified

20 oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient.

25 Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and

30 monkeys.

An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various

formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of PKIN, antibodies to PKIN, and mimetics, agonists, antagonists, or inhibitors of PKIN.

The compositions utilized in this invention may be administered by any number of routes
5 including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the
10 case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without
15 needle injection, and obviates the need for potentially toxic penetration enhancers.

Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of compositions may be prepared for direct intracellular delivery of
20 macromolecules comprising PKIN or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, PKIN or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et
25 al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for
30 administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example PKIN or fragments thereof, antibodies of PKIN, and agonists, antagonists or inhibitors of PKIN, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by

standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Compositions which exhibit large
5 therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

10 The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response
15 to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μg to 100,000 μg , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art.

20 Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind PKIN may be used for the
25 diagnosis of disorders characterized by expression of PKIN, or in assays to monitor patients being treated with PKIN or agonists, antagonists, or inhibitors of PKIN. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for PKIN include methods which utilize the antibody and a label to detect PKIN in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and
30 may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring PKIN, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of PKIN expression. Normal

or standard values for PKIN expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to PKIN under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of PKIN expressed in subject, 5 control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding PKIN may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect 10 and quantify gene expression in biopsied tissues in which expression of PKIN may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of PKIN, and to monitor regulation of PKIN levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding PKIN or closely related molecules may be used to 15 identify nucleic acid sequences which encode PKIN. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding PKIN, allelic variants, or related sequences.

20 Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the PKIN encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:23-44 or from genomic sequences including promoters, enhancers, and introns of the PKIN gene.

Means for producing specific hybridization probes for DNAs encoding PKIN include the 25 cloning of polynucleotide sequences encoding PKIN or PKIN derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, 30 such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding PKIN may be used for the diagnosis of disorders associated with expression of PKIN. Examples of such disorders include, but are not limited to, a cancer, such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma,

- teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus, leukemias such as multiple myeloma and lymphomas such as Hodgkin's disease; an immune disorder,
- 5 such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins,
- 10 erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis,
- 15 thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a growth and developmental disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and
- 20 cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus, renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker
- 25 muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, anencephaly,
- 30 craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; a cardiovascular disease, such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, and complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary

artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic

5 endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation, congenital lung anomalies, atelectasis, pulmonary congestion and edema, pulmonary embolism, pulmonary hemorrhage, pulmonary infarction, pulmonary hypertension, vascular sclerosis, obstructive pulmonary disease, restrictive pulmonary disease, chronic obstructive pulmonary

10 disease, emphysema, chronic bronchitis, bronchial asthma, bronchiectasis, bacterial pneumonia, viral and mycoplasmal pneumonia, lung abscess, pulmonary tuberculosis, diffuse interstitial diseases, pneumoconioses, sarcoidosis, idiopathic pulmonary fibrosis, desquamative interstitial pneumonitis, hypersensitivity pneumonitis, pulmonary eosinophilia bronchiolitis obliterans-organizing pneumonia, diffuse pulmonary hemorrhage syndromes, Goodpasture's syndromes, idiopathic pulmonary

15 hemosiderosis, pulmonary involvement in collagen-vascular disorders, pulmonary alveolar proteinosis, lung tumors, inflammatory and noninflammatory pleural effusions, pneumothorax, pleural tumors, drug-induced lung disease, radiation-induced lung disease, and complications of lung transplantation; and a lipid disorder such as fatty liver, cholestasis, primary biliary cirrhosis, carnitine deficiency, carnitine palmitoyltransferase deficiency, myoadenylate deaminase deficiency, hypertriglyceridemia, lipid

20 storage disorders such Fabry's disease, Gaucher's disease, Niemann-Pick's disease, metachromatic leukodystrophy, adrenoleukodystrophy, GM₂ gangliosidosis, and ceroid lipofuscinosis, abetalipoproteinemia, Tangier disease, hyperlipoproteinemia, diabetes mellitus, lipodystrophy, lipomatosis, acute panniculitis, disseminated fat necrosis, adiposis dolorosa, lipoid adrenal hyperplasia, minimal change disease, lipomas, atherosclerosis, hypercholesterolemia, hypercholesterolemia with

25 hypertriglyceridemia, primary hypoalphalipoproteinemia, hypothyroidism, renal disease, liver disease, lecithin:cholesterol acyltransferase deficiency, cerebrotendinous xanthomatosis, sitosterolemia, hypocholesterolemia, Tay-Sachs disease, Sandhoff's disease, hyperlipidemia, hyperlipemia, lipid myopathies, and obesity. The polynucleotide sequences encoding PKIN may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick,

30 pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered PKIN expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding PKIN may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide

sequences encoding PKIN may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding PKIN in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of PKIN, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding PKIN, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding PKIN may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding PKIN, or a fragment of a polynucleotide complementary to the polynucleotide encoding PKIN, and will be employed under optimized conditions for identification of a specific gene or

condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding PKIN may be used to detect single nucleotide polymorphisms (SNPs). SNPs are
5 substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding PKIN are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal
10 tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSSCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed *in silico* SNP
15 (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the
20 high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

Methods which may also be used to quantify the expression of PKIN include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) *J. Immunol. Methods* 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 212:229-236.) The speed of quantitation of multiple samples may be
25 accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray
30 can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor

progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, PKIN, fragments of PKIN, or antibodies specific for PKIN may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

10 A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent No. 15 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention 25 may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson (2000) 30 Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression

provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a
5 toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed
10 gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be
15 quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global
20 pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is
25 achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, *supra*). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot
30 is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for

example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein
5 identification.

A proteomic profile may also be generated using antibodies specific for PKIN to quantify the levels of PKIN expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) *Anal. Biochem.* 270:103-
10 111; Mendoze, L.G. et al. (1999) *Biotechniques* 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and
15 should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) *Electrophoresis* 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid
20 degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample.
25 A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological
30 sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the

two samples is indicative of a toxic response to the test compound in the treated sample.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

In another embodiment of the invention, nucleic acid sequences encoding PKIN may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding PKIN on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery

techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant
5 invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, PKIN, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a
10 solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between PKIN and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are
15 synthesized on a solid substrate. The test compounds are reacted with PKIN, or fragments thereof, and washed. Bound PKIN is then detected by methods well known in the art. Purified PKIN can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

20 In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding PKIN specifically compete with a test compound for binding PKIN. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PKIN.

In additional embodiments, the nucleotide sequences which encode PKIN may be used in any
25 molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore,
30 to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific

embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. No. 60/242,410, U.S. Ser. No. 60/244,068, U.S. Ser. No. 60/245,708, U.S. Ser. No. 60/247,672, U.S. Ser. No. 60/249,565, U.S. Ser. No. 60/252,730, and U.S. Ser. No. 60/250,807, are hereby expressly incorporated by reference.

EXAMPLES

I. Construction of cDNA Libraries

10 Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA) and shown in Table 4, column 5. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl
15 cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles
20 (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the
25 UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, *supra*, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-
30 1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSORT1 plasmid (Life Technologies), PCDNA2.1 plasmid

- (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA plasmid (Invitrogen), PCMV-ICIS plasmid (Stratagene), pIGEN (Incyte Genomics, Palo Alto CA), or pINCY (Incyte Genomics), or derivatives thereof. Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or
- 5 ElectromAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

- Plasmids obtained as described in Example I were recovered from host cells by *in vivo* excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Miniprep DNA purification system (Promega); an
- 10 AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

- Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a
- 15 high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

20 III. Sequencing and Analysis

- Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the
- 25 MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the
- 30 ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, *supra*, unit 7.7). Some of the cDNA sequences were selected for extension using the

techniques disclosed in Example VIII.

- The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The
- 5 Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S.R. (1996) *Curr. Opin. Struct. Biol.* 6:361-365.)
- 10 The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and
- 15 Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein
- 20 databases (genpept), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as
- 25 incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second

30 column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the

identity between two sequences).

The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:23-44. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 4.

IV. Identification and Editing of Coding Sequences from Genomic DNA

Putative human kinases were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) *J. Mol. Biol.* 268:78-94, and Burge, C. and S. Karlin (1998) *Curr. Opin. Struct. Biol.* 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode human kinases, the encoded polypeptides were analyzed by querying against PFAM models for human kinases. Potential human kinases were also identified by homology to Incyte cDNA sequences that had been annotated as human kinases. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

V. Assembly of Genomic Sequence Data with cDNA Sequence Data

"Stitched" Sequences

Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm

based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants.

Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpi public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

"Stretched" Sequences

Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

VI. Chromosomal Mapping of PKIN Encoding Polynucleotides

The sequences which were used to assemble SEQ ID NO:23-44 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:23-44 were assembled into clusters of contiguous and overlapping sequences using

assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO., to that map location.

Map locations are represented by ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (<http://www.ncbi.nlm.nih.gov/genemap/>), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

In this manner, SEQ ID NO:29 was mapped to chromosome 1 within the interval from 199.20 to 203.00 centiMorgans, to chromosome 13 within the interval from 105.20 centiMorgans to the q terminus, and to chromosome 6 within the interval from 59.60 to 72.20 centiMorgans. More than one map location is reported for SEQ ID NO:29, indicating that sequences having different map locations were assembled into a single cluster. This situation occurs, for example, when sequences having strong similarity, but not complete identity, are assembled into a single cluster.

VII. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, *supra*, ch. 7; Ausubel (1995) *supra*, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum} \{ \text{length}(\text{Seq. 1}), \text{length}(\text{Seq. 2}) \}}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

Alternatively, polynucleotide sequences encoding PKIN are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding PKIN. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

VIII. Extension of PKIN Encoding Polynucleotides

Full length polynucleotide sequences were also produced by extension of an appropriate

fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector

(Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

5 The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 10 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

 In like manner, full length polynucleotide sequences are verified using the above procedure or 15 are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Labeling and Use of Individual Hybridization Probes

 Hybridization probes derived from SEQ ID NO:23-44 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base 20 pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 µCi of [γ -³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a 25 SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

 The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon 30 membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and

compared.

X. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra.), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999), supra.). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

25 Tissue or Cell Sample Preparation

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/ μ l oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/ μ l RNase inhibitor, 500 μ M dATP, 500 μ M dGTP, 500 μ M dTTP, 40 μ M dCTP, 40 μ M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)⁺ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr, each reaction sample (one

with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 μ l 5X SSC/0.2% SDS.

Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μ g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in U.S. Patent No. 5,807,522, incorporated herein by reference. 1 μ l of the array element DNA, at an average concentration of 100 ng/ μ l, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C followed by washes in 0.2% SDS and distilled water as before.

Hybridization

Hybridization reactions contain 9 μ l of sample mixture consisting of 0.2 μ g each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly

larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μ l of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

5 Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide
10 containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477,
15 Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore,
20 are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC
30 computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission

spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used
5 for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

XI. Complementary Polynucleotides

Sequences complementary to the PKIN-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring PKIN. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with
10 smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of PKIN. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the PKIN-encoding transcript.

15 XII. Expression of PKIN

Expression and purification of PKIN is achieved using bacterial or virus-based expression systems. For expression of PKIN in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid
20 promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express PKIN upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of PKIN in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly
25 known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding PKIN by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the
30 latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, PKIN is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step,

affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from PKIN at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified PKIN obtained by these methods can be used directly in the assays shown in Examples XVI, XVII, and XVIII, where applicable.

XIII. Functional Assays

PKIN function is assessed by expressing the sequences encoding PKIN at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of PKIN on gene expression can be assessed using highly purified populations

of cells transfected with sequences encoding PKIN and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success
5 NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding PKIN and other genes of interest can be analyzed by northern analysis or microarray techniques.

XIV. Production of PKIN Specific Antibodies

PKIN substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g.,
10 Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the PKIN amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for
15 selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, *supra*, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using Fmoc chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to
20 increase immunogenicity. (See, e.g., Ausubel, 1995, *supra*.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-PKIN activity by, for example, binding the peptide or PKIN to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

25 XV. Purification of Naturally Occurring PKIN Using Specific Antibodies

Naturally occurring or recombinant PKIN is substantially purified by immunoaffinity chromatography using antibodies specific for PKIN. An immunoaffinity column is constructed by covalently coupling anti-PKIN antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is
30 blocked and washed according to the manufacturer's instructions.

Media containing PKIN are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PKIN (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt

antibody/PKIN binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and PKIN is collected.

XVI. Identification of Molecules Which Interact with PKIN

PKIN, or biologically active fragments thereof, are labeled with ^{125}I Bolton-Hunter reagent.

- 5 (See, e.g., Bolton, A.E. and W.M. Hunter (1973) *Biochem. J.* 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled PKIN, washed, and any wells with labeled PKIN complex are assayed. Data obtained using different concentrations of PKIN are used to calculate values for the number, affinity, and association of PKIN with the candidate molecules.

- 10 Alternatively, molecules interacting with PKIN are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) *Nature* 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

- PKIN may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions
15 between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

XVII. Demonstration of PKIN Activity

- Generally, protein kinase activity is measured by quantifying the phosphorylation of a protein
20 substrate by PKIN in the presence of gamma-labeled ^{32}P -ATP. PKIN is incubated with the protein substrate, ^{32}P -ATP, and an appropriate kinase buffer. The ^{32}P incorporated into the substrate is separated from free ^{32}P -ATP by electrophoresis and the incorporated ^{32}P is counted using a radioisotope counter. The amount of incorporated ^{32}P is proportional to the activity of PKIN. A determination of the specific amino acid residue phosphorylated is made by phosphoamino acid
25 analysis of the hydrolyzed protein.

- In one alternative, protein kinase activity is measured by quantifying the transfer of gamma phosphate from adenosine triphosphate (ATP) to a serine, threonine or tyrosine residue in a protein substrate. The reaction occurs between a protein kinase sample with a biotinylated peptide substrate and gamma ^{32}P -ATP. Following the reaction, free avidin in solution is added for binding to the
30 biotinylated ^{32}P -peptide product. The binding sample then undergoes a centrifugal ultrafiltration process with a membrane which will retain the product-avidin complex and allow passage of free gamma ^{32}P -ATP. The reservoir of the centrifuged unit containing the ^{32}P -peptide product as retentate is then counted in a scintillation counter. This procedure allows assay of any type of protein kinase

sample, depending on the peptide substrate and kinase reaction buffer selected. This assay is provided in kit form (ASUA, Affinity Ultrafiltration Separation Assay, Transbio Corporation, Baltimore MD, U.S. Patent No. 5,869,275). Suggested substrates and their respective enzymes are as follows: Histone H1 (Sigma) and p34^{cdc2}kinase, Annexin I, Angiotensin (Sigma) and EGF receptor kinase, 5 Annexin II and *src* kinase, ERK1 & ERK2 substrates and MEK, and myelin basic protein and ERK (Pearson, J.D. et al. (1991) Methods in Enzymology 200:62-81).

In another alternative, protein kinase activity of PKIN is demonstrated *in vitro* in an assay containing PKIN, 50µl of kinase buffer, 1µg substrate, such as myelin basic protein (MBP) or synthetic peptide substrates, 1 mM DTT, 10 µg ATP, and 0.5µCi [γ -³³P]ATP. The reaction is 10 incubated at 30°C for 30 minutes and stopped by pipetting onto P81 paper. The unincorporated [γ -³³P]ATP is removed by washing and the incorporated radioactivity is measured using a radioactivity scintillation counter. Alternatively, the reaction is stopped by heating to 100°C in the presence of SDS loading buffer and visualized on a 12% SDS polyacrylamide gel by autoradiography. Incorporated radioactivity is corrected for reactions carried out in the absence of PKIN or in the presence of the 15 inactive kinase, K38A.

In yet another alternative, adenylate kinase or guanylate kinase activity may be measured by the incorporation of ³²P from gamma-labeled ³²P-ATP into ADP or GDP using a gamma radioisotope counter. The enzyme, in a kinase buffer, is incubated together with the appropriate nucleotide mono-phosphate substrate (AMP or GMP) and ³²P-labeled ATP as the phosphate donor. The 20 reaction is incubated at 37°C and terminated by addition of trichloroacetic acid. The acid extract is neutralized and subjected to gel electrophoresis to separate the mono-, di-, and triphosphonucleotide fractions. The diphosphonucleotide fraction is cut out and counted. The radioactivity recovered is proportional to the enzyme activity.

In yet another alternative, other assays for PKIN include scintillation proximity assays (SPA), 25 scintillation plate technology and filter binding assays. Useful substrates include recombinant proteins tagged with glutathione transferase, or synthetic peptide substrates tagged with biotin. Inhibitors of PKIN activity, such as small organic molecules, proteins or peptides, may be identified by such assays.

Kinase activity of PKIN may be determined by its ability to convert polyphosphate substrate (PolyP) to ATP in the presence of ADP. PKIN and Poly P are incubated at 37°C for 40 minutes and 30 then at 90°C for 2 minutes in a buffer containing 50 mM Tris-HCl, pH 7.4, 40 mM ammonium sulfate, 4 mM MgCl₂, and 5 µM ADP. The reaction mixture is diluted 1:100 in 100 mM Tris-HCl (pH 8.0), 4 mM EDTA, which is then diluted 1:1 in luciferase reaction mixture (ATP Bioluminescence Assay Kit CLS II; Boehringer Mannheim). The ATP generated is then quantitated using a luminometer

(Kornberg, A. et al. (1999) *Annu. Rev. Biochem.* 68:89-125; Ault-Riché, D. et al. (1998) *J. Bacteriol.* 180:1841-1847).

Kinase activity of PKIN, as measured by phosphorylation of substrate, may be determined using an immune complex kinase assay well known in the art. COS7 cells are transfected with an expression plasmid constructed from a FLAG tag expression vector (pME18S-FLAG) containing PKIN DNA. A control transfection using vector alone without the PKIN DNA insert is done in parallel. After 48 hours, the cells are lysed in buffer A (20 mM HEPES-NaOH, pH 7.5, 3 mM $MgCl_2$, 100 mM NaCl, 1 mM dithiothreitol, 1 mM phenylmethanesulfonyl fluoride, 1 μ g/ml leupeptin, 1 mM EGTA, 1 mM Na_3VO_4 , 10 mM NaF, 20 mM β -glycerophosphate, and 0.5% Triton X-100) and centrifuged at 14,000 rpm. Supernatants are incubated with anti-FLAG antibody (M2 monoclonal antibody; Eastman Kodak Co.) in a 50% slurry of protein A-Sepharose (Amersham Pharmacia Biotech) for 1.5 hours at 4°C. Immune complexes are precipitated and washed twice in buffer A and twice in buffer B (20 mM HEPES-NaOH, pH 7.5, 1 mM dithiothreitol, 10 μ M Na_3VO_4 , 2 mM β -glycerophosphate, 0.1 mM phenylmethanesulfonyl fluoride, 0.1 μ g/ml leupeptin, 0.1 mM EGTA.) Precipitates are incubated in buffer B containing 0.17 mg/ml myelin basic protein (MBP) (Sigma), 20 μ M ATP, and 5 μ Ci of [γ - 32 P]ATP (NEN Life Science Products) at 30°C for 20 minutes. The reaction is stopped by the addition of 4X Laemmli sample buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 30 mM dithiothreitol, and 10% glycerol) and heated at 95°C for 5 minutes. Proteins are separated by SDS-polyacrylamide gel electrophoresis and radioactivity incorporated into MBP is detected by autoradiography (Nakano, K. et al. (2000) *J. Biol. Chem.* 275:20533-20539.)

In yet another alternative, an assay for PanK activity of PKIN includes the enzyme preparation method as described in Vallari, D.S. et al., (1987) *J. Biol. Chem.* 262:2468-247. Pantothenate kinase-specific activities in cell lysates are calculated as a function of protein concentration with the assay being linear with respect to both time and protein input. Protein concentrations are measured using the Bradford assay using bovine γ -globulin as a standard. Standard assays contain D-[1- 14 C]pantothenate (45.5 μ M; specific activity 55 mCi/mmol), ATP (2.5 mM, pH 7.0), $MgCl_2$ (2.5 mM), Tris-HCl (0.1 M, pH 7.5), and 15 μ g of protein from a soluble cell extract in a total volume of 40 μ l. The mixture is incubated for 10 min. at 37 °C, and the reaction is stopped by depositing a 30- μ l aliquot onto a Whatman DE81 ion-exchange filter disc which is then washed in three changes of 1% acetic acid in 95% ethanol (25 ml/disc) to remove unreacted pantothenate. 4'-Phosphopantothenate is quantitated by counting the dried disc in 3 ml of scintillation solution (Rock, *supra*).

XVIII. Enhancement/Inhibition of Protein Kinase Activity

Agonists or antagonists of PKIN activation or inhibition may be tested using assays described in section XVII. Agonists cause an increase in PKIN activity and antagonists cause a decrease in PKIN activity.

- 5 Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious
10 to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
7482896	1	7482896CD1	23	7482896CB1
7483046	2	7483046CD1	24	7483046CB1
71636374	3	71636374CD1	25	71636374CB1
7480597	4	7480597CD1	26	7480597CB1
3227248	5	3227248CD1	27	3227248CB1
4207273	6	4207273CD1	28	4207273CB1
7483334	7	7483334CD1	29	7483334CB1
7483337	8	7483337CD1	30	7483337CB1
6035509	9	6035509CD1	31	6035509CB1
7373485	10	7373485CD1	32	7373485CB1
5734965	11	5734965CD1	33	5734965CB1
7473788	12	7473788CD1	34	7473788CB1
3107989	13	3107989CD1	35	3107989CB1
7482887	14	7482887CD1	36	7482887CB1
2963414	15	2963414CD1	37	2963414CB1
7477139	16	7477139CD1	38	7477139CB1
55009053	17	55009053CD1	39	55009053CB1
7474648	18	7474648CD1	40	7474648CB1
7483053	19	7483053CD1	41	7483053CB1
7483117	20	7483117CD1	42	7483117CB1
7484498	21	7484498CD1	43	7484498CB1
7638121	22	7638121CD1	44	7638121CB1

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank NO:	ID	Probability Score	GenBank Homolog
1	7482896CD1	g852055		2.90E-167	[Homo sapiens] casein kinase I-alpha Fish, K.J. et al., (1995) J. Biol. Chem. 270:14875-14883
2	7483046CD1	g2736151		4.20E-167	[Rattus norvegicus] myotonic dystrophy kinase-related Leung, T. et al., (1998) Mol. Cell. Biol. 18:130-140
3	71636374CD1	g7549223	0		[Mus musculus] PALS1 (proteins associated with Lin-7, a membrane-associated guanylate kinase) Kamberov, E. et al., (2000) J. Biol. Chem. 275:11425-11431
4	7480597CD1	g2224679		1.40E-97	[Homo sapiens] KIAA0369 doublecortin-like kinase Nagase, T. et al., (1997) DNA Res. 4:141-150
5	3227248CD1	g6690020		4.90E-199	Burgess, H.A. et al. (1999) J. Neurosci. Res. 58:567-575 [Mus musculus] pantothenate kinase 1 beta
6	4207273CD1	g4028547		4.70E-68	Rock, C.O. et al. (2000) J. Biol. Chem. 275:1377-1383 [Dictyostelium discoideum] MEK kinase alpha
7	7483334CD1	g479173		1.70E-251	Chung, C.Y. et al. (1998) Genes Dev. 12:3564-3578 [Homo sapiens] protein kinase
8	7483337CD1	g9280288		3.10E-27	Schultz, S.J. et al. (1994) Cell Growth Differ. 5:625-635 [Arabidopsis thaliana] receptor protein kinase
9	6035509CD1	g6110362		3.60E-76	Kaneko, T. et al. (2000) DNA Res. 7:217-221 [Homo sapiens] Traf2 and NCK interacting kinase, splice variant 7
10	7373485CD1	g4200446	0		Fu, C.A. et al. (1999) J. Biol. Chem. 274:30729-30737 [Mus musculus] FYVE finger-containing phosphoinositide kinase
11	5734965CD1	g2905643		4.60E-109	Shisheva, A. et al. (1999) Mol. Cell. Biol. 19:623-634 [Klebsiella pneumoniae] ribitol kinase
12	7473788CD1	g7160989		1.70E-148	Heuel, H. et al. (1998) Microbiology 144(Pt 6):1631-9 [Homo sapiens] serine/threonine protein kinase
13	3107989CD1	g6690020		1.60E-129	Ruiz-Perez VL, et al. (2000) Nat. Genet. 24(3):283-6 [Mus musculus] pantothenate kinase 1 beta Rock, C.O. et al. (2000) J. Biol. Chem. 275:1377-1383

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank NO:	ID	Probability Score	GenBank Homolog
14	7482887CD1	g205662		3.90E-48	[Rattus norvegicus] nucleoside diphosphate kinase Kimura, N. et al. J. Biol. Chem. (1990) 265:15744-15749
15	2963414CD1	g6524024		8.90E-106	[Mus musculus] mammalian inositol hexakisphosphate kinase 1 Saiardi, A. et al. Curr. Biol. (1999) 9:1323-1326
16	7477139CD1	g6472874		0	[Mus musculus] Nck-interacting kinase-like embryo specific kinase Nakano, K. et al. J. Biol. Chem. (2000) 275:20533-20539
17	55009053CD1	g15131540		0	[fl][Homo sapiens] (AJ316534) serine/threonine protein kinase
18	7474648CD1	g14346040		0	[fl][Homo sapiens] serine/threonine kinase PSKH2
19	7483053CD1	g5419753		0	[Homo sapiens] RET tyrosine kinase receptor Bordeaux, M.C. et al. (2000) EMBO J. 19:4056-4063
20	7483117CD1	g644770		2.70E-136	[Xenopus laevis] Wee1A kinase Mueller, P.R. et al. (1995) Mol. Biol. Cell 6:119-134
21	7484498CD1	g3599509		0	[Mus musculus] rho/rac-interacting citron kinase Di Cunto, F. et al. (1998) J. Biol. Chem. 273:29706-29711
22	7638121CD1	g212661		1.20E-60	[Gallus gallus] smooth muscle myosin light chain kinase precursor Olson, N.J. et al. (1990) Proc. Natl. Acad. Sci. U.S.A. 87:2284-2288

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1	7482896CD1	337	S105 S122 S199 S237 S242 S27 S49 S7 S96 T109 T146 T184 T228 T243 T323 T327 T38 Y209 Y274	N167 N215 N3	Eukaryotic protein kinase domain: Y17-F211 Protein kinases signatures and profile: T112-R168 PROTEIN KINASE DOMAIN DM00004 P35506 19-273: L19-Y274 P54367 22-276: L19-Y274 P48730 11-265: L19-Y274 B56406 19-273: L19-Y274 CASEIN KINASE I TRANSFERASE SERINE/THREONINE PROTEIN ATP-BINDING ISOFORM ALPHA CKI ALPHA MULTIGENE PD006522: R282-G324 Tyrosine kinase catalytic domain PR00109: Y126-M144 Kinase Protein Domain PD00584: V20-G29 Protein kinases ATP-binding region signature: I23-K46 Serine/Threonine protein kinases active-site signature: F132-M144 signal_cleavage: M1-G40	HMMER-PFAM PROFILE-SCAN BLAST-DOMO BLAST-PRODROM BLIMPS-PRINTS BLIMPS-PRODROM MOTIFS MOTIFS SPSCAN HMMER-PFAM
2	7483046CD1	475	S161 S280 S307 S363 S407 S430 T455		Eukaryotic protein kinase domain: F71-F337	

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
3	71636374CD1	675	S130 S14 S143 S25 S383 S432 S517 S562 S569 S576 S581 S646 S84 T137 T253 T270 T422 T465 T514 T558 T584 T97 Y593	N82	PROTEIN KINASE DOMAIN DM00004 Q09013 83-336: I73-R325 S42867 75-498: I73-H252 I38133 90-369: E72-L220 P53894 353-658: L74-G215 KINASE PHORBOLESTER BINDING DYSTROPHY KINASE RELATED CDC42 BINDING SIMILAR SERINE/THREONINE PROTEIN GENGHIS KHAN PD012280: L25-D70 Tyrosine kinase catalytic domain PR00109: M148-S161, S185-L203, C257-E279 Protein kinase C terminal domain: P351-D366 Protein kinases ATP-binding region signature: I77-K100 Serine/Threonine protein kinases active-site signature: Y191-L203 signal_cleavage: M1-S37 Guanylate kinase: T515-I624	BLAST-DOMO
					GUANYLATE KINASE DM00755 A57653 370-570: P475-P670 P54936 769-955: R478-P670 I38757 709-898: Q474-P670 P31016 529-718: R480-P670	BLAST-DOMO

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
4	7480597CD1	835	S11 S153 S174 S223 S249 S271 S292 S349 S369 S380 S389 S393 S405 S525 S54 S59 S633 S713 T129 T194 T246 T278 T300 T319 T33 T451 T477 T499 T514 T545 T610 T63 T681 T790 T808	N768	PROTEIN DOMAIN SH3 KINASE GUANYLATE TRANSFERASE ATP-BINDING REPEAT GMP MEMBRANE PD001338: T514-E620	BLAST-PRODROM
					SIMILAR TO GUANYLATE KINASE PD065809: G41-Q337	BLAST-PRODROM
					Guanylate kinase protein BL00856: V511-V531, D539-R586	BLIMPS-BLOCKS
					SH3 domain signature PR00452: D386-E395, I348-P358, L369-Q384	BLIMPS-PRINTS
					PDZ domain (Also known as DHR or GLGF). PDZ: I256-S335.	HMMER-PFAM
					SH3 domain SH3:I348-Q415	HMMER-PFAM
					ATP/GTP-binding site motif A (P-loop): A404-S411	MOTIFS
					Guanylate_Kinase signature and profile: T514-V531	MOTIFS
					Eukaryotic protein kinase domain pkinase: Y543-I800	HMMER-PFAM
					Protein kinases signatures and profile: D640-I697	PROFILE-SCAN
					PROTEIN KINASE DOMAIN DM00004	BLAST-DOMO
					S57347 21-266: V548-T790	
					P08414 44-285: I549-T790	
					A44412 16-262: I549-A791	
					JU0270 16-262: I549-A791	

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					KINASE PROTEIN TRANSFERASE ATP-BINDING SERINE/THREONINE PROTEIN PHOSPHORYLATION RECEPTOR TYROSINE PROTEIN PRECURSOR TRANSMEMBRANE PD000001: E609-V693 Octicosapeptide repeat p PF00564: Y543-S597, H605-M655, K473-G526 Tyrosine kinase catalytic domain PR00109: L618-I631, H654-V672 Protein kinases ATP-binding region signature: I549-K572 Serine/Threonine protein kinases active-site signature: I660-V672	BLAST- PRODOM
5	3227248CD1	373	S100 S283 S285 S330 S47 T10 T167 T209 T226 T230 T244 T34	N103 N72	PROTEIN KINASE DOMAIN DM00004 A48084 98-348:K470-A722 DM00004 Q01389 1176-1430:K470-A722 DM00004 P41892 11-249:G471-R719 DM00004 Q10407 826-1084:K470-A722	BLAST- DOMO
6	4207273CD1	735	S100 S111 S113 S124 S152 S170 S179 S185 S186 S20 S202 S215 S221 S225 S240 S267 S271 S302 S459 S503 S729 S9 T10 T105 T13 T30 T402 T417 T425 T469 T626 T663 T669 T84 Y512	N289 N312 N341 N392 N400 N61 N624 N647	KINASE PROTEIN TRANSFERASE ATP-BINDING SERINE/THREONINE PROTEIN PHOSPHORYLATION RECEPTOR TYROSINE PROTEIN PRECURSOR TRANSMEMBRANE PD000001: L631-P673, E472-C537, Y533-S633, S701-S734	BLAST- PRODOM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
7	7483334CD1	506	S148 S206 S243 S319 S325 S354 S47 T197 T288 T293 T308 T321 T373 T386 T402 T403 T479	N181 N345 N377 N401	Tyrosine kinase catalytic domain signature PR00109:M547-N560, Y583-L601, G636-I646, S655-M677	BLIMPS- PRINTS
					Eukaryotic protein kinase domain pkinase:W468-L731	HMMER- PFAM
					Protein_Kinase_Atp L474-K496	MOTIFS
					Protein_Kinase_St V589-L601	MOTIFS
					Protein kinases signatures and profile protein_kinase_1yr.prf:V569-A619	PROFILE- SCAN
					PROTEIN KINASE DOMAIN DM00004 P51954 6-248:L7-S247 P51957 8-251:L7-S247 P51955 10-261:V6-S247 Q08942 22-269:M9-S247	BLAST- DOMO
					Tyrosine kinase catalytic domain signature PR00109:M79-K92, H117-L135, S183-N205, Y226-A248	BLIMPS- PRINTS
8	7483337CD1	2014	S1076 S1151 S1177 S1217 S1274 S1279 S1454 S15 S1515 S1679 S1700 S1811 S1833 S1887 S1890 S1999	N1024 N1119 N1338 N1599 N1674 N307 N371 N409	Eukaryotic protein kinase domain pkinase: Y4-V257	HMMER- PFAM
					Protein_Kinase_Atp I10-K33	MOTIFS
					Protein_Kinase_St V123-L135	MOTIFS
					Protein kinases signatures and profile protein_kinase_1yr.prf:M103-M156	PROFILE- SCAN
					PROTEIN KINASE DOMAIN DM00004 I38044 100-349:11295-P1549 I49663 194-437:E1341-P1549 A53800 119-368:R1343-P1549 S29851 157-404:E1341-P1549	BLAST- DOMO

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
9	6035509CD1	348	S203 S25 S321 S337 S401 S531 S56 S565 S599 S81 S843 S863 S887 S900 T1091 T1099 T1113 T1187 T1189 T1234 T1401 T1543 T1605 T1634 T1660 T1872 T1895 T2010 T280 T494 T517 T524 T533 T537 T680 T687 T699 T702 T703 T753 T795 T811 T835 T909 Y1225 Y1997 Y907 S101 S171 S199 S271 S50 S7 T178 T213 T311 T318 T333	N177	Tyrosine kinase catalytic domain signature PR00109: Y1414-V1432, V1483-H1505, Q1529-A1551	BLIMPS-PRINTS
					transmembrane domain transmem: P1367-N1387	HMMER
					Eukaryotic protein kinase domain pkinase: E1280-P1549	HMMER-PFAM
					Protein kinases signatures and profile protein_kinase_1yr.prf: L1400-E1457 Atp_Grp_A G672-S679	PROFILE-SCAN
						MOTIFS
					PROTEIN KINASE DOMAIN DM00004 P10676 18-272:117-P270 A53714 17-262:117-S271 P38692 24-266:E19-S271 P08458 20-262:121-S271	BLAST-DOMO
					Tyrosine kinase catalytic domain signature PR00109: H134-L152, G181-I191, W250-V272	BLIMPS-PRINTS
					Eukaryotic protein kinase domain pkinase: W15-I281	HMMER-PFAM
					Protein_Kinase_Atp I21-K44	MOTIFS
10	7373485CD1	2042	S1020 S105 S1079 S1125 S1130 S1148 S13	N1061 N1274 N1647 N1671	Protein_Kinase_St I140-L152	MOTIFS
					Protein kinases signatures and profile protein_kinase_1yr.prf: M120-T172	PROFILE-SCAN
					Probable phosphatidyl inositol 4-phosphate 5-kinase FAB1 EC 2.7.1.68 1-phosphatidyl inositol 4-	BLAST-PRODOR

Table 3

SEQ ID NO:	Incye Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
			S1377 S1419 S1429 S1440 S1466 S1483 S1488 S1544 S1545 S1620 S1639 S1648 S168 S1685 S1703 S1784 S1785 S1830 S1899 S228 S244 S257 S261 S286 S291 S367 S423 S475 S502 S576 S789 S810 S835 S85 S872 S896 S977 T1005 T1013 T109 T1149 T1295 T1386 T1524 T1567 T1670 T1674 T1681 T1708 T1722 T173 T1743 T1813 T1852 T1872 T1909 T1970 T341 T342 T591 T666 T731 T782 T976 T984 Y1290 Y1716Y1933 Y659	N1870 N303 N310 N333	phosphate 5-kinase diphosphoinositide transferase PD136025:H461-F821, W1147-K1437, L1375- S1702, K638-K767, P1663-V1780, D1372-Q1458, F959-I1069, R960-D1053, F200-R262, D1895- S1950; PD041996:L1974-W2035	
					5-KINASE PHOSPHATIDYL INOSITOL 4- PHOSPHATE KINASE TYPE TRANSFERASE DIPHOSPHOINOSITIDE 1-PHOSPHATIDYL INOSITOL 4-PHOSPHATE II ALPHA PHOSPHATIDYL INOSITOL PD002308:P1751- G1966, L1974-F2028, I493-H533 FYVE zinc finger FYV:Q153-C213 Phosphatidylinositol-4-phosphate 5-Kinase PIP5:R1791-F2028	BLAST- PRODOM MOTIFS MOTIFS
11	S734965CD1	551	S107 S176 S2 S21 S257 S368 S502 S54 T183 T286 T334 T356 T403 T66 Y526 Y531	N127 N219	FGGY family of carbohydrate kinases: L423-A490 FGGY FAMILY OF CARBOHYDRATE KINASES DM01757[P21939]1-480: V13-A184 XYLULOKINASE DM02388[P18157]1-492: T383- E539	HMMER- PFAM BLAST- DOMO BLAST- DOMO

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					FGGY FAMILY OF CARBOHYDRATE KINASES DM01757 P37677 I-479: R10-D260 FGGY FAMILY OF CARBOHYDRATE KINASES DM01757 P46834 I-488: Y11-V268 MPA43 PROTEIN PD130314:V13-I210 FGGY family of carbohydrate kinases proteins BL00933: Y11-L34, R109-A119, V137-N156, G456-I471	BLAST-DOMO BLAST-DOMO BLAST-DOMO PRODOM BLIMPS-BLOCKS
12	7473788CD1	485	S10 S159 S3 S343 S362 S415 S417 T115 T192 T466 T469 T76 Y119	N405	Eukaryotic protein kinase domain: F93-Q345 PROTEIN KINASE DOMAIN DM00004 P54644 I22-362: I95-S342 PROTEIN KINASE DOMAIN DM00004 P28178 I55-393: I95-L341 PROTEIN KINASE DOMAIN DM08046 P05986 I-397: K65-P372 P06244 I-396: F93-P372 Tyrosine kinase catalytic domain signature PR00109:V170-Q183, Y206-L224 Protein kinases ATP-binding region signature I99-K122 Serine/Threonine protein kinases active-site signature I212-L224 signal_cleavage:M1-A24 signal_cleavage: M1-A27	HMMER-PFAM BLAST-DOMO BLAST-DOMO BLAST-DOMO BLIMPS-PRINTS MOTIFS MOTIFS SPSCAN SPSCAN
13	3107989CD1	282	S148 S152 S192 S194 S239 S78 T118 T138 T139 T153 T36	N12		

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
14	7482887CD1	151	S42 S97 T35 Y141		NUCLEOSIDE DIPHOSPHATE KINASES DM00773 P488173-152:I7-Y150 DM00773 I39074 19-168:I7-Y150 DM00773 Q07661 1-148:I7-Y150 DM00773 P50590 1-150:I7-Y150 KINASE DIPHOSPHATE NUCLEOSIDE TRANSFERASE NDK NDP ATP-BINDING PROTEIN I PRECURSOR PD001018:I7-Y150 Nucleoside diphosphate kinases proteins BL00469:E77-L131 Nucleoside diphosphate kinases NDK:I7-A151	BLAST- DOMO
15	2963414CD1	410	S134 S156 S276 S318 T259 T361 T374 T383 T62	N117 N290	Nucleoside diphosphate kinases active site ndp_kinases:G96-R142 PROTEIN ARGININE METABOLISM REGULATION III TRANSCRIPTION SIMILARITY SACCHAROMYCES CEREVISIAE PUTATIVE PD011544:S188-Q333, S355-L403 PUTATIVE BZIP TRANSCRIPTION FACTOR CHROMOSOME IV READING FRAME ORF YDR017C PD024140:G15-R197 Aldo/keto reductase family putative active site signature I312-L327	BLAST- PRODOM BLAST- PRODOM BLIMPS- BLOCKS HMMER- PFAM PROFILE- SCAN BLAST- PRODOM BLAST- PRODOM MOTIFS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
16	7477139CD1	1581	S101 S1107 S1112 S1139 S1178 S1233 S1291 S1346 S136 S1400 S1426 S1435 S148 S1537 S1577 S211 S283 S376 S498 S580 S671 S676 S700 S709 S718 S749 S807 S84 S890 S891 S892 S910 T1071 T1123 T1194 T1367 T1508 T1546 T1556 T246 T276 T294 T357 T573 T664 T690 T899 T981 T992	N1137 N1201 N146 N654 N668 N990	PROTEIN KINASE DOMAIN DM00004 P10676 18-272:Y83-P302 DM00004 A53714 17-262:L43-S304 DM00004 P38692 24-266:S84-C293, K29-N57 DM00004 P50527 388-627:K77-S304, I31-E65	BLAST_DO MO
17	55009053CD1	1084	S1024 S1031 S1038 S1042 S1058 S157 S172 S231 S25 S422 S452 S478 S52 S521 S552 S569 S604 S623 S709 S80 S862 S882 S895 S914 S962 S968 S969 S981 S988 T102 T1037 T167 T230 T256 T263 T37 T420 T48 T543 T593 T631 T8 Y1005	N953	Serine/Threonine protein kinases active-site signature I139-I151 Protein kinases signatures and profile protein_kinase_1yr.prf: L118-F173 Eukaryotic protein kinase domain pkinase: L15-F273 Tyrosine kinase catalytic domain PR00109: T95- R108, H133-I151, V197-C219, K242-I264 PROTEIN KINASE DOMAIN DM00004 S49611 39- 259: I21-K242 Q05609 553-797: E20-C253 P51957 8-251: I21-R261 P41892 11-249: I21-R261	MOTIFS PROFILE- SCAN HMMER- PFAM BLIMPS- PRINTS BLAST- DOMO
18	7474648CD1	600	S206 S331 S369 S425 S456 S543 S55 S571	N18 N495	Protein kinases ATP-binding region signature I284- K307	MOTIFS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
			S577 S585 T117 T14 T25 T299 T300 T356 T371 T395 T433 T58		Eukaryotic protein kinase domain pkinase: Y278-V535 Tyrosine kinase catalytic PR00109: M352-I365, Y388-Y406, V458-E480 PROTEIN KINASE DOMAIN DM00004 S57347[21-266: D279-L516 P08414[44-285: I280-S525 JN0323[25-268: I284-R523 S46284[28-274: I284-A526	HMMER-PFAM BLIMPS-PRINTS BLAST-DOMO
19	7483053CD1	1114	S1034 S104 S110 S131 S159 S173 S224 S363 S413 S457 S522 S561 S65 S670 S691 S696 S765 S811 S819 S836 S922 T1022 T1055 T1078 T261 T295 T315 T328 T350 T456 T492 T538 T564 T675 T729 T75 T847 T930 Y1096 Y483 Y905	N1092 N151 N199 N336 N343 N361 N367 N377 N394 N448 N468 N554 N834 N975 N98	signal peptide: M1-G28 Signal_cleavage: M1-A26 Transmembrane domain: L13-F31 Protein kinases ATP-binding region signature L730-K758 Tyrosine protein kinases specific active-site signature L870-V882 Protein kinases signatures and profile protein_kinase_tyr.prf: D850-D903 Receptor tyrosine kinase class II signature receptor_tyr_kin_ii.prf: R878-D925 Cadherin domain cadherin: P172-T261 Eukaryotic protein kinase domain pkinase: L724-L1005	HMMER SPSCAN HMMER MOTIFS MOTIFS PROFILE-SCAN PROFILE-SCAN HMMER-PFAM HMMER-PFAM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
20	7483117CD1	567	S162 S17 S206 S243 S278 S543 S552 S70 T112 T125 T22 T246 T544 T559 T68 Y238		Receptor tyrosine kinase BL00239: D903-Y952, P957-I1001, E775-V822, L851-R873, A876-E901 BL00240: K716-A764, A764-E818, D850-K887, E902-G949, G949-I1001 BL00790: G748-L801, A855-A876, A877-D903, Q910-W942, H968-L1016	BLIMPS-BLOCKS
					Tyrosine kinase catalyti PR00109: V804-R817, Y864-V882, I913-L923, S932-G954, C976-F998	BLIMPS-PRINTS
					RECEPTOR KINASE PRECURSOR SIGNAL RET TYROSINE PROTOONCOGENE TYROSINE CRET TRANSFERASE PD014372: P273-K666, D300-V725; PD014143: Y30-C197; PD007958: V1010-G1063, PD010335:M1064-S1114	BLAST-PRODROM
					PROTEIN-TYROSINE KINASE RET DM05080 P07949 302-723: D302-L724 I48735 303-724: D302-L724 PROTEIN KINASE DOMAIN DM00004 JN0290 88-360: V725-F998 P07949 725-997: V725-F998	BLAST-DOMO
	7483117CD1	567	S162 S17 S206 S243 S278 S543 S552 S70 T112 T125 T22 T246 T544 T559 T68 Y238	N15 N332	Protein kinases ATP-binding region signature I218-K241	MOTIFS
					Serine/Threonine protein kinases active-site signature M335-I347	MOTIFS
					Eukaryotic protein kinase domain pkinase: F212-L480	HMMER-PFAM
					Tyrosine kinase catalytic site PR00109: N289-S302, Y329-I347, A415-G437, L455-A477	BLIMPS-PRINTS

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					WEE1 HOMOLOG WEE1 LIKE PROTEIN KINASE MITOSIS TRANSFERASE TYROSINE PROTEIN ATP BINDING PHOSPHORYLATION PD028078: N483-G561 PROTEIN KINASE DOMAIN DM00004 P47817 211-470: L213-A477 P30291 300-559: E214-A477 P54350 241-507: E214-A477 A57247 104-343: K217-I347, A366-R474 CNH (NIK-1 like kinase) domain: L1619-Y1916	BLAST- PRODOM
21	7484498CD1	2054	S81 S93 S140 S248 S308 S361 S381 S386 S410 S436 S445 S480 S487 S501 S516 S529 S546 S577 S582 S699 S883 S888 S924 S1031 S1049 S1097 S1158 S1160 S1234 S1315 S1364 S1365 S1370 S1371 S1377 S1574 S1845 S1915 S1933 S2014 S2028 T83 T378 T498 T604 T840 T951 T956 T989 T1041 T1062 T1112 T1186 T1231 T1309 T1326 T1336 T1372 T1543 T1583	N835 N1622 N1745 N1768	Phorbol esters/diacylglycerol binding: H1390-C1438 PH (pleckstrin homology) domain: L1471-A1590 Eukaryotic protein kinase domain: F97-F360 Phorbol esters / diacylglycerol binding domain dag_pe_binding_domain.prf: C1403-E1466 Tyrosine kinase catalytic domain signature PR00109: S211-V229, C284-G306, M174-N187 Domain found in NIK 1-like kinase, mouse citron and yeast ROM1, ROM2 PF00780: K534-I542, N891- T933, I964-Q975, Q1015-Q1067, Q1217-E1255, I1388-L1434, E1759-A1802, N1819-F1831, K1851- Q1880	HMMER- PFAM HMMER- PFAM HMMER- PFAM HMMER- PFAM PROFILE- SCAN BLIMPS- PRINTS BLIMPS- PFAM

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
			T1775 T1787 T1943 T1955 T1961 T2015 Y763		CITRON PROTEIN COILED COIL RHO/RACINTERACTING KINASE PD155701: F859-L1071 PD143273: G1439-V1631 PD082663: L1201-P1389 PD143272: A1881-V2054 PROTEIN KINASE DOMAIN DM00004 Q09013 83-336: V99-L349 S42867 75-498: S101-G241, I258-S445 S42864 41-325: E98-G241, N249-L349 P53894 353-658: L102-G241 I258-L349 Protein kinases ATP-binding region signature V103-K126	BLAST- PRODOM
					Serine/Threonine protein kinases active-site signature: Y217-V229 Leucine zipper pattern: L854-L875, L991-L1012, L1057-L1078, L1159-L1180 Carbamoyl-phosphate synthase subdomain signature 2: M1172-S1179 Phorbol esters / diacylglycerol binding domain: H1390-C1438 Immunoglobulin domain: G68-A128, G1174-V1235	MOTIFS
22	763812ICD1	1665	S97 S152 S156 S163 S242 S364 S450 S459 S491 S493 S528 S536 S588 S762 S827 S875 S915 S917 S929 S947 S961 S997 S1087 S1147	N1005	Eukaryotic protein kinase domain: Y165-F418, F1369-L1621 Protein kinases signatures and profile protein_kinase_tyr.prf: E260-A314	HMMER- PFAM HMMER- PFAM PROFILE- SCAN

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
			S1203 S1336 S1351 S1365 S1391 S1434 S1446 S1459 S1461 S1521 T59 T230 T257 T312 T668 T870 T966 T1211 T1310 T1320 T1638		Tyrosine kinase catalytic domain signature PR00109: S341-E363, L387-A409, L238-Y251, Y274-M292	BLIMPS-PRINTS
					KINASE PROTEIN TRANSFERASE ATPBINDING SERINE/THREONINEPROTEIN PHOSPHORYLATION RECEPTOR TYROSINEPROTEIN PRECURSOR TRANSMEMBRANE PD000001: V256-V327, S323-D365, S380-P423	BLAST-PRODOM
					PROTEIN KINASE DOMAIN DM00004 JN0583 727-969: V167-R401, Q1372-P1563 P07313 298-541: K168-A409, Q1378-P1563 P53355 15-257: E169-R406, Q1374-P1563 S07571 5152-5396: E166-R406, Q1374-P1606	BLAST-DOMO
					Protein kinases ATP-binding region signature I171-K194	MOTIFS
					Tyrosine protein kinases specific active-site signature I1484-I1496	MOTIFS
					Protein kinase St V280-M192	MOTIFS

Table 4

Polynucleotide SEQ ID NO:	Incye ID	Sequence Length	Selected Fragments	Sequence Fragments	5' Position	3' Position
23	7482896CB1	1014	982-1014	GNN.g7899226_000043_002 .edit	1	1014
24	7483046CB1	1530	719-770, 1-61, 1036-1104, 1271-1461, 313-464	71583296V1 71581650V1 71601507V1 55143579J1 71579961V1 55140831J1	889 778 1124 1 266 118	1476 1455 1530 272 884 522
25	71636374CB1	3150	1294-1806, 1-115, 2593-2616	183812R7 (CARDNOT01) 7676860H1 (NOSETUE01) 8252304H1 (BRAHDIT10) 5223511F9 (OVARDT07) GB1.g7452884_edit GB1.g8919852_edit 7214961H1 (LUNGFEC01) 7710619J1 (TESTTUE02) 7391509H1 (LIVRFEE02) 5958404H1 (BRATNOT05) 5971916H1 (BRAZNOT01)	2581 250 25 1225 1125 1099 1 1611 751 2796 2211	3148 864 804 1397 2085 1898 250 2273 1302 3150 2832
26	7480597CB1	2901	1907-1981, 1-156, 748-1606, 255-313	55150024J1 55073631J1 55150108J1 2841337T6 (DRGLNOT01) 55144761T1 5543295F7 (TESTNOC01) GNN.g7658410_000016_002 56001404J1	1377 630 1711 2251 2132 137 1 1790	2056 1518 2070 2901 2833 574 2013 2434

Table 4

Polynucleotide SEQ ID NO:	Incye ID	Sequence Length	Selected Fragments	Sequence Fragments	5' Position	3' Position
27	3227248CB1	1671	1-85, 1593-1671, 1327-1360	70944845V1 7207691H1 (FIBPFEA01) 8283762T1 (LIVRNON08) GBL.g9796547_edit 71281138V1 5260904F6 (CONDUTUT01) 5543515F6 (TESTNOC01) 5357164H1 (TESTNOC01) 55144823H1 GNN.g9230839_000001_002	997 451 180 1 1089 569 907 238 2112 1	1646 1050 562 1539 1671 1065 1376 440 2577 1293
28	4207273CB1	2577	1-1641, 1845-1889	55073166J1 4919885T6 (TESTNOT11) 71341632V1 71341335V1 940589R6 (ADRENOT03) 6512850H1 (THYMDIT01) 6102073H1 (UTRENOT09) 4970029F7 (KIDEUNC10) 7659406H1 (OVARNOE02)	1115 1445 1559 1145 1916 1007 797 1 509	1773 2141 2110 1708 2110 1688 1087 677 1081
29	7483334CB1	2110	1-640, 1255-1314, 948-1005	7383958R8 (FTUBTUE01) 3245584H1 (BRAINOT19) 72334852V1 7383958F8 (FTUBTUE01) 58002303T1 70771904V1 GNN.g6693375_000016_002 .edit 55046508H1	1 2681 5219 537 6221 5851 986 2906	694 2928 5761 1196 7093 6475 3303 3666
30	7483337CB1	7093	1-3002, 4789-5840, 7069-7093, 3561-3671			

Table 4

Polynucleotide SEQ ID NO:	Incye ID	Sequence Length	Selected Fragments	Sequence Fragments	5' Position	3' Position
				5514427J1	5514	6397
				5208289H1 (BRAFNOT02)	4900	5138
				7036825F6 (UTRSTMR02)	3953	4647
				55046508J1	3448	4132
				70772942V1	5079	5680
				6436908H1 (LUNGNON07)	908	1407
				GNN.g6721428_000012_004 .edit	3780	6267
31	6035509CB1	1800	152-333, 1-25, 1463-1800, 770-862	71927475V1	1340	1800
				6035509F8 (PITUNOT06)	848	1614
				55071284J1	818	1098
				72420180D1	1	729
				55071288J1	480	1096
32	7373485CB1	6347	4445-5413, 728-786, 6321-6347, 1497-3441, 4019-4079, 877-1082	72375809V1	2075	2717
				8116978H1 (TONSDIC01)	1	659
				GNN.g6114949_010.edit5p	1497	3728
				6919538R8 (PLACFER06)	1156	1644
				GNN.g6850654_000027_002	998	1496
				7368965H1 (ADREFEC01)	5742	6347
				6460173H2 (OSTEUNC01)	5357	5883
				6801172F6 (COLENOR03)	4290	4817
				7212618T8 (LUNGFEC01)	3001	3712
				6919538F8 (PLACFER06)	390	1143
				55073317H1	2592	3387
				58003367H1	4871	5725
				7271932R8 (OVARDIJ01)	3542	4220
				5623962R8 (THYMNOR02)	4544	5050

Table 4

Polynucleotide SEQ ID NO:	Incute ID	Sequence Length	Selected Fragments	Sequence Fragments	5' Position	3' Position
				72373545V1	1602	2203
				5623962F8 (THYMNOR02)	3970	4319
33	5734965CB1	1876	1-902	3254961T6 (OVRTUN01)	1276	1876
				5897065H1 (BRAYDIN03)	1	291
				70810516V1	181	806
				70162895V1	1002	1658
				70809778V1	915	1490
				70807962V1	302	989
34	7473788CB1	1487	1-121, 1450-1487	70995937V1	1024	1487
				7177378H1 (BRAXDIC01)	29	554
				GNN:g3983531_000002_00	1	260
				2.edit.1		
				70996158V1	594	1243
				7177563H2 (BRAXDIC01)	489	1180
35	3107989CB1	1884	1-306, 1253-1884	70942785V1	1153	1507
				3107989F6 (BRSTTUT15)	232	609
				7363877H1 (OVARDIC01)	1358	1884
				GNN:g9368012.edit1	375	1465
				2243506F6 (PANCUTUT02)	1	385
36	7482887CB1	1070	1-660, 891-948	56009164H1	1	725
				GBL:g5815507.edit	612	997
				GBL:g9716284_order_0.edit2	988	1070
37	2963414CB1	2890	1-270, 1973-2064, 2658-2890, 726-1584	71883559V1	470	1087
				6741017F6 (BRAFDIT02)	1687	2299
				72524920V1	984	1725
				7090654H1 (BRAUTDR03)	2284	2876

Table 4

Polynucleotide SEQ ID NO:	Incye ID	Sequence Length	Selected Fragments	Sequence Fragments	5' Position	3' Position
				7595015H1 (LJVRNOC07)	1	450
				71882107V1	424	985
				70523289V1	1123	1749
				7236935H1 (BRAINOY02)	1904	2302
				2601508H1 (UTRSNOT10)	2660	2890
38	7477139CB1	5198	2528-2698, 1296-2145, 2792-4455, 528-724, 177-214	GNN.g1149521_002	948	3957
				71143326V1	4891	5198
				55117016H1	1	919
				2879284F6 (UTRSTUT05)	4388	4874
				3900926H1 (LUNGNON03)	3689	3971
				GNN.g2780172_002.edit	3433	4943
				72615067V1	701	1315
				6775332H1 (OVARDIR01)	4605	5193
				7369832H1 (ADREFEC01)	4063	4606
39	55009053CB1	3969	1393-2860, 1-649	8036923H1 (SMCRUNE01)	1289	2065
				72480126D1	3325	3969
				7263320F6 (PROSTMC02)	1510	2343
				55009061H1	570	1318
				72476437D1	3306	3968
				6583144F8 (BRAVIXC01)	1	452
				72508467V1	2287	3200
				72509180V1	2494	3329
				55009045J1	288	982
40	7474648CB1	1803	198-1803	FL7474648_g7596812_0000	823	1497
				12_g7981277_1_1		
				GNN.g7596812_2	1	1803
41	7483053CB1	3472	1-305, 3134-3472	GB1.g6981824_000001.edit	1	337
				2493520F6 (ADRETUT05)	2055	2525

Table 4

Polynucleotide SEQ ID NO:	Incye ID	Sequence Length	Selected Fragments	Sequence Fragments	5' Position	3' Position
				72498890V1	1524	2231
				GNN.g6981824_000001_042 .edit	74	3187
				55081239H1	847	1704
				6872245H1 (BRAGNON02)	2354	3059
				7995993H1 (ADRETUC01)	2942	3472
				7742567H1 (ADRETUE04)	647	1183
42	7483117CB1	1704	1-342, 509-539, 582-758	GBI.g4153871_000001.edit	1536	1704
				7369322F8 (ADREFEC01)	343	501
				GNN.g4153871_006.edit	1	1678
43	7484498CB1	6298	4050-4677, 1-195, 623-1785, 2406-2578, 3211-3637, 2139-2261	55058386H1	601	1357
				7073440H1 (BRAUTDR04)	5165	5621
				7032228R8 (BRAXTDR12)	4000	4590
				55053104J1	1618	2321
				7014254F6 (KIDNNOC01)	4579	5133
				7066070H1 (BRATNOR01)	2926	3470
				55053152H1	848	1564
				55058386J1	1	701
				7073642H1 (BRAUTDR04)	5045	5617
				6892089F6 (BRAITDR03)	2294	2708
				8267244H1 (MIXDUNF04)	4401	5097
				7076436H1 (BRAUTDR04)	3497	4047
				7068147R8 (BRATNOR01)	5186	5924
				GNN.g4508157_002.edit	1166	1941

Table 4

Polynucleotide SEQ ID NO:	Incye ID	Sequence Length	Selected Fragments	Sequence Fragments	5' Position	3' Position
				7741468H1 (THYMNOE01)	3001	3627
				6850478H1 (BRAIFEN08)	5720	6298
				7068147F8 (BRATNOR01)	4092	4592
44	7638121CB1	5454	1718-3145,	6756753J1 (SINTFER02)	3907	4637
			1-989,	7361161H1 (BRAIFEE05)	1	637
			3982-4016	55057003J1	252	937
				56000546J1	1303	2019
				7354408H1 (HEARNON03)	5008	5454
				5863411F6 (MUSLTDT01)	3355	4178
				71873215V1	4520	5227
				71875134V1	3114	3669
				6496171T6 (COLNNOT41)	4710	5416
				55141853J2	810	1390
				7647137H1 (UTRSTUE01)	1920	2257
				7600017R6 (ESOGTME01)	1475	2041
				6200811F6 (PITUNON01)	3037	3632
				55052669H1	2245	3081

Table 5

Polynucleotide SEQ ID NO:	Incyte Project ID:	Representative Library
24	7483046CB1	COLCTUT03
25	71636374CB1	CARDNOT01
26	7480597CB1	DRGLNOT01
27	3227248CB1	COTRNOT01
28	4207273CB1	TESTNOC01
29	7483334CB1	ADRENOT03
30	7483337CB1	UTRSTMR02
31	6035509CB1	PITUNOT06
32	7373485CB1	MCLDTXT02
33	5734965CB1	PROSTUS23
34	7473788CB1	BRAINOT19
35	3107989CB1	STOMFET02
37	2963414CB1	SCORNOT04
38	7477139CB1	PLACFER06
39	55009053CB1	SINITME01
41	7483053CB1	BRAYDIN03
42	7483117CB1	ADREFEC01
43	7484498CB1	BRAITDR03
44	7638121CB1	MUSLTDR02

Table 6

Library	Vector	Library Description
ADREFEC01	pINCY	This large size-fractionated library was constructed using RNA isolated from adrenal tissue removed from a Caucasian female fetus who died from anencephalus after 16-weeks' gestation. Serology was negative. Family history included taking daily prenatal vitamins and mitral valve prolapse in the mother.
ADRENOT03	PSPORT1	Library was constructed using RNA isolated from the adrenal tissue of a 17-year-old Caucasian male, who died from cerebral anoxia.
BRAINOT19	pINCY	Library was constructed using RNA isolated from diseased brain tissue removed from the left frontal lobe of a 27-year-old Caucasian male during a brain lobectomy. Pathology indicated a focal deep white matter lesion, characterized by marked gliosis, calcifications, and hemosiderin-laden macrophages, consistent with a remote perinatal injury. This tissue also showed mild to moderate generalized gliosis, predominantly subpial and subcortical, consistent with chronic seizure disorder. The left temporal lobe, including the mesial temporal structures, showed focal, marked pyramidal cell loss and gliosis in hippocampal sector CA1, consistent with mesial temporal sclerosis. GFAP was positive for astrocytes. The patient presented with intractable epilepsy, focal epilepsy, hemiplegia, and an unspecified brain injury. Patient history included cerebral palsy, abnormality of gait, and depressive disorder. Family history included brain cancer.
BRAITDR03	PCDNA2.1	This random primed library was constructed using RNA isolated from allocortex, cingulate posterior tissue removed from a 55-year-old Caucasian female who died from cholangiocarcinoma. Pathology indicated mild meningeal fibrosis predominately over the convexities, scattered axonal spheroids in the white matter of the cingulate cortex and the thalamus, and a few scattered neurofibrillary tangles in the entorhinal cortex and the periaqueductal gray region. Pathology for the associated tumor tissue indicated well-differentiated cholangiocarcinoma of the liver with residual or relapsed tumor. Patient history included cholangiocarcinoma, post-operative Budd-Chiari syndrome, biliary ascites, hydrothorax, dehydration, malnutrition, oliguria and acute renal failure. Previous surgeries included cholecystectomy and resection of 85% of the liver.
BRAYDIN03	pINCY	This normalized library was constructed from 6.7 million independent clones from a brain tissue library. Starting RNA was made from RNA isolated from diseased hypothalamus tissue removed from a 57-year-old Caucasian male who died from a cerebrovascular accident. Patient history included Huntington's disease and emphysema. The library was normalized in 2 rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228 and Bernaldo et al., Genome Research (1996) 6:791, except that a significantly longer (48 -hours/round) reannealing hybridization was used. The library was linearized and recircularized to select for insert containing clones.
CARDNOT01	PBLUESCRIPT	Library was constructed using RNA isolated from the cardiac muscle of a 65-year-old Caucasian male, who died from a gunshot wound.

Table 6

Library	Vector	Library Description
COLCTUT03	pINCY	Library was constructed using RNA isolated from cecal tumor tissue removed from a 70-year-old Caucasian female during right hemicolectomy, open liver biopsy, flexible sigmoidoscopy, colonoscopy, and permanent colostomy. Pathology indicated invasive grade 2 adenocarcinoma forming an ulcerated mass 2 cm distal to the ileocecal valve and invading the muscularis propria. One regional lymph node (of 16) was positive for metastatic adenocarcinoma. Patient history included a deficiency anemia, malignant breast neoplasm, type II diabetes, hyperlipidemia, viral hepatitis, an unspecified thyroid disorder, osteoarthritis, a malignant skin neoplasm, and normal delivery. Family history included cardiovascular and cerebrovascular disease, hyperlipidemia, and breast and ovarian cancer.
COTRNOT01	pINCY	Library was constructed using RNA isolated from diseased transverse colon tissue obtained from a 26-year-old Caucasian male during a total abdominal colectomy and colostomy. Pathology indicated minimally active pancolitis with areas of focal severe colitis with perforation, consistent with Crohn's disease.
DRGLNOT01	pINCY	Library was constructed using RNA isolated from dorsal root ganglion tissue removed from the cervical spine of a 32-year-old Caucasian male who died from acute pulmonary edema and bronchopneumonia, bilateral pleural and pericardial effusions, and malignant lymphoma (natural killer cell type). Patient history included probable cytomegalovirus infection, hepatic congestion and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, and Bell's palsy. Surgeries included colonoscopy, large intestine biopsy, adenotonsillectomy, and nasopharyngeal endoscopy and biopsy; treatment included radiation therapy.
MCLDXT02	pINCY	Library was constructed using RNA isolated from treated umbilical cord blood dendritic cells removed from a male. The cells were treated with granulocyte/macrophage colony stimulating factor (GM-CSF), tumor necrosis factor alpha (TNF alpha), stem cell factor (SCF), phorbol myristate acetate (PMA), and ionomycin. The GM-CSF was added at time 0 at 100 ng/ml, the TNF alpha was added at time 0 at 2.5 ng/ml, the SCF was added at time 0 at 25 ng/ml. The PMA and ionomycin were added at 13 days for five hours. Incubation time was 13 days.
MUSLTDR02	PCDNA2.1	This random primed library was constructed using RNA isolated from right lower thigh muscle tissue removed from a 58-year-old Caucasian male during a wide resection of the right posterior thigh. Pathology indicated no residual tumor was identified in the right posterior thigh soft tissue. Changes were consistent with a previous biopsy site. On section through the soft tissue and muscle there was a smooth cystic cavity with hemorrhage around the margin on one side. The wall of the cyst was smooth and pale-tan. Pathology for the matched tumor tissue indicated a grade II liposarcoma. Patient history included liposarcoma (right thigh), and hypercholesterolemia. Previous surgeries included resection of right thigh mass. Family history included myocardial infarction and an unspecified rare blood disease.

Table 6

Library	Vector	Library Description
PITUNOT06	pINCY	Library was constructed using RNA isolated from pituitary gland tissue removed from a 55-year-old male who died from chronic obstructive pulmonary disease. Neuropathology indicated there were no gross abnormalities, other than mild ventricular enlargement. There was no apparent microscopic abnormality in any of the neocortical areas examined, except for a number of silver positive neurons with apical dendrite staining, particularly in the frontal lobe. The significance of this was undetermined. The only other microscopic abnormality was that there was prominent silver staining with some swollen axons in the CA3 region of the anterior and posterior hippocampus. Microscopic sections of the cerebellum revealed mild Bergmann's gliosis in the Purkinje cell layer. Patient history included schizophrenia.
PLACFER06	pINCY	This random primed library was constructed using RNA isolated from placental tissue removed from a Caucasian fetus who died after 16 weeks' gestation from fetal demise and hydrocephalus. Patient history included umbilical cord wrapped around the head (3 times) and the shoulders (1 time). Serology was positive for anti-CMV. Family history included multiple pregnancies and live births, and an abortion.
PROSTUS23	pINCY	This subtracted prostate tumor library was constructed using 10 million clones from a pooled prostate tumor library that was subjected to 2 rounds of subtractive hybridization with 10 million clones from a pooled prostate tissue library. The starting library for subtraction was constructed by pooling equal numbers of clones from 4 prostate tumor libraries using mRNA isolated from prostate tumor removed from Caucasian males at ages 58 (A), 61 (B), 66 (C), and 68 (D) during prostatectomy with lymph node excision. Pathology indicated adenocarcinoma in all donors. History included elevated PSA, induration and tobacco abuse in donor A; elevated PSA, induration, prostate hyperplasia, renal failure, osteoarthritis, renal artery stenosis, benign HTN, thrombocytopenia, hyperlipidemia, tobacco/alcohol abuse and hepatitis C (carrier) in donor B; elevated PSA, induration, and tobacco abuse in donor C; and elevated PSA, induration, hypercholesterolemia, and kidney calculus in donor D. The hybridization probe for subtraction was constructed by pooling equal numbers of cDNA clones from 3 prostate tissue libraries derived from prostate tissue, prostate epithelial cells, and fibroblasts from prostate tissue.
SCORNOT04	pINCY	Library was constructed using RNA isolated from cervical spinal cord tissue removed from a 32-year-old Caucasian male who died from acute pulmonary edema and bronchopneumonia, bilateral pleural and pericardial effusions, and malignant lymphoma (natural killer cell type). Patient history included probable cytomegalovirus, infection, hepatic congestion and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, and Bell's palsy. Surgeries included colonoscopy, large intestine biopsy, adenotonsillectomy, and nasopharyngeal endoscopy and biopsy; treatment included radiation therapy.

Table 6

Library	Vector	Library Description
SINITME01	pINCY	This 5' biased random primed library was constructed using RNA isolated from ileum tissue removed from a 70-year-old Caucasian female during right hemicolectomy, open liver biopsy, flexible sigmoidoscopy, colonoscopy, and permanent colostomy. Pathology for the matched tumor tissue indicated invasive grade 2 adenocarcinoma forming an ulcerated mass, situated 2 cm distal to the ileocecal valve. Patient history included a malignant breast neoplasm, type II diabetes, hyperlipidemia, viral hepatitis, an unspecified thyroid disorder, osteoarthritis, a malignant skin neoplasm, deficiency anemia, and normal delivery. Family history included breast cancer, atherosclerotic coronary artery disease, benign hypertension, cerebrovascular disease, ovarian cancer, and hyperlipidemia.
STOMFET02	pINCY	Library was constructed using RNA isolated from stomach tissue removed from a Hispanic male fetus, who died at 18 weeks' gestation.
TESTNOC01	PBLUESCRIPT	This large size fractionated library was constructed using RNA isolated from testicular tissue removed from a pool of eleven, 10 to 61-year-old Caucasian males.
UTRSTMR02	PCDNA2.1	This random primed library was constructed using pooled cDNA from two different donors. cDNA was generated using mRNA isolated from endometrial tissue removed from a 32-year-old female (donor A) and using mRNA isolated from myometrium removed from a 45-year-old female (donor B) during vaginal hysterectomy and bilateral salpingo-oophorectomy. In donor A, pathology indicated the endometrium was secretory phase. The cervix showed severe dysplasia (CIN III) focally involving the squamocolumnar junction at the 1, 6 and 7 o'clock positions. Mild koilocytotic dysplasia was also identified within the cervix. In donor B, pathology for the matched tumor tissue indicated multiple (23) subserosal, intramural, and submucosal leiomyomata. Patient history included stress incontinence, extrinsic asthma without status asthmaticus and normal delivery in donor B. Family history included cerebrovascular disease, depression, and atherosclerotic coronary artery disease in donor B.

Table 7

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	ESTs: Probability value= 1.0E-8 or less; Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6; Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value= 1.0E-8 or less; Full Length sequences: fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Probability value= 1.0E-3 or less

Table 7

Program	Description	Reference	Parameter Threshold
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) <i>J. Mol. Biol.</i> 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) <i>Nucleic Acids Res.</i> 26:320-322; Durbin, R. et al. (1998) <i>Our World View</i> , in a Nutshell, Cambridge Univ. Press, pp. 1-350.	PFAM hits: Probability value=1.0E-3 or less; Signal peptide hits: Score= 0 or greater
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) <i>CABIOS</i> 4:61-66; Gribskov, M. et al. (1989) <i>Methods Enzymol.</i> 183:146-159; Baistroch, A. et al. (1997) <i>Nucleic Acids Res.</i> 25:217-221.	Normalized quality score \geq GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) <i>Genome Res.</i> 8:175-185; Ewing, B. and P. Green (1998) <i>Genome Res.</i> 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) <i>Adv. Appl. Math.</i> 2:482-489; Smith, T.F. and M.S. Waterman (1981) <i>J. Mol. Biol.</i> 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) <i>Genome Res.</i> 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) <i>Protein Engineering</i> 10:1-6; Claverie, J.M. and S. Audic (1997) <i>CABIOS</i> 12:431-439.	Score=3.5 or greater

Table 7

Program	Description	Reference	Parameter Threshold
TMAP	A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.	Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.	
TMHMMER	A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.	Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. Conf. On Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence (AAAI) Press, Menlo Park, CA, and MIT Press, Cambridge, MA, pp. 175-182.	
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:
 - a) a polypeptide comprising an amino acid sequence selected from the group consisting
5 of SEQ ID NO:1-22,
 - b) a polypeptide comprising a naturally occurring amino acid sequence at least 90%
identical to an amino acid sequence selected from the group consisting of SEQ ID
NO:1-22,
 - c) a biologically active fragment of a polypeptide having an amino acid sequence
10 selected from the group consisting of SEQ ID NO:1-22, and
 - d) an immunogenic fragment of a polypeptide having an amino acid sequence selected
from the group consisting of SEQ ID NO:1-22.
2. An isolated polypeptide of claim 1 comprising an amino acid sequence selected from the
15 group consisting of SEQ ID NO:1-22.
3. An isolated polynucleotide encoding a polypeptide of claim 1.
4. An isolated polynucleotide encoding a polypeptide of claim 2.
20
5. An isolated polynucleotide of claim 4 comprising a polynucleotide sequence selected from
the group consisting of SEQ ID NO:23-44.
6. A recombinant polynucleotide comprising a promoter sequence operably linked to a
25 polynucleotide of claim 3.
7. A cell transformed with a recombinant polynucleotide of claim 6.
8. A transgenic organism comprising a recombinant polynucleotide of claim 6.
30
9. A method of producing a polypeptide of claim 1, the method comprising:
 - a) culturing a cell under conditions suitable for expression of the polypeptide, wherein
said cell is transformed with a recombinant polynucleotide, and said recombinant

polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and

- b) recovering the polypeptide so expressed.

5 10. A method of claim 9, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-22.

11. An isolated antibody which specifically binds to a polypeptide of claim 1.

10 12. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44,
- b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ
- 15 ID NO:23-44,
- c) a polynucleotide complementary to a polynucleotide of a),
- d) a polynucleotide complementary to a polynucleotide of b), and
- e) an RNA equivalent of a)-d).

20 13. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 12.

14. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:

- 25 a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
- 30 b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

15. A method of claim 14, wherein the probe comprises at least 60 contiguous nucleotides.

16. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
- 5 b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

17. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

10

18. A composition of claim 17, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-22.

19. A method for treating a disease or condition associated with decreased expression of functional PKIN, comprising administering to a patient in need of such treatment the composition of claim 17.

15

20. A method of screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

20

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting agonist activity in the sample.

21. A composition comprising an agonist compound identified by a method of claim 20 and a pharmaceutically acceptable excipient.

25

22. A method for treating a disease or condition associated with decreased expression of functional PKIN, comprising administering to a patient in need of such treatment a composition of claim 21.

30

23. A method of screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

24. A composition comprising an antagonist compound identified by a method of claim 23 and a pharmaceutically acceptable excipient.

25. A method for treating a disease or condition associated with overexpression of functional PKIN, comprising administering to a patient in need of such treatment a composition of claim 24.

26. A method of screening for a compound that specifically binds to the polypeptide of claim 1, the method comprising:

- 10 a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
- b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

27. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, the method comprising:

- 15 a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
- 20 c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

28. A method of screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:

- 30 a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
- b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

29. A method of assessing toxicity of a test compound, the method comprising:
- a) treating a biological sample containing nucleic acids with the test compound,
 - b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 12 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 12 or fragment thereof,
 - c) quantifying the amount of hybridization complex, and
 - d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
30. A diagnostic test for a condition or disease associated with the expression of PKIN in a biological sample, the method comprising:
- a) combining the biological sample with an antibody of claim 11, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex, and
 - b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.
31. The antibody of claim 11, wherein the antibody is:
- a) a chimeric antibody,
 - b) a single chain antibody,
 - c) a Fab fragment,
 - d) a F(ab')₂ fragment, or
 - e) a humanized antibody.
32. A composition comprising an antibody of claim 11 and an acceptable excipient.
33. A method of diagnosing a condition or disease associated with the expression of PKIN in a subject, comprising administering to said subject an effective amount of the composition of claim 32.

34. A composition of claim 32, wherein the antibody is labeled.

35. A method of diagnosing a condition or disease associated with the expression of PKIN in a subject, comprising administering to said subject an effective amount of the composition of claim 34.

5

36. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibodies from said animal, and
- c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22.

15

37. A polyclonal antibody produced by a method of claim 36.

38. A composition comprising the polyclonal antibody of claim 37 and a suitable carrier.

39. A method of making a monoclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibody producing cells from the animal,
- c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells,
- d) culturing the hybridoma cells, and
- e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22.

25
30

40. A monoclonal antibody produced by a method of claim 39.

41. A composition comprising the monoclonal antibody of claim 40 and a suitable carrier.

42. The antibody of claim 11, wherein the antibody is produced by screening a Fab expression library.

5

43. The antibody of claim 11, wherein the antibody is produced by screening a recombinant immunoglobulin library.

44. A method of detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22 in a sample, the method comprising:

10

- a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22 in the sample.

15

45. A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22 from a sample, the method comprising:

20

- a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-22.

46. A microarray wherein at least one element of the microarray is a polynucleotide of claim 13.

25

47. A method of generating a transcript image of a sample which contains polynucleotides, the method comprising:

30

- a) labeling the polynucleotides of the sample,
- b) contacting the elements of the microarray of claim 46 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and
- c) quantifying the expression of the polynucleotides in the sample.

48. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, and wherein said target polynucleotide is a polynucleotide of claim 12.

5

49. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.

50. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is
10 completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.

51. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to said target polynucleotide.

15 52. An array of claim 48, which is a microarray.

53. An array of claim 48, further comprising said target polynucleotide hybridized to a nucleotide molecule comprising said first oligonucleotide or polynucleotide sequence.

20 54. An array of claim 48, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.

55. An array of claim 48, wherein each distinct physical location on the substrate contains multiple nucleotide molecules, and the multiple nucleotide molecules at any single distinct physical
25 location have the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another distinct physical location on the substrate.

56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

30

57. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.

58. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.

59. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.

60. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.

5 61. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.

62. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.

63. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.

10

64. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.

65. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.

15 66. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:11.

67. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:12.

68. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.

20

69. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.

70. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:15.

25 71. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:16.

72. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:17.

73. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:18.

30

74. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:19.

75. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:20.

76. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:21.

77. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:22.

5 78. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:23.

79. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:24.

10 80. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:25.

81. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:26.

82. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:27.

15 83. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:28.

84. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:29.

20 85. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:30.

86. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:31.

87. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:32.

25 88. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:33.

89. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:34.

30 90. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:35.

91. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:36.

92. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:37.

93. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:38.

94. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:39.

5 95. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:40.

96. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:41.

10 97. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:42.

98. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:43.

99. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:44.

<110> INCYTE GENOMICS, INC.
GURURAJAN, Rajagopal
BAUGHN, Mariah R.
WALIA, Narinder K.
ELLIOTT, Vicki S.
XU, Yuming
ARVIZU, Chandra
YAO, Monique G.
RAMKUMAR, Jayalaxmi
DING, Li
TANG, Y. Tom
HAFALIA, April J.A.
NGUYEN, Danniel B.
GANDHI, Ameena R.
LU, Yan
YUE, Henry
BURFORD, Neil
BANDMAN, Olga
TRIBOULEY, Catherine
LAL, Preeti G.
RECIPON, Shirley A.
LU, Dyung Aina M.
BOROWSKY, Mark L.
THORNTON, Michael
SWARNAKER Anita
THANGAVELU, Kavitha
KHAN, Farrah A.
ISON, Craig H.

<120> HUMAN KINASES

<130> PI-0262 PCT

<140> To Be Assigned
<141> Herewith

<150> 60/242,410; 60/244,068; 60/245,708; 60/247,672; 60/249,565;
60/252,730; 60/250,807
<151> 2000-10-20; 2000-10-27; 2000-11-03; 2000-11-09; 2000-11-16
2000-11-22; 2000-12-01

<160> 44
<170> PERL Program

<210> 1
<211> 337
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7482896CD1

<400> 1
Met Thr Asn Asn Ser Gly Ser Lys Ala Glu Leu Val Val Gly Gly
1 5 10 15

```

Val Tyr Leu Gly Ile Thr Thr Thr Asn Gly Glu Asp Val Ala Val
      35                      40                      45
Lys Leu Glu Ser Gln Lys Val Lys His Pro Gln Leu Leu Tyr Glu
      50                      55                      60
Ser Lys Leu Tyr Thr Ile Leu Gln Gly Gly Val Gly Ile Pro His
      65                      70                      75
Met His Trp Tyr Gly Gln Glu Lys Asp Asn Asn Val Leu Val Met
      80                      85                      90
Asp Leu Leu Gly Pro Ser Leu Glu Asp Leu Phe Asn Phe Cys Ser
      95                      100                     105
Arg Arg Phe Thr Met Lys Thr Val Leu Met Leu Ala Asp Gln Met
      110                     115                     120
Ile Ser Arg Ile Glu Tyr Val His Thr Lys Asn Phe Leu His Arg
      125                     130                     135
Asp Ile Lys Pro Asp Asn Phe Leu Met Gly Thr Gly Arg His Cys
      140                     145                     150
Asn Lys Leu Phe Leu Ile Asp Phe Gly Leu Ala Lys Lys Tyr Arg
      155                     160                     165
Asp Asn Arg Thr Arg Gln His Ile Pro Tyr Arg Glu Asp Lys His
      170                     175                     180
Leu Ile Gly Thr Val Arg Tyr Ala Ser Ile Asn Ala His Leu Gly
      185                     190                     195
Ile Glu Gln Ser Arg Arg Asp Asp Met Glu Ser Leu Gly Tyr Val
      200                     205                     210
Phe Met Tyr Phe Asn Arg Thr Ser Leu Pro Trp Gln Gly Leu Arg
      215                     220                     225
Ala Met Thr Lys Lys Gln Lys Tyr Glu Lys Ile Ser Glu Lys Lys
      230                     235                     240
Met Ser Thr Pro Val Glu Val Leu Cys Lys Gly Phe Pro Ala Glu
      245                     250                     255
Phe Ala Met Tyr Leu Asn Tyr Cys Arg Gly Leu Arg Phe Glu Glu
      260                     265                     270
Val Pro Asp Tyr Met Tyr Leu Arg Gln Leu Phe Arg Ile Leu Phe
      275                     280                     285
Arg Thr Leu Asn His Gln Tyr Asp Tyr Thr Phe Asp Trp Thr Met
      290                     295                     300
Leu Lys Gln Lys Ala Ala Gln Gln Ala Ala Ser Ser Ser Gly Gln
      305                     310                     315
Gly Gln Gln Ala Gln Thr Gln Thr Gly Lys Gln Thr Glu Lys Asn
      320                     325                     330
Lys Asn Asn Val Lys Asp Asn
      335

```

<210> 2

<211> 475

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7483046CD1

<400> 2

```

Met Glu Arg Arg Leu Arg Ala Leu Glu Gln Leu Ala Arg Gly Glu
  1              5              10              15
Ala Gly Gly Cys Pro Gly Leu Asp Gly Leu Leu Asp Leu Leu Leu

```

	20		25		30
Ala Leu His His	Glu Leu Ser Ser Gly	Pro Leu Arg Arg	Glu Arg		
	35		40		45
Ser Val Ala Gln	Phe Leu Ser Trp Ala	Ser Pro Phe Val	Ser Lys		
	50		55		60
Val Lys Glu Leu	Arg Leu Gln Arg Asp	Asp Phe Glu Ile	Leu Lys		
	65		70		75
Val Ile Gly Arg	Gly Ala Phe Gly Glu	Val Thr Val Val	Arg Gln		
	80		85		90
Arg Asp Thr Gly	Gln Ile Phe Ala Met	Lys Met Leu His	Lys Trp		
	95		100		105
Glu Met Leu Lys	Arg Ala Glu Thr Ala	Cys Phe Arg Glu	Glu Arg		
	110		115		120
Asp Val Leu Val	Lys Gly Asp Ser Arg	Trp Val Thr Thr	Leu His		
	125		130		135
Tyr Ala Phe Gln	Asp Glu Glu Tyr Leu	Tyr Leu Val Met	Asp Tyr		
	140		145		150
Tyr Ala Gly Gly	Asp Leu Leu Thr Leu	Leu Ser Arg Phe	Glu Asp		
	155		160		165
Arg Leu Pro Pro	Glu Leu Ala Gln Phe	Tyr Leu Ala Glu	Met Val		
	170		175		180
Leu Ala Ile His	Ser Leu His Gln Leu	Gly Tyr Val His	Arg Asp		
	185		190		195
Val Lys Pro Asp	Asn Val Leu Leu Asp	Val Asn Gly His	Ile Arg		
	200		205		210
Leu Ala Asp Phe	Gly Ser Cys Leu Arg	Leu Asn Thr Asn	Gly Met		
	215		220		225
Val Asp Ser Ser	Val Ala Val Gly Thr	Pro Asp Tyr Ile	Ser Pro		
	230		235		240
Glu Ile Leu Gln	Ala Met Glu Glu Gly	Lys Gly His Tyr	Gly Pro		
	245		250		255
Gln Cys Asp Trp	Trp Ser Leu Gly Val	Cys Ala Tyr Glu	Leu Leu		
	260		265		270
Phe Gly Glu Thr	Pro Phe Tyr Ala Glu	Ser Leu Val Glu	Thr Tyr		
	275		280		285
Gly Lys Ile Met	Asn His Glu Asp His	Leu Gln Phe Pro	Pro Asp		
	290		295		300
Val Pro Asp Val	Pro Ala Ser Ala Gln	Asp Leu Ile Arg	Gln Leu		
	305		310		315
Leu Cys Arg Gln	Glu Glu Arg Leu Gly	Arg Gly Gly Leu	Asp Asp		
	320		325		330
Phe Arg Asn His	Pro Phe Phe Glu Gly	Val Asp Trp Glu	Arg Leu		
	335		340		345
Ala Ser Ser Thr	Ala Pro Tyr Ile Pro	Glu Leu Arg Gly	Pro Met		
	350		355		360
Asp Thr Ser Asn	Phe Asp Val Asp Asp	Asp Thr Leu Asn	His Pro		
	365		370		375
Gly Thr Leu Pro	Pro Pro Ser His Gly	Ala Phe Ser Gly	His His		
	380		385		390
Leu Pro Phe Val	Gly Phe Thr Tyr Thr	Ser Gly Ser His	Ser Pro		
	395		400		405
Glu Ser Ser Ser	Glu Ala Trp Ala Ala	Leu Glu Arg Lys	Leu Gln		
	410		415		420
Cys Leu Glu Gln	Glu Lys Val Glu Leu	Ser Arg Lys His	Gln Glu		
	425		430		435
Ala Leu His Ala	Pro Thr Asp His Arg	Glu Leu Glu Gln	Leu Arg		

	440	445	450
Lys Glu Val Gln Thr Leu Arg Asp Arg Leu Pro Gly Ile Pro Ser			
	455	460	465
Ala His Pro His Pro Leu Leu Glu Phe Leu			
	470	475	

<210> 3

<211> 675

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 71636374CD1

<400> 3

Met Thr Thr Ser His Met Asn Gly His Val Thr Glu Glu Ser Asp		
1	5	10
Ser Glu Val Lys Asn Val Asp Leu Ala Ser Pro Glu Glu His Gln		
	20	25
Lys His Arg Glu Met Ala Val Asp Cys Pro Gly Asp Leu Gly Thr		
	35	40
Arg Met Met Pro Ile Arg Arg Ser Ala Gln Leu Glu Arg Ile Arg		
	50	55
Gln Gln Gln Glu Asp Met Arg Arg Arg Arg Glu Glu Glu Gly Lys		
	65	70
Lys Gln Glu Leu Asp Leu Asn Ser Ser Met Arg Leu Lys Lys Leu		
	80	85
Ala Gln Ile Pro Pro Lys Thr Gly Ile Asp Asn Pro Met Phe Asp		
	95	100
Thr Glu Glu Gly Ile Val Leu Glu Ser Pro His Tyr Ala Val Lys		
	110	115
Ile Leu Glu Ile Glu Asp Leu Phe Ser Ser Leu Lys His Ile Gln		
	125	130
His Thr Leu Val Asp Ser Gln Ser Gln Glu Asp Ile Ser Leu Leu		
	140	145
Leu Gln Leu Val Gln Asn Lys Asp Phe Gln Asn Ala Phe Lys Ile		
	155	160
His Asn Ala Ile Thr Val His Met Asn Lys Ala Ser Pro Pro Phe		
	170	175
Pro Leu Ile Ser Asn Ala Gln Asp Leu Ala Gln Glu Val Gln Thr		
	185	190
Val Leu Lys Pro Val His His Lys Glu Gly Gln Glu Leu Thr Ala		
	200	205
Leu Leu Asn Thr Pro His Ile Gln Ala Leu Leu Leu Ala His Asp		
	215	220
Lys Val Ala Glu Gln Glu Met Gln Leu Glu Pro Ile Thr Asp Glu		
	230	235
Arg Val Tyr Glu Ser Ile Gly Gln Tyr Gly Gly Glu Thr Val Lys		
	245	250
Ile Val Arg Ile Glu Lys Ala Arg Asp Ile Pro Leu Gly Ala Thr		
	260	265
Val Arg Asn Glu Met Asp Ser Val Ile Ile Ser Arg Ile Val Lys		
	275	280
Gly Gly Ala Ala Glu Lys Ser Gly Leu Leu His Glu Gly Asp Glu		
	290	295

Val Leu Glu Ile Asn Gly Ile Glu Ile Arg Gly Lys Asp Val Asn	305	310	315
Glu Val Phe Asp Leu Leu Ser Asp Met His Gly Thr Leu Thr Phe	320	325	330
Val Leu Ile Pro Ser Gln Gln Ile Lys Pro Pro Pro Ala Lys Glu	335	340	345
Thr Val Ile His Val Lys Ala His Phe Asp Tyr Asp Pro Ser Asp	350	355	360
Asp Pro Tyr Val Pro Cys Arg Glu Leu Gly Leu Ser Phe Gln Lys	365	370	375
Gly Asp Ile Leu His Val Ile Ser Gln Glu Asp Pro Asn Trp Trp	380	385	390
Gln Ala Tyr Arg Glu Gly Asp Glu Asp Asn Gln Pro Leu Ala Gly	395	400	405
Leu Val Pro Gly Lys Ser Phe Gln Gln Gln Arg Glu Ala Met Lys	410	415	420
Gln Thr Ile Glu Glu Asp Lys Glu Pro Glu Lys Ser Gly Lys Leu	425	430	435
Trp Cys Ala Lys Lys Asn Lys Lys Lys Arg Lys Lys Val Leu Tyr	440	445	450
Asn Ala Asn Lys Asn Asp Asp Tyr Asp Asn Glu Glu Ile Leu Thr	455	460	465
Tyr Glu Glu Met Ser Leu Tyr His Gln Pro Ala Asn Arg Lys Arg	470	475	480
Pro Ile Ile Leu Ile Gly Pro Gln Asn Cys Gly Gln Asn Glu Leu	485	490	495
Arg Gln Arg Leu Met Asn Lys Glu Lys Asp Arg Phe Ala Ser Ala	500	505	510
Val Pro His Thr Thr Arg Ser Arg Arg Asp Gln Glu Val Ala Gly	515	520	525
Arg Asp Tyr His Phe Val Ser Arg Gln Ala Phe Glu Ala Asp Ile	530	535	540
Ala Ala Gly Lys Phe Ile Glu His Gly Glu Phe Glu Lys Asn Leu	545	550	555
Tyr Gly Thr Ser Ile Asp Ser Val Arg Gln Val Ile Asn Ser Gly	560	565	570
Lys Ile Cys Leu Leu Ser Leu Arg Thr Gln Ser Leu Lys Thr Leu	575	580	585
Arg Asn Ser Asp Leu Lys Pro Tyr Ile Ile Phe Ile Ala Pro Pro	590	595	600
Ser Gln Glu Arg Leu Arg Ala Leu Leu Ala Lys Glu Gly Lys Asn	605	610	615
Pro Lys Pro Glu Glu Leu Arg Glu Ile Ile Glu Lys Thr Arg Glu	620	625	630
Met Glu Gln Asn Asn Gly His Tyr Phe Asp Thr Ala Ile Val Asn	635	640	645
Ser Asp Leu Asp Lys Ala Tyr Gln Glu Leu Leu Arg Leu Ile Asn	650	655	660
Lys Leu Asp Thr Glu Pro Gln Trp Val Pro Ser Thr Trp Leu Arg	665	670	675

<210> 4

<211> 835

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7480597CD1

<400> 4

```

Met Ala Glu Gly Lys Glu Gly Gln Val Pro Ser Tyr Met Asp Gly
  1              5              10              15
Ser Arg Gln Arg Glu Asn Glu Glu Asp Ala Lys Ala Glu Thr Pro
              20              25              30
Asp Val Thr Ile Arg Ser Tyr Glu Ile Tyr Ser Leu Pro Trp Asn
              35              40              45
Arg Gln Gln Gly Leu Cys Asp His Ser Leu Lys Tyr Leu Ser Ser
              50              55              60
Arg Ile Thr Glu Arg Lys Leu Gln Gly Ser Trp Leu Pro Ala Ser
              65              70              75
Arg Gly Asn Leu Glu Lys Pro Phe Leu Gly Pro Arg Gly Pro Val
              80              85              90
Val Pro Leu Phe Cys Pro Arg Asn Gly Leu His Ser Ala His Pro
              95              100             105
Glu Asn Ser Pro Leu Lys Pro Arg Val Val Thr Val Val Lys Leu
              110             115             120
Gly Gly Gln Arg Pro Arg Lys Ile Thr Leu Leu Leu Asn Arg Arg
              125             130             135
Ser Val Gln Thr Phe Glu Gln Leu Leu Ala Asp Ile Ser Glu Ala
              140             145             150
Leu Gly Ser Pro Arg Trp Lys Asn Asp Arg Val Arg Lys Leu Phe
              155             160             165
Asn Leu Lys Gly Arg Glu Ile Arg Ser Val Ser Asp Phe Phe Arg
              170             175             180
Glu Gly Asp Ala Phe Ile Ala Met Gly Lys Glu Pro Leu Thr Leu
              185             190             195
Lys Ser Ile Gln Val Ala Val Glu Glu Leu Tyr Pro Asn Lys Ala
              200             205             210
Arg Ala Leu Thr Leu Ala Gln His Ser Arg Ala Pro Ser Pro Arg
              215             220             225
Leu Arg Ser Arg Leu Phe Ser Lys Ala Leu Lys Gly Asp His Arg
              230             235             240
Cys Gly Glu Thr Glu Thr Pro Lys Ser Cys Ser Glu Val Ala Gly
              245             250             255
Cys Lys Ala Ala Met Arg His Gln Gly Lys Ile Pro Glu Glu Leu
              260             265             270
Ser Leu Asp Asp Arg Ala Arg Thr Gln Lys Lys Trp Gly Arg Gly
              275             280             285
Lys Trp Glu Pro Glu Pro Ser Ser Lys Pro Pro Arg Glu Ala Thr
              290             295             300
Leu Glu Glu Arg His Ala Arg Gly Glu Lys His Leu Gly Val Glu
              305             310             315
Ile Glu Lys Thr Ser Gly Glu Ile Ile Arg Cys Glu Lys Cys Lys
              320             325             330
Arg Glu Arg Glu Leu Gln Gln Ser Leu Glu Arg Glu Arg Leu Ser
              335             340             345
Leu Gly Thr Ser Glu Leu Asp Met Gly Lys Gly Pro Met Tyr Asp
              350             355             360
Val Glu Lys Leu Val Arg Thr Arg Ser Cys Arg Arg Ser Pro Glu
              365             370             375
Ala Asn Pro Ala Ser Gly Glu Glu Gly Trp Lys Gly Asp Ser His

```

380	385	390
Arg Ser Ser Pro Arg Asn Pro Thr Gln Glu Leu Arg Arg Pro Ser		
395	400	405
Lys Ser Met Asp Lys Lys Glu Asp Arg Gly Pro Glu Asp Gln Glu		
410	415	420
Ser His Ala Gln Gly Ala Ala Lys Ala Lys Lys Asp Leu Val Glu		
425	430	435
Val Leu Pro Val Thr Glu Glu Gly Leu Arg Glu Val Lys Lys Asp		
440	445	450
Thr Arg Pro Met Ser Arg Ser Lys His Gly Gly Trp Leu Leu Arg		
455	460	465
Glu His Gln Ala Gly Phe Glu Lys Leu Arg Arg Thr Arg Gly Glu		
470	475	480
Glu Lys Glu Ala Glu Lys Glu Lys Lys Pro Cys Met Ser Gly Gly		
485	490	495
Arg Arg Met Thr Leu Arg Asp Asp Gln Pro Ala Lys Leu Glu Lys		
500	505	510
Glu Pro Lys Thr Arg Pro Glu Glu Asn Lys Pro Glu Arg Pro Ser		
515	520	525
Gly Arg Lys Pro Arg Pro Met Gly Ile Ile Ala Ala Asn Val Glu		
530	535	540
Lys His Tyr Glu Thr Gly Arg Val Ile Gly Asp Gly Asn Phe Ala		
545	550	555
Val Val Lys Glu Cys Arg His Arg Glu Thr Arg Gln Ala Tyr Ala		
560	565	570
Met Lys Ile Ile Asp Lys Ser Arg Leu Lys Gly Lys Glu Asp Met		
575	580	585
Val Asp Ser Glu Ile Leu Ile Ile Gln Ser Leu Ser His Pro Asn		
590	595	600
Ile Val Lys Leu His Glu Val Tyr Glu Thr Asp Met Glu Ile Tyr		
605	610	615
Leu Ile Leu Glu Tyr Val Gln Gly Gly Asp Leu Phe Asp Ala Ile		
620	625	630
Ile Glu Ser Val Lys Phe Pro Glu Pro Asp Ala Ala Leu Met Ile		
635	640	645
Met Asp Leu Cys Lys Ala Leu Val His Met His Asp Lys Ser Ile		
650	655	660
Val His Arg Asp Leu Lys Pro Glu Asn Leu Leu Val Gln Arg Asn		
665	670	675
Glu Asp Lys Ser Thr Thr Leu Lys Leu Ala Asp Phe Gly Leu Ala		
680	685	690
Lys His Val Val Arg Pro Ile Phe Thr Val Cys Gly Thr Pro Thr		
695	700	705
Tyr Val Ala Pro Glu Ile Leu Ser Glu Lys Gly Tyr Gly Leu Glu		
710	715	720
Val Asp Met Trp Ala Ala Gly Val Ile Leu Tyr Ile Leu Leu Cys		
725	730	735
Gly Phe Pro Pro Phe Arg Ser Pro Glu Arg Asp Gln Asp Glu Leu		
740	745	750
Phe Asn Ile Ile Gln Leu Gly His Phe Glu Phe Leu Pro Pro Tyr		
755	760	765
Trp Asp Asn Ile Ser Asp Ala Ala Lys Asp Leu Val Ser Arg Leu		
770	775	780
Leu Val Val Asp Pro Lys Lys Arg Tyr Thr Ala His Gln Val Leu		
785	790	795
Gln His Pro Trp Ile Glu Thr Ala Gly Lys Thr Asn Thr Val Lys		

800	805	810
Arg Gln Lys Gln Val Ser Pro Ser Ser Glu Gly His Phe Arg Ser		
815	820	825
Gln His Lys Arg Val Val Glu Gln Val Ser		
830	835	

<210> 5

<211> 373

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3227248CD1

<400> 5

Met Lys Leu Ile Asn Gly Lys Lys Gln Thr Phe Pro Trp Phe Gly		
1	5	10
Met Asp Ile Gly Gly Thr Leu Val Lys Leu Val Tyr Phe Glu Pro		
20	25	30
Lys Asp Ile Thr Ala Glu Glu Glu Gln Glu Glu Val Glu Asn Leu		
35	40	45
Lys Ser Ile Arg Lys Tyr Leu Thr Ser Asn Thr Ala Tyr Gly Lys		
50	55	60
Thr Gly Ile Arg Asp Val His Leu Glu Leu Lys Asn Leu Thr Met		
65	70	75
Cys Gly Arg Lys Gly Asn Leu His Phe Ile Arg Phe Pro Ser Cys		
80	85	90
Ala Met His Arg Phe Ile Gln Met Gly Ser Glu Lys Asn Phe Ser		
95	100	105
Ser Leu His Thr Thr Leu Cys Ala Thr Gly Gly Gly Ala Phe Lys		
110	115	120
Phe Glu Glu Asp Phe Arg Met Ile Ala Asp Leu Gln Leu His Lys		
125	130	135
Leu Asp Glu Leu Asp Cys Leu Ile Gln Gly Leu Leu Tyr Val Asp		
140	145	150
Ser Val Gly Phe Asn Gly Lys Pro Glu Cys Tyr Tyr Phe Glu Asn		
155	160	165
Pro Thr Asn Pro Glu Leu Cys Gln Lys Lys Pro Tyr Cys Leu Asp		
170	175	180
Asn Pro Tyr Pro Met Leu Leu Val Asn Met Gly Ser Gly Val Ser		
185	190	195
Ile Leu Ala Val Tyr Ser Lys Asp Asn Tyr Lys Arg Val Thr Gly		
200	205	210
Thr Ser Leu Gly Gly Gly Thr Phe Leu Gly Leu Cys Cys Leu Leu		
215	220	225
Thr Gly Cys Glu Thr Phe Glu Glu Ala Leu Glu Met Ala Ala Lys		
230	235	240
Gly Asp Ser Thr Asn Val Asp Lys Leu Val Lys Asp Ile Tyr Gly		
245	250	255
Gly Asp Tyr Glu Arg Phe Gly Leu Gln Gly Ser Ala Val Ala Ser		
260	265	270
Ser Phe Gly Asn Met Met Ser Lys Glu Lys Arg Asp Ser Ile Ser		
275	280	285
Lys Glu Asp Leu Ala Arg Ala Thr Leu Val Thr Ile Thr Asn Asn		
290	295	300

Ile Gly Ser Ile Ala Arg Met Cys Ala Leu Asn Glu Asn Ile Asp		
	305	310 315
Arg Val Val Phe Val Gly Asn Phe Leu Arg Ile Asn Met Val Ser		
	320	325 330
Met Lys Leu Leu Ala Tyr Ala Met Asp Phe Trp Ser Lys Gly Gln		
	335	340 345
Leu Lys Ala Leu Phe Leu Glu His Glu Gly Tyr Phe Gly Ala Val		
	350	355 360
Gly Ala Leu Leu Glu Leu Phe Lys Met Thr Asp Asp Lys		
	365	370

<210> 6

<211> 735

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4207273CD1

<400> 6

Met Pro Gln Ile Ala Lys Lys Gln Ser Thr His Arg Thr Gln Lys		
1	5	10 15
Pro Lys Lys Gln Ser Phe Pro Cys Ile Cys Lys Asn Pro Gly Thr		
	20	25 30
Gln Lys Ser Cys Val Pro Leu Ser Val Gln Pro Thr Glu Pro Arg		
	35	40 45
Leu Asn Tyr Leu Asp Leu Lys Tyr Ser Asp Met Phe Lys Glu Ile		
	50	55 60
Asn Ser Thr Ala Asn Gly Pro Gly Ile Tyr Glu Met Phe Gly Thr		
	65	70 75
Pro Val Tyr Cys His Val Arg Glu Thr Glu Arg Asp Glu Asn Thr		
	80	85 90
Tyr Tyr Arg Glu Ile Cys Ser Ala Pro Ser Gly Arg Arg Ile Thr		
	95	100 105
Asn Lys Cys Arg Ser Ser His Ser Glu Arg Lys Ser Asn Ile Arg		
	110	115 120
Thr Arg Leu Ser Gln Lys Lys Thr His Met Lys Cys Pro Lys Thr		
	125	130 135
Ser Phe Gly Ile Lys Gln Glu His Lys Val Leu Ile Ser Lys Glu		
	140	145 150
Lys Ser Ser Lys Ala Val His Ser Asn Leu His Asp Ile Glu Asn		
	155	160 165
Gly Asp Gly Ile Ser Glu Pro Asp Trp Gln Ile Lys Ser Ser Gly		
	170	175 180
Asn Glu Phe Leu Ser Ser Lys Asp Glu Ile His Pro Met Asn Leu		
	185	190 195
Ala Gln Thr Pro Glu Gln Ser Met Lys Gln Asn Glu Phe Pro Pro		
	200	205 210
Val Ser Asp Leu Ser Ile Val Glu Glu Val Ser Met Glu Glu Ser		
	215	220 225
Thr Gly Asp Arg Asp Ile Ser Asn Asn Gln Ile Leu Thr Thr Ser		
	230	235 240
Leu Arg Asp Leu Gln Glu Leu Glu Glu Leu His His Gln Ile Pro		
	245	250 255
Phe Ile Pro Ser Glu Asp Ser Trp Ala Val Pro Ser Glu Lys Asn		

260	265	270
Ser Asn Lys Tyr Val Gln Gln Glu Lys Gln Asn Thr Ala Ser Leu		
275	280	285
Ser Lys Val Asn Ala Ser Arg Ile Leu Thr Asn Asp Leu Glu Phe		
290	295	300
Asp Ser Val Ser Asp His Ser Lys Thr Leu Thr Asn Phe Ser Phe		
305	310	315
Gln Ala Lys Gln Glu Ser Ala Ser Ser Gln Thr Tyr Gln Tyr Trp		
320	325	330
Val His Tyr Leu Asp His Asp Ser Leu Ala Asn Lys Ser Ile Thr		
335	340	345
Tyr Gln Met Phe Gly Lys Thr Leu Ser Gly Thr Asn Ser Ile Ser		
350	355	360
Gln Glu Ile Met Asp Ser Val Asn Asn Glu Glu Leu Thr Asp Glu		
365	370	375
Leu Leu Gly Cys Leu Ala Ala Glu Leu Leu Ala Leu Asp Glu Lys		
380	385	390
Asp Asn Asn Ser Cys Gln Lys Met Ala Asn Glu Thr Asp Pro Glu		
395	400	405
Asn Leu Asn Leu Val Leu Arg Trp Arg Gly Ser Thr Pro Lys Glu		
410	415	420
Met Gly Arg Glu Thr Thr Lys Val Lys Ile Gln Arg His Ser Ser		
425	430	435
Gly Leu Arg Ile Tyr Asp Arg Glu Glu Lys Phe Leu Ile Ser Asn		
440	445	450
Glu Lys Lys Ile Phe Ser Glu Asn Ser Leu Lys Ser Glu Glu Pro		
455	460	465
Ile Leu Trp Thr Lys Gly Glu Ile Leu Gly Lys Gly Ala Tyr Gly		
470	475	480
Thr Val Tyr Cys Gly Leu Thr Ser Gln Gly Gln Leu Ile Ala Val		
485	490	495
Lys Gln Val Ala Leu Asp Thr Ser Asn Lys Leu Ala Ala Glu Lys		
500	505	510
Glu Tyr Arg Lys Leu Gln Glu Glu Val Asp Leu Leu Lys Ala Leu		
515	520	525
Lys His Val Asn Ile Val Ala Tyr Leu Gly Thr Cys Leu Gln Glu		
530	535	540
Asn Thr Val Ser Ile Phe Met Glu Phe Val Pro Gly Gly Ser Ile		
545	550	555
Ser Ser Ile Ile Asn Arg Phe Gly Pro Leu Pro Glu Met Val Phe		
560	565	570
Cys Lys Tyr Thr Lys Gln Ile Leu Gln Gly Val Ala Tyr Leu His		
575	580	585
Glu Asn Cys Val Val His Arg Asp Ile Lys Gly Asn Asn Val Met		
590	595	600
Leu Met Pro Thr Gly Ile Ile Lys Leu Ile Asp Phe Gly Cys Ala		
605	610	615
Arg Arg Leu Ala Trp Ala Gly Leu Asn Gly Thr His Ser Asp Met		
620	625	630
Leu Lys Ser Met His Gly Thr Pro Tyr Trp Met Ala Pro Glu Val		
635	640	645
Ile Asn Glu Ser Gly Tyr Gly Arg Lys Ser Asp Ile Trp Ser Ile		
650	655	660
Gly Cys Thr Val Phe Glu Met Ala Thr Gly Lys Pro Pro Leu Ala		
665	670	675
Ser Met Asp Arg Met Ala Ala Met Phe Tyr Ile Gly Ala His Arg		

	680		685		690
Gly Leu Met Pro	Pro Leu Pro Asp His	Phe Ser Glu Asn Ala	Ala		
	695		700		705
Asp Phe Val Arg	Met Cys Leu Thr Arg	Asp Gln His Glu Arg	Pro		
	710		715		720
Ser Ala Leu Gln	Leu Leu Lys His Ser	Phe Leu Glu Arg Ser	His		
	725		730		735

<210> 7

<211> 506

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7483334CD1

<400> 7

Met Asp Asp Tyr	Met Val Leu Arg	Met Ile Gly Glu Gly Ser	Phe
1	5	10	15
Gly Arg Ala Leu	Leu Val Gln Leu Glu Ser	Ser Asn Gln Met	Phe
	20	25	30
Ala Met Lys Glu	Ile Arg Leu Pro Lys Ser	Phe Ser Asn Thr	Gln
	35	40	45
Asn Ser Arg Lys	Glu Ala Val Leu Leu Ala Lys	Met Lys His	Pro
	50	55	60
Asn Ile Val Ala	Phe Lys Glu Ser Phe Glu	Ala Glu Gly His	Leu
	65	70	75
Tyr Ile Val Met	Glu Tyr Cys Asp Gly Gly	Asp Leu Met Gln	Lys
	80	85	90
Ile Lys Gln Gln	Lys Gly Lys Leu Phe Pro	Glu Asp Met Ile	Leu
	95	100	105
Asn Trp Phe Thr	Gln Met Cys Leu Gly Val	Asn His Ile His	Lys
	110	115	120
Lys Arg Val Leu	His Arg Asp Ile Lys Ser	Lys Asn Ile Phe	Leu
	125	130	135
Thr Gln Asn Gly	Lys Val Lys Leu Gly Asp	Phe Gly Ser Ala	Arg
	140	145	150
Leu Leu Ser Asn	Pro Met Ala Phe Ala Cys	Thr Tyr Val Gly	Thr
	155	160	165
Pro Tyr Tyr Val	Pro Pro Glu Ile Trp Glu	Asn Leu Pro Tyr	Asn
	170	175	180
Asn Lys Ser Asp	Ile Trp Ser Leu Gly Cys	Ile Leu Tyr Glu	Leu
	185	190	195
Cys Thr Leu Lys	His Pro Phe Gln Ala Asn	Ser Trp Lys Asn	Leu
	200	205	210
Ile Leu Lys Val	Cys Gln Gly Cys Ile Ser	Pro Leu Pro Ser	His
	215	220	225
Tyr Ser Tyr Glu	Leu Gln Phe Leu Val Lys	Gln Met Phe Lys	Arg
	230	235	240
Asn Pro Ser His	Arg Pro Ser Ala Thr Thr	Leu Leu Ser Arg	Gly
	245	250	255
Ile Val Ala Arg	Leu Val Gln Lys Cys Leu	Pro Pro Glu Ile	Ile
	260	265	270
Met Glu Tyr Gly	Glu Glu Val Leu Glu Glu	Ile Lys Asn Ser	Lys

275	280	285
His Asn Thr Pro Arg Lys Lys Thr Asn Pro Ser Arg Ile Arg Ile		
290	295	300
Ala Leu Gly Asn Glu Ala Ser Thr Val Gln Glu Glu Glu Gln Asp		
305	310	315
Arg Lys Gly Ser His Thr Asp Leu Glu Ser Ile Asn Glu Asn Leu		
320	325	330
Val Glu Ser Ala Leu Arg Arg Val Asn Arg Glu Glu Lys Gly Asn		
335	340	345
Lys Ser Val His Leu Arg Lys Ala Ser Ser Pro Asn Leu His Arg		
350	355	360
Arg Gln Trp Glu Lys Asn Val Pro Asn Thr Ala Leu Thr Ala Leu		
365	370	375
Glu Asn Ala Ser Ile Leu Thr Ser Ser Leu Thr Ala Glu Asp Asp		
380	385	390
Arg Gly Gly Ser Val Ile Lys Tyr Ser Lys Asn Thr Thr Arg Lys		
395	400	405
Gln Trp Leu Lys Glu Thr Pro Asp Thr Leu Leu Asn Ile Leu Lys		
410	415	420
Asn Ala Asp Leu Ser Leu Ala Phe Gln Thr Tyr Thr Ile Tyr Arg		
425	430	435
Pro Gly Ser Glu Gly Phe Leu Lys Gly Pro Leu Ser Glu Glu Thr		
440	445	450
Glu Ala Ser Asp Ser Val Asp Gly Gly His Asp Ser Val Ile Leu		
455	460	465
Asp Pro Glu Arg Leu Glu Pro Gly Leu Asp Glu Glu Asp Thr Asp		
470	475	480
Phe Glu Glu Glu Asp Asp Asn Pro Asp Trp Val Ser Glu Leu Lys		
485	490	495
Lys Arg Ala Gly Trp Gln Gly Leu Cys Asp Arg		
500	505	

<210> 8

<211> 2014

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7483337CD1

<400> 8

Met Glu Thr Leu Asn Gly Ala Gly Asp Thr Gly Gly Lys Pro Ser	
1	5
Thr Arg Gly Gly Asp Pro Ala Ala Arg Ser Arg Arg Thr Glu Gly	10
20	25
Ile Arg Ala Ala Tyr Arg Arg Gly Asp Arg Gly Gly Ala Arg Asp	30
35	40
Leu Leu Glu Glu Ala Cys Asp Gln Cys Ala Ser Gln Leu Glu Lys	45
50	55
Gly Gln Leu Leu Ser Ile Pro Ala Ala Tyr Gly Asp Leu Glu Met	60
65	70
Val Arg Tyr Leu Leu Ser Lys Arg Leu Val Glu Leu Pro Thr Glu	75
80	85
Pro Thr Asp Asp Asn Pro Ala Val Val Ala Ala Tyr Phe Gly His	90
95	100
	105

Thr Ala Val Val	Gln Asn Thr Leu Pro	Thr Glu Pro Thr Asp Asp	
	110	115	120
Asn Pro Ala Val	Val Ala Ala Tyr Phe	Gly His Thr Ala Val Val	
	125	130	135
Gln Glu Leu Leu	Glu Ser Leu Pro Gly	Pro Cys Ser Pro Gln Arg	
	140	145	150
Leu Leu Asn Trp	Met Leu Ala Leu Ala	Cys Gln Arg Gly His Leu	
	155	160	165
Gly Val Val Lys	Leu Leu Val Leu Thr	His Gly Ala Asp Pro Glu	
	170	175	180
Ser Tyr Ala Val	Arg Lys Asn Glu Phe	Pro Val Ile Val Arg Leu	
	185	190	195
Pro Leu Tyr Ala	Ala Ile Lys Ser Gly	Asn Glu Asp Ile Ala Ile	
	200	205	210
Phe Leu Leu Arg	His Gly Ala Tyr Phe	Cys Ser Tyr Ile Leu Leu	
	215	220	225
Asp Ser Pro Asp	Pro Ser Lys His Leu	Leu Arg Lys Tyr Phe Ile	
	230	235	240
Glu Ala Ser Pro	Leu Pro Ser Ser Tyr	Pro Gly Lys Thr Ala Leu	
	245	250	255
Arg Val Lys Trp	Ser His Leu Arg Leu	Pro Trp Val Asp Leu Asp	
	260	265	270
Trp Leu Ile Asp	Ile Ser Cys Gln Ile	Thr Glu Leu Asp Leu Ser	
	275	280	285
Ala Asn Cys Leu	Ala Thr Leu Pro Ser	Val Ile Pro Trp Gly Leu	
	290	295	300
Ile Asn Leu Arg	Lys Leu Asn Leu Ser	Asp Asn His Leu Gly Glu	
	305	310	315
Leu Pro Gly Val	Gln Ser Ser Asp Glu	Ile Ile Cys Ser Arg Leu	
	320	325	330
Leu Glu Ile Asp	Ile Ser Ser Asn Lys	Leu Ser His Leu Pro Pro	
	335	340	345
Gly Phe Leu His	Leu Ser Lys Leu Gln	Lys Leu Thr Ala Ser Lys	
	350	355	360
Asn Cys Leu Glu	Lys Leu Phe Glu Glu	Glu Asn Ala Thr Asn Trp	
	365	370	375
Ile Gly Leu Arg	Lys Leu Gln Glu Leu	Asp Ile Ser Asp Asn Lys	
	380	385	390
Leu Thr Glu Leu	Pro Ala Leu Phe Leu	His Ser Phe Lys Ser Leu	
	395	400	405
Asn Ser Leu Asn	Val Ser Arg Asn Asn	Leu Lys Val Phe Pro Asp	
	410	415	420
Pro Trp Ala Cys	Pro Leu Lys Cys Cys	Lys Ala Ser Arg Asn Ala	
	425	430	435
Leu Glu Cys Leu	Pro Asp Lys Met Ala	Val Phe Trp Lys Asn His	
	440	445	450
Leu Lys Asp Val	Asp Phe Ser Glu Asn	Ala Leu Lys Glu Val Pro	
	455	460	465
Leu Gly Leu Phe	Gln Leu Asp Ala Leu	Met Phe Leu Arg Leu Gln	
	470	475	480
Gly Asn Gln Leu	Ala Ala Leu Pro Pro	Gln Glu Lys Trp Thr Cys	
	485	490	495
Arg Gln Leu Lys	Thr Leu Asp Leu Ser	Arg Asn Gln Leu Gly Lys	
	500	505	510
Asn Glu Asp Gly	Leu Lys Thr Lys Arg	Ile Ala Phe Phe Thr Thr	
	515	520	525

Arg Gly Arg Gln Arg Ser Gly Thr Glu Ala Glu Thr Thr Met Glu		
	530	535 540
Phe Ser Ala Ser Leu Val Thr Ile Val Phe Leu Ser Asn Asn Cys		
	545	550 555
Asn Leu Cys Ala Tyr Thr Cys Ala Ala Ser Val Leu Glu Phe Pro		
	560	565 570
Ala Phe Leu Ser Glu Ser Leu Glu Val Leu Cys Leu Asn Asp Asn		
	575	580 585
His Leu Asp Thr Val Pro Pro Ser Val Cys Leu Leu Lys Ser Leu		
	590	595 600
Ser Glu Leu Tyr Leu Gly Asn Asn Pro Gly Leu Arg Glu Leu Pro		
	605	610 615
Pro Glu Leu Gly Gln Leu Gly Asn Leu Trp Gln Leu Asp Thr Glu		
	620	625 630
Asp Leu Thr Ile Ser Asn Val Pro Ala Glu Ile Gln Lys Glu Gly		
	635	640 645
Pro Lys Ala Met Leu Ser Tyr Leu Arg Ala Gln Leu Arg Lys Ala		
	650	655 660
Glu Lys Cys Lys Leu Met Lys Met Ile Ile Val Gly Pro Pro Arg		
	665	670 675
Gln Gly Lys Ser Thr Leu Leu Glu Ile Leu Gln Thr Gly Arg Ala		
	680	685 690
Pro Gln Val Val His Gly Glu Ala Thr Ile Arg Thr Thr Lys Trp		
	695	700 705
Glu Leu Gln Arg Pro Ala Gly Ser Arg Ala Lys Val Lys Asp Gly		
	710	715 720
Leu Arg Ala Glu Ser Leu Trp Val Glu Ser Val Glu Phe Asn Val		
	725	730 735
Trp Asp Ile Gly Gly Pro Ala Ser Met Ala Thr Val Asn Gln Cys		
	740	745 750
Phe Phe Thr Asp Lys Ala Leu Tyr Val Val Val Trp Asn Leu Ala		
	755	760 765
Leu Gly Glu Glu Ala Val Ala Asn Leu Gln Phe Trp Leu Leu Asn		
	770	775 780
Ile Glu Ala Lys Ala Pro Asn Ala Val Val Leu Val Val Gly Thr		
	785	790 795
His Leu Asp Leu Ile Glu Ala Lys Phe Arg Val Glu Arg Ile Ala		
	800	805 810
Thr Leu Arg Ala Tyr Val Leu Ala Leu Cys Arg Ser Pro Ser Gly		
	815	820 825
Ser Arg Ala Thr Gly Phe Pro Asp Ile Thr Phe Lys His Leu His		
	830	835 840
Glu Ile Ser Cys Lys Ser Leu Glu Gly Gln Glu Gly Leu Arg Gln		
	845	850 855
Leu Ile Phe His Val Thr Cys Ser Met Lys Asp Val Gly Ser Thr		
	860	865 870
Ile Gly Cys Gln Arg Leu Ala Gly Arg Leu Ile Pro Arg Ser Tyr		
	875	880 885
Leu Ser Leu Gln Glu Ala Val Leu Ala Glu Gln Gln Arg Arg Ser		
	890	895 900
Arg Asp Asp Asp Val Gln Tyr Leu Thr Asp Arg Gln Leu Glu Gln		
	905	910 915
Leu Val Glu Gln Thr Pro Asp Asn Asp Ile Lys Asp Tyr Glu Asp		
	920	925 930
Leu Gln Ser Ala Ile Ser Phe Leu Ile Glu Thr Gly Thr Leu Leu		
	935	940 945

His Phe Pro Asp Thr Ser His Gly Leu Arg Asn Leu Tyr Phe Leu		
950	955	960
Asp Pro Ile Trp Leu Ser Glu Cys Leu Gln Arg Ile Phe Asn Ile		
965	970	975
Lys Gly Ser Arg Ser Val Ala Lys Asn Gly Val Ile Arg Ala Glu		
980	985	990
Asp Leu Arg Met Leu Leu Val Gly Thr Gly Phe Thr Gln Gln Thr		
995	1000	1005
Glu Glu Gln Tyr Phe Gln Phe Leu Ala Lys Phe Glu Ile Ala Leu		
1010	1015	1020
Pro Val Ala Asn Asp Ser Tyr Leu Leu Pro His Leu Leu Pro Ser		
1025	1030	1035
Lys Pro Gly Leu Asp Thr His Gly Met Arg His Pro Thr Ala Asn		
1040	1045	1050
Thr Ile Gln Arg Val Phe Lys Met Ser Phe Val Pro Val Gly Phe		
1055	1060	1065
Trp Gln Arg Phe Ile Ala Arg Met Leu Ile Ser Leu Ala Glu Met		
1070	1075	1080
Asp Leu Gln Leu Phe Glu Asn Lys Lys Asn Thr Lys Ser Arg Asn		
1085	1090	1095
Arg Lys Val Thr Ile Tyr Ser Phe Thr Gly Asn Gln Arg Asn Arg		
1100	1105	1110
Cys Ser Thr Phe Arg Val Lys Arg Asn Gln Thr Ile Tyr Trp Gln		
1115	1120	1125
Glu Gly Leu Leu Val Thr Phe Asp Gly Gly Tyr Leu Ser Val Glu		
1130	1135	1140
Ser Ser Asp Val Asn Trp Lys Lys Lys Ser Gly Gly Met Lys		
1145	1150	1155
Ile Val Cys Gln Ser Glu Val Arg Asp Phe Ser Ala Met Ala Phe		
1160	1165	1170
Ile Thr Asp His Val Asn Ser Leu Ile Asp Gln Trp Phe Pro Ala		
1175	1180	1185
Leu Thr Ala Thr Glu Ser Asp Gly Thr Pro Leu Met Glu Gln Tyr		
1190	1195	1200
Val Pro Cys Pro Val Cys Glu Thr Ala Trp Ala Gln His Thr Asp		
1205	1210	1215
Pro Ser Glu Lys Ser Glu Asp Val Gln Tyr Phe Asp Met Glu Asp		
1220	1225	1230
Cys Val Leu Thr Ala Ile Glu Arg Asp Phe Ile Ser Cys Pro Arg		
1235	1240	1245
His Pro Asp Leu Pro Val Pro Leu Gln Glu Leu Val Pro Glu Leu		
1250	1255	1260
Phe Met Thr Asp Phe Pro Ala Arg Leu Phe Leu Glu Asn Ser Lys		
1265	1270	1275
Leu Glu His Ser Glu Asp Glu Gly Ser Val Leu Gly Gln Gly Gly		
1280	1285	1290
Ser Gly Thr Val Ile Tyr Arg Ala Arg Tyr Gln Gly Gln Pro Val		
1295	1300	1305
Ala Val Lys Arg Phe His Ile Lys Lys Phe Lys Asn Phe Ala Asn		
1310	1315	1320
Val Pro Ala Asp Thr Met Leu Arg His Leu Arg Ala Thr Asp Ala		
1325	1330	1335
Met Lys Asn Phe Ser Glu Phe Arg Gln Glu Ala Ser Met Leu His		
1340	1345	1350
Ala Leu Gln His Pro Cys Ile Val Ala Leu Ile Gly Ile Ser Ile		
1355	1360	1365

His Pro Leu Cys Phe Ala Leu Glu Leu Ala Pro Leu Ser Ser Leu		
1370	1375	1380
Asn Thr Val Leu Ser Glu Asn Ala Arg Asp Ser Ser Phe Ile Pro		
1385	1390	1395
Leu Gly His Met Leu Thr Gln Lys Ile Ala Tyr Gln Ile Ala Ser		
1400	1405	1410
Gly Leu Ala Tyr Leu His Lys Lys Asn Ile Ile Phe Cys Asp Leu		
1415	1420	1425
Lys Ser Asp Asn Ile Leu Val Trp Ser Leu Asp Val Lys Glu His		
1430	1435	1440
Ile Asn Ile Lys Leu Ser Asp Tyr Gly Ile Ser Arg Gln Ser Phe		
1445	1450	1455
His Glu Gly Ala Leu Gly Val Glu Gly Thr Pro Gly Tyr Gln Ala		
1460	1465	1470
Pro Glu Ile Arg Pro Arg Ile Val Tyr Asp Glu Lys Val Asp Met		
1475	1480	1485
Phe Ser Tyr Gly Met Val Leu Tyr Glu Leu Leu Ser Gly Gln Arg		
1490	1495	1500
Pro Ala Leu Gly His His Gln Leu Gln Ile Ala Lys Lys Leu Ser		
1505	1510	1515
Lys Gly Ile Arg Pro Val Leu Gly Gln Pro Glu Glu Val Gln Phe		
1520	1525	1530
Arg Arg Leu Gln Ala Leu Met Met Glu Cys Trp Asp Thr Lys Pro		
1535	1540	1545
Glu Lys Arg Pro Leu Ala Leu Ser Val Val Ser Gln Met Lys Asp		
1550	1555	1560
Pro Thr Phe Ala Thr Phe Met Tyr Glu Leu Cys Cys Gly Lys Gln		
1565	1570	1575
Thr Ala Phe Phe Ser Ser Gln Gly Gln Glu Tyr Thr Val Val Phe		
1580	1585	1590
Trp Asp Gly Lys Glu Glu Ser Arg Asn Tyr Thr Val Val Asn Thr		
1595	1600	1605
Glu Lys Gly Leu Met Glu Val Gln Arg Met Cys Cys Pro Gly Met		
1610	1615	1620
Lys Val Ser Cys Gln Leu Gln Val Gln Arg Ser Leu Trp Thr Ala		
1625	1630	1635
Thr Glu Asn Ser Tyr Leu Val Leu Ala Gly Leu Ala Asp Gly Leu		
1640	1645	1650
Val Ala Val Phe Pro Val Val Arg Gly Thr Pro Lys Asp Ser Cys		
1655	1660	1665
Ser Tyr Leu Cys Ser His Thr Ala Asn Arg Ser Lys Phe Ser Ile		
1670	1675	1680
Ala Asp Glu Asp Ala Arg Gln Asn Pro Tyr Pro Val Lys Ala Met		
1685	1690	1695
Glu Val Val Asn Ser Gly Ser Glu Val Trp Tyr Ser Asn Gly Pro		
1700	1705	1710
Gly Leu Leu Val Ile Asp Cys Ala Ser Leu Glu Ile Cys Arg Arg		
1715	1720	1725
Leu Glu Pro Tyr Met Ala Pro Ser Met Val Thr Ser Val Val Cys		
1730	1735	1740
Ser Ser Glu Gly Arg Gly Glu Glu Val Val Trp Cys Leu Asp Asp		
1745	1750	1755
Lys Ala Asn Ser Leu Val Met Tyr His Ser Thr Thr Tyr Gln Leu		
1760	1765	1770
Cys Ala Arg Tyr Phe Cys Gly Val Pro Ser Pro Leu Arg Asp Met		
1775	1780	1785

Phe Pro Val Arg Pro Leu Asp Thr Glu Pro Pro Ala Ala Ser His
 1790 1795 1800
 Thr Ala Asn Pro Lys Val Pro Glu Gly Asp Ser Ile Ala Asp Val
 1805 1810 1815
 Ser Ile Met Tyr Ser Glu Glu Leu Gly Thr Gln Ile Leu Ile His
 1820 1825 1830
 Gln Glu Ser Leu Thr Asp Tyr Cys Ser Met Ser Ser Tyr Ser Ser
 1835 1840 1845
 Ser Pro Pro Arg Gln Ala Ala Arg Ser Pro Ser Ser Leu Pro Ser
 1850 1855 1860
 Ser Pro Ala Ser Ser Ser Ser Val Pro Phe Ser Thr Asp Cys Glu
 1865 1870 1875
 Asp Ser Asp Met Leu His Thr Pro Gly Ala Ala Ser Asp Arg Ser
 1880 1885 1890
 Glu His Asp Leu Thr Pro Met Asp Gly Glu Thr Phe Ser Gln His
 1895 1900 1905
 Leu Gln Ala Val Lys Ile Leu Ala Val Arg Asp Leu Ile Trp Val
 1910 1915 1920
 Pro Arg Arg Gly Gly Asp Val Ile Val Ile Gly Leu Glu Lys Asp
 1925 1930 1935
 Ser Gly Ala Gln Arg Gly Arg Val Ile Ala Val Leu Lys Ala Arg
 1940 1945 1950
 Glu Leu Thr Pro His Gly Val Leu Val Asp Ala Ala Val Val Ala
 1955 1960 1965
 Lys Asp Thr Val Val Cys Thr Phe Glu Asn Glu Asn Thr Glu Trp
 1970 1975 1980
 Cys Leu Ala Val Trp Arg Gly Trp Gly Ala Arg Glu Phe Asp Ile
 1985 1990 1995
 Phe Tyr Gln Ser Tyr Glu Glu Leu Gly Arg Leu Glu Ala Cys Thr
 2000 2005 2010
 Arg Lys Arg Arg

<210> 9

<211> 348

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 6035509CD1

<400> 9

Met Met Leu Gly Leu Glu Ser Leu Pro Asp Pro Thr Asp Thr Trp
 1 5 10 15
 Glu Ile Ile Glu Thr Ile Gly Lys Gly Thr Tyr Gly Lys Val Tyr
 20 25 30
 Lys Val Thr Asn Lys Arg Asp Gly Ser Leu Ala Ala Val Lys Ile
 35 40 45
 Leu Asp Pro Val Ser Asp Met Asp Glu Glu Ile Glu Ala Glu Tyr
 50 55 60
 Asn Ile Leu Gln Phe Leu Pro Asn His Pro Asn Val Val Lys Phe
 65 70 75
 Tyr Gly Met Phe Tyr Lys Ala Asp His Cys Val Gly Gly Gln Leu
 80 85 90
 Trp Leu Val Leu Glu Leu Cys Asn Gly Gly Ser Val Thr Glu Leu

	95		100		105
Val	Lys	Gly	Leu	Leu	Arg
	110		115		120
Ile	Ser	Tyr	Ile	Leu	Tyr
	125		130		135
His	Asn	Asn	Arg	Ile	Ile
	140		145		150
Leu	Leu	Thr	Thr	Glu	Gly
	155		160		165
Ser	Ala	Gln	Leu	Thr	Ser
	170		175		180
Gly	Thr	Pro	Phe	Trp	Met
	185		190		195
Gln	Tyr	Asp	Ser	Ser	Tyr
	200		205		210
Gly	Ile	Thr	Ala	Ile	Glu
	215		220		225
Asp	Met	His	Pro	Val	Lys
	230		235		240
Pro	Pro	Thr	Leu	Leu	His
	245		250		255
His	Phe	Ile	Ser	Gln	Cys
	260		265		270
Ser	Val	Thr	His	Leu	Leu
	275		280		285
Gly	Lys	Val	Leu	Phe	Leu
	290		295		300
Asp	Gln	Lys	His	Gln	Asn
	305		310		315
Met	His	Thr	Arg	Arg	Pro
	320		325		330
Cys	Leu	Glu	Asp	Asp	Leu
	335		340		345
Leu	Asn	Ile			

<210> 10

<211> 2042

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7373485CD1

<400> 10

Met	Ala	Thr	Asp	Asp	Lys	Thr	Ser	Pro	Thr	Leu	Asp	Ser	Ala	Asn
1				5					10					15
Asp	Leu	Pro	Arg	Ser	Pro	Thr	Ser	Pro	Ser	His	Leu	Thr	His	Phe
				20					25					30
Lys	Pro	Leu	Thr	Pro	Asp	Gln	Asp	Glu	Pro	Pro	Phe	Lys	Ser	Ala
				35					40					45
Tyr	Ser	Ser	Phe	Val	Asn	Leu	Phe	Arg	Phe	Asn	Lys	Glu	Arg	Ala
				50					55					60
Glu	Gly	Gly	Gln	Gly	Glu	Gln	Gln	Pro	Leu	Ser	Gly	Ser	Trp	Thr
				65					70					75

Ser	Pro	Gln	Leu	Pro	Ser	Arg	Thr	Gln	Ser	Val	Arg	Ser	Pro	Thr	80	85	90
Pro	Tyr	Lys	Lys	Gln	Leu	Asn	Glu	Glu	Leu	Gln	Arg	Arg	Ser	Ser	95	100	105
Ala	Leu	Asp	Thr	Arg	Arg	Lys	Ala	Glu	Pro	Thr	Phe	Gly	Gly	His	110	115	120
Asp	Pro	Arg	Thr	Ala	Val	Gln	Leu	Arg	Ser	Leu	Ser	Thr	Val	Leu	125	130	135
Lys	Arg	Leu	Lys	Glu	Ile	Met	Glu	Gly	Lys	Ser	Gln	Asp	Ser	Asp	140	145	150
Leu	Lys	Gln	Tyr	Trp	Met	Pro	Asp	Ser	Gln	Cys	Lys	Glu	Cys	Tyr	155	160	165
Asp	Cys	Ser	Glu	Lys	Phe	Thr	Thr	Phe	Arg	Arg	Arg	His	His	Cys	170	175	180
Arg	Leu	Cys	Gly	Gln	Ile	Phe	Cys	Ser	Arg	Cys	Cys	Asn	Gln	Glu	185	190	195
Ile	Pro	Gly	Lys	Phe	Met	Gly	Tyr	Thr	Gly	Asp	Leu	Arg	Ala	Cys	200	205	210
Thr	Tyr	Cys	Arg	Lys	Ile	Ala	Leu	Ser	Tyr	Ala	His	Ser	Thr	Asp	215	220	225
Ser	Asn	Ser	Ile	Gly	Glu	Asp	Leu	Asn	Ala	Leu	Ser	Asp	Ser	Ala	230	235	240
Cys	Ser	Val	Ser	Val	Leu	Asp	Pro	Ser	Glu	Pro	Arg	Thr	Pro	Val	245	250	255
Gly	Ser	Arg	Lys	Ala	Ser	Arg	Asn	Ile	Phe	Leu	Glu	Asp	Asp	Leu	260	265	270
Ala	Trp	Gln	Ser	Leu	Ile	His	Pro	Asp	Ser	Ser	Asn	Thr	Pro	Leu	275	280	285
Ser	Thr	Arg	Leu	Val	Ser	Val	Gln	Glu	Asp	Ala	Gly	Lys	Ser	Pro	290	295	300
Ala	Arg	Asn	Arg	Ser	Ala	Ser	Ile	Thr	Asn	Leu	Ser	Leu	Asp	Arg	305	310	315
Ser	Gly	Ser	Pro	Met	Val	Pro	Ser	Tyr	Glu	Thr	Ser	Val	Ser	Pro	320	325	330
Gln	Ala	Asn	Arg	Thr	Tyr	Val	Arg	Thr	Glu	Thr	Thr	Glu	Asp	Glu	335	340	345
Arg	Lys	Ile	Leu	Leu	Asp	Ser	Val	Gln	Leu	Lys	Asp	Leu	Trp	Lys	350	355	360
Lys	Ile	Cys	His	His	Ser	Ser	Gly	Met	Glu	Phe	Gln	Asp	His	Arg	365	370	375
Tyr	Trp	Leu	Arg	Thr	His	Pro	Asn	Cys	Ile	Val	Gly	Lys	Glu	Leu	380	385	390
Val	Asn	Trp	Leu	Ile	Arg	Asn	Gly	His	Ile	Ala	Thr	Arg	Ala	Gln	395	400	405
Ala	Ile	Ala	Ile	Gly	Gln	Ala	Met	Val	Asp	Gly	Arg	Trp	Leu	Asp	410	415	420
Cys	Val	Ser	His	His	Asp	Gln	Leu	Phe	Arg	Asp	Glu	Tyr	Ala	Leu	425	430	435
Tyr	Arg	Pro	Leu	Gln	Ser	Thr	Glu	Phe	Ser	Glu	Thr	Pro	Ser	Pro	440	445	450
Asp	Ser	Asp	Ser	Val	Asn	Ser	Val	Glu	Gly	His	Ser	Glu	Pro	Ser	455	460	465
Trp	Phe	Lys	Asp	Ile	Lys	Phe	Asp	Asp	Ser	Asp	Thr	Glu	Gln	Ile	470	475	480
Ala	Glu	Glu	Gly	Asp	Asp	Asn	Leu	Ala	Lys	Tyr	Leu	Ile	Ser	Asp	485	490	495

Thr Gly Gly Gln Gln Leu Ser Ile Ser Asp Ala Phe Ile Lys Glu	500	505	510
Ser Leu Phe Asn Arg Arg Val Glu Glu Lys Ser Lys Glu Leu Pro	515	520	525
Phe Thr Pro Leu Gly Trp His His Asn Asn Leu Glu Leu Leu Arg	530	535	540
Glu Glu Asn Gly Glu Lys Gln Ala Met Glu Arg Leu Leu Ser Ala	545	550	555
Asn His Asn His Met Met Ala Leu Leu Gln Gln Leu Leu His Ser	560	565	570
Asp Ser Leu Ser Ser Ser Trp Arg Asp Ile Ile Val Ser Leu Val	575	580	585
Cys Gln Val Val Gln Thr Val Arg Pro Asp Val Lys Asn Gln Asp	590	595	600
Asp Asp Met Asp Ile Arg Gln Phe Val His Ile Lys Lys Ile Pro	605	610	615
Gly Gly Lys Lys Phe Asp Ser Val Val Val Asn Gly Phe Val Cys	620	625	630
Thr Lys Asn Ile Ala His Lys Lys Met Asn Ser Cys Ile Lys Asn	635	640	645
Pro Lys Ile Leu Leu Leu Lys Cys Ser Ile Glu Tyr Leu Tyr Arg	650	655	660
Glu Glu Thr Lys Phe Thr Cys Ile Asp Pro Ile Val Leu Gln Glu	665	670	675
Arg Glu Phe Leu Lys Asn Tyr Val Gln Arg Ile Val Asp Val Arg	680	685	690
Pro Thr Leu Val Leu Val Glu Lys Thr Val Ser Arg Ile Ala Gln	695	700	705
Asp Met Leu Leu Glu His Gly Ile Thr Leu Val Ile Asn Val Lys	710	715	720
Ser Gln Val Leu Glu Arg Ile Ser Arg Met Thr Gln Gly Asp Leu	725	730	735
Val Met Ser Met Asp Gln Leu Leu Thr Lys Pro Arg Leu Gly Thr	740	745	750
Cys His Lys Phe Tyr Met Gln Ile Phe Gln Leu Pro Asn Glu Gln	755	760	765
Thr Lys Thr Leu Met Phe Phe Glu Gly Cys Pro Gln His Leu Gly	770	775	780
Cys Thr Ile Lys Leu Arg Gly Gly Ser Asp Tyr Glu Leu Ala Arg	785	790	795
Val Lys Glu Ile Leu Ile Phe Met Ile Cys Val Ala Tyr His Ser	800	805	810
Gln Leu Glu Ile Ser Phe Leu Met Asp Glu Phe Ala Met Pro Pro	815	820	825
Thr Leu Met Gln Asn Pro Ser Phe His Ser Leu Ile Glu Gly Arg	830	835	840
Gly His Glu Gly Ala Val Gln Glu Gln Tyr Gly Gly Gly Ser Ile	845	850	855
Pro Trp Asp Pro Asp Ile Pro Pro Glu Ser Leu Pro Cys Asp Asp	860	865	870
Ser Ser Leu Leu Glu Ser Arg Ile Val Phe Glu Lys Gly Glu Gln	875	880	885
Glu Asn Lys Asn Leu Pro Gln Ala Val Ala Ser Val Lys His Gln	890	895	900
Glu His Ser Thr Thr Ala Cys Pro Ala Gly Leu Pro Cys Ala Phe	905	910	915

Phe Ala Pro Val	Pro Glu Ser Leu Leu	Pro Leu Pro Val	Asp Asp
920		925	930
Gln Gln Asp Ala	Leu Gly Ser Glu Leu	Pro Glu Ser Leu	Gln Gln
935		940	945
Thr Val Val Leu	Gln Asp Pro Lys Ser	Gln Ile Arg Ala	Phe Arg
950		955	960
Asp Pro Leu Gln	Asp Asp Thr Gly Leu	Tyr Val Thr Glu	Glu Val
965		970	975
Thr Ser Ser Glu	Asp Lys Arg Lys Thr	Tyr Ser Leu Ala	Phe Lys
980		985	990
Gln Glu Leu Lys	Asp Val Ile Leu Cys	Ile Ser Pro Val	Ile Thr
995		1000	1005
Phe Arg Glu Pro	Phe Leu Leu Thr	Glu Lys Gly Met	Arg Cys Ser
1010		1015	1020
Thr Arg Asp Tyr	Phe Ala Glu Gln	Val Tyr Trp Ser	Pro Leu Leu
1025		1030	1035
Asn Lys Glu Phe	Lys Glu Met Glu	Asn Arg Arg Lys	Lys Gln Leu
1040		1045	1050
Leu Arg Asp Leu	Ser Gly Leu Gln	Gly Met Asn Gly	Ser Ile Gln
1055		1060	1065
Ala Lys Ser Ile	Gln Val Leu Pro	Ser His Glu Leu	Val Ser Thr
1070		1075	1080
Arg Ile Ala Glu	His Leu Gly Asp	Ser Gln Ser Leu	Gly Arg Met
1085		1090	1095
Leu Ala Asp Tyr	Arg Ala Arg Gly	Gly Arg Ile Gln	Pro Lys Asn
1100		1105	1110
Ser Asp Pro Phe	Ala His Ser Lys	Asp Ala Ser Ser	Thr Ser Ser
1115		1120	1125
Gly Lys Ser Gly	Ser Lys Asn Glu	Gly Asp Glu Glu	Arg Gly Leu
1130		1135	1140
Ile Leu Ser Asp	Ala Val Trp Ser	Thr Lys Val Asp	Cys Leu Asn
1145		1150	1155
Pro Ile Asn His	Gln Arg Leu Cys	Val Leu Phe Ser	Ser Ser Ser
1160		1165	1170
Ala Gln Ser Ser	Asn Ala Pro Ser	Ala Cys Val Ser	Pro Trp Ile
1175		1180	1185
Val Thr Met Glu	Phe Tyr Gly Lys	Asn Asp Leu Thr	Leu Gly Ile
1190		1195	1200
Phe Leu Glu Arg	Tyr Cys Phe Arg	Pro Ser Tyr Gln	Cys Pro Ser
1205		1210	1215
Met Phe Cys Asp	Thr Pro Met Val	His His Ile Arg	Arg Phe Val
1220		1225	1230
His Gly Gln Gly	Cys Val Gln Ile	Ile Leu Lys Glu	Leu Asp Ser
1235		1240	1245
Pro Val Pro Gly	Tyr Gln His Thr	Ile Leu Thr Tyr	Ser Trp Cys
1250		1255	1260
Arg Ile Cys Lys	Gln Val Thr Pro	Val Val Ala Leu	Ser Asn Glu
1265		1270	1275
Ser Trp Ser Met	Ser Phe Ala Lys	Tyr Leu Glu Leu	Arg Phe Tyr
1280		1285	1290
Gly His Gln Tyr	Thr Arg Arg Ala	Asn Ala Glu Pro	Cys Gly His
1295		1300	1305
Ser Ile His His	Asp Tyr His Gln	Tyr Phe Ser Tyr	Asn Gln Met
1310		1315	1320
Val Ala Ser Phe	Ser Tyr Ser Pro	Ile Arg Leu Leu	Glu Val Cys
1325		1330	1335

Val Pro Leu Pro Lys Ile Phe Ile Lys Arg Gln Ala Pro Leu Lys	1340	1345	1350
Val Ser Leu Leu Gln Asp Leu Lys Asp Phe Phe Gln Lys Val Ser	1355	1360	1365
Gln Val Tyr Val Ala Ile Asp Glu Arg Leu Ala Ser Leu Lys Thr	1370	1375	1380
Asp Thr Phe Ser Lys Thr Arg Glu Glu Lys Met Glu Asp Ile Phe	1385	1390	1395
Ala Gln Lys Glu Met Glu Glu Gly Glu Phe Lys Asn Trp Ile Glu	1400	1405	1410
Lys Met Gln Ala Arg Leu Met Ser Ser Ser Val Asp Thr Pro Gln	1415	1420	1425
Gln Leu Gln Ser Val Phe Glu Ser Leu Ile Ala Lys Lys Gln Ser	1430	1435	1440
Leu Cys Glu Val Leu Gln Ala Trp Asn Asn Arg Leu Gln Asp Leu	1445	1450	1455
Phe Gln Gln Glu Lys Gly Arg Lys Arg Pro Ser Val Pro Pro Ser	1460	1465	1470
Pro Gly Arg Leu Arg Gln Gly Glu Glu Ser Lys Ile Ser Ala Met	1475	1480	1485
Asp Ala Ser Pro Arg Asn Ile Ser Pro Gly Leu Gln Asn Gly Glu	1490	1495	1500
Lys Glu Asp Arg Phe Leu Thr Thr Leu Ser Ser Gln Ser Ser Thr	1505	1510	1515
Ser Ser Thr His Leu Gln Leu Pro Thr Pro Pro Glu Val Met Ser	1520	1525	1530
Glu Gln Ser Val Gly Gly Pro Pro Glu Leu Asp Thr Ala Ser Ser	1535	1540	1545
Ser Glu Asp Val Phe Asp Gly His Leu Leu Gly Ser Thr Asp Ser	1550	1555	1560
Gln Val Lys Glu Lys Ser Thr Met Lys Ala Ile Phe Ala Asn Leu	1565	1570	1575
Leu Pro Gly Asn Ser Tyr Asn Pro Ile Pro Phe Pro Phe Asp Pro	1580	1585	1590
Asp Lys His Tyr Leu Met Tyr Glu His Glu Arg Val Pro Ile Ala	1595	1600	1605
Val Cys Glu Lys Glu Pro Ser Ser Ile Ile Ala Phe Ala Leu Ser	1610	1615	1620
Cys Lys Glu Tyr Arg Asn Ala Leu Glu Glu Leu Ser Lys Ala Thr	1625	1630	1635
Gln Trp Asn Ser Ala Glu Glu Gly Leu Pro Thr Asn Ser Thr Ser	1640	1645	1650
Asp Ser Arg Pro Lys Ser Ser Ser Pro Ile Arg Leu Pro Glu Met	1655	1660	1665
Ser Gly Gly Gln Thr Asn Arg Thr Thr Glu Thr Glu Pro Gln Pro	1670	1675	1680
Thr Lys Lys Ala Ser Gly Met Leu Ser Phe Phe Arg Gly Thr Ala	1685	1690	1695
Gly Lys Ser Pro Asp Leu Ser Ser Gln Lys Arg Glu Thr Leu Arg	1700	1705	1710
Gly Ala Asp Ser Ala Tyr Tyr Gln Val Gly Gln Thr Gly Lys Glu	1715	1720	1725
Gly Thr Glu Asn Gln Gly Val Glu Pro Gln Asp Glu Val Asp Gly	1730	1735	1740
Gly Asp Thr Gln Lys Lys Gln Leu Ile Asn Pro His Val Glu Leu	1745	1750	1755

Gln Phe Ser Asp Ala Asn Ala Lys Phe Tyr Cys Arg Leu Tyr Tyr
 1760 1765 1770
 Ala Gly Glu Phe His Lys Met Arg Glu Val Ile Leu Asp Ser Ser
 1775 1780 1785
 Glu Glu Asp Phe Ile Arg Ser Leu Ser His Ser Ser Pro Trp Gln
 1790 1795 1800
 Ala Arg Gly Gly Lys Ser Gly Ala Ala Phe Tyr Ala Thr Glu Asp
 1805 1810 1815
 Asp Arg Phe Ile Leu Lys Gln Met Pro Arg Leu Glu Val Gln Ser
 1820 1825 1830
 Phe Leu Asp Phe Ala Pro His Tyr Phe Asn Tyr Ile Thr Asn Ala
 1835 1840 1845
 Val Gln Gln Lys Arg Pro Thr Ala Leu Ala Lys Ile Leu Gly Val
 1850 1855 1860
 Tyr Arg Ile Gly Tyr Lys Asn Ser Gln Asn Asn Thr Glu Lys Lys
 1865 1870 1875
 Leu Asp Leu Leu Val Met Glu Asn Leu Phe Tyr Gly Arg Lys Met
 1880 1885 1890
 Ala Gln Val Phe Asp Leu Lys Gly Ser Leu Arg Asn Arg Asn Val
 1895 1900 1905
 Lys Thr Asp Thr Gly Lys Glu Ser Cys Asp Val Val Leu Leu Asp
 1910 1915 1920
 Glu Asn Leu Leu Lys Met Val Arg Asp Asn Pro Leu Tyr Ile Arg
 1925 1930 1935
 Ser His Ser Lys Ala Val Leu Arg Thr Ser Ile His Ser Asp Ser
 1940 1945 1950
 His Phe Leu Ser Ser His Leu Ile Ile Asp Tyr Ser Leu Leu Val
 1955 1960 1965
 Gly Arg Asp Asp Thr Ser Asn Glu Leu Val Val Gly Ile Ile Asp
 1970 1975 1980
 Tyr Ile Arg Thr Phe Thr Trp Asp Lys Lys Leu Glu Met Val Val
 1985 1990 1995
 Lys Ser Thr Gly Ile Leu Gly Gly Gln Gly Lys Met Pro Thr Val
 2000 2005 2010
 Val Ser Pro Glu Leu Tyr Arg Thr Arg Phe Cys Glu Ala Met Asp
 2015 2020 2025
 Lys Tyr Phe Leu Met Val Pro Asp His Trp Thr Gly Leu Gly Leu
 2030 2035 2040
 Asn Cys

<210> 11

<211> 551

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5734965CD1

<400> 11

Met Ser Gly Gly Glu Gln Lys Pro Glu Arg Tyr Tyr Val Gly Val
 1 5 10 15
 Asp Val Gly Thr Gly Ser Val Arg Ala Ala Leu Val Asp Gln Ser
 20 25 30
 Gly Val Leu Leu Ala Phe Ala Asp Gln Pro Ile Lys Asn Trp Glu

	35	40	45
Pro Gln Phe Asn His His Glu Gln Ser Ser Glu Asp Ile Trp Ala			
	50	55	60
Ala Cys Cys Val Val Thr Lys Lys Val Val Gln Gly Ile Asp Leu			
	65	70	75
Asn Gln Ile Arg Gly Leu Gly Phe Asp Ala Thr Cys Ser Leu Val			
	80	85	90
Val Leu Asp Lys Gln Phe His Pro Leu Pro Val Asn Gln Glu Gly			
	95	100	105
Asp Ser His Arg Asn Val Ile Met Trp Leu Asp His Arg Ala Val			
	110	115	120
Ser Gln Val Asn Arg Ile Asn Glu Thr Lys His Ser Val Leu Gln			
	125	130	135
Tyr Val Gly Gly Val Met Ser Val Glu Met Gln Ala Pro Lys Leu			
	140	145	150
Leu Trp Leu Lys Glu Asn Leu Arg Glu Ile Cys Trp Asp Lys Ala			
	155	160	165
Gly His Phe Phe Asp Leu Pro Asp Phe Leu Ser Trp Lys Ala Thr			
	170	175	180
Gly Val Thr Ala Arg Ser Leu Cys Ser Leu Val Cys Lys Trp Thr			
	185	190	195
Tyr Ser Ala Glu Lys Gly Trp Asp Asp Ser Phe Trp Lys Met Ile			
	200	205	210
Gly Leu Glu Asp Phe Val Ala Asp Asn Tyr Ser Lys Ile Gly Asn			
	215	220	225
Gln Val Leu Pro Pro Gly Ala Ser Leu Gly Asn Gly Leu Thr Pro			
	230	235	240
Glu Ala Ala Arg Asp Leu Gly Leu Leu Pro Gly Ile Ala Val Ala			
	245	250	255
Ala Ser Leu Ile Asp Ala His Ala Gly Gly Leu Gly Val Ile Gly			
	260	265	270
Ala Asp Val Arg Gly His Gly Leu Ile Cys Glu Gly Gln Pro Val			
	275	280	285
Thr Ser Arg Leu Ala Val Ile Cys Gly Thr Ser Ser Cys His Met			
	290	295	300
Gly Ile Ser Lys Asp Pro Ile Phe Val Pro Gly Val Trp Gly Pro			
	305	310	315
Tyr Phe Ser Ala Met Val Pro Gly Phe Trp Leu Asn Glu Gly Gly			
	320	325	330
Gln Ser Val Thr Gly Lys Leu Ile Asp His Met Val Gln Gly His			
	335	340	345
Ala Ala Phe Pro Glu Leu Gln Val Lys Ala Thr Ala Arg Cys Gln			
	350	355	360
Ser Ile Tyr Ala Tyr Leu Asn Ser His Leu Asp Leu Ile Lys Lys			
	365	370	375
Ala Gln Pro Val Gly Phe Leu Thr Val Asp Leu His Val Trp Pro			
	380	385	390
Asp Phe His Gly Asn Arg Ser Pro Leu Ala Asp Leu Thr Leu Lys			
	395	400	405
Gly Met Val Thr Gly Leu Lys Leu Ser Gln Asp Leu Asp Asp Leu			
	410	415	420
Ala Ile Leu Tyr Leu Ala Thr Val Gln Ala Ile Ala Leu Gly Thr			
	425	430	435
Arg Phe Ile Ile Glu Ala Met Glu Ala Ala Gly His Ser Ile Ser			
	440	445	450
Thr Leu Phe Leu Cys Gly Gly Leu Ser Lys Asn Pro Leu Phe Val			

455	460	465
Gln Met His Ala Asp Ile Thr Gly Met	Pro Val Val Leu Ser Gln	
470	475	480
Glu Val Glu Ser Val Leu Val Gly Ala	Ala Val Leu Gly Ala Cys	
485	490	495
Ala Ser Gly Asp Phe Ala Ser Val Gln	Glu Ala Met Ala Lys Met	
500	505	510
Ser Lys Val Gly Lys Val Val Phe Pro	Arg Leu Gln Asp Lys Lys	
515	520	525
Tyr Tyr Asp Lys Lys Tyr Gln Val Phe	Leu Lys Leu Val Glu His	
530	535	540
Gln Lys Glu Tyr Leu Ala Ile Met Asn	Asp Asp	
545	550	

<210> 12

<211> 485

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7473788CD1

<400> 12

Met Arg Ser Gly Ala Glu Arg Arg Gly Ser Ser Ala Ala Ala Ser		
1	5	10 15
Pro Gly Ser Pro Pro Pro Gly Arg Ala Arg Pro Ala Gly Ser Asp		
20	25	30
Ala Pro Ser Ala Leu Pro Pro Pro Ala Ala Gly Gln Pro Arg Ala		
35	40	45
Arg Asp Ser Gly Asp Val Arg Ser Gln Pro Arg Pro Leu Phe Gln		
50	55	60
Trp Ser Lys Trp Lys Lys Arg Met Gly Ser Ser Met Ser Ala Ala		
65	70	75
Thr Ala Arg Arg Pro Val Phe Asp Asp Lys Glu Asp Val Asn Phe		
80	85	90
Asp His Phe Gln Ile Leu Arg Ala Ile Gly Lys Gly Ser Phe Gly		
95	100	105
Lys Val Cys Ile Val Gln Lys Arg Asp Thr Glu Lys Met Tyr Ala		
110	115	120
Met Lys Tyr Met Asn Lys Gln Gln Cys Ile Glu Arg Asp Glu Val		
125	130	135
Arg Asn Val Phe Arg Glu Leu Glu Ile Leu Gln Glu Ile Glu His		
140	145	150
Val Phe Leu Val Asn Leu Trp Tyr Ser Phe Gln Asp Glu Glu Asp		
155	160	165
Met Phe Met Val Val Asp Leu Leu Leu Gly Gly Asp Leu Arg Tyr		
170	175	180
His Leu Gln Gln Asn Val Gln Phe Ser Glu Asp Thr Val Arg Leu		
185	190	195
Tyr Ile Cys Glu Met Ala Leu Ala Leu Asp Tyr Leu Arg Gly Gln		
200	205	210
His Ile Ile His Arg Asp Val Lys Pro Asp Asn Ile Leu Leu Asp		
215	220	225
Glu Arg Gly His Ala His Leu Thr Asp Phe Asn Ile Ala Thr Ile		
230	235	240

```

Ile Lys Asp Gly Glu Arg Ala Thr Ala Leu Ala Gly Thr Lys Pro
245 250 255
Tyr Met Ala Pro Glu Ile Phe His Ser Phe Val Asn Gly Gly Thr
260 265 270
Gly Tyr Ser Phe Glu Val Asp Trp Trp Ser Val Gly Val Met Ala
275 280 285
Tyr Glu Leu Leu Arg Gly Trp Arg Pro Tyr Asp Ile His Ser Ser
290 295 300
Asn Ala Val Glu Ser Leu Val Gln Leu Phe Ser Thr Val Ser Val
305 310 315
Gln Tyr Val Pro Thr Trp Ser Lys Glu Met Val Ala Leu Leu Arg
320 325 330
Lys Leu Leu Thr Val Asn Pro Glu His Arg Leu Ser Ser Leu Gln
335 340 345
Asp Val Gln Ala Ala Pro Ala Leu Ala Gly Val Leu Trp Asp His
350 355 360
Leu Ser Glu Lys Arg Val Glu Pro Gly Phe Val Pro Asn Lys Gly
365 370 375
Arg Leu His Cys Asp Pro Thr Phe Glu Leu Glu Glu Met Ile Leu
380 385 390
Glu Ser Arg Pro Leu His Lys Lys Lys Lys Arg Leu Ala Lys Asn
395 400 405
Lys Ser Arg Asp Asn Ser Arg Asp Ser Ser Gln Ser Glu Asn Asp
410 415 420
Tyr Leu Gln Asp Cys Leu Asp Ala Ile Gln Gln Asp Phe Val Ile
425 430 435
Phe Asn Arg Glu Lys Leu Lys Arg Ser Gln Asp Leu Pro Arg Glu
440 445 450
Pro Leu Pro Ala Leu Ser Pro Gly Met Leu Arg Ser Leu Trp Arg
455 460 465
Thr Arg Arg Thr Leu Arg Leu Pro Met Cys Gly Pro Ile Cys Pro
470 475 480
Ser Ala Gly Ser Gly
485

```

<210> 13

<211> 282

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3107989CD1

<400> 13

```

Met Pro Ala Phe Ile Gln Met Gly Arg Asp Lys Asn Phe Ser Ser
1 5 10 15
Leu His Thr Val Phe Cys Ala Thr Gly Gly Gly Ala Tyr Lys Phe
20 25 30
Glu Gln Asp Phe Leu Thr Ile Gly Asp Leu Gln Leu Cys Lys Leu
35 40 45
Asp Glu Leu Asp Cys Leu Ile Lys Gly Ile Leu Tyr Ile Asp Ser
50 55 60
Val Gly Phe Asn Gly Arg Ser Gln Cys Tyr Tyr Phe Glu Asn Pro
65 70 75
Ala Asp Ser Glu Lys Cys Gln Lys Leu Pro Phe Asp Leu Lys Asn

```

	80		85		90
Pro Tyr Pro Leu	Leu Leu Val Asn Ile Gly Ser Gly Val Ser Ile				
	95		100		105
Leu Ala Val Tyr	Ser Lys Asp Asn Tyr Lys Arg Val Thr Gly Thr				
	110		115		120
Ser Leu Gly Gly	Gly Thr Phe Phe Gly Leu Cys Cys Leu Leu Thr				
	125		130		135
Gly Cys Thr Thr	Phe Glu Glu Ala Leu Glu Met Ala Ser Arg Gly				
	140		145		150
Asp Ser Thr Lys	Val Asp Lys Leu Val Arg Asp Ile Tyr Gly Gly				
	155		160		165
Asp Tyr Glu Arg	Phe Gly Leu Pro Gly Trp Ala Val Ala Ser Ser				
	170		175		180
Phe Gly Asn Met	Met Ser Lys Glu Lys Arg Asp Ser Ile Ser Lys				
	185		190		195
Glu Asp Leu Ala	Arg Ala Thr Leu Val Thr Ile Thr Asn Asn Ile				
	200		205		210
Gly Ser Ile Ala	Arg Met Cys Ala Leu Asn Glu Asn Ile Asp Arg				
	215		220		225
Val Val Phe Val	Gly Asn Phe Leu Arg Ile Asn Met Val Ser Met				
	230		235		240
Lys Leu Leu Ala	Tyr Ala Met Asp Phe Trp Ser Lys Gly Gln Leu				
	245		250		255
Lys Ala Leu Phe	Leu Glu His Glu Gly Tyr Phe Gly Ala Val Gly				
	260		265		270
Ala Leu Leu Glu	Leu Phe Lys Met Thr Asp Asp Lys				
	275		280		

<210> 14

<211> 151

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7482887CD1

<400> 14

Met Ala Asn Thr	Glu Ser Ile Ile Ile Asn Pro Ser Ala Val Gln	
1	5	10 15
His Ser Leu Val	Gly Glu Ile Ile Lys Tyr Ser Glu Gln Lys Gly	
	20	25 30
Phe Tyr Leu Val	Thr Met Lys Phe Leu Arg Ala Ser Glu Lys Pro	
	35	40 45
Leu Lys Pro His	Tyr Thr Asn Leu Lys Asp His Pro Phe Phe Pro	
	50	55 60
Asp Leu Val Lys	Tyr Met Asn Ser Gly Gln Val Val Ala Met Val	
	65	70 75
Leu Glu Gly Leu	Asn Val Ala Lys Thr Gly Leu Arg Met Leu Gly	
	80	85 90
Glu Thr Asn Ser	Leu Gly Ser Met Leu Glu Thr Ile Ile Arg Arg	
	95	100 105
Asp Phe Cys Ala	Lys Ile Gly Gly Asn Val Ile Gly Gly Ser Asp	
	110	115 120
Ser Leu Gln Ser	Ala Glu Lys Glu Ile Ser Leu Trp Phe Lys Pro	
	125	130 135

Lys Glu Pro Val Asp Tyr Arg Ser Cys Ala Tyr Asp Trp Val Tyr
 140 145 150

Ala

<210> 15

<211> 410

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2963414CD1

<400> 15

Met Val Val Gln Asn Ser Ala Asp Ala Gly Asp Met Arg Ala Gly
 1 5 10 15
 Val Gln Leu Glu Pro Phe Leu His Gln Val Gly Gly His Met Ser
 20 25 30
 Val Met Lys Tyr Asp Glu His Thr Val Cys Lys Pro Leu Val Ser
 35 40 45
 Arg Glu Gln Arg Phe Tyr Glu Ser Leu Pro Leu Ala Met Lys Arg
 50 55 60
 Phe Thr Pro Gln Tyr Lys Gly Thr Val Thr Val His Leu Trp Lys
 65 70 75
 Asp Ser Thr Gly His Leu Ser Leu Val Ala Asn Pro Val Lys Glu
 80 85 90
 Ser Gln Glu Pro Phe Lys Val Ser Thr Glu Ser Ala Ala Val Ala
 95 100 105
 Ile Trp Gln Thr Leu Gln Gln Thr Thr Gly Ser Asn Gly Ser Asp
 110 115 120
 Cys Thr Leu Ala Gln Trp Pro His Ala Gln Leu Ala Arg Ser Pro
 125 130 135
 Lys Glu Ser Pro Ala Lys Ala Leu Leu Arg Ser Glu Pro His Leu
 140 145 150
 Asn Thr Pro Ala Phe Ser Leu Val Glu Asp Thr Asn Gly Asn Gln
 155 160 165
 Val Glu Arg Lys Ser Phe Asn Pro Trp Gly Leu Gln Cys His Gln
 170 175 180
 Ala His Leu Thr Arg Leu Cys Ser Glu Tyr Pro Glu Asn Lys Arg
 185 190 195
 His Arg Phe Leu Leu Leu Glu Asn Val Val Ser Gln Tyr Thr His
 200 205 210
 Pro Cys Val Leu Asp Leu Lys Met Gly Thr Arg Gln His Gly Asp
 215 220 225
 Asp Ala Ser Glu Glu Lys Lys Ala Arg His Met Arg Lys Cys Ala
 230 235 240
 Gln Ser Thr Ser Ala Cys Leu Gly Val Arg Ile Cys Gly Met Gln
 245 250 255
 Val Tyr Gln Thr Asp Lys Lys Tyr Phe Leu Cys Lys Asp Lys Tyr
 260 265 270
 Tyr Gly Arg Lys Ser Val Glu Gly Phe Arg Gln Ala Leu Tyr
 275 280 285
 Gln Phe Leu His Asn Gly Ser His Leu Arg Arg Glu Leu Leu Glu
 290 295 300
 Pro Ile Leu His Gln Leu Arg Ala Leu Leu Ser Ile Ile Arg Ser

	305	310	315
Gln Ser Ser Tyr	Arg Phe Tyr Ser Ser	Ser Leu Leu Val Ile	Tyr
	320	325	330
Asp Gly Gln Glu	Pro Pro Glu Arg Ala	Pro Gly Ser Pro His	Pro
	335	340	345
His Glu Ala Pro	Gln Ala Ala His Gly	Ser Ser Pro Gly Gly	Leu
	350	355	360
Thr Lys Val Asp	Ile Arg Met Ile Asp	Phe Ala His Thr Thr	Tyr
	365	370	375
Lys Gly Tyr Trp	Asn Glu His Thr Thr	Tyr Asp Gly Pro Asp	Pro
	380	385	390
Gly Tyr Ile Phe	Gly Leu Glu Asn Leu	Ile Arg Ile Leu Gln	Asp
	395	400	405
Ile Gln Glu Gly	Glu		
	410		

<210> 16

<211> 1581

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7477139CD1

<400> 16

Met Ala Gly Pro Gly Gly Trp Arg Asp Arg Glu Val Thr Asp Leu		
1	5	10 15
Gly His Leu Pro Asp Pro Thr Gly Ile Phe Ser Leu Asp Lys Thr		
	20	25 30
Ile Gly Leu Gly Thr Tyr Gly Arg Ile Tyr Leu Gly Leu His Glu		
	35	40 45
Lys Thr Gly Ala Phe Thr Ala Val Lys Val Met Asn Ala Arg Lys		
	50	55 60
Thr Pro Leu Pro Glu Ile Gly Arg Arg Val Arg Val Asn Lys Tyr		
	65	70 75
Gln Lys Ser Val Gly Trp Arg Tyr Ser Asp Glu Glu Glu Asp Leu		
	80	85 90
Arg Thr Glu Leu Asn Leu Leu Arg Lys Tyr Ser Phe His Lys Asn		
	95	100 105
Ile Val Ser Phe Tyr Gly Ala Phe Phe Lys Leu Ser Pro Pro Gly		
	110	115 120
Gln Arg His Gln Leu Trp Met Val Met Glu Leu Cys Ala Ala Gly		
	125	130 135
Ser Val Thr Asp Val Val Arg Met Thr Ser Asn Gln Ser Leu Lys		
	140	145 150
Glu Asp Trp Ile Ala Tyr Ile Cys Arg Glu Ile Leu Gln Gly Leu		
	155	160 165
Ala His Leu His Ala His Arg Val Ile His Arg Asp Ile Lys Gly		
	170	175 180
Gln Asn Val Leu Leu Thr His Asn Ala Glu Val Lys Leu Val Asp		
	185	190 195
Phe Gly Val Ser Ala Gln Val Ser Arg Thr Asn Gly Arg Arg Asn		
	200	205 210
Ser Phe Ile Gly Thr Pro Tyr Trp Met Ala Pro Glu Val Ile Asp		
	215	220 225

Cys Asp Glu Asp Pro Arg Arg Ser Tyr Asp Tyr Arg Ser Asp Val		
230	235	240
Trp Ser Val Gly Ile Thr Ala Ile Glu Met Ala Glu Gly Ala Pro		
245	250	255
Pro Leu Cys Asn Leu Gln Pro Leu Glu Ala Leu Phe Val Ile Leu		
260	265	270
Arg Glu Ser Ala Pro Thr Val Lys Ser Ser Gly Trp Ser Arg Lys		
275	280	285
Phe His Asn Phe Met Glu Lys Cys Thr Ile Lys Asn Phe Leu Phe		
290	295	300
Arg Pro Thr Ser Ala Asn Met Leu Gln His Pro Phe Val Arg Asp		
305	310	315
Ile Lys Asn Glu Arg His Val Val Glu Ser Leu Thr Arg His Leu		
320	325	330
Thr Gly Ile Ile Lys Lys Arg Gln Lys Lys Gly Ile Pro Leu Ile		
335	340	345
Phe Glu Arg Glu Glu Ala Ile Lys Glu Gln Tyr Thr Val Arg Arg		
350	355	360
Phe Arg Gly Pro Ser Cys Thr His Glu Leu Leu Arg Leu Pro Thr		
365	370	375
Ser Ser Arg Cys Arg Pro Leu Arg Val Leu His Gly Glu Pro Ser		
380	385	390
Gln Pro Arg Trp Leu Pro Asp Arg Glu Glu Pro Gln Val Gln Ala		
395	400	405
Leu Gln Gln Leu Gln Gly Ala Ala Arg Val Phe Met Pro Leu Gln		
410	415	420
Ala Leu Asp Ser Ala Pro Lys Pro Leu Lys Gly Gln Ala Gln Ala		
425	430	435
Pro Gln Arg Leu Gln Gly Ala Ala Arg Val Phe Met Pro Leu Gln		
440	445	450
Ala Gln Val Lys Ala Lys Ala Ser Lys Pro Leu Gln Met Gln Ile		
455	460	465
Lys Ala Pro Pro Arg Leu Arg Arg Ala Ala Arg Val Leu Met Pro		
470	475	480
Leu Gln Ala Gln Val Arg Ala Pro Arg Leu Leu Gln Val Gln Ser		
485	490	495
Gln Val Ser Lys Lys Gln Gln Ala Gln Thr Gln Thr Ser Glu Pro		
500	505	510
Gln Asp Leu Asp Gln Val Pro Glu Glu Phe Gln Gly Gln Asp Gln		
515	520	525
Val Pro Glu Gln Gln Arg Gln Gly Gln Ala Pro Glu Gln Gln Gln		
530	535	540
Arg His Asn Gln Val Pro Glu Gln Glu Leu Glu Gln Asn Gln Ala		
545	550	555
Pro Glu Gln Pro Glu Val Gln Glu Gln Ala Ala Glu Pro Ala Gln		
560	565	570
Ala Glu Thr Glu Ala Glu Glu Pro Glu Ser Leu Arg Val Asn Ala		
575	580	585
Gln Val Phe Leu Pro Leu Leu Ser Gln Asp His His Val Leu Leu		
590	595	600
Pro Leu His Leu Asp Thr Gln Val Leu Ile Pro Val Glu Gly Gln		
605	610	615
Thr Glu Gly Ser Pro Gln Ala Gln Ala Trp Thr Leu Glu Pro Pro		
620	625	630
Gln Ala Ile Gly Ser Val Gln Ala Leu Ile Glu Gly Leu Ser Arg		
635	640	645

Asp	Leu	Leu	Arg	Ala	Pro	Asn	Ser	Asn	Asn	Ser	Lys	Pro	Leu	Gly	650	655	660
Pro	Leu	Gln	Thr	Leu	Met	Glu	Asn	Leu	Ser	Ser	Asn	Arg	Phe	Tyr	665	670	675
Ser	Gln	Pro	Glu	Gln	Ala	Arg	Glu	Lys	Lys	Ser	Lys	Val	Ser	Thr	680	685	690
Leu	Arg	Gln	Ala	Leu	Ala	Lys	Arg	Leu	Ser	Pro	Lys	Arg	Phe	Arg	695	700	705
Ala	Lys	Ser	Ser	Trp	Arg	Pro	Glu	Lys	Leu	Glu	Leu	Ser	Asp	Leu	710	715	720
Glu	Ala	Arg	Arg	Gln	Arg	Arg	Gln	Arg	Arg	Trp	Glu	Asp	Ile	Phe	725	730	735
Asn	Gln	His	Glu	Glu	Glu	Leu	Arg	Gln	Val	Asp	Lys	Thr	Ser	Trp	740	745	750
Arg	Gln	Trp	Gly	Pro	Ser	Asp	Gln	Leu	Ile	Asp	Asn	Ser	Phe	Thr	755	760	765
Gly	Met	Gln	Asp	Leu	Lys	Lys	Tyr	Leu	Lys	Gly	Lys	Thr	Thr	Phe	770	775	780
His	Asn	Val	Gln	Val	Val	Ile	Tyr	Arg	Ala	Val	Lys	Gly	Asn	Asp	785	790	795
Asp	Val	Ala	Thr	Arg	Ser	Thr	Val	Pro	Gln	Arg	Ser	Leu	Leu	Glu	800	805	810
Gln	Ala	Gln	Lys	Pro	Ile	Asp	Ile	Arg	Gln	Arg	Ser	Ser	Gln	Asn	815	820	825
Arg	Gln	Asn	Trp	Leu	Ala	Ala	Ser	Gly	Asp	Ser	Lys	His	Lys	Ile	830	835	840
Leu	Ala	Gly	Lys	Thr	Gln	Ser	Tyr	Cys	Leu	Thr	Ile	Tyr	Ile	Ser	845	850	855
Glu	Val	Lys	Lys	Glu	Glu	Phe	Gln	Glu	Gly	Met	Asn	Gln	Lys	Cys	860	865	870
Gln	Gly	Ala	Gln	Val	Gly	Leu	Gly	Pro	Glu	Gly	His	Cys	Ile	Trp	875	880	885
Gln	Leu	Gly	Glu	Ser	Ser	Ser	Glu	Glu	Glu	Ser	Pro	Val	Thr	Gly	890	895	900
Arg	Arg	Ser	Gln	Ser	Ser	Pro	Pro	Tyr	Ser	Thr	Ile	Asp	Gln	Lys	905	910	915
Leu	Leu	Val	Asp	Ile	His	Val	Pro	Asp	Gly	Phe	Lys	Val	Gly	Lys	920	925	930
Ile	Ser	Pro	Pro	Val	Tyr	Leu	Thr	Asn	Glu	Trp	Val	Gly	Tyr	Asn	935	940	945
Ala	Leu	Ser	Glu	Ile	Phe	Arg	Asn	Asp	Trp	Leu	Thr	Pro	Ala	Pro	950	955	960
Val	Ile	Gln	Pro	Pro	Glu	Glu	Asp	Gly	Asp	Tyr	Val	Glu	Leu	Tyr	965	970	975
Asp	Ala	Ser	Ala	Asp	Thr	Asp	Gly	Asp	Asp	Asp	Asp	Glu	Ser	Asn	980	985	990
Asp	Thr	Phe	Glu	Asp	Thr	Tyr	Asp	His	Ala	Asn	Gly	Asn	Asp	Asp	995	1000	1005
Leu	Asp	Asn	Gln	Val	Asp	Gln	Ala	Asn	Asp	Val	Cys	Lys	Asp	His	1010	1015	1020
Asp	Asp	Asp	Asn	Asn	Lys	Phe	Val	Asp	Asp	Val	Asn	Asn	Asn	Tyr	1025	1030	1035
Tyr	Glu	Ala	Pro	Ser	Cys	Pro	Ser	Leu	Leu	Ser	Gly	Gln	Ala	Met	1040	1045	1050
Ala	Glu	Met	Glu	Ala	Ala	Ser	Lys	Met	Val	Met	Met	Glu	Val	Val	1055	1060	1065

Glu Lys Arg Lys Pro Thr Glu Ala Met Glu Ala Ile Gln Pro Ile		
1070	1075	1080
Glu Ala Met Glu Glu Val Gln Pro Val Arg Asp Asn Ala Ala Ile		
1085	1090	1095
Gly Asp Gln Glu Glu His Ala Ala Asn Ile Gly Ser Glu Arg Arg		
1100	1105	1110
Gly Ser Glu Gly Asp Gly Gly Lys Gly Val Val Arg Thr Ser Glu		
1115	1120	1125
Glu Ser Gly Ala Leu Gly Leu Asn Gly Glu Glu Asn Cys Ser Glu		
1130	1135	1140
Thr Asp Gly Pro Gly Leu Lys Arg Pro Ala Ser Gln Asp Phe Glu		
1145	1150	1155
Tyr Leu Gln Glu Glu Pro Gly Gly Gly Asn Glu Ala Ser Asn Ala		
1160	1165	1170
Ile Asp Ser Gly Ala Ala Pro Ser Ala Pro Asp His Glu Ser Asp		
1175	1180	1185
Asn Lys Asp Ile Ser Glu Ser Ser Thr Gln Ser Asp Phe Ser Ala		
1190	1195	1200
Asn His Ser Ser Pro Ser Lys Gly Ser Gly Met Ser Ala Asp Ala		
1205	1210	1215
Asn Phe Ala Ser Ala Ile Leu Tyr Ala Gly Phe Val Glu Val Pro		
1220	1225	1230
Glu Glu Ser Pro Lys Gln Pro Ser Glu Val Asn Val Asn Pro Leu		
1235	1240	1245
Tyr Val Ser Pro Ala Cys Lys Lys Pro Leu Ile His Met Tyr Glu		
1250	1255	1260
Lys Glu Phe Thr Ser Glu Ile Cys Cys Gly Ser Leu Trp Gly Val		
1265	1270	1275
Asn Leu Leu Leu Gly Thr Arg Ser Asn Leu Tyr Leu Met Asp Arg		
1280	1285	1290
Ser Gly Lys Ala Asp Ile Thr Lys Leu Ile Arg Arg Arg Pro Phe		
1295	1300	1305
Arg Gln Ile Gln Val Leu Glu Pro Leu Asn Leu Leu Ile Thr Ile		
1310	1315	1320
Ser Gly His Lys Asn Arg Leu Arg Val Tyr His Leu Thr Trp Leu		
1325	1330	1335
Arg Asn Lys Ile Leu Asn Asn Asp Pro Glu Ser Lys Arg Arg Gln		
1340	1345	1350
Glu Glu Met Leu Lys Thr Glu Glu Ala Cys Lys Ala Ile Asp Lys		
1355	1360	1365
Leu Thr Gly Cys Glu His Phe Ser Val Leu Gln His Glu Glu Thr		
1370	1375	1380
Thr Tyr Ile Ala Ile Ala Leu Lys Ser Ser Ile His Leu Tyr Ala		
1385	1390	1395
Trp Ala Pro Lys Ser Phe Asp Glu Ser Thr Ala Ile Lys Val Phe		
1400	1405	1410
Pro Thr Leu Asp His Lys Pro Val Thr Val Asp Leu Ala Ile Gly		
1415	1420	1425
Ser Glu Lys Arg Leu Lys Ile Phe Phe Ser Ser Ala Asp Gly Tyr		
1430	1435	1440
His Leu Ile Asp Ala Glu Ser Glu Val Met Ser Asp Val Thr Leu		
1445	1450	1455
Pro Lys Asn Asn Ile Ile Leu Pro Asp Cys Leu Gly Ile Gly		
1460	1465	1470
Met Met Leu Thr Phe Asn Ala Glu Ala Leu Ser Val Glu Ala Asn		
1475	1480	1485

Glu Gln Leu Phe Lys Lys Ile Leu Glu Met Trp Lys Asp Ile Pro
 1490 1495 1500
 Ser Ser Ile Ala Phe Glu Cys Thr Gln Arg Thr Thr Gly Trp Gly
 1505 1510 1515
 Gln Lys Ala Ile Glu Val Arg Ser Leu Gln Ser Arg Val Leu Glu
 1520 1525 1530
 Ser Glu Leu Lys Arg Arg Ser Ile Lys Lys Leu Arg Phe Leu Cys
 1535 1540 1545
 Thr Arg Gly Asp Lys Leu Phe Phe Thr Ser Thr Leu Arg Asn His
 1550 1555 1560
 His Ser Arg Val Tyr Phe Met Thr Leu Gly Lys Leu Glu Glu Leu
 1565 1570 1575
 Gln Ser Asn Tyr Asp Val
 1580

<210> 17

<211> 1084

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 55009053CD1

<400> 17

Met Glu Thr Gln Ala Val Ala Thr Ser Pro Asp Gly Arg Tyr Leu
 1 5 10 15
 Lys Phe Asp Ile Glu Ile Gly Arg Gly Ser Phe Lys Thr Val Tyr
 20 25 30
 Arg Gly Leu Asp Thr Asp Thr Thr Val Glu Val Ala Trp Cys Glu
 35 40 45
 Leu Gln Thr Arg Lys Leu Ser Arg Ala Glu Arg Gln Arg Phe Ser
 50 55 60
 Glu Glu Val Glu Met Leu Lys Gly Leu Gln His Pro Asn Ile Val
 65 70 75
 Arg Phe Tyr Asp Ser Trp Lys Ser Val Leu Arg Gly Gln Val Cys
 80 85 90
 Ile Val Leu Val Thr Glu Leu Met Thr Ser Gly Thr Leu Lys Thr
 95 100 105
 Tyr Leu Arg Arg Phe Arg Glu Met Lys Pro Arg Val Leu Gln Arg
 110 115 120
 Trp Ser Arg Gln Ile Leu Arg Gly Leu His Phe Leu His Ser Arg
 125 130 135
 Val Pro Pro Ile Leu His Arg Asp Leu Lys Cys Asp Asn Val Phe
 140 145 150
 Ile Thr Gly Pro Ser Gly Ser Val Lys Ile Gly Asp Leu Gly Leu
 155 160 165
 Ala Thr Leu Lys Arg Ala Ser Phe Ala Lys Ser Val Ile Gly Thr
 170 175 180
 Pro Glu Phe Met Ala Pro Glu Met Tyr Glu Glu Lys Tyr Asp Glu
 185 190 195
 Ala Val Asp Val Tyr Ala Phe Gly Met Cys Met Leu Glu Met Ala
 200 205 210
 Thr Ser Glu Tyr Pro Tyr Ser Glu Cys Gln Asn Ala Ala Gln Ile
 215 220 225
 Tyr Arg Lys Val Thr Ser Gly Arg Lys Pro Asn Ser Phe His Lys

230	235	240
Val Lys Ile Pro Glu Val Lys Glu Ile Ile Glu Gly Cys Ile Arg		
245	250	255
Thr Asp Lys Asn Glu Arg Phe Thr Ile Gln Asp Leu Leu Ala His		
260	265	270
Ala Phe Phe Arg Glu Glu Arg Gly Val His Val Glu Leu Ala Glu		
275	280	285
Glu Asp Asp Gly Glu Lys Pro Gly Leu Lys Leu Trp Leu Arg Met		
290	295	300
Glu Asp Ala Arg Arg Gly Gly Arg Pro Arg Asp Asn Gln Ala Ile		
305	310	315
Glu Phe Leu Phe Gln Leu Gly Arg Asp Ala Ala Glu Glu Val Ala		
320	325	330
Gln Glu Met Val Ala Leu Gly Leu Val Cys Glu Ala Asp Tyr Gln		
335	340	345
Pro Val Ala Arg Ala Val Arg Glu Arg Val Ala Ala Ile Gln Arg		
350	355	360
Lys Arg Glu Lys Leu Arg Lys Ala Arg Glu Leu Glu Ala Leu Pro		
365	370	375
Pro Glu Pro Gly Pro Pro Pro Ala Thr Val Pro Met Ala Pro Gly		
380	385	390
Pro Pro Ser Val Phe Pro Pro Glu Pro Glu Glu Pro Glu Ala Asp		
395	400	405
Gln His Gln Pro Phe Leu Phe Arg His Ala Ser Tyr Ser Ser Thr		
410	415	420
Thr Ser Asp Cys Glu Thr Asp Gly Tyr Leu Ser Ser Ser Gly Phe		
425	430	435
Leu Asp Ala Ser Asp Pro Ala Leu Gln Pro Pro Gly Gly Val Pro		
440	445	450
Ser Ser Leu Ala Glu Ser His Leu Cys Leu Pro Ser Ala Phe Ala		
455	460	465
Leu Ser Ile Pro Arg Ser Gly Pro Gly Ser Asp Phe Ser Pro Gly		
470	475	480
Asp Ser Tyr Ala Ser Asp Ala Ala Ser Gly Leu Ser Asp Val Gly		
485	490	495
Glu Gly Met Gly Gln Met Arg Arg Pro Pro Gly Arg Asn Leu Arg		
500	505	510
Arg Arg Pro Arg Ser Arg Leu Arg Val Thr Ser Val Ser Asp Gln		
515	520	525
Asn Asp Arg Val Val Glu Cys Gln Leu Gln Thr His Asn Ser Lys		
530	535	540
Met Val Thr Phe Arg Phe Asp Leu Asp Gly Asp Ser Pro Glu Glu		
545	550	555
Ile Ala Ala Ala Met Val Tyr Asn Glu Phe Ile Leu Pro Ser Glu		
560	565	570
Arg Asp Gly Phe Leu Arg Arg Ile Arg Glu Ile Ile Gln Arg Val		
575	580	585
Glu Thr Leu Leu Lys Arg Asp Thr Gly Pro Met Glu Ala Ala Glu		
590	595	600
Asp Thr Leu Ser Pro Gln Glu Glu Pro Ala Pro Leu Pro Ala Leu		
605	610	615
Pro Val Pro Leu Pro Asp Pro Ser Asn Glu Glu Leu Gln Ser Ser		
620	625	630
Thr Ser Leu Glu His Arg Ser Trp Thr Ala Phe Ser Thr Ser Ser		
635	640	645
Ser Ser Pro Gly Thr Pro Leu Ser Pro Gly Asn Pro Phe Ser Pro		

650	655	660
Gly Thr Pro Ile Ser Pro Gly Pro Ile	Phe Pro Ile Thr Ser Pro	
665	670	675
Pro Cys His Pro Ser Pro Ser Pro Phe	Ser Pro Ile Ser Ser Gln	
680	685	690
Val Ser Ser Asn Pro Ser Pro His Pro	Thr Ser Ser Pro Leu Pro	
695	700	705
Phe Ser Ser Ser Thr Pro Glu Phe Pro	Val Pro Leu Ser Gln Cys	
710	715	720
Pro Trp Ser Ser Leu Pro Thr Thr Ser	Pro Pro Thr Phe Ser Pro	
725	730	735
Thr Cys Ser Gln Val Thr Leu Ser Ser	Pro Phe Phe Pro Pro Cys	
740	745	750
Pro Ser Thr Ser Ser Phe Pro Ser Thr	Thr Ala Ala Pro Leu Leu	
755	760	765
Ser Leu Ala Ser Ala Phe Ser Leu Ala	Val Met Thr Val Ala Gln	
770	775	780
Ser Leu Leu Ser Pro Ser Pro Gly Leu	Leu Ser Gln Ser Pro Pro	
785	790	795
Ala Pro Pro Ser Pro Leu Pro Ser Leu	Pro Leu Pro Pro Pro Val	
800	805	810
Ala Pro Gly Gly Gln Glu Ser Pro Ser	Pro His Thr Ala Glu Val	
815	820	825
Glu Ser Glu Ala Ser Pro Pro Pro Ala	Arg Pro Leu Pro Gly Glu	
830	835	840
Ala Arg Leu Ala Pro Ile Ser Glu Glu	Gly Lys Pro Gln Leu Val	
845	850	855
Gly Arg Phe Gln Val Thr Ser Ser Lys	Glu Pro Ala Glu Pro Leu	
860	865	870
Pro Leu Gln Pro Thr Ser Pro Thr Leu	Ser Gly Ser Pro Lys Pro	
875	880	885
Ser Thr Pro Gln Leu Thr Ser Glu Ser	Ser Asp Thr Glu Asp Ser	
890	895	900
Ala Gly Gly Gly Pro Glu Thr Arg Glu	Ala Leu Ala Glu Ser Asp	
905	910	915
Arg Ala Ala Glu Gly Leu Gly Ala Gly	Val Glu Glu Glu Gly Asp	
920	925	930
Asp Gly Lys Glu Pro Gln Val Gly Gly	Ser Pro Gln Pro Leu Ser	
935	940	945
His Pro Ser Pro Val Trp Met Asn Tyr	Ser Tyr Ser Ser Leu Cys	
950	955	960
Leu Ser Ser Glu Glu Ser Glu Ser Ser	Gly Glu Asp Glu Glu Phe	
965	970	975
Trp Ala Glu Leu Gln Ser Leu Arg Gln	Lys His Leu Ser Glu Val	
980	985	990
Glu Thr Leu Gln Thr Leu Gln Lys Lys	Glu Ile Glu Asp Leu Tyr	
995	1000	1005
Ser Arg Leu Gly Lys Gln Pro Pro Pro	Gly Ile Val Ala Pro Ala	
1010	1015	1020
Ala Met Leu Ser Ser Arg Gln Arg Arg	Leu Ser Lys Gly Ser Phe	
1025	1030	1035
Pro Thr Ser Arg Arg Asn Ser Leu Gln	Arg Ser Glu Pro Pro Gly	
1040	1045	1050
Pro Gly Ile Met Arg Arg Asn Ser Leu	Ser Gly Ser Ser Thr Gly	
1055	1060	1065
Ser Gln Glu Gln Arg Ala Ser Lys Gly	Val Thr Phe Ala Gly Asp	

1070
 Val Gly Arg Met

1075
 1080

<210> 18
 <211> 600
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7474648CD1

<400> 18
 Met Gly Glu Ser Gly Asn His His Phe Gln Gln Thr Asn Thr Gly
 1 5 10 15
 Thr Glu Asn Gln Thr Ala His Val Leu Thr His Lys Trp Glu Leu
 20 25 30
 Asp Asn Glu Asn Ile Trp Ala Gln Gly Gly Glu His His Lys Leu
 35 40 45
 Gly Pro Val Met Gly Trp Lys Ala Arg Ser Gly Lys Thr Leu Gly
 50 55 60
 Glu Ile Pro Asn Val Gly Thr Leu Thr Leu Leu Thr Gly Tyr Gly
 65 70 75
 Gly Cys Gln Leu Pro Cys Cys Lys Asp Thr Gln Ala Ala Tyr Gly
 80 85 90
 Glu Thr His Val Val Arg Ser Gly Gly Leu Leu Pro Thr Ala Ser
 95 100 105
 Trp Glu Leu Arg Pro Ala Asp Ser His Thr Val Thr Ser Asp Asp
 110 115 120
 Pro Gly Val Ser Val Val Ser Gly Tyr Pro Gly Gly Cys Leu Pro
 125 130 135
 Asp His Asp Pro Pro Val Gly Phe Leu Ser Glu Gly Pro Ala Pro
 140 145 150
 Arg Ser Cys Ser Leu Ile Lys Gly Gly Gly Thr Gly Leu Ala Ala
 155 160 165
 Ser Arg Val Pro Arg Ser Arg Glu Arg Arg Ala Cys Cys Gly Tyr
 170 175 180
 Gly Val Arg Arg Gln Gln Glu Gly Gly Pro Gly Ala Thr Ser Ala
 185 190 195
 Gly Leu Gly Gln Ala Arg Arg Ser Lys Pro Ser Arg Arg Arg Arg
 200 205 210
 Arg Gly Ala Trp Ala Arg Gly Gly Gly Pro Gly Gly Ala Glu Asp
 215 220 225
 Thr Gly Gly Ser Leu Pro Ser Gln Val Arg Pro Pro Gly Pro Cys
 230 235 240
 Gln Cys Pro Val Gln Phe Leu Phe Asp Ile Ser Glu Gln Gly Val
 245 250 255
 Gln Arg Met Gly Lys Lys Arg Ala Gly Ala Ala Ala Asn Lys Gly
 260 265 270
 Arg Asn Ser Tyr Leu Arg Arg Tyr Asp Ile Lys Ala Leu Ile Gly
 275 280 285
 Thr Gly Ser Phe Ser Arg Val Val Arg Val Glu Gln Lys Thr Thr
 290 295 300
 Lys Lys Pro Phe Ala Ile Lys Val Met Glu Thr Arg Glu Arg Glu
 305 310 315

Gly Arg Glu Ala Cys Val Ser Glu Leu Ser Val Leu Arg Arg Val	320	325	330
Ser His Arg Tyr Ile Val Gln Leu Met Glu Ile Phe Glu Thr Glu	335	340	345
Asp Gln Val Tyr Met Val Met Glu Leu Ala Thr Gly Gly Glu Leu	350	355	360
Phe Asp Arg Leu Ile Ala Gln Gly Ser Phe Thr Glu Arg Asp Ala	365	370	375
Val Arg Ile Leu Gln Met Val Ala Asp Gly Ile Arg Tyr Leu His	380	385	390
Ala Leu Gln Ile Thr His Arg Asn Leu Lys Pro Glu Asn Leu Leu	395	400	405
Tyr Tyr His Pro Gly Glu Glu Ser Lys Ile Leu Ile Thr Asp Phe	410	415	420
Gly Leu Ala Tyr Ser Gly Lys Lys Ser Gly Asp Trp Thr Met Lys	425	430	435
Thr Leu Cys Gly Thr Pro Glu Tyr Ile Ala Pro Glu Val Leu Leu	440	445	450
Arg Lys Pro Tyr Thr Ser Ala Val Asp Met Trp Ala Leu Gly Val	455	460	465
Ile Thr Tyr Ala Leu Leu Ser Gly Phe Leu Pro Phe Asp Asp Glu	470	475	480
Ser Gln Thr Arg Leu Tyr Arg Lys Ile Leu Lys Gly Lys Tyr Asn	485	490	495
Tyr Thr Gly Glu Pro Trp Pro Ser Ile Ser His Leu Ala Lys Asp	500	505	510
Phe Ile Asp Lys Leu Leu Ile Leu Glu Ala Gly His Arg Met Ser	515	520	525
Ala Gly Gln Ala Leu Asp His Pro Trp Val Ile Thr Met Ala Ala	530	535	540
Gly Ser Ser Met Lys Asn Leu Gln Arg Ala Ile Ser Arg Asn Leu	545	550	555
Met Gln Arg Ala Ser Pro His Ser Gln Ser Pro Gly Ser Ala Gln	560	565	570
Ser Ser Lys Ser His Tyr Ser His Lys Ser Arg His Met Trp Ser	575	580	585
Lys Arg Asn Leu Arg Ile Val Glu Ser Pro Leu Ser Ala Leu Leu	590	595	600

<210> 19

<211> 1114

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7483053CD1

<400> 19

Met Ala Lys Ala Thr Ser Gly Ala Ala Gly Leu Arg Leu Leu Leu	1	5	10	15
Leu Leu Leu Leu Pro Leu Leu Gly Lys Val Ala Leu Gly Leu Tyr	20	25	30	
Phe Ser Arg Asp Ala Tyr Trp Glu Lys Leu Tyr Val Asp Gln Ala	35	40	45	

Ala Gly Thr Pro Leu Leu Tyr Val His Ala Leu Arg Asp Ala Pro	50	55	60
Glu Glu Val Pro Ser Phe Arg Leu Gly Gln His Leu Tyr Gly Thr	65	70	75
Tyr Arg Thr Arg Leu His Glu Asn Asn Trp Ile Cys Ile Gln Glu	80	85	90
Asp Thr Gly Leu Leu Tyr Leu Asn Arg Ser Leu Asp His Ser Ser	95	100	105
Trp Glu Lys Leu Ser Val Arg Asn Arg Gly Phe Pro Leu Leu Thr	110	115	120
Val Tyr Leu Lys Val Phe Leu Ser Pro Thr Ser Leu Arg Glu Gly	125	130	135
Glu Cys Gln Trp Pro Gly Cys Ala Arg Val Tyr Phe Ser Phe Phe	140	145	150
Asn Thr Ser Phe Pro Ala Cys Ser Ser Leu Lys Pro Arg Glu Leu	155	160	165
Cys Phe Pro Glu Thr Arg Pro Ser Phe Arg Ile Arg Glu Asn Arg	170	175	180
Pro Pro Gly Thr Phe His Gln Phe Arg Leu Leu Pro Val Gln Phe	185	190	195
Leu Cys Pro Asn Ile Ser Val Ala Tyr Arg Leu Leu Glu Gly Glu	200	205	210
Gly Leu Pro Phe Arg Cys Ala Pro Asp Ser Leu Glu Val Ser Thr	215	220	225
Arg Trp Ala Leu Asp Arg Glu Gln Arg Glu Lys Tyr Glu Leu Val	230	235	240
Ala Val Cys Thr Val His Ala Gly Ala Arg Glu Glu Val Val Met	245	250	255
Val Pro Phe Pro Val Thr Val Tyr Asp Glu Asp Asp Ser Ala Pro	260	265	270
Thr Phe Pro Ala Gly Val Asp Thr Ala Ser Ala Val Val Glu Phe	275	280	285
Lys Arg Lys Glu Asp Thr Val Val Ala Thr Leu Arg Val Phe Asp	290	295	300
Ala Asp Val Val Pro Ala Ser Gly Glu Leu Val Arg Arg Tyr Thr	305	310	315
Ser Thr Leu Leu Pro Gly Asp Thr Trp Ala Gln Gln Thr Phe Arg	320	325	330
Val Glu His Trp Pro Asn Glu Thr Ser Val Gln Ala Asn Gly Ser	335	340	345
Phe Val Arg Ala Thr Val His Asp Tyr Arg Leu Val Leu Asn Arg	350	355	360
Asn Leu Ser Ile Ser Glu Asn Arg Thr Met Gln Leu Ala Val Leu	365	370	375
Val Asn Asp Ser Asp Phe Gln Gly Pro Gly Ala Gly Val Leu Leu	380	385	390
Leu His Phe Asn Val Ser Val Leu Pro Val Ser Leu His Leu Pro	395	400	405
Ser Thr Tyr Ser Leu Ser Val Ser Arg Arg Ala Arg Arg Phe Ala	410	415	420
Gln Ile Gly Lys Val Cys Val Glu Asn Cys Gln Ala Phe Ser Gly	425	430	435
Ile Asn Val Gln Tyr Lys Leu His Ser Ser Gly Ala Asn Cys Ser	440	445	450
Thr Leu Gly Val Val Thr Ser Ala Glu Asp Thr Ser Gly Ile Leu	455	460	465

Phe Val Asn Asp Thr Lys Ala Leu Arg Arg Pro Lys Cys Ala Glu	470	475	480
Leu His Tyr Met Val Val Ala Thr Asp Gln Gln Thr Ser Arg Gln	485	490	495
Ala Gln Ala Gln Leu Leu Val Thr Val Glu Gly Ser Tyr Val Ala	500	505	510
Glu Glu Ala Gly Cys Pro Leu Ser Cys Ala Val Ser Lys Arg Arg	515	520	525
Leu Glu Cys Glu Glu Cys Gly Gly Leu Gly Ser Pro Thr Gly Arg	530	535	540
Cys Glu Trp Arg Gln Gly Asp Gly Lys Gly Ile Thr Arg Asn Phe	545	550	555
Ser Thr Cys Ser Pro Ser Thr Lys Thr Cys Pro Asp Gly His Cys	560	565	570
Asp Val Val Glu Thr Gln Asp Ile Asn Ile Cys Pro Gln Asp Cys	575	580	585
Leu Arg Gly Ser Ile Val Gly Gly His Glu Pro Gly Glu Pro Arg	590	595	600
Gly Ile Lys Ala Gly Tyr Gly Thr Cys Asn Cys Phe Pro Glu Glu	605	610	615
Glu Lys Cys Phe Cys Glu Pro Glu Asp Ile Gln Asp Pro Leu Cys	620	625	630
Asp Glu Leu Cys Arg Thr Val Ile Ala Ala Ala Val Leu Phe Ser	635	640	645
Phe Ile Val Ser Val Leu Leu Ser Ala Phe Cys Ile His Cys Tyr	650	655	660
His Lys Phe Ala His Lys Pro Pro Ile Ser Ser Ala Glu Met Thr	665	670	675
Phe Arg Arg Pro Ala Gln Ala Phe Pro Val Ser Tyr Ser Ser Ser	680	685	690
Ser Ala Arg Arg Pro Ser Leu Asp Ser Met Glu Asn Gln Val Ser	695	700	705
Val Asp Ala Phe Lys Ile Leu Glu Asp Pro Lys Trp Glu Phe Pro	710	715	720
Arg Lys Asn Leu Val Leu Gly Lys Thr Leu Gly Glu Gly Glu Phe	725	730	735
Gly Lys Val Val Lys Ala Thr Ala Phe His Leu Lys Gly Arg Ala	740	745	750
Gly Tyr Thr Thr Val Ala Val Lys Met Leu Lys Glu Asn Ala Ser	755	760	765
Pro Ser Glu Leu Arg Asp Leu Leu Ser Glu Phe Asn Val Leu Lys	770	775	780
Gln Val Asn His Pro His Val Ile Lys Leu Tyr Gly Ala Cys Ser	785	790	795
Gln Asp Gly Pro Leu Leu Leu Ile Val Glu Tyr Ala Lys Tyr Gly	800	805	810
Ser Leu Arg Gly Phe Leu Arg Glu Ser Arg Lys Val Gly Pro Gly	815	820	825
Tyr Leu Gly Ser Gly Gly Ser Arg Asn Ser Ser Ser Leu Asp His	830	835	840
Pro Asp Glu Arg Ala Leu Thr Met Gly Asp Leu Ile Ser Phe Ala	845	850	855
Trp Gln Ile Ser Gln Gly Met Gln Tyr Leu Ala Glu Met Lys Leu	860	865	870
Val His Arg Asp Leu Ala Ala Arg Asn Ile Leu Val Ala Glu Gly	875	880	885

Arg Lys Met Lys Ile Ser Asp Phe Gly Leu Ser Arg Asp Val Tyr
 890 895 900
 Glu Glu Asp Ser Tyr Val Lys Arg Ser Gln Gly Arg Ile Pro Val
 905 910 915
 Lys Trp Met Ala Ile Glu Ser Leu Phe Asp His Ile Tyr Thr Thr
 920 925 930
 Gln Ser Asp Val Trp Ser Phe Gly Val Leu Leu Trp Glu Ile Val
 935 940 945
 Thr Leu Gly Gly Asn Pro Tyr Pro Gly Ile Pro Pro Glu Arg Leu
 950 955 960
 Phe Asn Leu Leu Lys Thr Gly His Arg Met Glu Arg Pro Asp Asn
 965 970 975
 Cys Ser Glu Glu Met Tyr Arg Leu Met Leu Gln Cys Trp Lys Gln
 980 985 990
 Glu Pro Asp Lys Arg Pro Val Phe Ala Asp Ile Ser Lys Asp Leu
 995 1000 1005
 Glu Lys Met Met Val Lys Arg Arg Asp Tyr Leu Asp Leu Ala Ala
 1010 1015 1020
 Ser Thr Pro Ser Asp Ser Leu Ile Tyr Asp Asp Gly Leu Ser Glu
 1025 1030 1035
 Glu Glu Thr Pro Leu Val Asp Cys Asn Asn Ala Pro Leu Pro Arg
 1040 1045 1050
 Ala Leu Pro Ser Thr Trp Ile Glu Asn Lys Leu Tyr Gly Met Ser
 1055 1060 1065
 Asp Pro Asn Trp Pro Gly Glu Ser Pro Val Pro Leu Thr Arg Ala
 1070 1075 1080
 Asp Gly Thr Asn Thr Gly Phe Pro Arg Tyr Pro Asn Asp Ser Val
 1085 1090 1095
 Tyr Ala Asn Trp Met Leu Ser Pro Ser Ala Ala Lys Leu Met Asp
 1100 1105 1110
 Thr Phe Asp Ser

<210> 20

<211> 567

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7483117CD1

<400> 20

Met Asp Asp Lys Asp Ile Asp Lys Glu Leu Arg Gln Lys Leu Asn
 1 5 10 15
 Phe Ser Tyr Cys Glu Glu Thr Glu Ile Glu Gly Gln Lys Lys Val
 20 25 30
 Glu Glu Ser Arg Glu Ala Ser Ser Gln Thr Pro Glu Lys Gly Glu
 35 40 45
 Val Gln Asp Ser Glu Ala Lys Gly Thr Pro Pro Trp Thr Pro Leu
 50 55 60
 Ser Asn Val His Glu Leu Asp Thr Ser Ser Glu Lys Asp Lys Glu
 65 70 75
 Ser Pro Asp Gln Ile Leu Arg Thr Pro Val Ser His Pro Leu Lys
 80 85 90
 Cys Pro Glu Thr Pro Ala Gln Pro Asp Ser Arg Ser Lys Leu Leu

	95		100		105
Pro Ser Asp Ser	Pro Ser Thr Pro Lys	Thr Met Leu Ser Arg	Leu		
	110		115		120
Val Ile Ser Pro	Thr Gly Lys Leu Pro	Ser Arg Gly Pro Lys	His		
	125		130		135
Leu Lys Leu Thr	Pro Ala Pro Leu Lys	Asp Glu Met Thr Ser	Leu		
	140		145		150
Ala Leu Val Asn	Ile Asn Pro Phe Thr	Pro Glu Ser Tyr Lys	Lys		
	155		160		165
Leu Phe Leu Gln	Ser Gly Gly Lys Arg	Lys Ile Arg Gly Asp	Leu		
	170		175		180
Glu Glu Ala Gly	Pro Glu Glu Gly Lys	Gly Gly Leu Pro Ala	Lys		
	185		190		195
Arg Cys Val Leu	Arg Glu Thr Asn Met	Ala Ser Arg Tyr Glu	Lys		
	200		205		210
Glu Phe Leu Glu	Val Glu Lys Ile Gly	Val Gly Glu Phe Gly	Thr		
	215		220		225
Val Tyr Lys Cys	Ile Lys Arg Leu Asp	Gly Cys Val Tyr Ala	Ile		
	230		235		240
Lys Arg Ser Met	Lys Thr Phe Thr Glu	Leu Ser Asn Glu Asn	Ser		
	245		250		255
Ala Leu His Glu	Val Tyr Ala His Ala	Val Leu Gly His His	Pro		
	260		265		270
His Val Val Arg	Tyr Ser Ser Trp	Ala Glu Asp Asp His	Met		
	275		280		285
Ile Ile Gln Asn	Glu Tyr Cys Asn Gly	Gly Ser Leu Gln Ala	Ala		
	290		295		300
Ile Ser Glu Asn	Thr Lys Ser Gly Asn	His Phe Glu Glu Pro	Lys		
	305		310		315
Leu Lys Asp Ile	Leu Leu Gln Ile Ser	Leu Gly Leu Asn Tyr	Ile		
	320		325		330
His Asn Ser Ser	Met Val His Leu Asp	Ile Lys Pro Ser Asn	Ile		
	335		340		345
Phe Ile Cys His	Lys Met Gln Ser Glu	Ser Ser Gly Val Ile	Glu		
	350		355		360
Glu Val Glu Asn	Glu Ala Asp Trp Phe	Leu Ser Ala Asn Val	Met		
	365		370		375
Tyr Lys Ile Gly	Asp Leu Gly His Ala	Thr Ser Ile Asn Lys	Pro		
	380		385		390
Lys Val Glu Glu	Gly Asp Ser Arg Phe	Leu Ala Asn Glu Ile	Leu		
	395		400		405
Gln Glu Asp Tyr	Arg His Leu Pro Lys	Ala Asp Ile Phe Ala	Leu		
	410		415		420
Gly Leu Thr Ile	Ala Val Ala Ala Gly	Ala Glu Ser Leu Pro	Thr		
	425		430		435
Asn Gly Ala Ala	Trp His His Ile Arg	Lys Gly Asn Phe Pro	Asp		
	440		445		450
Val Pro Gln Glu	Leu Ser Glu Ser Phe	Ser Ser Leu Leu Lys	Asn		
	455		460		465
Met Ile Gln Pro	Asp Ala Glu Gln Arg	Pro Ser Ala Ala Ala	Leu		
	470		475		480
Ala Arg Asn Thr	Val Leu Arg Pro Ser	Leu Gly Lys Thr Glu	Glu		
	485		490		495
Leu Gln Gln Gln	Leu Asn Leu Glu Lys	Phe Lys Thr Ala Thr	Leu		
	500		505		510
Glu Arg Glu Leu	Arg Glu Ala Gln Gln	Ala Gln Ser Pro Gln	Gly		

	515	520	525
Tyr Thr His His Gly Asp Thr Gly Val Ser Gly Thr His Thr Gly			
	530	535	540
Ser Arg Ser Thr Lys Arg Leu Val Gly Gly Lys Ser Ala Arg Ser			
	545	550	555
Ser Ser Phe Thr Ser Gly Glu Arg Glu Pro Leu His			
	560	565	

<210> 21

<211> 2054

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7484498CD1

<400> 21

Met Leu Lys Phe Lys Tyr Gly Ala Arg Asn Pro Leu Asp Ala Gly		
1	5	10
Ala Ala Glu Pro Ile Ala Ser Arg Ala Ser Arg Leu Asn Leu Phe		
	20	25
Phe Gln Gly Lys Pro Pro Phe Met Thr Gln Gln Gln Met Ser Pro		
	35	40
Leu Ser Arg Glu Gly Ile Leu Asp Ala Leu Phe Val Leu Phe Glu		
	50	55
Glu Cys Ser Gln Pro Ala Leu Met Lys Ile Lys His Val Ser Asn		
	65	70
Phe Val Arg Lys Tyr Ser Asp Thr Ile Ala Glu Leu Gln Glu Leu		
	80	85
Gln Pro Ser Ala Lys Asp Phe Glu Val Arg Ser Leu Val Gly Cys		
	95	100
Gly His Phe Ala Glu Val Gln Val Val Arg Glu Lys Ala Thr Gly		
	110	115
Asp Ile Tyr Ala Met Lys Val Met Lys Lys Lys Ala Leu Leu Ala		
	125	130
Gln Glu Gln Val Ser Phe Phe Glu Glu Glu Arg Asn Ile Leu Ser		
	140	145
Arg Ser Thr Ser Pro Trp Ile Pro Gln Leu Gln Tyr Ala Phe Gln		
	155	160
Asp Lys Asn His Leu Tyr Leu Val Met Glu Tyr Gln Pro Gly Gly		
	170	175
Asp Leu Leu Ser Leu Leu Asn Arg Tyr Glu Asp Gln Leu Asp Glu		
	185	190
Asn Leu Ile Gln Phe Tyr Leu Ala Glu Leu Ile Leu Ala Val His		
	200	205
Ser Val His Leu Met Gly Tyr Val His Arg Asp Ile Lys Pro Glu		
	215	220
Asn Ile Leu Val Asp Arg Thr Gly His Ile Lys Leu Val Asp Phe		
	230	235
Gly Ser Ala Ala Lys Met Asn Ser Asn Lys Met Val Asn Ala Lys		
	245	250
Leu Pro Ile Gly Thr Pro Asp Tyr Met Ala Pro Glu Val Leu Thr		
	260	265
Val Met Asn Gly Asp Gly Lys Gly Thr Tyr Gly Leu Asp Cys Asp		
	275	280
		285

Trp Trp Ser Val Gly Val Ile Ala Tyr Glu Met Ile Tyr Gly Arg	290	295	300
Ser Pro Phe Ala Glu Gly Thr Ser Ala Arg Thr Phe Asn Asn Ile	305	310	315
Met Asn Phe Gln Arg Phe Leu Lys Phe Pro Asp Asp Pro Lys Val	320	325	330
Ser Ser Asp Phe Leu Asp Leu Ile Gln Ser Leu Leu Cys Gly Gln	335	340	345
Lys Glu Arg Leu Lys Phe Glu Gly Leu Cys Cys His Pro Phe Phe	350	355	360
Ser Lys Ile Asp Trp Asn Asn Ile Arg Asn Ser Pro Pro Pro Phe	365	370	375
Val Pro Thr Leu Lys Ser Asp Asp Asp Thr Ser Asn Phe Asp Glu	380	385	390
Pro Glu Lys Asn Ser Trp Val Ser Ser Ser Pro Cys Gln Leu Ser	395	400	405
Pro Ser Gly Phe Ser Gly Glu Glu Leu Pro Phe Val Gly Phe Ser	410	415	420
Tyr Ser Lys Ala Leu Gly Ile Leu Gly Arg Ser Glu Ser Val Val	425	430	435
Ser Gly Leu Asp Ser Pro Ala Lys Thr Ser Ser Met Glu Lys Lys	440	445	450
Leu Leu Ile Lys Ser Lys Glu Leu Gln Asp Ser Gln Asp Lys Cys	455	460	465
His Lys Met Glu Gln Glu Met Thr Arg Leu His Arg Arg Val Ser	470	475	480
Glu Val Glu Ala Val Leu Ser Gln Lys Glu Val Glu Leu Lys Ala	485	490	495
Ser Glu Thr Gln Arg Ser Leu Leu Glu Gln Asp Leu Ala Thr Tyr	500	505	510
Ile Thr Glu Cys Ser Ser Leu Lys Arg Ser Leu Glu Gln Ala Arg	515	520	525
Met Glu Val Ser Gln Glu Asp Asp Lys Ala Leu Gln Leu Leu His	530	535	540
Asp Ile Arg Glu Gln Ser Arg Lys Leu Gln Glu Ile Lys Glu Gln	545	550	555
Glu Tyr Gln Ala Gln Val Glu Glu Met Arg Leu Met Met Asn Gln	560	565	570
Leu Glu Glu Asp Leu Val Ser Ala Arg Arg Arg Ser Asp Leu Tyr	575	580	585
Glu Ser Glu Leu Arg Glu Ser Arg Leu Ala Ala Glu Glu Phe Lys	590	595	600
Arg Lys Ala Thr Glu Cys Gln His Lys Leu Leu Lys Ala Lys Asp	605	610	615
Gln Gly Lys Pro Glu Val Gly Glu Tyr Ala Lys Leu Glu Lys Ile	620	625	630
Asn Ala Glu Gln Gln Leu Lys Ile Gln Glu Leu Gln Glu Lys Leu	635	640	645
Glu Lys Ala Val Lys Ala Ser Thr Glu Ala Thr Glu Leu Leu Gln	650	655	660
Asn Ile Arg Gln Ala Lys Glu Arg Ala Glu Arg Glu Leu Glu Lys	665	670	675
Leu Gln Asn Arg Glu Asp Ser Ser Glu Gly Ile Arg Lys Lys Leu	680	685	690
Val Glu Ala Glu Glu Arg Arg His Ser Leu Glu Asn Lys Val Lys	695	700	705

Arg Leu Glu Thr Met Glu Arg Arg Glu Asn Arg Leu Lys Asp Asp	710	715	720
Ile Gln Thr Lys Ser Gln Gln Ile Gln Gln Met Ala Asp Lys Ile	725	730	735
Leu Glu Leu Glu Glu Lys His Arg Glu Ala Gln Val Ser Ala Gln	740	745	750
His Leu Glu Val His Leu Lys Gln Lys Glu Gln His Tyr Glu Glu	755	760	765
Lys Ile Lys Val Leu Asp Asn Gln Ile Lys Lys Asp Leu Ala Asp	770	775	780
Lys Glu Thr Leu Glu Asn Met Met Gln Arg His Glu Glu Glu Ala	785	790	795
His Glu Lys Gly Lys Ile Leu Ser Glu Gln Lys Ala Met Ile Asn	800	805	810
Ala Met Asp Ser Lys Ile Arg Ser Leu Glu Gln Arg Ile Val Glu	815	820	825
Leu Ser Glu Ala Asn Lys Leu Ala Ala Asn Ser Ser Leu Phe Thr	830	835	840
Gln Arg Asn Met Lys Ala Gln Glu Glu Met Ile Ser Glu Leu Arg	845	850	855
Gln Gln Lys Phe Tyr Leu Glu Thr Gln Ala Gly Lys Leu Glu Ala	860	865	870
Gln Asn Arg Lys Leu Glu Glu Gln Leu Glu Lys Ile Ser His Gln	875	880	885
Asp His Ser Asp Lys Asn Arg Leu Leu Glu Leu Glu Thr Arg Leu	890	895	900
Arg Glu Val Ser Leu Glu His Glu Glu Gln Lys Leu Glu Leu Lys	905	910	915
Arg Gln Leu Thr Glu Leu Gln Leu Ser Leu Gln Glu Arg Glu Ser	920	925	930
Gln Leu Thr Ala Leu Gln Ala Ala Arg Ala Ala Leu Glu Ser Gln	935	940	945
Leu Arg Gln Ala Lys Thr Glu Leu Glu Glu Thr Thr Ala Glu Ala	950	955	960
Glu Glu Glu Ile Gln Ala Leu Thr Ala His Arg Asp Glu Ile Gln	965	970	975
Arg Lys Phe Asp Ala Leu Arg Asn Ser Cys Thr Val Ile Thr Asp	980	985	990
Leu Glu Glu Gln Leu Asn Gln Leu Thr Glu Asp Asn Ala Glu Leu	995	1000	1005
Asn Asn Gln Asn Phe Tyr Leu Ser Lys Gln Leu Asp Glu Ala Ser	1010	1015	1020
Gly Ala Asn Asp Glu Ile Val Gln Leu Arg Ser Glu Val Asp His	1025	1030	1035
Leu Arg Arg Glu Ile Thr Glu Arg Glu Met Gln Leu Thr Ser Gln	1040	1045	1050
Lys Gln Thr Met Glu Ala Leu Lys Thr Thr Cys Thr Met Leu Glu	1055	1060	1065
Glu Gln Val Met Asp Leu Glu Ala Leu Asn Asp Glu Leu Leu Glu	1070	1075	1080
Lys Glu Arg Gln Trp Glu Ala Trp Arg Ser Val Leu Gly Asp Glu	1085	1090	1095
Lys Ser Gln Phe Glu Cys Arg Val Arg Glu Leu Gln Arg Met Leu	1100	1105	1110
Asp Thr Glu Lys Gln Ser Arg Ala Arg Ala Asp Gln Arg Ile Thr	1115	1120	1125

Glu Ser Arg Gln Val Val Glu Leu Ala Val Lys Glu His Lys Ala		
1130	1135	1140
Glu Ile Leu Ala Leu Gln Gln Ala Leu Lys Glu Gln Lys Leu Lys		
1145	1150	1155
Ala Glu Ser Leu Ser Asp Lys Leu Asn Asp Leu Glu Lys Lys His		
1160	1165	1170
Ala Met Leu Glu Met Asn Ala Arg Ser Leu Gln Gln Lys Leu Glu		
1175	1180	1185
Thr Glu Arg Glu Leu Lys Gln Arg Leu Leu Glu Glu Gln Ala Lys		
1190	1195	1200
Leu Gln Gln Gln Met Asp Leu Gln Lys Asn His Ile Phe Arg Leu		
1205	1210	1215
Thr Gln Gly Leu Gln Glu Ala Leu Asp Arg Ala Asp Leu Leu Lys		
1220	1225	1230
Thr Glu Arg Ser Asp Leu Glu Tyr Gln Leu Glu Asn Ile Gln Val		
1235	1240	1245
Leu Tyr Ser His Glu Lys Val Lys Met Glu Gly Thr Ile Ser Gln		
1250	1255	1260
Gln Thr Lys Leu Ile Asp Phe Leu Gln Ala Lys Met Asp Gln Pro		
1265	1270	1275
Ala Lys Lys Lys Lys Val Pro Leu Gln Tyr Asn Glu Leu Lys Leu		
1280	1285	1290
Ala Leu Glu Lys Glu Lys Ala Arg Cys Ala Glu Leu Glu Glu Ala		
1295	1300	1305
Leu Gln Lys Thr Arg Ile Glu Leu Arg Ser Ala Arg Glu Glu Ala		
1310	1315	1320
Ala His Arg Lys Ala Thr Asp His Pro His Pro Ser Thr Pro Ala		
1325	1330	1335
Thr Ala Arg Gln Gln Ile Ala Met Ser Ala Ile Val Arg Ser Pro		
1340	1345	1350
Glu His Gln Pro Ser Ala Met Ser Leu Leu Ala Pro Pro Ser Ser		
1355	1360	1365
Arg Arg Lys Glu Ser Ser Thr Pro Glu Glu Phe Ser Arg Arg Leu		
1370	1375	1380
Lys Glu Arg Met His His Asn Ile Pro His Arg Phe Asn Val Gly		
1385	1390	1395
Leu Asn Met Arg Ala Thr Lys Cys Ala Val Cys Leu Asp Thr Val		
1400	1405	1410
His Phe Gly Arg Gln Ala Ser Lys Cys Leu Glu Cys Gln Val Met		
1415	1420	1425
Cys His Pro Lys Cys Ser Thr Cys Leu Pro Ala Thr Cys Gly Leu		
1430	1435	1440
Pro Ala Glu Tyr Ala Thr His Phe Thr Glu Ala Phe Cys Arg Asp		
1445	1450	1455
Lys Met Asn Ser Pro Gly Leu Gln Thr Lys Glu Pro Ser Ser Ser		
1460	1465	1470
Leu His Leu Glu Gly Trp Met Lys Val Pro Arg Asn Asn Lys Arg		
1475	1480	1485
Gly Gln Gln Gly Trp Asp Arg Lys Tyr Ile Val Leu Glu Gly Ser		
1490	1495	1500
Lys Val Leu Ile Tyr Asp Asn Glu Ala Arg Glu Ala Gly Gln Arg		
1505	1510	1515
Pro Val Glu Glu Phe Glu Leu Cys Leu Pro Asp Gly Asp Val Ser		
1520	1525	1530
Ile His Gly Ala Val Gly Ala Ser Glu Leu Ala Asn Thr Ala Lys		
1535	1540	1545

Ala Asp Val Pro Tyr Ile Leu Lys Met Glu Ser His Pro His Thr	1550	1555	1560
Thr Cys Trp Pro Gly Arg Thr Leu Tyr Leu Leu Ala Pro Ser Phe	1565	1570	1575
Pro Asp Lys Gln Arg Trp Val Thr Ala Leu Glu Ser Val Val Ala	1580	1585	1590
Gly Gly Arg Val Ser Arg Glu Lys Ala Glu Ala Asp Ala Lys Leu	1595	1600	1605
Leu Gly Asn Ser Leu Leu Lys Leu Glu Gly Asp Asp Arg Leu Asp	1610	1615	1620
Met Asn Cys Thr Leu Pro Phe Ser Asp Gln Val Val Leu Val Gly	1625	1630	1635
Thr Glu Glu Gly Leu Tyr Ala Leu Asn Val Leu Lys Asn Ser Leu	1640	1645	1650
Thr His Val Pro Gly Ile Gly Ala Val Phe Gln Ile Tyr Ile Ile	1655	1660	1665
Lys Asp Leu Glu Lys Leu Leu Met Ile Ala Gly Glu Glu Arg Ala	1670	1675	1680
Leu Cys Leu Val Asp Val Lys Lys Val Lys Gln Ser Leu Ala Gln	1685	1690	1695
Ser His Leu Pro Ala Gln Pro Asp Ile Ser Pro Asn Ile Phe Glu	1700	1705	1710
Ala Val Lys Gly Cys His Leu Phe Gly Ala Gly Lys Ile Glu Asn	1715	1720	1725
Gly Leu Cys Ile Cys Ala Ala Met Pro Ser Lys Val Val Ile Leu	1730	1735	1740
Arg Tyr Asn Glu Asn Leu Ser Lys Tyr Cys Ile Arg Lys Glu Ile	1745	1750	1755
Glu Thr Ser Glu Pro Cys Ser Cys Ile His Phe Thr Asn Tyr Ser	1760	1765	1770
Ile Leu Ile Gly Thr Asn Lys Phe Tyr Glu Ile Asp Met Lys Gln	1775	1780	1785
Tyr Thr Leu Glu Glu Phe Leu Asp Lys Asn Asp His Ser Leu Ala	1790	1795	1800
Pro Ala Val Phe Ala Ala Ser Ser Asn Ser Phe Pro Val Ser Ile	1805	1810	1815
Val Gln Val Asn Ser Ala Gly Gln Arg Glu Glu Tyr Leu Leu Cys	1820	1825	1830
Phe His Glu Phe Gly Val Phe Val Asp Ser Tyr Gly Arg Arg Ser	1835	1840	1845
Arg Thr Asp Asp Leu Lys Trp Ser Arg Leu Pro Leu Ala Phe Ala	1850	1855	1860
Tyr Arg Glu Pro Tyr Leu Phe Val Thr His Phe Asn Ser Leu Glu	1865	1870	1875
Val Ile Glu Ile Gln Ala Arg Ser Ser Ala Gly Thr Pro Ala Arg	1880	1885	1890
Ala Tyr Leu Asp Ile Pro Asn Pro Arg Tyr Leu Gly Pro Ala Ile	1895	1900	1905
Ser Ser Gly Ala Ile Tyr Leu Ala Ser Ser Tyr Gln Asp Lys Leu	1910	1915	1920
Arg Val Ile Cys Cys Lys Gly Asn Leu Val Lys Glu Ser Gly Thr	1925	1930	1935
Glu His His Arg Gly Pro Ser Thr Ser Arg Ser Ser Pro Asn Lys	1940	1945	1950
Arg Gly Pro Pro Thr Tyr Asn Glu His Ile Thr Lys Arg Val Ala	1955	1960	1965

Ser Ser Pro Ala Pro Pro Glu Gly Pro Ser His Pro Arg Glu Pro
 1970 1975 1980
 Ser Thr Pro His Arg Tyr Arg Glu Gly Arg Thr Glu Leu Arg Arg
 1985 1990 1995
 Asp Lys Ser Pro Gly Arg Pro Leu Glu Arg Glu Lys Ser Pro Gly
 2000 2005 2010
 Arg Met Leu Ser Thr Arg Arg Glu Arg Ser Pro Gly Arg Leu Phe
 2015 2020 2025
 Glu Asp Ser Ser Arg Gly Arg Leu Pro Ala Gly Ala Val Arg Thr
 2030 2035 2040
 Pro Leu Ser Gln Val Asn Lys Val Trp Asp Gln Ser Ser Val
 2045 2050

<210> 22

<211> 1665

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7638121CD1

<400> 22

Met Gly Cys Cys Arg Leu Gly Cys Gly Gly Cys Ser Val Ala His
 1 5 10 15
 Ser Val Ser Gln Gly Leu Thr Asn His Pro Ser Met Val Gly Cys
 20 25 30
 Gly Trp His Pro Gly Leu Cys Gly Trp Gly Gly Gly Leu His Ser
 35 40 45
 Ser Leu Pro Ala Leu Pro Gly Pro Pro Ser Met Gln Val Thr Ile
 50 55 60
 Glu Asp Val Gln Ala Gln Thr Gly Gly Thr Ala Gln Phe Glu Ala
 65 70 75
 Ile Ile Glu Gly Asp Pro Gln Pro Ser Val Thr Trp Tyr Lys Asp
 80 85 90
 Ser Val Gln Leu Val Asp Ser Thr Arg Leu Ser Gln Gln Gln Glu
 95 100 105
 Gly Thr Thr Tyr Ser Leu Val Leu Arg His Met Ala Ser Lys Asp
 110 115 120
 Ala Gly Val Tyr Thr Cys Leu Ala Gln Asn Thr Gly Gly Gln Val
 125 130 135
 Leu Cys Lys Ala Glu Leu Leu Val Leu Gly Gly Asp Asn Glu Pro
 140 145 150
 Asp Ser Glu Lys Gln Ser His Arg Arg Lys Leu His Ser Phe Tyr
 155 160 165
 Glu Val Lys Glu Glu Ile Gly Arg Gly Val Phe Gly Phe Val Lys
 170 175 180
 Arg Val Gln His Lys Gly Asn Lys Ile Leu Cys Ala Ala Lys Phe
 185 190 195
 Ile Pro Leu Arg Ser Arg Thr Arg Ala Gln Ala Tyr Arg Glu Arg
 200 205 210
 Asp Ile Leu Ala Ala Leu Ser His Pro Leu Val Thr Gly Leu Leu
 215 220 225
 Asp Gln Phe Glu Thr Arg Lys Thr Leu Ile Leu Ile Leu Glu Leu
 230 235 240
 Cys Ser Ser Glu Glu Leu Leu Asp Arg Leu Tyr Arg Lys Gly Val

245	250	255
Val Thr Glu Ala Glu Val Lys Val Tyr	Ile Gln Gln Leu Val Glu	
260	265	270
Gly Leu His Tyr Leu His Ser His Gly	Val Leu His Leu Asp Ile	
275	280	285
Lys Pro Ser Asn Ile Leu Met Val His	Pro Ala Arg Glu Asp Ile	
290	295	300
Lys Ile Cys Asp Phe Gly Phe Ala Gln	Asn Ile Thr Pro Ala Glu	
305	310	315
Leu Gln Phe Ser Gln Tyr Gly Ser Pro	Glu Phe Val Ser Pro Glu	
320	325	330
Ile Ile Gln Gln Asn Pro Val Ser Glu	Ala Ser Asp Ile Trp Ala	
335	340	345
Met Gly Val Ile Ser Tyr Leu Ser Leu	Thr Cys Ser Ser Pro Phe	
350	355	360
Ala Gly Glu Ser Asp Arg Ala Thr Leu	Leu Asn Val Leu Glu Gly	
365	370	375
Arg Val Ser Trp Ser Ser Pro Met Ala	Ala His Leu Ser Glu Asp	
380	385	390
Ala Lys Asp Phe Ile Lys Ala Thr Leu	Gln Arg Ala Pro Gln Ala	
395	400	405
Arg Pro Ser Ala Ala Gln Cys Leu Ser	His Pro Trp Phe Leu Lys	
410	415	420
Ser Met Pro Ala Glu Glu Ala His Phe	Ile Asn Thr Lys Gln Leu	
425	430	435
Lys Phe Leu Leu Ala Arg Ser Arg Trp	Gln Arg Ser Leu Met Ser	
440	445	450
Tyr Lys Ser Ile Leu Val Met Arg Ser	Ile Pro Glu Leu Leu Arg	
455	460	465
Gly Pro Pro Asp Ser Pro Ser Leu Gly	Val Ala Arg His Leu Cys	
470	475	480
Arg Asp Thr Gly Gly Ser Ser Ser Ser	Ser Ser Ser Ser Asp Asn	
485	490	495
Glu Leu Ala Pro Phe Ala Arg Ala Lys	Ser Leu Pro Pro Ser Pro	
500	505	510
Val Thr His Ser Pro Leu Leu His Pro	Arg Gly Phe Leu Arg Pro	
515	520	525
Ser Ala Ser Leu Pro Glu Glu Ala Glu	Ala Ser Glu Arg Ser Thr	
530	535	540
Glu Ala Pro Ala Pro Pro Ala Ser Pro	Glu Gly Ala Gly Pro Pro	
545	550	555
Ala Ala Gln Gly Cys Val Pro Arg His	Ser Val Ile Arg Ser Leu	
560	565	570
Phe Tyr His Gln Ala Gly Glu Ser Pro	Glu His Gly Ala Leu Ala	
575	580	585
Pro Gly Ser Arg Arg His Pro Ala Arg	Arg Arg His Leu Leu Lys	
590	595	600
Gly Gly Tyr Ile Ala Gly Ala Leu Pro	Gly Leu Arg Glu Pro Leu	
605	610	615
Met Glu His Arg Val Leu Glu Glu Glu	Ala Ala Arg Glu Glu Gln	
620	625	630
Ala Thr Leu Leu Ala Lys Ala Pro Ser	Phe Glu Thr Ala Leu Arg	
635	640	645
Leu Pro Ala Ser Gly Thr His Leu Ala	Pro Gly His Ser His Ser	
650	655	660
Leu Glu His Asp Ser Pro Ser Thr Pro	Arg Pro Ser Ser Glu Ala	

	665		670		675
Cys Gly Glu Ala	Gln Arg Leu Pro Ser	Ala Pro Ser Gly Gly Ala			
	680		685		690
Pro Ile Arg Asp	Met Gly His Pro Gln Gly	Ser Lys Gln Leu Pro			
	695		700		705
Ser Thr Gly Gly	His Pro Gly Thr Ala	Gln Pro Glu Arg Pro Ser			
	710		715		720
Pro Asp Ser Pro	Trp Gly Gln Pro Ala	Pro Phe Cys His Pro Lys			
	725		730		735
Gln Gly Ser Ala	Pro Gln Glu Gly Cys	Ser Pro His Pro Ala Val			
	740		745		750
Ala Pro Cys Pro	Pro Gly Ser Phe Pro	Pro Gly Ser Cys Lys Glu			
	755		760		765
Ala Pro Leu Val	Pro Ser Ser Pro Phe	Leu Gly Gln Pro Gln Ala			
	770		775		780
Pro Leu Ala Pro	Ala Lys Ala Ser Pro	Pro Leu Asp Ser Lys Met			
	785		790		795
Gly Pro Gly Asp	Ile Ser Leu Pro Gly	Arg Pro Lys Pro Gly Pro			
	800		805		810
Cys Ser Ser Pro	Gly Ser Ala Ser Gln	Ala Ser Ser Ser Gln Val			
	815		820		825
Ser Ser Leu Arg	Val Gly Ser Ser Gln	Val Gly Thr Glu Pro Gly			
	830		835		840
Pro Ser Leu Asp	Ala Glu Gly Trp Thr	Gln Glu Ala Glu Asp Leu			
	845		850		855
Ser Asp Ser Thr	Pro Thr Leu Gln Arg	Pro Gln Glu Gln Val Thr			
	860		865		870
Met Arg Lys Phe	Ser Leu Gly Gly Arg	Gly Gly Tyr Ala Gly Val			
	875		880		885
Ala Gly Tyr Gly	Thr Phe Ala Phe Gly	Gly Asp Ala Gly Gly Met			
	890		895		900
Leu Gly Gln Gly	Pro Met Trp Ala Arg	Ile Ala Trp Ala Val Ser			
	905		910		915
Gln Ser Glu Glu	Glu Gln Glu Glu Ala	Arg Ala Glu Ser Gln			
	920		925		930
Ser Glu Glu Gln	Gln Glu Ala Arg Ala	Glu Ser Pro Leu Pro Gln			
	935		940		945
Val Ser Ala Arg	Pro Val Pro Glu Val	Gly Arg Ala Pro Thr Arg			
	950		955		960
Ser Ser Pro Glu	Pro Thr Pro Trp Glu	Asp Ile Gly Gln Val Ser			
	965		970		975
Leu Val Gln Ile	Arg Asp Leu Ser Gly	Asp Ala Glu Ala Ala Asp			
	980		985		990
Thr Ile Ser Leu	Asp Ile Ser Glu Val	Asp Pro Ala Tyr Leu Asn			
	995		1000		1005
Leu Ser Asp Leu	Tyr Asp Ile Lys Tyr	Leu Pro Phe Glu Phe Met			
	1010		1015		1020
Ile Phe Arg Lys	Val Pro Lys Ser Ala	Gln Pro Glu Pro Pro Ser			
	1025		1030		1035
Pro Met Ala Glu	Glu Glu Leu Ala Glu	Phe Pro Glu Pro Thr Trp			
	1040		1045		1050
Pro Trp Pro Gly	Glu Leu Gly Pro His	Ala Gly Leu Glu Ile Thr			
	1055		1060		1065
Glu Glu Ser Glu	Asp Val Asp Ala Leu	Leu Ala Glu Ala Ala Val			
	1070		1075		1080
Gly Arg Lys Arg	Lys Trp Ser Ser Pro	Ser Arg Ser Leu Phe His			

1085	1090	1095
Phe Pro Gly Arg His Leu Pro Leu Asp Glu Pro Ala Glu Leu Gly		
1100	1105	1110
Leu Arg Glu Arg Val Lys Ala Ser Val Glu His Ile Ser Arg Ile		
1115	1120	1125
Leu Lys Gly Arg Pro Glu Gly Leu Glu Lys Glu Gly Pro Pro Arg		
1130	1135	1140
Lys Lys Pro Gly Leu Ala Ser Phe Arg Leu Ser Gly Leu Lys Ser		
1145	1150	1155
Trp Asp Arg Ala Pro Thr Phe Leu Arg Glu Leu Ser Asp Glu Thr		
1160	1165	1170
Val Val Leu Gly Gln Ser Val Thr Leu Ala Cys Gln Val Ser Ala		
1175	1180	1185
Gln Pro Ala Ala Gln Ala Thr Trp Ser Lys Asp Gly Ala Pro Leu		
1190	1195	1200
Glu Ser Ser Ser Arg Val Leu Ile Ser Ala Thr Leu Lys Asn Phe		
1205	1210	1215
Gln Leu Leu Thr Ile Leu Val Val Val Ala Glu Asp Leu Gly Val		
1220	1225	1230
Tyr Thr Cys Ser Val Ser Asn Ala Leu Gly Thr Val Thr Thr Thr		
1235	1240	1245
Gly Val Leu Arg Lys Ala Glu Arg Pro Ser Ser Ser Pro Cys Pro		
1250	1255	1260
Asp Ile Gly Glu Val Tyr Ala Asp Gly Val Leu Leu Val Trp Lys		
1265	1270	1275
Pro Val Glu Ser Tyr Gly Pro Val Thr Tyr Ile Val Gln Cys Ser		
1280	1285	1290
Leu Glu Gly Gly Ser Trp Thr Thr Leu Ala Ser Asp Ile Phe Asp		
1295	1300	1305
Cys Cys Tyr Leu Thr Ser Lys Leu Ser Arg Gly Gly Thr Tyr Thr		
1310	1315	1320
Phe Arg Thr Ala Cys Val Ser Lys Ala Gly Met Gly Pro Tyr Ser		
1325	1330	1335
Ser Pro Ser Glu Gln Val Leu Leu Gly Gly Pro Ser His Leu Ala		
1340	1345	1350
Ser Glu Glu Glu Ser Gln Gly Arg Ser Ala Gln Pro Leu Pro Ser		
1355	1360	1365
Thr Lys Thr Phe Ala Phe Gln Thr Gln Ile Gln Arg Gly Arg Phe		
1370	1375	1380
Ser Val Val Arg Gln Cys Trp Glu Lys Ala Ser Gly Arg Ala Leu		
1385	1390	1395
Ala Ala Lys Ile Ile Pro Tyr His Pro Lys Asp Lys Thr Ala Val		
1400	1405	1410
Leu Arg Glu Tyr Glu Ala Leu Lys Gly Leu Arg His Pro His Leu		
1415	1420	1425
Ala Gln Leu His Ala Ala Tyr Leu Ser Pro Arg His Leu Val Leu		
1430	1435	1440
Ile Leu Glu Leu Cys Ser Gly Pro Glu Leu Leu Pro Cys Leu Ala		
1445	1450	1455
Glu Arg Ala Ser Tyr Ser Glu Ser Glu Val Lys Asp Tyr Leu Trp		
1460	1465	1470
Gln Met Leu Ser Ala Thr Gln Tyr Leu His Asn Gln His Ile Leu		
1475	1480	1485
His Leu Asp Leu Arg Ser Glu Asn Met Ile Ile Thr Glu Tyr Asn		
1490	1495	1500
Leu Leu Lys Val Val Asp Leu Gly Asn Ala Gln Ser Leu Ser Gln		

1505	1510	1515
Glu Lys Val Leu Pro Ser Asp Lys Phe Lys Asp Tyr Leu Glu Thr		
1520	1525	1530
Met Ala Pro Glu Leu Leu Glu Gly Gln Gly Ala Val Pro Gln Thr		
1535	1540	1545
Asp Ile Trp Ala Ile Gly Val Thr Ala Phe Ile Met Leu Ser Ala		
1550	1555	1560
Glu Tyr Pro Val Ser Ser Glu Gly Ala Arg Asp Leu Gln Arg Gly		
1565	1570	1575
Leu Arg Lys Gly Leu Val Arg Leu Ser Arg Cys Tyr Ala Gly Leu		
1580	1585	1590
Ser Gly Gly Ala Val Ala Phe Leu Arg Ser Thr Leu Cys Ala Gln		
1595	1600	1605
Pro Trp Gly Arg Pro Cys Ala Ser Ser Cys Leu Gln Cys Pro Trp		
1610	1615	1620
Leu Thr Glu Glu Gly Pro Ala Cys Ser Arg Pro Ala Pro Val Thr		
1625	1630	1635
Phe Pro Thr Ala Arg Leu Arg Val Phe Val Arg Asn Arg Glu Lys		
1640	1645	1650
Arg Arg Ala Leu Leu Tyr Lys Arg His Asn Leu Ala Gln Val Arg		
1655	1660	1665

<210> 23
 <211> 1014
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7482896CB1

<400> 23
 atgacaaaca acagcggctc caaagccgaa ctcgttgttg gagggaaata caaactggtg 60
 cggaagatcg ggtctggctc ctttggagac gtttatctgg gcatcaccac caccaacggc 120
 gaggacgtag cagtgaagct ggaatctcag aaggtcaagc acccccagtt gctgtatgag 180
 agcaaaactct acacgattct tcaaggtggg gttggcatcc cccacatgca ctggtatggt 240
 caggaaaaaag acaacaatgt gctagtcacg gaccttctgg gacccagcct cgaagacctc 300
 tttaatttct gttcaagaag gttcaccatg aaaactgtac ttatgttagc cgaccagatg 360
 atcagcagaa ttgaatacgt gcatacaaag aattttctac accgagacat taaaccagat 420
 aacttctga tgggtactgg gcgtcactgt aataagttgt tccttattga ttttggtttg 480
 gccaaaaagt acagagacaa caggaccagg caacacatac cgtacagaga agataaacac 540
 ctcatggca ctgtccgata tgccagcatc aatgcacatc ttggtattga gcagagccgc 600
 cgagatgaca tggaatcctt aggctacgtt ttcattgtatt ttaatagaac cagcctgccg 660
 tggcaaggac taagggctat gacaaaaaaa caaaaatatg aaaagattag tgagaagaag 720
 atgtccaccc ctgttgaagt tttatgtaag gggtttcctg cagaattcgc catgtacttg 780
 aactactgtc gtgggctgcg ctttgaggaa gtcccagatt acatgtatct gaggcagcta 840
 ttccgcattc ttttcaggac cctgaaccac caatatgact acacatttga ttggacgatg 900
 ttaaagcaga aagcagcaca gcaggcagcc tcttccagtg ggcagggtca gcaggcccaa 960
 acccagacag gcaagcaaac tgaaaaaac aagaataatg tgaaagataa ctaa 1014

<210> 24
 <211> 1530
 <212> DNA
 <213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7483046CB1

<400> 24

```
cggcctgaca ggcgggcatg cgggcgggcca gactgtagcc gagcagcgag gctccggccg 60
cagccatgga gcggcggtg cgcgcgctgg agcagctggc gcggggcgag gccggcggt 120
gcccggggct cgacggcctc ctagatctgc tgctggcgct gcaccacgag ctccagcagc 180
gccccctacg gcgggagcgc agcgtggcgc agttcctgag ctggggccagc cccttcgtat 240
caaaggtgaa agaactgctg ctgcagagag atgactttga gatcttgaag gtgatcggcc 300
gaggagcctt tggggaggtc accgtggtga ggcagaggga cactgggcag atttttgcca 360
tgaaaaatgct gcacaagtgg gagatgctga agagggctga gacagcctgt ttccgggagg 420
agcgggatgt gctcgtgaaa ggggacagcc gttgggtgac cactctgcac tatgccttcc 480
aagacgagga gtacctgtac cttgtgatgg actactatgc tgggtggggac ctctgacgc 540
tgctgagccg cttcgaggac cgtctcccgc ccgagctggc ccagttctac ctggctgaga 600
tggtgctggc catccactcg ctgcaccagc tgggttatgt ccacaggga gtcaagccag 660
acaacgtcct gctggatgtg aacgggcaca ttgcctggc tgacttcggc tctgcctgc 720
gtctcaacac caacggcatg gtggattcat cagtggcagt agggagcccg gactatatct 780
ccctgagat cctgcaggcc atggaggagg gcaaggggcca ctacggccca cagtgtgact 840
ggtggtcgct tggagtctgc gcctatgagc tgctctttgg ggagacgccc ttctatgctg 900
agtcttgggt ggaaacctac ggcaagatca tgaaccacga ggaccacctg cagttcccc 960
cggacgtgcc tgacgtgcca gccagcgccc aagacctgat ccgccagctg ctgtgtgcc 1020
aggaagagcg gctagccgtt ggtgggctgg atgacttccg gaaccatcct ttcttcgaag 1080
gcgtggactg ggagcggtcg gcgagcagca cggcccccta tttcctgag ctgcgggggc 1140
ccatggacac ctccaacttt gatgtgatg acgacacct caaccatcca gggaccctgc 1200
caccgccctc ccacggggcc ttctccggcc atcacctgcc attcgtgggc ttacacctaca 1260
cctcaggcag tcacagtcct gagagcagct ctgaggttg ggctgcctg gagcggaagc 1320
tccagtgtct ggagcaggag aaggtggagc tgagcaggaa gcaccaagag gccctgcacg 1380
ccccacaga ccacgggag ctggagcagc tacggaagga agtgacagct ctgcgggaca 1440
ggctgccagg tatcccttcc gccaccccc accctctcct tgagtttctg tgaattaaaa 1500
tatttgcaa tccaaaaaaa aaaaaaagg 1530
```

<210> 25

<211> 3150

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 71636374CB1

<400> 25

```
attggcttat aggaaaaatt gatttataaa aagtgttaca ggttttcata gataaccatg 60
acaacatccc atatgaatgg gcatgttaca gaggaatcag acagcgaagt aaaaaatgtt 120
gatcttgcac caccagagga acatcagaag caccgagaga tggctgttga ctgccctgga 180
gatttgggca ccaggatgat gccaatacgt cgaagtgcac agttggagcg tattcggcaa 240
caacaggagg acatgaggcg taggagagag gaagaaggga aaaagcaaga acttgacctt 300
aattcttcca tgagacttaa gaaactagcc caaattcctc caaagaccgg aatagataac 360
cctatgtttg atacagagga aggaattgtc ttagaaagtc ctcatatgac tgtgaaaata 420
ttagaaatag aagacttgtt ttcttcactt aaacatatcc aacatacttt ggtagattct 480
cagagccagg aggatatttc actgctttta caactgttc aaaataagga tttccagaat 540
gcatttaaga tacacaatgc catcacagta cacatgaaca aggccagtc tccatttctc 600
cttatctcca acgcacaaga tcttgctcaa gaggtacaaa ctgttttgaa gccagttcat 660
cataaggga gacaagaact aactgctttg ctgaatactc cacatattca ggcactttta 720
ctggcccacg ataagggttg tgagcaggaa atgcagctag agccattac agatgagaga 780
gtttatgaaa gtattggcca gtatggagga gaaactgtaa aaatagttcg tatagaaaag 840
```

```

gctcgtgata ttccggtggg tgctacagtt cgtaatgaaa tggactctgt catcattagc 900
cggatagtaa aaggggggtgc tgcagagaaa agtgggtctgt tgcataagag agatgaagt 960
ctagagatta atggcattga aattcggggg aaagatgtca atgagggttt tgacttgttg 1020
tctgataigc atggtacttt gacttttgtc ctgattccca gtcaacagat caagccgcct 1080
cctgccaagg aaacagtaat ccatgtaaaa gctcattttg actatgaccc ctcagatgac 1140
ccttatgttc catgtcgaga gttagggtctg tcttttcaaa aaggtgatat acttcattgt 1200
atcagtcaag aagatccaaa ctgggtggcag gcctacaggg aaggggacga agataatcaa 1260
cctctagccg ggcttgttcc agggaaaagc ttctagcagc aaagggagc catgaaacaa 1320
accatagaag aagataagga gccagaaaaa tcaggaaaaa tgtggtgtgc aaagaagaat 1380
aaaaagaaga ggaaaaaggt ttatataaat gccataaaaa atgatgatta tgacaacgag 1440
gagatcttaa cctatgagga aatgtcactt tatcatcagc cagcaaatag gaagagacct 1500
atcatcttga ttggtccaca gaactgtggc cagaatgaat tgcgtcagag gctcatgaac 1560
aaagaaaagg accgctttgc atctgcagtt cctcatacaa cccggagtag gcgagaccaa 1620
gaagtagccg gtagagatta ccactttgtt tcgcggaag cattcgaggc agacatagca 1680
gctggaaaagt tcattgagca tggatgaatt gagaagaatt tgtatggaac tagcatagat 1740
tctgtacggc aagtgtacaa ctctggcaaa atatgtcttt taagtcttcg tacacagtca 1800
ttgaagactc tccggaattc agatttgaaa ccatatatta tcttcattgc acccccttca 1860
caagaaagac ttcgggcatt attggccaaa gaaggcaaga atccaaagcc tgaagagttg 1920
agagaaatca ttgagaagac aagagagatg gagcagaaca atggccacta ctttgatacg 1980
gcaattgtga attccgatct tgataaagcc tatcaggaat tgcttaggtt aattaacaaa 2040
cttgatactg aacctcagtg ggtaccatcc acttggtctg ggtgaaagaa acatccattc 2100
tgtggcatgt tggacttgat ctggcaaaaa ctgccaatag gaggactgcc cgacactgca 2160
gcaagattga ggataagatg gaaggcagca gtataagctg tagatctgtt cttagatctc 2220
ttgaattagt gagacgacag ttcccttagg cagtttgtgc atggcatcct ttattctcta 2280
tacatggctt tagcggttct tgcctcattt tgggattcta aatggaagct ttcaacagag 2340
cattccattt tgtcctgtta aaaccttttg tttcaccta aacctttct gcttagttgt 2400
atctctgtga aaaacttgta tacacaagcg tccatgtctc acacaaatat tgatgtgatt 2460
attcttaagt gttaaactat taacacttaa atgacttcat tgggaatatt gagcagaggg 2520
actgtgcttc tatgactgg gcaaggcagt atttgcttag gaaactaatt tagtcatcag 2580
agatactttc ctaaaaagga aaaataaaaa acaaaatggt gccactttgg gttgaagcta 2640
ctttgttagg cttgaattca tttatatgtc ttttgattct taaaaaaca aaaacattc 2700
cattagaagc accagttttt ttgctcagac tttgtggatc agactctaca ctcaacacac 2760
tctaactctac ttaaagggtat acaaaaatag ctgatctttt ttaaattatg atttcctgaa 2820
tttttttctt aagtcgtctc aactgattta ctacttagc ttcccttccc tcatcagcat 2880
agtataaatg aatgtatgtt acatttttat gaatggcagg tgttcattat aatctgtatt 2940
gacttaaaaa gtttcttctc catgatgcta atagtttttt gtatacatgg gaggatagca 3000
catttgacag tttttgcatt tttatgtatg agcacagtat cctatgactg tgctacgtat 3060
atataggtaa taaactggaa ttctgttgat gaatatagct gctgtactgt atattaatat 3120
ttaatagatc aacaaatggt cattgaaaa 3150

```

<210> 26

<211> 2901

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7480597CB1

<400> 26

```

atggcggaag gcaaggaagg gcaagtcacca tcttacatgg atggcagcag gcaaagagag 60
aatgaggaag atgcaaaaagc ggaaaccctt gatgtaacca tcagatctta tgagatttat 120
tcactaccat ggaacagaca gcaaggccta tgtgaccatt ctctaaaata tttaagctcg 180
agaatcacag agcggaagct gcaaggctcc tggctgctcg ccagccgagg gaatctggag 240
aaaccattcc tggggccgcg tggccccgtc gtgcccttgt tctgccctcg gaatggcctt 300
cactcagcac atcctgagaa cagccctctg aagcccaggg tcgtgaccgt agtgaagctg 360

```



```

gggtgggcagc gccccgaaa gatcactctg ctccctcaaca ggcgatcagt gcagacgttc 420
gagcagctct tagctgacat ctcagaagcc ttgggtctct ccagatggaa gaatgaccgt 480
gtgaggaaac tgtttaacct caagggcagg gaaatcagga gcgtctctga tttcttcagg 540
gaaggggatg ctttcatagc tatgggcaaa gaaccactga cactgaagag cattcagggtg 600
gctgtagaag aactgtaccc caacaaagcc cgggccctga cactggccca gcacagccgt 660
gccccctctc caaggctgag gagcaggctg tttagcaagg ctctgaaagg agaccaccgc 720
tgtggggaga ccgagacccc caagagctgc agcgaagttg caggatgcaa ggcagccatg 780
aggcaccagg ggaagatccc cgaggagctt tcactagatg acagagcgag gaccagaag 840
aagtggggga gggggaaatg ggagccagaa ccagtagca agccccccag ggaagccact 900
ctggaagaga ggcacgcaag gggagagaag catcttgggg tggagattga aaagacctcg 960
gggtgaaatta tcagatgcga gaagtgaag agagagaggg agctccagca gagcctggag 1020
cgtgagaggc tttctctggg gaccagttag ctggatatgg ggaagggccc aatgtatgat 1080
gtggagaagc tggtagaggc cagaagctgc aggaggtctc ccgaggcaaa tcctgcaagt 1140
ggggaggaag ggtggaaggg tgacagccac aggagcagcc ccaggaatcc cactcaagag 1200
ctgaggagac ccagcaagag catggacaag aaagaggaca gaggccaga ggatcaagaa 1260
agccatgctc agggagcagc caaggccaag aaggaccttg tggagttct tcctgtcaca 1320
gaggaggggc tgaggaggt gaagaaggac accaggcca tgagcaggag caaacatggt 1380
ggctggctcc tgagagagca ccaggcgggc tttgagaagc tccgcaggac ccgaggagaa 1440
gagaaggagg cagagaagga gaaaaagcca tgtatgtctg gaggcagaag gatgactctc 1500
agagatgacc aacctgcaaa gctagaaaag gagcccaaga cgaggccaga agagaacaag 1560
ccagagcggc ccagcgtcg gaagccacgg cccatgggca tcattgccgc caatgtggaa 1620
aagcattatg agactggccg ggtcattggg gatgggaact ttgctgtcgt gaaggagtgc 1680
agacaccgcy agaccaggca ggctatgcy atgaagatca ttgacaagtc cagactcaag 1740
ggcaaggagg acatggtgga cagttagatc ttgatcatcc agagcctctc tcacccaac 1800
atcgtgaaat tgcataagct ctacgaaaca gacatggaaa tctacctgat cctggagtac 1860
gtgcaggag gagaccttt tgacgccatc atagaaagtg tgaagttccc ggagcccgat 1920
gtgcacctca tgatcatgga cttatgcaaa gccctcgtcc acatgcacga caagagcatt 1980
gtccaccggg acctcaagcc gaaaaacctt ttggttcagc gaaatgagga caaatctact 2040
accttgaaat tggctgattt tggacttgca aagcatgtgg tgagacctat attactgtg 2100
tgtgggaccc caacttacgt agctcccga attctttctg agaaaggtta tggactggag 2160
gtggacatgt gggctgctgg cgtgatcctc tatatcctgc tgtgtggctt tccccattc 2220
cgcagccctg agagggacca ggacgagctc tttaacatca tccagctggg ccactttgag 2280
ttcctcccc cttactggga caatatctct gatgctgcta aagatctggt gagccggtt 2340
ctggtggtag accccaaaaa gcgctacaca gctcatcagg ttcttcagca cccctggatc 2400
gaaacagctg gcaagaccaa tacagtgaag cgacagaagc aggtgtcccc cagcagcgag 2460
ggtcacttcc ggagccagca caagagggtt gtggagcagg tatcatagtc accaccttgg 2520
gaatctgtcc agccccagt tctgctcaag cacagagaaa aggatagaag tttgagagaa 2580
aaacaatgaa agaggcttct tcacataatt ggtgaatcag agggagagac actgagtata 2640
ttttaaaagca tattaaaaaa attaatgcaa tgttaaatgt cacaacatat ttttagattt 2700
gtatatttaa agcctttaat acatttttgg ggggtaagca ttgtcatcag tgaggaattt 2760
tggtataaat gatgtgtttt gcttccccct tgtaaccaag tttattctgt actacaggag 2820
tggtgcttac cagggtctaa actccccctg tgagattaat aaggtgcatt gtggtcttcc 2880
tgtgttaata aaatgtggtc c
2901

```

<210> 27

<211> 1671

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3227248CB1

<400> 27

```

atgaagctta taaatggcaa aaagcaaaca ttcccatggg ttggcatgga catcggtgga 60
acgctgggta aattggtgta ttccgagccg aaggatatta cagccgaaga ggagcaagag 120

```

```

gaagtggaga acctgaagag catccggaag tatttgactt ctaatactgc ttatgggaaa 180
actgggatcc gagacgtcca cctggaactg aaaaacctga ccatgtgtgg acgcaaaggg 240
aacctgcact tcatccgctt tcccagctgt gctatgcaca gggttcattca gatgggcagc 300
gagaagaact tctctagcct tcacaccacc ctctgtgccca caggaggcgg ggctttcaaa 360
ttcgaagagg acttcagaat gattgctgac ctgcagctgc ataaactgga tgaactggac 420
tgtctgattc agggcctgct ttatgtcgac tctgttggct tcaacggcaa gccagaatgt 480
tactattttg aaaatcccac aaatcctgaa ttgtgtcaaa aaaagccgta ctgccttgat 540
aaccctatcc ctatgttgct ggtaacatg ggctcagggt tcagcattct agccgtgtac 600
tccaaggaca actataaaaag agttacaggg accagtcttg gagtggaac attcctaggc 660
ctatgttgct tgctgactgg ttgtgagacc tttgaagaag ctctggaaat ggcagctaaa 720
ggcgacagca ccaatgttga taaactggtg aaggacattt acggaggaga ctatgaacga 780
tttggccttc aaggatctgc tgtagcatca agctttggca acatgatgag taaagaaaag 840
cgagattcca tcagcaagga agacctcgcc cgggccacat tggtcacat caccaacaac 900
attggctcca ttgctcggat gtgtcggtt aatgagaaca tagacagagt tgtgtttgtt 960
ggaaattttc tcagaatcaa tatggtctcc atgaagctgc tggcatatgc catggatttt 1020
tggtccaaag gacaactgaa agctctgttt ttggaacatg agggttattt tggagccgtt 1080
ggggcactgt tggaaactgtt caaaatgact gatgataagt agagacgagc agtggaggaa 1140
acagcctccc aaaaggacag agaactaaaa aattgctgct ggagaagggt aaagtcgctt 1200
tgggacggaa gccaagccat tatggcagat gaacctgctg gatttgtaaa taatttaaaa 1260
tccttcagga tgatctttta ctcttaggtt ttgagctaag gattcaaaac gggggaatat 1320
aaaagggttt ttttctgtat actgtatttt tttaaaaaaa tgggtgcagcg tggccaaacc 1380
taccaattgt atgcattaac ttgaaaagt tgtttgatgt ttaagaagga cctgatatgt 1440
aagcgtggtt ctttttctt ctggggttta ctgatcagtg tggtgatttt aacttcattt 1500
agtaattact ctaggagatt ttacctgac ttatattttt catgacgttt catgatttgc 1560
tgttggtttc aaatgaaact acaaatctgg catgttttac tgtgaacact tttgttattt 1620
gttttgtacc ctttttctt tgttttctg ttttagttgt cttctgaaaa a 1671

```

<210> 28

<211> 2577

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4207273CB1

<400> 28

```

atgccacaga tagcaaagaa gcaatcaact caccggactc agaaacctaa aaagcaatca 60
tttcttgc tctgtaaaaa tccaggaaca cagaagtcac gtgttcctct ctctgttcaa 120
ccgacagagc caagactaaa ttacctagat cttaagtata gtgatatgtt caaagaaatc 180
aattcaactg ctaatggacc tggaatctat gaaatgtttg ggacctctgt ttattgtcat 240
gtgcgagaga ctgaaaggga tgaaaacacg tattaccgtg agatatgttc ggctccatca 300
ggcagacgta tcaccaataa atgtcgatct tcacacagtg agaggaagag caatatcaga 360
acaagacttt ctcaaaaaa aacacatatg aaatgcccaa agacttcatt tggcattaaa 420
caagagcaca aagtcttaat ttctaaagaa aagagttcca aggtgtaca tagcaacct 480
catgacattg aaaatggtga tggatattca gaaccagact ggcagataaa gtcttcagga 540
aatgagtttc tatcttccaa agatgaaatt catcccatga acttggctca gacacctgag 600
cagtccatga aacagaatga attcctcct gtctcagatt tatccattgt tgaagaagtt 660
tctatggaag agtctactgg tgatagagac atttctaaca atcaaatact caccacaagc 720
ctcagagatc tgcaagaact tgaagagcta catcaccaga tcccatttat ccttcagaa 780
gacagctggg cagtgccag tgagaagaat tctaacaagt atgtacagca agaaaagcag 840
aatacagcat ctcttagtaa agtaaatgcc agccgaattt taactaatga tctagagttt 900
gatagtgttt cagatcactc taaaacactt acaaatttct ctttccaagc aaaacaagaa 960
agtgcattct cccagacata tcaatatgtg gtacattatt tggatcatga tagtttagca 1020
aataagtc aaatcatca aatgtttgga aaaaccttaa gtggcacaaa ttcaatttcc 1080
caagaaatta tggactctgt aaataatgaa gaattgacag atgaactatt aggttgtcta 1140

```

```

gctgcagaat tattagctct tgatgagaaa gataacaact cttgccaaaa aatggcacaat 1200
gaaacagatc ctgaaaacct aaatcttgtc ctcagatgga gaggaagtac cccaaaagaa 1260
atgggcagag agacaacaaa agtcaaaata cagaggcata gtagtgggct caggatatat 1320
gacagggagg agaaatttct catctcaaat gaaaagaaga tattttctga aaatagttta 1380
aagtctgaag aacctatcct atggaccaag ggtgagattc ttggaaggag agcctacggc 1440
acagtatact gtggtctcac tagtcaagga cagctaatac ctgtaaaaca ggtggctttg 1500
gataacctta ataaattagc tgctgaaaag gaataccgga aactacagga agaagtagat 1560
ttgctcaaag cactgaaaca tgtcaacatt gtggcctatt tggggacatg cttgcaagag 1620
aacactgtga gcattttcat ggagtttgtt cctggtggct caatctctag tattataaac 1680
cgttttgggc cattgcttga gatggtgttc tgtaaatata cgaaacaaat acttcaaggt 1740
gttgcttatc tccatgagaa ctgtgtggtg catcgcgata tcaaaggaaa taatgttatg 1800
ctcatgccaa ctggaataat aaagctgatt gactttggct gtgccaggcg tttggcctgg 1860
gcaggtttta atggcaccca cagtgcacatg cttaagtcca tgcattgggac tccatattgg 1920
atggccccag aagtcaccaa tgagtctggc tatggacgga aatcagatat ctggagcatt 1980
ggttgtagtg tgtttgagat ggctacaggg aagcctccac tggcttccat ggacaggatg 2040
gccgcatgtt ttacatcgg agcacaccga gggctgatgc ctctttacc agaccacttc 2100
tcagaaaatg cagcagactt tgtgcgcatg tgcctgacca gggaccagca tgagcgacct 2160
tctgctctcc agctcctgaa gcactccttc ttggagagaa gtactgaat atacatcaag 2220
actttcttcc cagttccact gcagatgttc ccttgcttaa ttgtggggaa tgatggctaa 2280
gggacttttg ttcccccact gaaaattcag tctaaccagg tttaagcaga tcctatggag 2340
tcattaactg aaagttgcag ttacatatta gctcctcaa gtgtcagaca ttattactca 2400
tagtatcaga aaacatgttc ttaataacaa caaaaaacta tttcagtgtt tacagttttg 2460
attgtccagg aactacattc tctagtgttt tatatgacat ttctttttat ttttggcctg 2520
tcctgtcaat ttaatgttg ttagtttaaa ataaattgta aaaacaaaaa aaaaaaa 2577

```

<210> 29

<211> 2110

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7483334CB1

<400> 29

```

ctagggctgc cggggaagcg gtttgggaga gcccatgggtg actgcgtgag tggagcccg 60
ctgtgtggat gcccagcat ggatgactac atggctctga gaattgttg ggagggctcc 120
ttcggcagag ctcttttggg tcagcttgaa agcagtaatc agatgtttgc catgaaagaa 180
ataaggcttc ccaagtcttt ctctaataca cagaattcta ggaaggaggc tgttctttta 240
gccaaaatga aacaccctaa tattgttgcc ttcaaagaat catttgaagc tgaaggacac 300
ttgtatatgg tgatggaata ctgtgatgga ggggatctaa tgcaaaagat taaacagcag 360
aaaggaaagt tatttcctga agacatgata cttaattggg ttacccaaat gtgccttgga 420
gtaaatcaca ttcacaagaa acgtgtgcta cacagagata tcaagtccaa gaatatcttc 480
ctcactcaga atggaaaagt gaaattggga gactttggat ctgccgtct tctctccaat 540
ccgatggcat ttgcttgtag ctatgtggga actccttatt atgtgcctcc agaaatttgg 600
gaaaacctgc cttataacaa taaaagtgc atctggtcct tgggttgcat cctgtatgaa 660
ctctgtaccc ttaagcatcc atttcaggca aatagttgga aaaatcttat cctcaaagta 720
tgtcaagggt gcatcagtc actgccgtct cattactcct atgaacttca gttcctagtc 780
aagcagatgt taaaaggaa tccctcacat cgcctctcgg ctacaacgct tctctctcga 840
ggcatcgtag ctcggttgt ccagaagtgc ttacccccg agatcatcat ggaatatggt 900
gaggaagtat tagaagaaat aaaaaattcg aagcataaca caccaagaaa aaaaacaaac 960
cccagcagaa tcaggatagc tttgggaaat gaagcaagca cagtgcgaaga ggaagaacaa 1020
gatagaaagg gtagccatac tgatttggaa agcattaatg aaaatttagt tgaaagtgc 1080
ttgagaagag taaacagaga agaaaaaggt aataagtcag tccatctgag gaaagccagt 1140
tcaccaaatc ttcatagacg acagtgggag aaaaatgtac ccaatacagc tcttacagct 1200
ttggaaaatg catccatact cacctccagt ttaacagcag aggacgatag aggtggttct 1260

```

gtaataaagt acagcaaaaa tactactcgt aagcagtggc tcaaagagac ccttgacact 1320
ttgttgaaca tccttaagaa tgctgatctc agcttggcct ttcaaacata cacaatatat 1380
agaccagggt cagaaggggt cttgaaaggc ccctgtctg aagaaacaga agcatcggac 1440
agtgttgatg gaggtcacga ttctgtcatt ttggatccag agcgacttga gcctgggcta 1500
gatgaggagg acacggactt tgaggaggaa gatgacaacc ccgactgggt gtcagagctg 1560
aagaagcgag ctggatggca aggcctgtgc gacagataat gcctgaggaa atgttcctga 1620
gtcacgctga ggagagcctt cactcaggag ttcatgctga gatgatcatg agttcatgcg 1680
acgtatattt tcctttggaa acagaatgaa gcagaggaaa ctcttaatac ttaaaatcgt 1740
tccttgattag tatcgtgagt ttgaaaagtc tagaactcct gtaagttttt gaactcaagg 1800
gagaaggtat agtggaatga gtgtgagcat cgggctttgc agtcccatag aacagaaatg 1860
ggatgctagc gtgccactac ctacttgtgt gatttgtgga aattacttaa cctcttcaag 1920
ccccatttc ctcaaccata aaatgaagat aataatgcct acctcagagg gatgctgacc 1980
acagaccttt atagcagccc gtatgatatt attcacatta tgatatgtgt ttattattat 2040
gtgactcttt ttacatttcc taaaggtttg agaattaaat atatttaatt atgatttaaa 2100
aaaaaaaaa 2110

<210> 30

<211> 7093

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7483337CB1

<400> 30

cgaggggacg cctcgcgacg gttcctggga gagctggcgg cggccttgcct ctgcgcgctc 60
ttcgcgcgcgc cctccccgcc cgccccgcctc aggattgagg aagtgcgtct gggcccgccc 120
ccggcgcgagg gggcagacgg cgggtgggacg gccaggcccc ggccccgccca gtgtgtccgc 180
ccggccccgc gtccccgagg agtcagctgt gtgtccagaa cgtgccatgg agacgcttaa 240
cgggtgccggg gacacggggc gcaagccgtc cacgcggggc ggtgaccctg cagcgcgggtc 300
ccgcaggacg gaaggcatcc gcgcgcgta caggcgggga gaccgcggcg gcgccccgga 360
cctgctggag gaggcctgcg accagtgcgc gtcccagctg gaaaagggcc agcttctgag 420
catccccgca gcctatgggg atctggagat ggtccgctac ctactcagca agagactggt 480
ggagctgccc accgagcccc cggatgacaa cccagccgtg gtggcagcgt attttggaca 540
cacggcagtt gtgcaaaata cgctgcccac cgagcccacg gatgacaacc cagccgtggt 600
ggcagcgtat ttggacaca cggcagttgt gcaggaattg cttgagtcct taccagggtc 660
ctgcagtcct cagcggcttc tgaactggat gctggccttg gcttgccagc gagggcacct 720
gggggttgtg aagctcctgg tctgacgca cggggctgac ccggagagct acgctgtcag 780
gaagaatgag ttccctgtca tcgtgcgctt gcccctgtat ggggccatca agtcagggaa 840
tgaagacatt gcaatattcc tgcttcggca tggggcctat ttctgttctt acatcttgc 900
ggatagtcct gaccccagca aacatctgct gagaaagtac ttcattgaag ccagtccctt 960
gccagcagc tatccgggaa aaacagctct ccgtgtgaaa tgggtccatc tcagactgcc 1020
ctgggtagac ctgactggc tcatagacat ctctgccag atcacggagc tcgaccttc 1080
tgccaactgc ctggcgacct tcccctcggg tatccctgg ggcctcatca atctccgga 1140
gctgaacctc tccgacaacc acctggggga gctgcctggc gtgcagtcac cggacgaaat 1200
catctgttcc aggctacttg aaattgacat ttccagcaac aagttgtccc acctccctcc 1260
tggattcttg cacctctcaa aacttcaaaa actgacagct tcaaaaaatt gtttagaaaa 1320
attgttcgaa gaagaaaatg cactaactg gataggttta cggaaagctac aggaacttga 1380
tatatctgac aataaattga cagaactccc tgccctgttc cttactctt tcaagtccct 1440
caattctctg aatgtctcca gaaacaacct gaaggtgttt ccagatccct gggcctgccc 1500
tttgaaatgt tgtaaagctt ccagaaatgc cctggaatgt ctgccagaca aaatggctgt 1560
cttttgaaa aatcacctga aggatgtgga tttctcagaa aacgcactca aagaagtcc 1620
cctgggactt ttccagcttg atgcccctcat gttcttgagg ttacagggga accagctggc 1680
ggcacttcca cctcaagaga agtggaacct caggcagctc aaaacctgg atctctccag 1740
aaaccaactt ggcaaaaaatg aagatggact gaaaacgaag cgtattgcct ttttaccac 1800

cagaggctgc cagcgctccg ggactgaggg agagacaact atggagttca gtgcatctct 1860
 ggtaaccatt gtgttccgtg ctaacaactg taacctctgt gcatacacat gtgcagcaag 1920
 tgtgctggaa tttccggcct tcctaagtga gtctttggaa gtccctttgcc tgaacgacaa 1980
 ccacctcgac acagtccttc cctcggtttg cctactgaag agcttatcag agctctactt 2040
 gggaaacaac cctggcctcc gggagctccc tcctgagctg gggcagctgg gcaacctctg 2100
 gcagctggac actgaagacc tgaccatcag caatgtgcct gcagaaatcc aaaaagaagg 2160
 ccccaaagca atgctgtctt acctgcgtgc tcagctgcgg aaagcggaaa agtgcaagct 2220
 gatgaagatg atcatcgtgg gtcccccgcg ccagggaag tccacctcc tggagatctt 2280
 acagacgggg agggccccc aggtggtgca tggagaggcc accatcagga ccaccaagtg 2340
 ggagctccag aggcgggtg gctcgagagc caaggtcaag gatggtctgc gtgcagagtc 2400
 cctgtgggtt gagtccgtgg agttcaacgt ctgggacatc gggggaccgg ccagcatggc 2460
 cactgtcaac cagtgtctt tcacggacaa ggccctgtac gtggtggtct ggaacctggc 2520
 gctgggggag gaggcgtgg ccaacctcca gttctggctg ctcaacatcg aggccaaagg 2580
 cccaaacgcc gtggtgctgg tggcggggac gcacctggat ttaattgaag ccaagttccg 2640
 tgtggaaagg attgcaacgc tgctgccta tgtgctggca ctctgccgt cccctccgg 2700
 ctccaggggc acaggcttcc cagacatcac ctcaaacac ttacatgaga tttctgcaa 2760
 gagcctggaa ggtcaggaag ggtgcgaca gctgatttcc cactgcagt gcagcatgaa 2820
 ggacgtcggc agcaccatcg gctgccagcg actggcagg cggtgatcc ccaggagcta 2880
 cctgagcctg caggaggccg tgctggcaga gcagcagcg cgcagccggg acgacgagct 2940
 gcagtacctg acggacaggg agctggagca gctggtggag cagacgccc acaacgacat 3000
 caaggactac gaggacctgc agtcagccat cagcttctc atagaaaccg gcacctgct 3060
 ccatttcccg gacaccagcc acggcctgag gaacctctac ttcctcgacc ctatttggct 3120
 ctccgaatgt ctgcagagga tctttaatat taagggtct cggtcagtgg ccaagaatgg 3180
 ggtgatcaga gcagaagacc tcaggatgct gctggtgggg actggcttca cgcagcagac 3240
 ggaagagcag tacttccagt tcctggccaa gtttgagatc gccctgcccg tcgccaatga 3300
 cagctacctc ctgccccatc tccttccatc taaacctggc ctggacacc acggtatgct 3360
 gcacccca cccaacacca ttcagagggt atttaagatg agcttcgttc ccgttggctt 3420
 ctggcaagg tttatagcac ggatgctgat cagcctggcg gagatggacc tgcagctttt 3480
 tgaacaag aagaatacta aaagcaggaa caggaaagtc accatttaca gttttacagg 3540
 aaaccagaga aatcgctgta gcacattcag agtgaaaaga aatcagacca tctattggca 3600
 ggaagggtc ctggtcactt ttgatgggg ctacctcagt gtggaatctt ccgacgtgaa 3660
 ctggaaaaag aagaaaagcg gaggaatgaa aattgtttgc caatcagaag tgagggactt 3720
 ctacgccatg gctttcatca cggaccagct caattccttg attgatcagt ggtttcccg 3780
 cctgacagcc acagagagcg acgggacgcc actcatggag cagtacgtgc cctgcccgg 3840
 ctgcgagaca gcctgggccc agcacagga cccagtgag aatcagagg atgtgcagta 3900
 cttcgacatg gaagactgtg tcctgacggc ctgcgagcg gacttcatct cctgcccag 3960
 acacccggac ctccccgtgc cgctgcagga gctggctcct gaactgttca tgaccgactt 4020
 cccggccagg ctcttctgga agaacagcaa gctggagcac agcaggagcg agggcagcgt 4080
 cctgggcccag ggcggcagtg gcaccgtcat ctaccgggcc cggtagcagg gccagcctgt 4140
 ggccgtcaag cgcttccaca tcaaaaaatt caagaacttt gctaacgtac cggcagacac 4200
 catgctgagg cacctgcccc ccaccgatgc catgaagaac ttctccgagt tccggcagga 4260
 ggccagcatg ctgcacgcgc tgcagcacc ctgcatcgtg gcgctcatcg gcatcagcat 4320
 ccaccgctc tgcttcgccc tggagctgc gccgctcagc agcctcaaca ccgtgctgtc 4380
 cgagaacgcc agagattctt cctttatacc cctgggacac atgctcacc aaaaaatagc 4440
 ctaccagatc gcctcgggcc tggcctacct gcacaagaaa aacatcatct tctgtgacct 4500
 gaagtccgac aacattctgg tgtgttcct tgacgtcaag gagcacatca acatcaagct 4560
 atctgactac gggatttcga ggcagtcatt ccatgagggc gccctaggcg tggagggcac 4620
 tcctggctac caggccccag agatcaggcc tcgcattgta tatgatgaga aggtagatat 4680
 gttctcctat ggaatggtg tctacgagtt gctgtcagga cagcgccctg cactgggcca 4740
 ccaccagctc cagattgcca agaagctgtc caagggcac cgcccggttc tggggcagcc 4800
 ggaggaagtg cagttccggc gactgcaggc gctcatgatg gagtgtctgg acactaagcc 4860
 agagaagcga ccgctggccc tgtcgggtgt gagccagatg aaggaccgca cttttgccac 4920
 cttcatgtat gaactgtgct gtgggaagca gacagcttc ttctcatccc agggccagga 4980
 gtacaccgtg gtgttttggg atggaaaaga ggagtcagg aactacacgg tggatgaac 5040
 agagaagggc ctcatggagg tgagaggat gtgctgccct gggatgaagg tgagctgcca 5100
 gctccaggtc cagagatccc tgtggacagc caccgagaat tcctacctgg tcttagcggg 5160

```

cctcgccgat gggcttgtgg ctgtgtttcc cgtggtgcgg ggcaccccaa aggacagctg 5220
ctcctacctg tgctcacaca cagccaacag gtccaagttc agcatcgagg atgaagacgc 5280
acggcagaac ccctaccag tgaaggccat ggagggtggtc aacagcggct ctgagggtctg 5340
gtacagcaat gggccggggcc tccttgtcat cgactgtgcc tccctggaga tctgcaggcg 5400
gctggagccc tacatggccc cctccatggt tacgtcagtc gtgtgcagct ctgaggggcag 5460
aggggaggag gtcgtctggt gcttgatga caaggccaac tccttgggtga tgtaccactc 5520
caccacctac cagctgtgtg ccgggtactt ctgcggggtc cccagccccc tcaggggacat 5580
gtttcccggtg cggcccttgg acacggaacc cccggcagcc agccacacgg ccaacccaaa 5640
gggtgcctgag ggggactcca tcgcgagcgt gagcatcatg tacagtgagg agctggggcag 5700
gcagatcctg atccaccagg aatcactcac tgactactgc tccatgtcct cctactcctc 5760
atccccaccc cgccaggctg ccagggtccc ctcaagcctc cccagctccc cagcaagttc 5820
ttccagtgtg cctttctcca ccgactgcga ggactcagac atgtacata cgcccggtgc 5880
tgctccgac aggtctgagc atgacctgac ccccatggac ggggagacct tcagccagca 5940
cctgcaggcc gtgaagatcc tcgccgtcag agacctcatt tgggtcccca ggcgcggtgg 6000
agatgttatc gtcattggcc tggagaagga ttctggcgcc cagcggggcc gagtcattgc 6060
cgtcttaaaa gcccgagagc tgactccgca tggggtgctg gtggatgctg ccgtggtggc 6120
aaaggacact gttgtgtgca cctttgaaaa tgaaaacaca gagggtggtc tggccgtctg 6180
gaggggctgg ggcgccaggg agttcgacat tttctaccag tcctacgagg agctggggcg 6240
gctggaggct tgcaactcga agagaaggta attcctgtgg aatgactgtc acacatcaga 6300
gctggctggc cgggggtgc agcctgactc ctctgccatc ggcctctagt tctccaagga 6360
cctagaagac agatggagtt ctcccctgaa ctcttctgtg ctaagaagtg ctgagaagtt 6420
actcgcctgg cgggtgctcc aggggttctct ggttctctgg agcagagttc tctgaatacc 6480
ccatccccca actgtctgatt ttacagcccc agggagaca gtggtatcag gctgggagcg 6540
gcctcctctg gcctccccc tcagtttgca ggagcagggg tgcaggatcc tgttctgagc 6600
tgggtcaaac aaagcagggc cgggccttcc tgccatcccc aggtctcaga tgggaattaca 6660
ctagaggccc tccgctggga agcacttgag gtagggcagg aggggggctg tgaccctgc 6720
cctttccccc ccagagacct caggctctca gcacattcca caggctcctg agtccccgag 6780
gcctgggcca gcttgggcaa gccaaagatc gatgtctctg tgttcgggaa ggtctccgtg 6840
tgggaaagcc cttgggggat cccgggtgag gagtgttgcc ccatccagag aatgaatgag 6900
ttcctttaag tgccaccgcc agcaagccca gaggcacaca ttctgagtgc acccgcttag 6960
cctttacatt cctctccacc gacaaaagga aggggaaact caatcagcag gacttcagaa 7020
agggccttgt gtttatagct ttgtcaagta aatttgagc cagctggaaa cacaggcctg 7080
tttgttgac ata 7093

```

<210> 31

<211> 1800

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 6035509CB1

<400> 31

```

gctgcagagt gctttacttt caacaagatg gagtcttgct ctgtttccca gcctgtagtg 60
cagtgacaca gtcttggctc actgtaacct ctgcctcctg ggttcaagtg attctcctgc 120
ctcagcctcc tgagtagctg ggattacagg aaacatctgt atggattatt tcactataat 180
cctatgatgc ttggacttga atcaattcca gatccacag acacctggga aattatagag 240
accatttgga aaggcaccta tggcaaagtc tacaaggtaa ctaacaagag agatgggagc 300
ctggctgcag tgaaaattct ggatccagtc agtgatatgg atgaagaaat tgaggcagaa 360
tacaacattt tgcagttcct tcctaatacat cccaatgttg taaagtttta tgggatgttt 420
tacaagcgg atcactgtgt agggggacag ctgtggctgg tcctggagct gtgtaatggg 480
ggctcagtca ctgagcttgt caaaggctca ctcagatgtg gccagcgggt ggatgaagca 540
atgatctcat acatcttgta cggggccctc ttgggccttc agcatttgca caacaaccga 600
atcatccacc gtgatgtgaa ggggaataac attcttctga caacagaagg aggagttaag 660
ctcgttgact ttggtgtttc agctcaactc accagtacac gtctgcggag aaacacatct 720

```

gttggcacc cgttctggat ggccctgag gtcattgcct gtgagcagca gtatgactct 780
tcctatgacg ctgcgtgtga cgtctggtcc ttggggatca cagctattga actgggggat 840
ggagaccctc ccctctttga catgcatcct gtgaaaacac tctttaagat tccaagaaat 900
cctccacctt ctttacttca tccagaaaaa tgggtgtgaag aattcaacca ctttatttca 960
cagtgtctta ttaaggattt tgaaggcgga ctttccgtca cacatctcct tgaccaccca 1020
tttattaaag gagtacatgg aaaagtctctg tttctgcaaa aacagctggc caaggttctc 1080
caagaccaga agcatcaaaa tcctgttgct aaaaccaggc atgagaggat gcataccaga 1140
agaccttatt atgtggaaga tgctgaaaaa tactgccttg aggatgattt ggtcaacctt 1200
gaggttcttg atgaggtact aaatatattg tagacaattc tcattgaaga catttgtttc 1260
atgtgaatgg tctgaacttt ctgtttaga ccatgtcttc ctaaggatcat ttgaaaattt 1320
aattgtttgt gtagctatgg gatgaagttc agggagcatt cagttgctgt gactatgatc 1380
ctgtgctgtg tttatttaga tagcccttag aatgatgaag agaaaaggat ttggattttt 1440
gcaataaagc tctttatatt gtagccttaa tgatggatta tatcagctga aaatatattg 1500
tttgataaaa tttgataaaa tatttcaatt aacccttaag aagtgtttt ttcttcataa 1560
gaaagagctt catttaggga aatagtgaag ttaatatagc ttgaattcta aatttgaagt 1620
ctgtgataat ccccatTTAA aatatgcattg tttatatagc ctgttaattg cactggacct 1680
gtttatgctg agtctaactc tggggattgt taccttcaat gtctaaatca ctaaagtgtt 1740
atacaaagtg gtttaattctg tatttatgcc acctagggtt taagtgcagt gctttgagaa 1800

<210> 32

<211> 6347

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7373485CB1

<400> 32

ggaagcgaga agccgcatca accatgtaag cagcttcgct tcctgccgca accgtccgcg 60
gcctgaggag cccaccgccc ctctcggggg ccgacttccc ggggctgagc cgttgaagcg 120
gaggctgggg cggggggagc ccggcgcggc cggggcagga ggcgcagact catgaaatgg 180
ccacagatga taagacgtcc ccaacactgg actctgctaa tgatttgcct cgatctccta 240
ctagtccttc tcatctcaca cactttaaac ctttgactcc tgatcaagat gagccccctt 300
ttaaatcagc ttatagtctt tttgtaaatc tctttcgttt taacaaagag agagcagaag 360
gaggccaggg agaacagcag cctttgagtg gaagttggac cagccctcag ctcccttcga 420
ggacacagtc tgttaggtca cccacacctt ataaaaagca gcttaatgag gaactccagc 480
ggcgctcttc agcattagac acaagaagga aagcagaacc tacctttgga ggtcatgacc 540
ctcgtacagc tgttcagctt cgaagcctca gcacagtatt aaaacgcctc aaggaaatca 600
tggaggggaa aagccaggat agtgacctga aacaatactg gatgccagat agccaatgta 660
aagagtgtga tgactgtagt gagaaattta caacctttag gcgcagacac cattgccgac 720
tatgtgggca gattttctgc agtcgttgct gtaatcaaga aatccctgga aaatttatgg 780
gctatacagg agacctccga gcttgacat attgtagaaa aatagcctta agttatgctc 840
attccacaga cagtaattct attggggaag acttgaatgc tctttcagat tctgcttgct 900
ctgtgtctgt gcttgatcca agtgaacccc gaacacctgt tgggagtagg aaagccagcc 960
gtaacatatt ttagaggat gatttggcct ggcaaagttt gattcatcca gattcctcaa 1020
atactcctct ttaacaaga cttgtatctg tgcaagagga tgctgggaaa tctcctgctc 1080
gaaatagatc agccagcatt actaacctgt cactggatag atctggttct cctatggtac 1140
cttcatatga gacatctgtc agtccccagg ctaaccgaac atatgttagg acagagacca 1200
ctgaggatga acgcaaaatt cttctggaca gtgtgcagtt aaaagacctg tggaaaaaaa 1260
tctgccatca cagcagtggg atggagtttc aggatcaccg ctactggttg agaacgcac 1320
ccaactgcat ttaggaaag gaattagtca actggctaac cgaatggg catattgcca 1380
caagggcaca agctatagca attggacaag caatggttga tggacgttg ctggattgtg 1440
ttagtcatca cgaccagctt ttcagagatg agtatgcgt gtatagacca ctgcagagta 1500
cagaattttc tgagacgcct tctcccgaca gtgactcagt gaactccgtg gaaggacact 1560
ctgagccatc ctggtttaaa gacataaagt ttgatgacag tgacacagaa cagatagctg 1620

aagaaggatga cgataatttg gctaagtatt tgattttctga cactggagga caacagctct 1680
caataagtga cgctttcatc aaagaatcct tatttaatcg ccgagtagag gaaaaatcca 1740
aagagctgcc tttcacacct ttgggctggc atcataacaa cctggagctc ctgagggagg 1800
agaatgggga gaaacaagcc atggagaggt tgctttcagc taatcataac cacatgatgg 1860
cactactcca gcagttgctc catagtgaact cactgtcatc atcttgaggg gacatcatcg 1920
tgtcattggg ctgccaggtt gttcagacag tccgacctga tgtcaagaac caggatgatg 1980
acatggatat ccgtcagttt gtccacatca aaaaaatccc aggtggaaag aagtttgatt 2040
ctgtggttgt caatggcttt gttgtacca agaacattgc acataaaaag atgaattctt 2100
gtattaaaaa ccctaaaatt cttctgttga agtggtccat tgagtatctc tacagagaag 2160
aaactaagtt tacttgcatg gatectattg tgcttcagga aagggaattc ttgaagaatt 2220
atgtccagcg aatagttgat gttcgaccca ccttggttct tggtgagaaa acagtgtctc 2280
ggattgcccc ggacatgta ttggaacatg gcattacttt ggtcattaat gtaaaagcac 2340
aagttttgga acgaatcagt cgaatgaccc aaggtgattt agtgatgtca atggaccagc 2400
tgcttacgaa accacgcctg ggcacttgct acaaatttta tatgcagata tttcagttgc 2460
ctaataaaca aaccaagaca ctgatgtttt ttgaaggttg tccacagcac ctaggctgta 2520
caatcaagct aagaggaggc tctgattatg agctggctcg agttaaggag atcctaata 2580
ttatgatctg tggtgcttat cattctcaac tagaaatctc ctttctcatg gatgaatttg 2640
ctatgcctcc cacattaatg caaaaccctt cattccattc cctgattgag ggacgagggc 2700
atgagggggc tgtccaagag cagtacgggt gaggttccat cccctgggat cctgacatcc 2760
ctctgagtc tctgccctgt gatgatagca gtttctgga atcgaggatt gtgtttgaga 2820
agggtgagca ggaaaaataa aatcttccgc aggtctgttc ctctgtgaag catcaagaac 2880
atagcacaac agcttgcccg gcgggtctcc cttgtgcttt ctttgcacct gtaccggaat 2940
cattgttgcc actccctgtg gatgaccaac aagatgcttt aggcagcgag ctgccagaga 3000
gtttgcagca aacagttgtg ctgcaggatc ccaaaagcca gataagagcc tttagagacc 3060
ctctacagga tgacactgga ttatatgtta ctgaggaagt cacctcctct gaagataaac 3120
gaaagactta ttctttggcc tttaagcagg aattaaaaga tgtgatctct tgtatctccc 3180
cagtaatcac atctcgagaa cctttctttt taactgaaaa ggggatgaga tgctctaccc 3240
gagattattt tgcaagcag gtttactggt ctctctctct caataaagaa ttcaagaaa 3300
tggagaacag gaggaagaaa cagctgtctc gggatctctc tggacttcag ggcattgaatg 3360
gaagtattca ggccaagtct attcaagtct taccctcaca tgagctagtg agcactagaa 3420
ttgctgagca tctggcgat agccagagct tgggtagaat gctggccgat tatcgagcca 3480
gaggaggaag aattcagccc aaaaattcag acccttttgc tcattcaaag gatgcatcaa 3540
gtacttcaag tggcaaatca ggaagcaaaa acgaggggtga tgaagagaga gggcttattc 3600
tgagtgatgc tgtgtggtca acaaggttg actgtctgaa tcccattaat caccagagac 3660
tttgtgtgct cttcagcagc tcttctgccc agtccagcaa tgctcctagt gctgtgtca 3720
gtccttggtt tgtaacaatg gaattttatg gaaagaatga tcttacatta ggaatatttt 3780
tagagagata ctgtttcagg ccttcttata agtgctcaag catgttctgt gataccccc 3840
tggtacatca tattcggcgc tttgttcatg gccaaggctg tgtgcagata atcctgaagg 3900
agttggattc tccagtacct ggatatcagc atacaattct tacatattcc tgggttagaa 3960
tctgcaaaac ggtaacacca gttgttgctc tttccaatga gtcttggtct atgtcatttg 4020
caaaatacct tgaacttagg ttttatgggc accagtatac tgcagagacc aacgctgagc 4080
cctgtggtca ctccatccat catgattatc accagtattt ctctataac cagatggttg 4140
cgtctttcag ttattctccc attcggcttc ttgaagtatg tgttccactc cccaaaatat 4200
tcattaagcg tcaggcccca ttaaaagtgt ccttcttca ggatctgaag gacttctttc 4260
aaaaagtctc acaggtatat gttgccattg atgaaagact tgcatctttg aaaactgata 4320
catttagtaa aacaagagag gaaaaaatgg aagatatttt tgacagaaa gagatggaag 4380
aaggtgagtt caagaactgg attgagaaga tgcaagcaag gctcatgtct tctctgtag 4440
ataccctca gcaactgcag tcggtctttg agtcactcat tgccaagaaa caaagtctct 4500
gtgaagtgtc gcaagcttgg aataacaggt tgcaggacct tttccaacag gaaaagggt 4560
gaaagagacc ttcagttcct ccaagtctg gaagactgag acaaggggaa gaaagcaaga 4620
taagtgcgat ggatgcatct ccacggaata tttctccagg acttcagaat ggagaaaaag 4680
aggatcgctt cttaacaact ttgtccagcc agagctccac cagttctact catctccaat 4740
tgctacgccc acctgaagtc atgtctgaac agtcagtggg agggccccct gagctagata 4800
cagccagcag ttccgaagat gtgtttgatg ggcatttgct gggatccaca gacagccaag 4860
tgaaggaaaa gtcaaccatg aaagccatct ttgcaaatct gcttccagga aatagctata 4920
atcctattcc atttctttt gatccagata aacactactt aatgtatgaa catgaacag 4980

tgccattgc agtctgag aaggaaccca gctccatcat tgcttttgct ctgattgta 5040.
aagaataaccg aaatgcctta gaggaattgt ctaaagcgac tcagtggaaac agtgccgaag 5100
aagggtctcc aacaaatagt acttcagata gcagaccaaa gtagtagcagc cctatcagat 5160
tacctgaaat gtagtgagga cagacaaatc gtacaacaga aacagaacca caaccaacca 5220
aaaaggcttc tggaatgctg tccttcttca gagggacagc agggaaaagc cccgatctct 5280
cttcccagaa gagagagacc ttacgtggag cagatagtgc ttactaccag gttgggcaga 5340
caggcaagga ggggaccgag aatcaaggcg ttgagcctca agatgaagta gatggaggag 5400
atacgcaaaa gaagcaactc ataaatcctc atgtggaaact tcaattttca gatgctaag 5460
ccaagtttta ctgtcggtc tactatgcgg gagagtttca taagatgctg gaagtattc 5520
tgacagcag tgaggaagat ttcatctgtt ccctctccca ctcatcacc tggcaggccc 5580
ggggaggcaa atcaggagct gccttctatg caactgagga tgatagattt attttgaagc 5640
aaatgcctcg tctggaagtc cagtccttcc tgcactttgc accacattac ttcaattata 5700
ttacaaatgc tgttcaacaa aagaggccca cggcgttggc caaaattctt ggagtttaca 5760
gaattggtta taagaactct cagaacaaca ctgagaagaa gttagatctc cttgtcatgg 5820
aaaatctttt ctacgggaga aagatggcac aggtttttga tttgaagggc tctcttagga 5880
atcggaatgt aaaaactgac actggaaaag agagtgtgta tgtggtcctg ctatagtaa 5940
atctcctaaa gatggttcga gacaaccctc tatatattcg ttctcattcc aaagtgtgc 6000
tgagaacctc gatccatagt gactcccatc tcctttctag ccacctcatt atagattatt 6060
ctttgctggt tgggcgagat gatactagca atgagctagt agttggaatt atagattata 6120
ttcgaacatt tacatgggac aaaaagcttg agatggttgt gaaatcaaca ggaatttttag 6180
gtggacaagg taaaatgcca acagtgggtg ctccggagtt gtacaggact aggttttgtg 6240
aggcaatgga caagtatttc ctaatggtac cagaccactg gacaggcttg ggtctgaatt 6300
gctgaaatca agacatattt gaaatggact gtgaggaaaa ggggaac 6347

<210> 33

<211> 1876

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5734965CB1

<400> 33

tggggttcgg cgcggctacg tgcagaatcc gtctagctaa aatgtaattt cagattggac 60
aagtactgtg gaggaactgc aatgtctggt ggagaacaga aaccagagag gtactatgtg 120
ggtgtggacg ttggaacagg cagtgtccgt gcagctctgg tggaccagag tggggtcctg 180
ttggcttttg cagaccagcc aattaagaat tgggagcccc agttcaacca ccatgagcag 240
tcctccgagg acatctgggc tgcgtgctgt gttgtcacia agaaagtgtg acaagggatt 300
gatttaaacc aaattcgagg acttgggttt gatgccacgt gttctctggt tgttttggat 360
aagcagtttc acccattacc agtcaaccag gaaggggatt cccatcgaaa cgtcatcatg 420
tggctggacc atcgagcagt cagtcaagtt aacaggatca atgagaccaa gcacagtgtc 480
ctccagtacg tcgggggggt gatgtctgtg gaaatgcagg ccccgaaact tctgtggctg 540
aaagagaact tgagagagat ttgctgggat aaggcgggac atttctttga tctcccgac 600
ttcttatcgt ggaaggcaac aggtgtcaca gcacggcttc tctgtccctt ggtgtgtaag 660
tggacatatt cagcagagaa aggctgggac gacagtttct ggaaaatgat tggtttggaa 720
gactttgttg cagataatta cagcaaaata ggaaaccaag tgctacctcc tggagcttct 780
cttggaatg ggctcacacc agaggcagca agagaccttg gccttctccc tgggattgctg 840
gtcgcagctt cactcattga tgccatgca ggaggactag gtagtattgg ggcagatgtg 900
agagggcacg gcctcatctg tgaggggcag ccagtgcagt cacggctggc tgtcatctgt 960
ggaacgtctt cttgtcacat ggggatcagc aaagaccga tttttgtacc aggcgtcttg 1020
gggccttatt tctcagccat ggtacctggg ttctggctga atgaagggtg tcagagcgtt 1080
actggaaaat tgatagacca catggtacaa ggccatgctg cttttccaga actacaagta 1140
aaggccacag ccagatgcca gagtatatat gcataattga acagtcacct ggatctgatt 1200
aagaaggctc agcctgtggg ttctcttact gttgatttac atgtttggcc agatttccat 1260
ggcaaccggt ctcccttagc agatctgaca ctaaagggca tggtcaccgg attgaaactg 1320

tctcaggacc ttgatgatct tgccattctc tacctggcca cagttcaagc cattgctttg 1380
gggactcgct tcattataga agccatggag gcagcagggc actcaatcag tactcttttc 1440
ctatgtggag gcctcagcaa gaatcccctt ttgtgcaaa tgcagcgga cattactggc 1500
atgcctgtgg tcctgtcgca agaggtggag tccgttcttg tgggtgctgc tgttctgggt 1560
gcctgtgcct caggggattt cgcttctgta caggaagcaa tggcaaaaat gagcaaagtt 1620
gggaaagtgt tgttcccag actacaggat aaaaaatact atgataagaa ataccaagta 1680
ttcctgaagc tgggtgaaca ccagaaggag tatttggcga tcatgaatga tgactgaaca 1740
gggcttgtag gtgctgatgc cagaagcttc tgtgccattg cattaagac ttctgtcatt 1800
tgatccatgt tcaagaccct tgaggtattg ttccatcatt tctgtattgt ctttcaataa 1860
agaatacaaa catgtg 1876

<210> 34

<211> 1487

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7473788CB1

<400> 34

atgaggagtg gcgccaacg caggggcagc agcgccgagg cgtccccggg ctgcgcgcc 60
cccgcccgcg cgcgccccgc cggctccgac gcgcctcagg cctgcccgc gcccgctgt 120
ggccagcccc gggcccgga ctccggcgat gtccgctcgc agccgcgcc cctgtttcag 180
tggagcaagt ggaagaagag gatgggctcg tccatgtcgg cgccaccgc gcggaggccg 240
gtgtttgacg acaaggagga cgtgaacttc gaccacttcc agatccttcg ggccattggg 300
aagggcagct ttggcaaggt gtgcattgtg cagaagcggg acacggagaa gatgtacgcc 360
atgaagtaca tgaacaagca gcagtgcac gcgcgcgac aggtccgcaa cgtcttcagg 420
gagctggaga tcctgcagga gatcgagcac gtcttcctgg tgaacctctg gtactccttc 480
caggacgagg aggacatgtt catggtcgtg gacctgctac tgggcgggga cctgcgctac 540
cacctgcagc agaacgtgca gttctccgag gacacggtga ggctgtacat ctgcgagatg 600
gcactggctc tggactacct gcgcggccag cacatcatcc acagagatgt caagcctgac 660
aacattctcc tggatgagag aggacatgca cacctgaccg acttcaacat tgccaccatc 720
atcaaggacg gggagcgggc gacggcatta gcaggcacca agccgtacat ggctccggag 780
atcttccact cttttgtcaa cggcgggacc ggctactcct tcgaggtgga ctggtggtcg 840
gtgggggtga tggcctatga gctgctgcga ggatggaggc cctatgacat ccactccagc 900
aacgccgtgg agtccctggt gcagctgttc agcacctga gcgtccagta tgtccccacg 960
tgggtcaagg agatggtggc cttgctgcgg aagctcctca ctgtgaaccc cgagcaccgg 1020
ctctccagcc tccaggacgt gcaggcagcc ccggcgctgg ccggcggtgt gtgggaccac 1080
ctgagcgaga agaggggtgga gccgggcttc gtgccaaca aaggccgtct gcactgcgac 1140
cccacctttg agctggagga gatgatcctg gactccaggc cctgcacaa gaagaagaag 1200
cgcttgcca agaacaagtc ccgggacaac agcagggaca gctcccagtc cgagaatgac 1260
tatcttcaag actgcctcga tgccatccag caagacttcg tgatttttaa cagagaaaag 1320
ctgaagagga gccaggacct cccgagggag cctctccccg ccctgagtc agggatgctg 1380
cggagcctgt ggaggacgag gcggacgctc cgctgcca tgtgcggccc catttgcccc 1440
tcggccggga gcggctaggc cgggacgccc gtggtcctca ccccttg 1487

<210> 35

<211> 1884

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3107989CB1

<400> 35

gagggtgacca attttctctc caaaagagaa aggaagttga ttaaaaaaag aatccatgct 60
ccaaagcggc agccaaatcc atctatggcc cccaatgcat caccagaaaa ggggttccag 120
actctcctgc aaaaggccaa ctctacttcc cggtcccccac ttcccctcct tcgccacagg 180
aggggtggcga aggatttata acccacctct ttctttcagt tgccatggag acaagcccca 240
gtcctttcat tccttctggt acctctctct ccaacgcagg cggaaaggag gcggttagc 300
ccaaacatgc tgggggaggg gctggcgccc tcgacggcag ctgcggaact aggccgaggg 360
acaaaggcta agtttttcca tggtttgac tggatatcgg tggaactctg gtcaagctgg 420
tatattttga acccaaagac atcactgctg aagaagaaga ggaagaagtg gaaagtctta 480
aaagcattcg gaagtacctg acctccaatg tggcttatgg gtctacaggc attcgggacg 540
tgcacctcga gctgaaggac ctgactctgt gtggacgcaa aggcaatctg cactttatac 600
gctttcccac tcatgacatg cctgctttta ttcaaatggg cagagataaa aacttctcga 660
gtctccacac tgtcttttgt gccactggag gtggagcgta caaatgtgag caggattttc 720
tcacaatagg tgatcttcag ctttgcaaac tggatgaact agattgcttg atcaaggaa 780
ttttatacat tgactcagtc ggattcaatg gacggtcaca gtgctattac tttgaaaacc 840
ctgctgattc tgaaaagtgt cagaagttac catttgattt gaaaaatccg tatcctctgc 900
ttctgggtgaa cattggctca ggggttagca tcttagcagt atattccaaa gataattaca 960
aacgggtcac aggtactagt cttggaggag gaactttttt tggctctctg tgtcttctta 1020
ctggctgtac cacttttgaa gaagctcttg aaatggcatc tcgtggagat agcaccaaaag 1080
tggataaact agtacgagat atttatggag gggactatga gaggtttgga ctgccaggct 1140
gggctgtggc ttcaagcttt ggaacatga tgagcaagga aaagcgagat tccatcagca 1200
aggaagacct cgcccgggcc acattggtca ccatcaccaa caacattggc tccattgctc 1260
ggatgtgtgc gttgaatgag aacatagaca gagttgtgtt tgttggaat tttctcagaa 1320
tcaatatggt ctccatgaag ctgctggcat atgccatgga tttttggtcc aaaggacaac 1380
tgaaagctct gtttttgaa catgaggggt attttgagc cgttggggca ctgttggaac 1440
tgttcaaat gactgatgac aagtagagac gagcagtgga ggaaacagcc tcccaaaagg 1500
acagagaact aaaaaattgc tgctggagaa ggtgaaagtc gctttgggac ggaagccaag 1560
ccattatggc agatgaacct gctggatttg taaataattt aaaatccttc cagatgatct 1620
tttactctta ggttttgagc taatgattca aaacggggga atataaaagg tttttttct 1680
gtatactgta tttttttaa aaaatggtgc agcgtggcca aacctacca ttgtatgcat 1740
taactttgaa aagttgtttg atgtttaaga aggacctgat atgtaagcgc tggtcatttt 1800
tcttctggg tttactgatc agtgtgtga ttttaacttc atttagtaat tactctagga 1860
gattttacct tgacttatat tttc 1884

<210> 36

<211> 1070

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7482887CB1

<400> 36

gcaaatcaca cagcatggca gctcccagtc ctctgcctc ttctgcattc cagacctgct 60
ctttaaaaac ctgggcattc cctccacaaa ttgaagagtg gaattttttt tcacctgctc 120
ttctctctgc tggcacagat cataaagtct tgctctctt ctatcacatc tcattattat 180
tttggtctct ttctacaagc aaggagcagc aggcctttt acattaccat tagtgaaggc 240
acttgagtta aatccgcaca acgaatctta ctcttgctg taatcccagc actttggaag 300
gccaaaggcg gtggatcacc tgaggtcagg agttcgagac cagcctggcc aatgtggtaa 360
aacctatctc tactaaaaat acaaaaaatt ggccagggtg ggtggtggg gcctgtaac 420
tcagctactt gggaggctaa ggcaggagaa ttgcttgaat ctgggagaca gaggttgagg 480
tgggccaaga tagcgccact gactccagc cttagcaaca agagcacaac tccatctcaa 540
aataataata ataatttctt ggctccaagt ctgagctccc gcaccacctg acactgtcag 600
atcctcagcg catggccaac actgagagca tcattatcaa tccgagtgct gttcagcaca 660
gcctgggtgg tgaaatcacc aaatactctg agcagaaggg attctacctg gtgacctga 720

```

agttccttcg ggcctctgag aaacccctga agccgcacta cactaacctg aaagaccacc 780
cattcttccc ggaccttctg aagtacatga actcagggca ggttggtggc atggtcctgg 840
aggggctgaa tgtggcaaaag acagggctaa ggatgcttgg ggagaccaat tcattgggct 900
ctatgctaga gactattatt cgcagggact tctgcgctaa aatagggcggg aacgtcattg 960
gtggcagtga ttcattacaa agtgctgaaa aagaaatcag cctatgggtt aagcccaaag 1020
aaccagttga ctacagatct tgtgcttatg actgggtcta tgcataatag 1070

```

<210> 37

<211> 2890

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2963414CB1

<400> 37

```

gtgacccttc cctccccagg ccacggcagc ccggccctcc cgggcagacc tcccgcacca 60
gggctctggt gaacagcaaa tgctccacgc tgggacgggc cattgcctga tgcctgtaca 120
tgggtgggcac tgagagacaa gattcctggg ccctgccttc catacactcc ccacgatctc 180
ggaggaagct ctgaggaccc cgctgagaac ccacagacag gaggacaact gcgctatgac 240
agcaataaag gccaaagaagg agaaagtga ggaccgctga cagccccgtg tgcgtgtggg 300
agctgccctt tctacttcaa accttctctc agcagactgt gcagggaccc cccaccacca 360
ccatctgccg ccatgggtgt gcaaaacagc gcagacgccg gggacatgag ggcaggcgtg 420
cagctggagc ccttctctga ccaggtcggg gggcacatga gcgtgatgaa gtatgacgag 480
catacgggtg gcaagcccc cgtctcccg ggcagaggt tctatgaatc cctgccgctg 540
gccatgaagc ggttcacccc acagtacaaa ggtaccgtca cagtgcacct ctggaaagac 600
agcacaggcc atctcagctt ggttgccaac ccagtgaagg agagccagga gcccttcaag 660
gtctccacag agtcggcgcc ggtggccata tggcagacgc tccagcagac caccggcagc 720
aatggcagcg actgcacct tgcccagtgg ccgcattgcc agctggcacg ctacaccaag 780
gagagcccg ccaaggctct tctgaggtcc gagccccacc tcaacactcc agccttctcg 840
ctggtggaag acaccaacgg aaaccagggt gagaggaaga gcttcaacc gtggggcctg 900
caatgccacc agggccacct gacccgcctg tgctccgagt acccagagaa caagcggcat 960
cggttcttgt tgctggaaaa tgtagtgtca cagtacacgc atccctgtgt cctggatctg 1020
aagatgggga cccggcagca cggcgatgat gcatcggagg agaagaaggc ccgccacatg 1080
aggaagtgtg cgcagagcac ctacgcctgc ctgggtgtgc gcatctgcgg catgcagggt 1140
tatcaaacag ataagaagta ctttctctgc ttctacata atggaagcca cctccggagg 1200
gtggagggggt tcagacaagc cctctatcag ttctacata atggaagcca cctccggagg 1260
gagctcctgg agcccatcct gcaccagctc cgggccctcc tctccatcat taggagccag 1320
agttcatacc gcttctatc cagctctctc cttgtcatct atgatgggca ggaaccacca 1380
gaaagagccc caggcagccc gcatcctcac gaggtcctcc aggcagccca cggtagctct 1440
cccgtgggtc tcaccaaggt tgacatccgc atgattgact ttgctcatac cacatacaag 1500
ggctactgga atgagcacac cactacgat ggaccagacc ctggctatat ttttggcctg 1560
gaaaaacctc tcaggatcct gcaggatatc caagaggagg aatgaaactt cctgggctta 1620
tctggattct tctgggctat agatctcaaa tagagacctg ttggttgcta gggtagtcca 1680
gacacccctt agatgtctc ataatagtcc tatctacctt caaaaacccat ctctatatat 1740
ggcagactat attaacagct gctgaacaaa tcagctctgg aggtgattcc acatcccctg 1800
gcattatgct ctaatgctgc tcatcggaga acagacagcc aggataaagt ggcaccttct 1860
ggagtacact ggagggggca gcccaagtta gagggcagca ttgctgacat tctggaatat 1920
ttgcatctaa aaatgtttac tcgttgccat gctgcagtc gcacaagctg tgaggcagaa 1980
aacttgactt gaagcagcct tgaagagtga gttcatgagc tcatggtttt tctccttgta 2040
tggtactgct gctccagggt caggcagagc tcatgaatgc ctcttatctt cctaagcgga 2100
gttttaggtg acacaggatg aagcagaaga gatctaccca tctcacctgc tctgcacca 2160
gcttctaagt ggacaaagcc aagcccaggc atgagctctg gcaaaagcaag accccagatt 2220
ctccattttt gcctgtggaa aggagggtcc ctttaacaggc ttttttttcc tttttttccc 2280
ccaaaatctc ttaaaatgag gaatctctta gcagactttg gaggttccca ttctgccaca 2340

```

ttctgaccat gagacgcggc ttgcagtggg ggtgaacgca cataaaaagg gaccactgac 2400
gtcctgctct actctctgct ttctatttat ttattttggg ggtgggttgg ggagtcagaa 2460
gaacctggag gacggaggaa accaggggca atgtttacaa gactggtgga caagtgtaaa 2520
tatggaataa gaacaaacag ttctaattaa ttccctcttc tgcagtacgg aaacctatta 2580
caatgccctt gagtcaagca ctgagatacg ttaccaatt agggaaataa atttggtaat 2640
aaaattgctg aggtcaccag tgattattgg tgtgccttat taccctttcc atttgtttat 2700
tctgatcaca ctgtgtggtg gttccaattt atgagcgact agcatatacc acaagaacag 2760
ttcactgatt tcctacaatc cttcagggaa ctcggttgga aatggtggct aataaaatat 2820
ttgcatgtat ctgcaaggga ggcaccagac ctgagaagtg gtccttttat ttgaatctca 2880
tacaatgtac 2890

<210> 38

<211> 5198

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7477139CB1

<400> 38

cgacacggag cacccttcta gcttcttcgt ctccaggact gacgctcagg ctctctcttc 60
gccttagccc aacttgcttt ccgcctcgc aaactccggg ttccctccac tcccaactct 120
tttactaca cgtttccctt cctctatctc ccacgccacg aaccccgatc cccagactcc 180
tctctccgc cctctcctt cctctctcct cccttcaact cttcatccgc ttccacctca 240
gactctgcgc gcaccaatt cagtcgccg ctcccgctcg gtcctcgaa gccatggcgg 300
gacctggggg ctggagggac agggaggta cggatctggg ccacctgccg gatccaactg 360
gaatattctc actagataaa accattggcc ttggtactta tggcagaatc tatttgggac 420
ttcatgagaa gactggtgca ttacagctg ttaaagtgat gaacgctcgt aagacctctt 480
tacctgaaat aggaaggcga gtgagagtga ataaatatca aaaatctgtt ggggtggagat 540
acagtgatga ggaagaggat ctccaggactg aactcaacct tctgaggaag tactctttcc 600
acaaaaacat tgtgtccttc tatggagcat ttttcaagct ggtccccctt ggtcagcggc 660
accaactttg gatggtgatg gagttatgtg cagcagggtt ggtcactgat gtagtgagaa 720
tgaccagtaa tcagagttaa aaagaagatt ggattgctta tatctgccga gaaatccttc 780
agggcttagc tcaccttcac gcacaccgag taattcaccg ggacatcaa ggtcagaatg 840
tgctgctgac tcataatgct gaagtaaac tgggtgattt tggagtgagt gcccagggtga 900
gcagaaacta tggagaagg aatagtttca ttgggacacc atactggatg gcacctgagg 960
tgattgactg tgatgaggac ccaagacgct cctatgatta cagaagtgat gtgtggtctg 1020
tggaattac tgccattgaa atggctgaag gagccccctc tctgtgtaac cttcaacctt 1080
tggaagctct cttcggtatt ttgcgggaat ctgctccac agtcaaatcc agcggatggt 1140
cccgtaaagt ccacaatttc atggaaaagt gtacgataaa aaatttcctg ttctgtccta 1200
cttctgcaaa catgcttcaa caccatttg ttcgggatat aaaaaatgaa cgacatgttg 1260
ttgagtcatt aacaaggcat cttactggaa tcattaaaaa aagacagaaa aaaggaatac 1320
ctttgatctt tgaaagagaa gaagctatta aggaacagta caccgtgaga agattcagag 1380
gacctcttg cactcacgag cttctgagat tgccaaccag cagcagatgc agaccactta 1440
gagtcctgca tggggaacct tctcagccaa ggtggctacc tgatcgagaa gagccacagg 1500
tccaggcact tcagcagcta caggagcag cagggtatt catgccactg caggctctgg 1560
acagtgcacc taagcctcta aaggggcagg ctccaggcacc tcaacgacta caaggggcag 1620
ctcgggtgtt catgccacta caggctcagg tgaaggctaa agcctctaaa cctctacaaa 1680
tgcaagattaa ggcacctcca cgactacgga gggcagccag ggtgctcatg ccactacagg 1740
cacaggttag ggcacctagg cttctgcagg tacagtccca ggtatccaaa aagcagcagg 1800
cccagaccca gacatcagaa ccacaagatt tggaccagggt accagaggaa ttccagggtc 1860
aagatcagggt acccgaacaa caaaggcagg gccaggcccc tgaacaacag cagaggcaca 1920
accagggtgc tgaacaagag ctggagcaga accaggcacc tgaacagcca gaggtacagg 1980
aacaggctgc cgagcctgca caggcagaga ctgaggcaga ggaacctgag tcattacgag 2040
taaagccca ggtatttctg ccctgtctat cacaagatca ccatgtgctg ttgccactac 2100

```

atttggatac tcaggtgctc attccagtag aggggcaaac tgaaggatca cctcaggcac 2160
aggcttggac actagaaccc ccacaggcaa ttggctcagt tcaagcactg atagagggac 2220
tatcaagaga cttgtctcgg gcaccaaact caaataactc aaagccactt ggtccgttgc 2280
aaaccctgat ggaaaatctg tcatcaaata ggttttactc acaaccagaa caggcacggg 2340
agaaaaaatc aaaagtctct actctgaggc aagcactggc aaaaagacta tcaccaaaga 2400
ggttcagggc aaagtcatca tggagacctg aaaagcttga actctcggat ttagaagccc 2460
gcaggcaaaag gcgccaacgc agatgggaag atatctttaa tcagcatgag gaagaattga 2520
gacaagttga taaaaccagt tggcgtcagt ggggtccttc agaccagttg attgacaata 2580
gtttcactgg tatgcaagac ctgaagaaat atctcaaagg aaaaacaaca tttcataatg 2640
ttcaagttgt tatctacaga gcagtttaagg ggaatgatga tgttgcaaca aggtctaccg 2700
ttcctcagcg gtctcttttg gaacaagctc agaagcccat tgacatcaga caaaggagtt 2760
cgcaaaatcg tcaaaatttg ctggcagcat caggtgattc aaagcacaaa attttagcag 2820
gcaaaacaca gagctactgt ttaacaattt atatttcaga agtcaagaaa gaagaatttc 2880
aagaaggaat gaatcaaaag tgtcagggag cccaagtagg attaggacct gaaggccatt 2940
gtatttggca attgggtgaa tcttcttctg aggaagaaag tcctgtgact ggaaggaggt 3000
ctcagtcac accaccttat tctactattg atcagaagtt gctggttgac atccatgttc 3060
cagatggatt taaagtagga aaaatatcac cccctgtata cttgacaaac gaatgggtag 3120
gctataatgc actctctgaa atcttccgga atgattgggt aactccggca cctgtcattc 3180
agccacctga agaggatggt gattatgttg aactctatga tgccagtgtc gatactgatg 3240
gtgatgatga tgatgagtct aatgatactt ttgaagatac ctatgatcat gccaatggca 3300
atgatgactt ggataaccag gttgatcagg ctaatgatgt ttgtaaagac catgatgatg 3360
acaacaataa gtttgttgat gatgtaaata ataattatta tgaggcgcct agttgtccaa 3420
gcttgttgtc agggcaagct atggcagaga tggaagctgc aagcaagatg gttatgatgg 3480
aagtcgtgga aaagaggaag cctacagagg ctatggaagc catacagcca atagaagcca 3540
tggaggaagt gcagccagtg agggacaatg cagccattgg agatcaggaa gaacatgcag 3600
ccaatatagg cagtgaagaa agaggcagtg agggtagatg aggttaagga gtcgttcgaa 3660
ccagtgaaga gaggtagacc cttggactca atggagaaga aaattgtcca gagacagatg 3720
gtccaggatt gaagagacct gcgtctcagg actttgaata tctacaggag gagccagggtg 3780
gtggaaatga ggcctcaaat gccattgact caggtgctgc accgtcagca cctgatcatg 3840
agagtgacaa taaggacata tcagaatcat caacacaatc agatttttct gccaatcact 3900
catctccttc caaaggttct gggatgtctg ctgatgctaa ctttgccagt gccatcttat 3960
acgctggatt cgtagaagta cctgaggaat cacctaagca accctctgaa gtcaatgtta 4020
accactcta tgtctctcct gcatgtaaaa aaccactaat ccacatgtat gaaaaggagt 4080
tcacttctga gatctgctgt ggttctttgt ggggagtcaa tttgctgttg ggaacccgat 4140
ctaacttata tctgatggac agaagtggaa aggctgacat tactaaactt ataaggcgaa 4200
gaccattccg ccagattcaa gtcttagagc cactcaattt gctgattacc atctcaggtc 4260
ataagaacag acttcgggtg tatcatctga cctgggttag gaacaagatt ttgaataatg 4320
atccagaag taaaagaagg caagaagaaa tgctgaagac agaggaagcc tgcaaagcta 4380
ttgataagtt aacaggctgt gaacacttca gtgtcctcca acatgaagaa acaacatata 4440
ttgcaattgc tttgaaatca tcaattcacc ttatgcatg ggcaccaaag tcctttgatg 4500
aaagcactgc tattaagta tttccaacac ttgatcataa gccagtgaca gttgacctgg 4560
ctattggttc tgaaaaaaga ctaaagattt tcttcagctc agcagatgga tatcacctca 4620
tcgatgcaga atctgaggtt atgtctgatg tgacctgcc aaagaataat atcatcattt 4680
tacctgattg cttgggaatt ggcatgatgc tcacctcaa tgctgaagcc ctctctgttg 4740
aagcaaatga acaactcttc aagaagatcc ttgaaatgtg gaaagacata ccatcttcta 4800
tagcttttga atgtacacag cgaaccacag gatggggcca aaaggccatt gaagtgcgct 4860
ctttgcaatc cagggttctg gaaagtgagc tgaagcgag gtcaattaag aagctgagat 4920
tcctgtgcac ccggggtgac aagctgttct ttacctctac cctgcgcaat caccacagcc 4980
gggtttactt catgacactt ggaaaacttg aagagctcca aagcaattat gatgtctaaa 5040
agtttccagt gatttattac cacattataa acatcatgta taggcagtct gcattctcag 5100
atttcagaga ttaaatgagt attcagtttt attttttagta aagattaaat ccaaaacttt 5160
acttttaatg tagcacagaa tagttttaat gagaaatg 5198

```

<210> 39

<211> 3969

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 55009053CB1

<400> 39

cttttttctt ttcagtgtgc ttcaaatgtc acgacacagg ttagctcagt cgacttgggg 60
ctgctgagct ctggtccctg ccagcctcac cgctcggacc ccccgatcc tccggactcc 120
gctggtcctg gccacgcgag gagcccacgc tagctccaaa gaatcccccg agggcacgtg 180
gaccgaggga gcccctgtga aggctgcgga agactccgag cgtcccgagc tcccgactcc 240
tgacgtgggc cgggggtcca gggagccgct aagggtccct gaagctgtgg ccctagagcg 300
gcggcgggag caggaagaaa aggaggacat ggagaccag gctgtggcaa cgtccccga 360
tggccgatac ctcaagtttg acatcgagat tggacgtggc tccttcaaga cgggtgatcg 420
agggttagac accgacacca cagtggagggt ggcctggtgt gagctgcaga ctccgaaact 480
gtctagagct gagcggcagc gcttctcaga ggaggtggag atgctcaagg ggctgcagca 540
cccaacatc gtccgcttct atgattcgtg gaagtcggtg ctgaggggccc aggtttgcat 600
cgtgctggtc accgaactca tgacctcggg cacgctcaag acgtacctga ggcggttccg 660
ggagatgaag ccgcggttcc ttacgctgag gagccgcaa atcctcggg gacttcattt 720
cctacactcc cgggttctct ccatcctgca cgggatctc aagtgcgaca atgtctttat 780
cacgggacct tctggtctg tcaaaatcgg ggacctgggc ctggccacgc tcaagcgcg 840
ctcctttgcc aagagtgtca tcgggacccc ggaattcatg gccccgaga tgtacgagga 900
aaagtacgat gaggccgtgg acgtgtacgc gttcggcatg tgcattgctg agatggccac 960
ctctgagtac ccgtactccg agtgccagaa tgcccgcaa atctaccga aggtcacttc 1020
gggcagaaa cgaacagct tccacaaggt gaagataccc gaggtgaagg agatcattga 1080
aggctgcac cgcacggata agaacgagag gttcaccatc caggacctcc tggcccacgc 1140
cttcttccgc gaggagcgcg gtgtgcacgt ggaactagcg gaggaggacg acggcgagaa 1200
gcccggcctc aagctctggc tgccgcatga ggacgcgagg cgccgggggg gcccacggga 1260
caaccaggcc atcgagttcc tgttccagct gggccgggac gcggccgagg aggtggcaca 1320
ggagatggtg gctctgggct tggctgtga agccgattac cagccagtgg cccgtgcagt 1380
acgtgaacgg gttgctgcca tccagcgaag gcgtgagaag ctgcgtaaa caagggaatt 1440
ggaggcactc ccaccagagc caggacctcc accagcaact gtgcccattg ccccggttcc 1500
ccccagtgtc tccccctctg agcctgagga gccagaggca gaccagacc agcccttctc 1560
tttcgcccac gccagctact catctaccac ttcggattgc gagactgatg gctacctcag 1620
ctcctccggc ttcttgatg cctcagaccc tgcccttcag cccctgggg ggttgccatc 1680
cagcctgggt gagtcccatc tctgcctgcc ctggctttt gccctatcca ttccacgttc 1740
tggccctgga agtgactttt ccccggggga cagctatgcc tcagatgcag cttcaggcct 1800
tagcgatgtg ggagaaggga tgggacaaat gaggagaccc ccaggaggga atctccggcg 1860
cagaccccca tcccggtgc gggctactag tgtctcagac cagaatgaca gagtggttga 1920
gtgccagcta cagaccata acagcaagat ggtgaccttc cgatttgatc tggatgggga 1980
cagcccgga gagattgcag ctgccatggt atataacgag ttcattctgc cttcggagcg 2040
agatggattt ctcagacgga ttcgggagat tatccagcga gtggagaccc tgttgaagag 2100
agacactggc cccatggagg ctgctgaaga caccctaagc ccccgaggag agccagcacc 2160
attacctgcc ctgcccgtcc cctcccaga cccatccaat gaagagctcc agagcagcac 2220
ctccctggag cacaggagct ggacagcctt ctccacctcc tcatcttctc ctggaactcc 2280
tttgtctctt ggaaaccat tttccctgg aacccccatt tccccaggte ccatcttccc 2340
catcacttct ccccatgtc atcccagccc ctcccattc tccccattt cttcccagg 2400
ctcctcaaat cctctccac accccaccag ctctccactt ccattctctc ccagcacacc 2460
cgagtttccg gtccactct ctcagtgtcc ctggagttct ctccccacga cttctccacc 2520
tacgttctct cccacttgtt ctcaggtcac tcttagttcc ctttcttctc ctccgtgccc 2580
ctccacttct tcttccctt ccaccacagc agccctctc cttctcttgg ctagtgcctt 2640
ctcactggct gtgatgactg tggcccagtc cctgctgtcc ccctcacctg ggtctcttcc 2700
ccagttctct ccagccctc ctagtccctt ccttagcctg ccccttcccc ctcccgttgc 2760
tctgtgtggc caggaagacc cttcaccaca cacagctgag gtggagagtg aggcctcacc 2820
acctcctgct cggccctcc caggggagc caggctggcg cccatctctg aagagggaaa 2880
gccgcagctt gttgggcgtt tcaagtgcac ttcacccaag gaaccggctg agcctcttcc 2940

cttgcagcca acatccccca ctctctctgg ttctccaaaa ccttcaaccc ctcagctcac 3000
ttcagagagc tcagatacag aggacagtgc tggaggcggg ccagagacca gggagctct 3060
ggctgagagc gaccgtgcag ctgagggtct gggggctgga gttgaggagg aaggagatga 3120
tgggaaggaa cccaagttg ggggcagccc ccaacccctg agccatccca gccagtggtg 3180
gatgaactac tcctacagca gcctgtgtt gagcagcgag gaggcagaaa gcagtgggga 3240
agatgaggag ttctgggctg agctgcagag tcttcggcag aagcacttgt cagaggtgga 3300
aacactacag acactacaga aaaaagaaat tgaagatttg tacagccggc tggggaagca 3360
gccccaccg ggtattgttg ccccgctgc tatgtgtcc agccgccagc gccgcctctc 3420
caagggcagc ttccccacct cccgccgcaa cagcctacag cgctctgagc cccaggccc 3480
tggcatcatg cgaaggaact ctctgagtgg cagcagcacc ggctcccagg agcagcgggc 3540
aagcaagggg gtgacattcg ccggggatgt tggcaggatg tgaattcaga acagaagcca 3600
tgtatctccc ccacaccagg gccaccatg gagcttgtgt tctcagaatc tgatgctttc 3660
tgatcaacaa aactgagcaa ggaagatccc aacactgaag gggtagaagg ccaggggggc 3720
atggagagtg cagctccatt atagtgaaga gccaaacata tgtgaactgt ttgctgtgtg 3780
gaggtgttag ttctgtgcc taccatcttc atctctagca cctcccctgc caagagtcaa 3840
ccactaagca atcccacca agcctggatg ctctagagg ggccactcc cagctgggag 3900
agtgtagggg atatgctcac accacattag cagcaaccaa taaaatgct ggaaacaaga 3960
aaaaaaaaa 3969

<210> 40

<211> 1803

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7474648CB1

<400> 40

atgggtgaaa gtggaaacca tcattttcag caaactaaca caggaacaga aaaccaaaaca 60
gcacatgttc tactcataa gtgggagtgt gacaatgaaa acatatgggc acagggaggg 120
gaacatcaca aactgggacc tgtcatgggt tgggaaggcta ggagtgggaa aacattagga 180
gaaataccta acgtaggcac actcacactc ctactgggt atgggggatg ccagctgcca 240
tgttgcaagg aactcaggc agcctatgga gaaacccacg tggcgaggag tggaggcctt 300
ctgccaacag ccagctggga actgaggcct gctgacagtc acacggtgac cagcgatgat 360
ccaggcgtct cggtcgtag cgggtatcct gggggctgtc tccctgacca cgacccccca 420
gtgggggttc ttcccgaggg tcccgccct cgcagctgct ctttgataaa gggcggaggga 480
acggggctgg ctgcttccc agtcccagg tcccgcgagc ggccggcggtg ttgcccgtat 540
gggggtcggc gccagcagga aggtggtccc ggggccacca gcgctggctt gggccaagca 600
cgaaggtcaa aaccaagccg gcgtcggagg cgccgggcct gggcccgagg cggcggccca 660
ggcggcgcag aggatacagg tggctcgctt ccgagccaag ttcgaccccc gggtccttgc 720
cagtgcccag tacaatttct ctttgacatc tctgaacagg gatttcagag gatgggaaa 780
aagagagcag gaggcagc aaacaaggga aggaattcct atcttcggag atatgacatc 840
aaagctctta ttgggacagg cagtttcagc agggttgtca gggtagagca gaagaccacc 900
aagaaacctt ttgcaataaa agtgatggaa accagagaga ggggaaggtag agaagcgtgc 960
gtgtctgagc tgagcgtcct gcggcgggtt agccatcgtt acattgtcca gctcatggag 1020
atctttgaga ctgaggatca agtttacatg gtaatggagc tggctaccgg aggggagctc 1080
tttgatcgac tcattgtcga gggatcctt acagagcggg atgccgtcag gatcctccag 1140
atgggtgtctg atgggattag gtatttgcag gcgctgcaga taactcatag gaatctaaag 1200
cctgaaaacc tcttatacta tcatccagggt gaagagtcca aaattttaat tacagatttt 1260
ggtttggcat actccgggaa aaaaagtggg gactggacaa tgaagacact ctgtgggacc 1320
ccagagtaca tagctcctga ggttttgcga aggaagcctt ataccagtgc agtggacatg 1380
tgggctcttg gtgtgatcac atatgcttta cttagcggat tctgccttt tgatgatgaa 1440
agccagacaa ggctttacag gaagattctg aaaggcaaat ataattatac aggagagcct 1500
tggccaagca tttcccactt gccgaaggac tttatagaca aactactgat tttggaggct 1560
ggtcatcgca tgtcagctgg ccaggccctg gaccatccct gggtagtcac catggctgca 1620

gggtcttcca tgaagaatct ccagagggcc atatcccgaa acctcatgca gagggcctct 1680
ccccactctc agagtcctgg atctgcacag tcttctaagt cacattattc tcacaaatcc 1740
aggcatatgt ggagcaagag aaacttaagg atagtagaat cgccactgtc tgcgcttttg 1800
taa 1803

<210> 41

<211> 3472

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7483053CB1

<400> 41

atggcggaagg cgacgtccgg tgcgcggggg ctgcgtctgc tgttgctgct gctgctgccg 60
ctgctaggca aagtggcatt gggcctctac ttctcgaggg atgcttactg ggagaagctg 120
tatgtggacc aggcagccgg cacgcccttg ctgtacgtcc atgccctgcg ggacgcccct 180
gaggaggtgc ccagcttccg cctggggccag catctctacg gcacgtaccg aacacggctg 240
catgagaaca actggatctg catccaggag gacaccggcc tcctctacct taaccggagc 300
ctggaccata gctcctggga gaagctcagt gtccgcaacc gcggccttcc cctgtctacc 360
gtctacctca aggtcttctc gtcaccaca tcccttcgtg agggcgagtg ccagtggcca 420
ggctgtgccc gcgtatactt ctccctcttc aacacctcct tccagccctg cagctccctc 480
aagccccggg agctctgctt cccagagaca aggccctcct tccgcattcg ggagaaccga 540
ccccaggca ccttccacca gttccgcctg ctgcctgtgc agttcttctg ccccaacatc 600
agcgtggcct acaggtcctt ggaggggtgag ggtctgcctt tccgctgcgc cccggacagc 660
ctggaggtga gcacgcgctg ggcctgggac cgcgagcagc gggagaagta cgagctgggt 720
gccgtgtgca ccgtgcacgc cggcgcgcg caggaggtgg tgatgggtgc cttcccggtg 780
accgtgtacg acgaggacga ctccggcgccc acctccccg cggcgctcga caccgccagc 840
gccgtgggtg agttcaagcg gaaggaggac accgtgggtg ccacgctgcg tgtcttcgat 900
gcagacgtgg tacctgcacg aggggagctg gtgaggcggg acacaagcac gctgctcccc 960
ggggacacct gggccagca gaccttccgg gtggaacact ggcccaacga gacctcgggtc 1020
caggccaacg gcagcttcgt gcgggcgacc gtacatgact ataggctggt tctcaaccgg 1080
aacctctcca tctcggagaa ccgcaccatg cagctggcgg tgctgggtcaa tgactcagac 1140
ttccaggggc caggagcggg cgtcctcttg ctccacttca acgtgtcggg gctgccgggtc 1200
agcctgcacc tgcccagtac ctactccctc tccgtgagca ggagggtcgc ccgatttgcg 1260
cagatcggga aagtctgtgt ggaaaactgc caggcgttca gtggcatcaa cgtccagta 1320
aagctgcatt cctctggtgc caactgcagc acgttagggg tggtcacctc agccgaggac 1380
acctcgggga tctctgttgt gaatgacacc aaggccctgc ggcggcccaa gtgtgccgaa 1440
cttactaca tgggtggtgg caccgaccag cagacctcta ggcaggccca ggcccagctg 1500
cttgtaacag tggaggggtc atatgtggcc gaggaggcgg gctgccccct gtctgtgca 1560
gtcagcaaga gacggctgga gtgtgaggag tgtggcggcc tgggctcccc aacaggcagg 1620
tgtgagtgga ggcaaggaga tggcaaagg atcaccagga acttctccac ctgctctccc 1680
agcaccaaga cctgccccga cggccactgc gatgttgttg agaccaaga catcaacatt 1740
tgccctcagg actgcctccg gggcagcatt gttgggggac acgagcctgg ggagccccgg 1800
gggattaaag ctggctatgg cacctgcaac tgcttccctg aggaggagaa gtgcttctgc 1860
gagcccgaag acatccagga tccactgtgc gacgagctgt gccgcacggt gatcgagcc 1920
gctgtcctct tctccttcat cgtctcgggt ctgctgtctg ccttctgcat ccaactgtac 1980
cacaagtttg cccacaagcc acccatctcc tcagctgaga tgaccttccg gaggcccgcc 2040
caggccttcc cggtcagcta ctctcttccc agtgcccgcc ggccctcgtg ggactccatg 2100
gagaaccagg tctccgtgga tgcttccaag atcctggagg atccaaagtg ggaattccct 2160
cggaagaact tggttcttgg aaaaactcta ggagaaggcg aatttggaaa agtgggtcaag 2220
gcaacggcct tccatctgaa aggcagagca gggtagacca cggtgggcgt gaagatgctg 2280
aaagagaacg cctccccgag tgagcttcca gacctgtgt cagagttcaa cgtcctgaag 2340
caggtaacc accacatgt catcaaattg tatggggcct gcagccagga tggcccgctc 2400
ctcctcatcg tggagtacgc caaatacggc tccctgcggg gcttccctcg cgagagccgc 2460

aaagtggggc ctggctacct gggcagtgga ggcagccgca actccagctc cctggaccac 2520
ccggatgagc gggccctcac catgggcgac ctcatctcat ttgcctggca gatctcacag 2580
gggatgagc atctggccga gatgaagctc gttcatcggg acttggcagc cagaaacatc 2640
ctggtagctg aggggcgga gatgaagatt tcggatttcg gcttgtcccg agatgtttat 2700
gaagaggatt cgtacgtgaa gaggagccag ggtcggattc cagttaaagc gatggcaatt 2760
gaatcccttt ttgatcatat ctacaccacg caaagtgatg tatggctctt tgggtgcctg 2820
ctgtggggaga tcgtgaccct aggggggaaac ccctatcctg ggattcctcc tgagcggctc 2880
ttcaaccttc tgaagaccg ccaccggatg gagaggccag acaactgcag cgaggagatg 2940
taccgcctga tgctgcaatg ctggaagcag gagccggaca aaaggccggt gtttgcggac 3000
atcagcaaag acctggagaa gatgatggtt aagaggagag actacttggc ctttgcggcg 3060
tccactccat ctgactccct gatttatgac gacggcctct cagaggagga gacaccgctg 3120
gtggactgta ataatgcccc cctccctcga gcctccctt ccacatggat tgaaaacaaa 3180
ctctatggca tgctcagacc gaactggcct ggagagagtc ctgtaccact cagagagct 3240
gatggcacta aactggggtt tccaagatat ccaaatgata gtgtatatgc taactggatg 3300
ctttcaccct cagcggcaaa attaatggac acgtttgata gttaacattt ctttgtgaaa 3360
ggtaatggac tcacaagggg aagaacatg ctgagaatgg aaagtctacc ggccctttct 3420
ttgtgaacgt cacattggcc gagccgtggt cagttcccag gtggcagact cg 3472

<210> 42

<211> 1704

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7483117CB1

<400> 42

atggatgaca aagatattga caaagaacta aggcagaaat taaacttttc ctattgtgag 60
gagactgaga ttgaagggca gaagaaagta gaagaaagca gggaggcttc gagccaaacc 120
ccagagaagg gtgaagtgca ggattcagag gcaaagggtg caccaccttg gactccccct 180
agcaacgtgc atgagctcga cacatcttcg gaaaaagaca aagaaagtcc agatcagatt 240
ttgaggactc cagtgtcaca ccctctcaaa tgccttgaga caccagccca accagacagc 300
aggagcaagc tgctgcccag tgacagcccc tctactccca aaaccatgct gagccggttg 360
gtgatttctc caacagggaa gcttctctcc agaggcccta agcatttgaa gctcacacct 420
gctccccca aggatgagat gacctcattg gctctgggta atattaatcc cttcactcca 480
gagtcctata aaaaattatt tcttcaatct ggtggcaaga ggaaaataag aggagatctt 540
gaggaagctg gtccagagga aggcaaggga gggctgcctg ccaagagatg tgttttacga 600
gaaaccaaca tggcttcccg ctatgaaaaa gaattcttgg aggttgaaaa aattgggggtt 660
ggcgaatttg gtacagtcta caagtgcatt aagaggctgg atggatgtgt ttatgcaata 720
aagcgtctta tgaaaacttt tacagaatta tcaaatgaga attcggcttt gcatgaagtt 780
tatgctcagc cagtgtcttg gcatcaccac catgtggtac gttactatcc ctcatgggca 840
gaagatgacc acatgatcat tcagaatgaa tactgcaatg gtgggagttt gcaagctgct 900
atatctgaaa acactaagtc tggcaatcat tttgaagagc caaaactcaa ggacatcctt 960
ctacagattt cccttggcct taattacatc cacaactcta gcatgggtaca cctggacatc 1020
aaacctagta atatattcat ttgtcacaag atgcaaatg aatcctctgg agtcatagaa 1080
gaagtggaaa atgaagctga ttggtttctc tctgccaatg tgatgtataa aattgggtgac 1140
ctgggcccag caacatcaat aaacaaaccc aaagtggaa aaggagatag tcgcttccctg 1200
gctaattgaga ttttgcaaga ggattaccgg caccttccca aagcagacat atttgccttg 1260
ggattaacaa ttgcagtggc tgcaggagca gagtcatgct ccaccaatgg tgctgcatgg 1320
caccatatcc gcaagggtaa ctttccggac gttcctcagg agctctcaga aagcttttcc 1380
agtctgtcga agaactgat ccaacctgat gccgaacaga gaccttctgc agcagctctg 1440
gccagaaata cagttctccg gccttccctg ggaaaaacag aagagctcca acagcagctg 1500
aatttggaaa agttcaagac tgccacactg gaaagggaac tgagagaagc ccagcaggcc 1560
cagtcacccc agggatatac ccatcatggt gacactgggg tctctgggac ccacacagga 1620
tcaagaagca caaaacgcct ggtgggagga aagagtgcaa ggtcttcaag ctttacctca 1680

ggagagcgtg agcctctgca ttaa

1704

<210> 43

<211> 6298

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7484498CB1

<400> 43

cgcggggagg aacagatcgc agacctgggg gttcgcagag ccgccagtgg ggagatgttg 60
aagttcaaat atggagcgcg gaatcctttg gatgctggtg ctgtgaacc cattgccagc 120
cgggcctcca ggctgaatct gttcttccag gggaaaccac cctttatgac tcaacagcag 180
atgtctcctc ttccccgaga agggatatta gatgccctct ttgttctctt tgaagaatgc 240
agtcagcctg ctctgatgaa gattaagcac gtgagcaact ttgtccggaa gtattccgac 300
accatagctg agttacagga gctccagcct tcggcaaagg acttcgaagt cagaagtctt 360
gtaggttgtg gtcactttgc tgaagtgcag gtggtaagag agaaagcaac cggggacatc 420
tatgctatga aagtgatgaa gaagaaggct ttattggccc aggagcaggt ttcatttttt 480
gaggaagagc ggaacatatt atctcgaagc acaagcccgt ggatcccca attacagtat 540
gcctttcagg acaaaaaatca cctttatctg gtcattggaat atcagcctgg aggggacttg 600
ctgtcacttt tgaatagata tgaggaccag ttagatgaaa acctgataca gttttaccta 660
gctgagctga ttttggtgtg tcacagcgtt catctgatgg gatacgtgca tcgagacatc 720
aagcctgaga acattctcgt tgaccgcaca aatgccaaac tcccgattgg gacccagat 780
gccgcgaaaa tgaattcaaa caagatggtg aatgccaaac tcccgattgg gacccagat 840
tacatggctc ctgaagtgtg gactgtgatg aacggggatg gaaaaggcac ctacggcctg 900
gactgtgact ggtggtcagt gggcgtgatt gcctatgaga tgatttatgg gagatccccc 960
ttcgcagagg gaacctctgc cagaaccttc aataacatta tgaatttcca gcggtttttg 1020
aaatttccag atgaccccaa agtgagcagt gactttcttg atctgattca aagcttggtg 1080
tgccggccaga aagagagact gaagtttgaa ggtctttgct gccatccttt cttctctaaa 1140
attgactgga acaacattcg taactctcct ccccccttcg tteccaccct caagtctgac 1200
gatgacacct ccaattttga tgaaccagag aagaattcgt ggggtttcatc ctctccgtgc 1260
cagctgagcc cctcaggctt ctccgggtgaa gaactgccgt ttgtgggggtt ttcgtacagc 1320
aaggcactgg ggattcttgg tagatctgag tctgttgtgt cgggtctgga ctcccctgcc 1380
aagactagct ccatggaaaa gaaacttctc atcaaaagca aagagctaca agactctcag 1440
gacaagtgtc acaagatgga gcaggaaatg acccggttac atcggagagt gtcagagggtg 1500
gaggctgtgc ttagtgcagaa ggaggtggag ctgaaggcct ctgagactca gagatccctc 1560
ctggagcagg accttgctac ctacatcaca gaatgcagta gcttaaaagc agttttggag 1620
caagcacgga tggaggtgtc ccaggaggat gacaaagcac tgcagcttct ccatgatatc 1680
agagagcaga gccggaagct ccaagaaatc aaagagcagg agtaccaggc tcaagtggaa 1740
gaaatgaggt tcatgatgaa tcagttggaa gaggatcttg tctcagcaag aagacggagt 1800
gatctctacg aatctgagct gagagagtct cggcttgctg ctgaagaatt caagcgaaa 1860
gcgacagaat gtcagcataa actgttgaag gctaaggatc aagggaagcc tgaagtggga 1920
gaatatgcga aactggagaa gatcaatgct gagcagcagc tcaaaattca ggagctccaa 1980
gagaaactgg agaaggctgt aaaagccagc acggaggcca ccgagctgct gcagaatata 2040
cgccaggcaa aggagcagc cgagaggagg ctggagaagc tgcagaaccg agaggattct 2100
tctgaaggca tcagaaagaa gctggtggaa gctgaggaaac gccgccattc tctggagaac 2160
aaggtaaaga gactagagac catggagcgt agagaaaaca gactgaagga tgacatccag 2220
acaaaatccc aacagatcca gcagatggct gataaaattc tggagctcga agagaaacat 2280
cgggaggccc aagtctcagc ccagcaccta gaagtgcacc tgaacagaa agagcagcac 2340
tatgaggaaa agattaaagt gttggacaat cagataaaga aagacctggc tgacaaggag 2400
acactggaga acatgatgca gagacacgag gaggaggccc atgagaaggg caaaattctc 2460
agcgaacaga aggcgatgat caatgctatg gattccaaga tcagatccct ggaacagagg 2520
attgtggaac tgtctgaagc caataaactt gcagcaaata gcagtctttt taccctaaagg 2580
aacatgaagg cccaagaaga gatgatttct gaactcaggc aacagaaatt ttacctggag 2640

acacaggctg ggaagttgga ggcccagaac cgaaaactgg aggagcagct ggagaagatc 2700
agccaccaag accacagtga caagaatcgg ctgctggaac tggagacaag attgctgggag 2760
gtcagtctag agcacgagga gcagaaactg gagctcaagc gccagctcac agagctacag 2820
ctctccctgc aggagcgcca gtcacagttg acagccctgc aggtctcacg gccggccctg 2880
gagagccagc ttcgccaggc gaagacagag ctggaagaga ccacagcaga agctgaagag 2940
gagatccagg cactcacggc acatagagat gaaatccagc gcaaatttga tgctcttctg 3000
aacagctgta ctgtaatcac agacctggag gagcagctaa accagctgac cgaggacaac 3060
gctgaactca acaacaaaaa cttctacttg tccaaacaac tcgatgaggc ttctggcgcc 3120
aacgacgaga ttgtacaact gcgaagtga gtggaccatc tccgccggga gatcacggaa 3180
cgagagatgc agcttaccag ccagaagcaa acgatggagg ctctgaagac cacgtgcacc 3240
atgctggagg aacagggtcat ggatttggag gccctaaacg atgagctgct agaaaaagag 3300
cggcagtgagg aggcctggag gagcgtcctg ggtgatgaga aatcccagtt tgagtgtcgg 3360
gttcgagagc tgcagaggat gctggacacc gagaacacaga gcagggcgag agccgatcag 3420
cggatcacccg agtctcgcca ggtggtggag ctggcagtgga aggagcaca ggctgagatt 3480
ctcgctctgc agcaggctct caaagagcag aagctgaagg ccgagagcct ctctgacaag 3540
ctcaatgacc tggagaagaa gcatgctatg cttgaaatga atgccgaag cttacagcag 3600
aagctggaga ctgaacgaga gctcaaacag aggtctctgg aagagcaagc caaattacag 3660
cagcagatgg acctgcagaa aaatcacatt ttccgtctga ctcaaggact gcaagaagct 3720
ctagatcggg ctgatctact gaagacagaa agaagtgact tggagtatca gctggaaaac 3780
attcaggttc tctattctca tgaagagggt aaaatggaag gcactatttc tcaacaaacc 3840
aaactcattg attttctgca agccaaaatg gaccaacctg ctaaaagaa aaaggttcct 3900
ctgcagtaca atgagctgaa gctggccctg gagaaggaga aagctcgctg tgcagagcta 3960
gaggaagccc ttcagaagac ccgcatcgag ctccggtccg ccggggaggga agctgcccac 4020
cgcaaaagcaa cggaccaccc acacccatcc acgccagcca ccgagaggca gcagatcgcc 4080
atgtccgcca ctgtgcggtc gccagagcac cagcccagtg ccagagcct gctggccccg 4140
ccatccagcc gcagaaagga gtcttcaact ccagaggaat ttagtcggcg tcttaaggaa 4200
cgcatgcacc acaatatttc tcaccgatc aacgtaggac tgaacatcg agccacaaag 4260
tgtgctgtgt gtctggatac cgtgcacttt ggacgccagg catccaaatg tctcgaatgt 4320
caggtgatgt gtcaccccaa gtgtccacg tgcttgccag ccacctgcgg cttgcctgct 4380
gaatatgcca cacacttcac cgaggccttc tgccgtgaca aaatgaactc cccagggtctc 4440
cagaccaagg agcccagcag cagcttgcac ctggaagggt ggatgaagg gcccaggaat 4500
aacaacagag gacagcaagg ctgggacagg aagtacattg tcctggaggg atcaaaagtc 4560
ctcatttatg acaatgaagc cagagaagct ggacagaggc cgggtggaaga atttgagctg 4620
tgccctcccg acggggatgt atctattcat ggtgccgttg gtgcttccga actcgcaaat 4680
acagccaaag cagatgtccc atacatactg aagatggaat ctaccccgca caccactgc 4740
tggcccgagg gaaccctcta cttgctagct cccagcttcc ctgacaaaca gcgctgggtc 4800
accgccttag aatcagttgt cgcaggtggg agagtttcta gggaaaaagc agaagctgat 4860
gctaaactgc ttggaaactc cctgctgaaa ctggaagggt atgacctct agacatgaac 4920
tgcacgtgc ccttcagtga ccaggtggtg ttggtgggca ccgaggaagg gctctacgcc 4980
ctgaatgtct tgaaaaactc cctaaccat gtcccaggaa ttggagcagt cttccaaatt 5040
tatattatca aggacctgga gaagctactc atgatagcag gagaagagcg ggcactgtgt 5100
cttgtggacg tgaagaaagt gaaacagtcc ctggcccagt cccacctgcc tgcccagccc 5160
gacatctcac ccaacatttt tgaagctgtc aagggtgcc acttgtttg ggcaggcaag 5220
attgagaacg ggctctgcat ctgtgcagcc atgcccagca aagtcgtcat tctccgtac 5280
aacgaaaacc tcagcaaata ctgcatccgg aaagagatag agacctcaga gccctgcagc 5340
tgtatccact tcaccaatta cagtatctc attggaacca ataaattcta cgaaatcgac 5400
atgaagcagt acacgctcga ggaattcctg gataagaatg accattcctt ggcacctgct 5460
gtgtttgccg cctcttccaa cagcttccct gtctcaatcg tgcaggtgaa cagcgcaggg 5520
cagcgagagg agtacttgct gtgtttccac gaatttggag tgttcgtgga ttcttacgga 5580
agacgtagcg gcacagacga tctcaagtgg agtcgcttac ctttggcctt tgcctacaga 5640
gaaccctate tgtttgtgac ccacttcaac tcaactgaag taattgagat ccaggcacgc 5700
tctcagcag ggaccctgc ccgagcgtac ctggacatcc cgaaccgcg ctacctgggc 5760
cctgccattt cctcaggagc gatttacttg gcgtcctcat accaggataa attaagggtc 5820
atttgctgca agggaaacct cgtgaaggag tccggcactg aacaccaccg gggcccgctc 5880
acctcccgca gcagcccaa caagcgaggc ccaccacgt acaacgagca catcaccaag 5940
cgcgtggcct ccagcccagc gccgcccga ggcccagcc acccgcgaga gccaaagcaca 6000

ccccaccgct accgcgaggg gcgaccgag ctgcgcaggg acaagtctcc tggccgcccc 6060
ctggagcgag agaagtcccc cgcccgatg ctgagcacgc ggagagagcg gtcccccggg 6120
aggctgtttg aagacagcag caggggcccg ctgcctgcgg gagccgtgag gaccccgctg 6180
tcccaggtga acaaggtctg ggaccagtct tcagtataaa tctcagccag aaaaaccaac 6240
tcctcatctt gatctgcagg aaaacaccaa acacactatg gaactctgct gatgggga 6298

<210> 44

<211> 5454

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7638121CB1

<400> 44

cacgcacacc gcacgtacgg ggttggggccc agctgggtta taagcgtgat ccccatgccc 60
cctgcccagg ctgggggggca tttgcacatc tgcaaaggcc tcccagcctg tcccagccct 120
gccccagcct gggaccccca cattctactc accgtgtctc ctgagagggg ccagaacctt 180
ccactgggga gaggcaagtg gcggtgaact tgggtgccat aggaccctgt ccctgagagc 240
gacagctgag ttagtgagct ccactggccc caccaactcc ttctgatcac ctggccagct 300
gaggtcagag tgggagaggg agtgggtcca ttgaaggagt actcctaact gtcagaagcc 360
tgggcgggtca ggtgggggtg ctgtcgcttg ggctgcgggg ggtgttcagt tgcccacagt 420
gtatctcagg gtctcaccaa ccactcaagc atggtaggct gtggctggca cccagggttg 480
tgtggctggg gaggtgggtc ccacagttcc ctccctgccc tcccagggcc cccatccatg 540
caggtaacca tcgaggatgt gcaggcacag acaggcggaa cggcccaatt cgaggctatc 600
attgagggcg acccacagcc ctcggtgacc tggtaacaagg acagcgtcca gctgggtggc 660
agcaccggcg ttagccagca gcaagaaggc accacatact ccctggtgct gaggcataatg 720
gcctcgaagg atgccggcgt ttacacctgc ctggcccaaa aactggtggg ccagggtgctc 780
tgcaaggcag agctgctggt gcttgggggg gacaatgagc cggactcaga gaagcaaagc 840
caccggagga agctgcactc cttctatgag gtcaaggagg agattggaag gggcgtgttt 900
ggcttcgtaa aaagagtga gcacaaagga aacaagatct tgtgcgtgc caagttcatc 960
ccctacgga gcagaactcg ggcccaggca tacaggggag gagacatcct ggccgctgctg 1020
agccaccggc tggtcacggg gctgctggac cagtttgaga ccgcaagac cctcatctc 1080
atcctggagc tgtgctcacc cgaggagctg ctggaccgcc tgtacaggaa gggcgtggtg 1140
acggaggccg aggtcaaggt ctacatccag cagctggtgg aggggctgca ctacctgcac 1200
agccatggcg ttctccacct ggacataaag ccctctaaca tcctgatggt gcactcctgcc 1260
cggaagaca taaaatctg cgaactttggc ttgcccaga acatcacccc agcagagctg 1320
cagttcagcc agtacggctc ccctgagttc gtctcccccg agatcatcca gcagaacct 1380
gtgagcgaag cctccgacat ttgggcccag ggtgtcatct cctacctcag cctgacctgc 1440
tcatcccat ttgcccggca gactgacct gccacctcc tgaacgtcct ggaggggctg 1500
gtgtcatgga gcagcccat ggctgcccac ctgagcgaag acgccaaga cttcatcaag 1560
gctacgtgc agagagcccc tcaggcccgg cctagtgcgg cccagtgcct ctcccacccc 1620
tggttcctga aatccatgcc tgcggaggag gccacttca tcaacaccaa gcagctcaag 1680
ttctcctgg ccgaagtgc ctggcagcgt tccctgatga gctacaagtc catcctggtg 1740
atgcgtccca tccctgagct gctgcggggc ccaccgaca gcccctccct cggcgtagcc 1800
cggcacctct gcagggacac tgggtggctcc tccagttcct cctcctcctc tgacaacgag 1860
ctgcccccat ttgcccgggc taagtactg ccacctccc cgtgacaca ctaccactg 1920
ctgcaccccc ggggttcct gcggccctcg gccagcctgc ctgaggaagc cgaggccagt 1980
gagcgtcca ccgagcccc agctccgct ccatctccc aggggtgccc gccaccggcc 2040
gccagggtc gcgtgcccc gcacagctc atccgagcc tgttctacca ccaggcgggt 2100
gagagccctg agcacggggc cctggccccg gggagcaggc ggacccggc cggcgggcg 2160
cacctgctga agggcgggta cattgcccgg gcgctgccag gcctgcgca gccactgatg 2220
gagcaccgag tgctggagga ggaggccgcc agggaggagc aggccacct cctggccaaa 2280
gccccctcat tcgagactgc cctccggctg cctgcctctg gacccactt ggccccctggc 2340
cacagccact ccctggaaca tgactctcg agcacccccc gccctcctc ggaggcctgc 2400

ggtgaggcac agcgactgcc ttcagccccc tccggggggg cccctatcag ggacatgggg 2460
caccctcagg gctccaagca gcttccatcc actggtggcc acccaggcac tgctcagcca 2520
gagaggccat ccccgagacag cccttggggg cagccagccc ctttctgcca ccccaagcag 2580
ggttctgccc cccaggaggg ctgcagcccc caccagcag tgccccatg ccctcctgga 2640
tccttccctc caggatcttg caaagaggcc cccttagtac cctcaagccc cttcttgga 2700
cagccccagg cacccttgcc ccctgccaaa gcaagccccc cattggactc taagatgggg 2760
cctggagaca tctctcttcc tgggaggcca aaacccggcc cctgcagttc cccagggtca 2820
gcctcccagg cgagctcttc ccaagtgagc tccctcaggg tgggctctc ccagggtggc 2880
acagagcctg gcccctccct ggatgaggag ggctggacc aggaggctga ggatctgtcc 2940
gactccacac ccaccttgca ggggcctcag gaacagggtga ccatgcgcaa gttctccctg 3000
ggtggtcgcg ggggctacgc aggcgtggct ggctatggca cctttgcctt tgggtggagat 3060
gcagggggca tgctggggca ggggcccag tgggcccagga tagcctgggc tgtgtcccag 3120
tcggaggagg aggagcagga ggaggccagg gctgagtcac agtcggagga gcagcaggag 3180
gccagggtg agagcccact gcccagggtc agtgcaaggc ctgtgcctga ggtcggcagg 3240
gtcctccacca ggagctctcc agagcccacc ccatgggagg acatcgggca ggtctccctg 3300
gtgcagatcc gggacctgtc aggtgatgag gaggcgccg acacaatatc cctggacatt 3360
tccgagggtg accccgcta cctcaacctc tcagacctgt acgatataa gtacctccca 3420
ttcaggttta tgatcttcag gaaagtcccc aagtcgctc agccagagcc gccctcccc 3480
atggctgagg aggagctggc cgagtccccg gagccacgt ggccctggcc aggtgaactg 3540
ggccccacg caggcctgga gatcacagag gactcagagg atgtggacgc gctgctggca 3600
gaggctgccc tgggcaggaa gcgcaagtgg tctcgccgt cagcagcct cttccacttc 3660
cctgggaggc acctgcccgt ggacgagcct gcagagctgg ggctgcgtga gagagtgaag 3720
gcctccgtgg agcacatctc ccggatcctg aagggcaggc cggaaggctc ggagaaggag 3780
gggccccca ggaagaagcc aggccttgct tccttccggc tctcaggctc gaagagctgg 3840
gaccgagcgc cgacattcct aaggagctc tcagatgaga ctgtggtcct gggccagtca 3900
gtgacactgg cctgccagg gtacgcccag ccagctgccc aggccacctg gagcaagac 3960
ggagcccccc tggagagcag cagccgtgtc ctcactctg ccacctcaa gaacttccag 4020
cttctgacca tctggtggt ggtggctgag gacctgggtg tgtacacctg cagcgtgagc 4080
aatgcgctgg ggacagtgc caccacgggc gtctccgga aggcagagcg cccctcatct 4140
tcgccaatgcc cggatatcgg ggaggtgtac gcggatgggg tgctgctggt ctggaagccc 4200
gtggaatcct acggccctgt gacctacatt gtgcagtga gcctagaagg cggcagctgg 4260
accacactgg cctccgacat ctttgactgc tgctacctga ccagcaagct ctccccgggt 4320
ggcacctaca ccttccgac ggcattgtgc agcaaggcag gaatgggtcc ctacagcagc 4380
ccctcgagc aagtctcct gggagggccc agccacctgg cctctgagga ggagagccag 4440
ggggcgtag cccaacccct gccagcaca aagacctcg cattccagac acagatccag 4500
aggggcccgt tcagcgtggt gcggcaatgc tgggagaagg ccagcgggcg ggcgctggcc 4560
gccaagatca tcccctacca cccaaggac aagacagcag tgctgcgga atacgagcc 4620
ctcaagggcc tgcgccacc gcacctggcc cagctgcacg cagcctacct cagccccgg 4680
cacctggtgc tcatcttgga gctgtgctct gggcccgagc tgcctccctg cctggccgag 4740
agggcctcct actcagaatc cgaggtgaag gactacctgt ggcagatgtt gactgccacc 4800
cagtacctgc acaaccagca catcctgcac ctggacctga ggtccgagaa catgatcatc 4860
accgaatca acctgctcaa ggtcgtggac ctgggcaatg cacagagcct cagccaggag 4920
aaggtgctgc cctcagacaa gttcaaggac tacctagaga ccatggctcc agagctcctg 4980
gagggccagg gggctgttcc acagacagac atctgggcca tgggtgtgac agccttcac 5040
atgctgagcg ccgagtaccc ggtgagcagc gagggtgcac gcgacctgca gagaggactg 5100
cgcaaggggc tggtcgggt gagccgctgc tacgcggggc tgtccggggg cgccgtggcc 5160
ttctcgca gactctgtg cgccagccc tggggccggc cctgcgctc cagctgctg 5220
cagtgcctgt ggctaacaga ggaggcccg gcctgttcgc ggcccgccg cgtgaccttc 5280
cctaccgccc ggtgcgctg cttcgtgcgc aatcgcgaga agagacgcg gctgctgtac 5340
aagaggcaca acctggccca ggtgcgctga ggtcgcccc ggccacaccc ttggtctccc 5400
cgctgggggt cgctgcagac gcgcaataa aaacgcacg ccggcgagaa aaaa 5454